


Identify the novelty:

Additional Comments:

Search compounds of formula (I), (II) as presented in the amendment filed on 8/8/99.

=> d que stat 19
L7 STR




VAR G1=CB/15/17/18/19/20
NODE ATTRIBUTES:
CONNECT IS M2 RC AT 17
CONNECT IS M2 RC AT 18
CONNECT IS M2 RC AT 19
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 13 5
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L9 27538 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 657226 ITERATIONS 27538 ANSWERS
SEARCH TIME: 00.00.19

=> d que stat 114
L7 STR



VAR G1=CB/15/17/18/19/20
NODE ATTRIBUTES:
CONNECT IS M2 RC AT 17
CONNECT IS M2 RC AT 18
CONNECT IS M2 RC AT 19
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 13 5

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L9 27538 SEA FILE=REGISTRY SSS FUL L7

L12 STR



VAR G1=O/S/21-3 22-15/22-3 21-15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 3 8

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L14 1556 SEA FILE=REGISTRY SUB=L9 SSS FUL L12

100.0% PROCESSED 3027 ITERATIONS

1556 ANSWERS

SEARCH TIME: 00.00.01

=> d que nos 132

L7 STR

L9 27538 SEA FILE=REGISTRY SSS FUL L7

L12 STR

L14 1556 SEA FILE=REGISTRY SUB=L9 SSS FUL L12

L15 QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH

L16 QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH

L17 QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH

L18 QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH

L21 99 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L14

L22 1883 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L9

L23 515 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L21 OR L22) (L) (THU
OR PKT OR PAC OR DMA OR BAC)/RL

L24 564 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L21 OR L22) AND
PHARM?/SC, SX

L25 178 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L21 OR L22) (L)
(TREAT? OR THERAP? OR REMED? OR MEDIC? OR ?PHARM? OR BIOPHARM?)

```


L26      656 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L23 OR L24 OR L25)
L27      55  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L26 AND L21
L28      QUE  SPE=ON  ABB=ON  PLU=ON  AY<2008 OR PY<2008 OR PRY<20
          08 OR MY<2008 OR REVIEW/DT
L29      1   SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L27 AND (L15 OR L16
          OR L17 OR L18)
L31      54  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L27 NOT L29
L32      38  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L31 AND L28

```

```

=> d que stat l34
L7      STR

```



```

VAR G1=CB/15/17/18/19/20
NODE ATTRIBUTES:
CONNECT IS M2 RC AT 17
CONNECT IS M2 RC AT 18
CONNECT IS M2 RC AT 19
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RSPEC 13 5
NUMBER OF NODES IS 20

```

```

STEREO ATTRIBUTES: NONE
L34      1954 SEA FILE=WPIX SSS FUL L7

```

```


100.0% PROCESSED 28803 ITERATIONS ( 1 INCOMPLETE) 1954 ANSWERS
SEARCH TIME: 00.00.37

```

```

=> d que stat l38
L7      STR

```

```

VAR G1=CB/15/17/18/19/20
NODE ATTRIBUTES:
CONNECT IS M2 RC AT 17
CONNECT IS M2 RC AT 18
CONNECT IS M2 RC AT 19
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RSPEC 13 5
NUMBER OF NODES IS 20

```

```

STEREO ATTRIBUTES: NONE
L12 STR

```



```

VAR G1=O/S/21-3 22-15/22-3 21-15
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RSPEC 3 8
NUMBER OF NODES IS 21

```

```

STEREO ATTRIBUTES: NONE
L34 1954 SEA FILE=WPIX SSS FUL L7
L38 116 SEA FILE=WPIX SUB=L34 SSS FUL L12

```

100.0% PROCESSED 195 ITERATIONS

116 ANSWERS

SEARCH TIME: 00.00.01

=> d que nos 143

```

L7      STR
L12     STR
L15     QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
L16     QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
L17     QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
L18     QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
L28     QUE SPE=ON ABB=ON PLU=ON AY<2008 OR PY<2008 OR PRY<20
        08 OR MY<2008 OR REVIEW/DT
L34     1954 SEA FILE=WPIX SSS FUL L7
L38     116 SEA FILE=WPIX SUB=L34 SSS FUL L12
L39     18 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L38/DCR
L40     1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L39 AND (L15 OR L16 OR
        L17 OR L18)
L42     17 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L39 NOT L40
L43     16 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L42 AND L28

```

=> d his 148

```

(FILE 'MEDLINE, BIOSIS, EMBASE, BIOTECHNO, CABA, AGRICOLA, DRUGU, VETU'
ENTERED AT 09:31:14 ON 24 NOV 2009)
L48     6 S L47 AND L28

```

=> d que nos 148

```

L7      STR
L9      27538 SEA FILE=REGISTRY SSS FUL L7
L15     QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
L16     QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
L17     QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
L18     QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
L28     QUE SPE=ON ABB=ON PLU=ON AY<2008 OR PY<2008 OR PRY<20
        08 OR MY<2008 OR REVIEW/DT
L44     2 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L9 AND (MEDLINE OR
        BIOSIS OR EMBASE OR BIOTECHNO OR CABA OR AGRICOLA OR DRUGU OR
        VETU OR CROPU)/LC
L45     6 SEA L44
L46     0 SEA L45 AND (L15 OR L16 OR L17 OR L18)
L47     6 SEA L45 NOT L46
L48     6 SEA L47 AND L28

```

=> dup rem 132 143 148

```

FILE 'HCAPLUS' ENTERED AT 09:37:45 ON 24 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

```

```

FILE 'WPIX' ENTERED AT 09:37:45 ON 24 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

```

```

FILE 'BIOSIS' ENTERED AT 09:37:45 ON 24 NOV 2009
Copyright (c) 2009 The Thomson Corporation
PROCESSING COMPLETED FOR L32
PROCESSING COMPLETED FOR L43
PROCESSING COMPLETED FOR L48

```

10/595,734

L52 50 DUP REM L32 L43 L48 (10 DUPLICATES REMOVED)
 ANSWERS '1-38' FROM FILE HCAPLUS
 ANSWERS '39-44' FROM FILE WPIX
 ANSWERS '45-50' FROM FILE BIOSIS

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:37:59 ON 24 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 20, 2009 (20091120/UP).

=> d bib ed abs hitind hitstr 1-20
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, BIOSIS' - CONTINUE? (Y)/N:y

L52 ANSWER 1 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2009:503321 HCAPLUS Full-text
 DOCUMENT NUMBER: 150:547810
 TITLE: Application of pyrimidinyl benzenepropanoic acid compounds in preparation of medical formulations for preventing and/or treating diabetes mellitus
 INVENTOR(S): Shen, Jianhua; Leng, Ying; Jiang, Hualiang; Ye, Yangliang
 PATENT ASSIGNEE(S): Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 39pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 101411704	A	20090422	CN 2007-10047039	20071015 <--
PRIORITY APPLN. INFO.:			CN 2007-10047039	20071015 <--
OTHER SOURCE(S):	MARPAT 150:547810			
ED Entered STN:	27 Apr 2009			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. are represented by formula I, II, III (R1 = H or C1-C6 linear-chain or branched-chain alkyl; R2 = H, C1-C6 linear-chain or branched-chain alkyl, C1-C8 alkoxy, sulfhydryl, etc.; R3 = H, C1-C8 linear-chain or branched-chain alkyl, biphenyl or substituted Ph or unsubstituted Ph, etc.; R4 = H, C1-C8 linear-chain or branched-chain alkyl, halogen, etc.; R5 = H, Ph, C1-C4 alkyl, C1-C4 alkoxy, etc.; R6 = H, C1-C4 alkoxy, halogen, etc.; R7 = substituted or unsubstituted benzyl or naphthyl methylene; R8 = H, C1-C8 linear-chain or branched-chain alkyl, halogen, C1-C4 halogenated alkyl, etc.).
 The inventive compds., as PPAR- γ agonist, can regulate gene transcription by activating RXR/PPAR heterodimer to effectively treat and/or prevent diabetes mellitus.

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT 956223-03-3P	956223-04-4P	956223-05-5P	956223-06-6P	956223-07-7P
956223-08-8P	956223-09-9P	956223-10-2P	956223-11-3P	956223-12-4P
956223-13-5P	956223-14-6P	956223-15-7P	956223-16-8P	956223-17-9P
956223-18-0P	1141923-27-4P	1141923-29-6P	1141923-32-1P	
1141923-42-3P	1141923-43-4P	1141923-44-5P	1141923-45-6P	
1141923-46-7P	1141923-47-8P	1141923-48-9P	1141923-49-0P	
1141923-55-8P	1141923-58-1P	1141923-59-2P	1141923-60-5P	
1141923-65-0P	1141923-66-1P	1141923-69-4P	1141923-71-8P	
1141923-73-0P	1141923-75-2P	1141923-77-4P	1141923-79-6P	
1141923-81-0P	1141923-83-2P	1152304-16-9DP, derivs.		

RL: PAC (Pharmacological activity); PRP (Properties); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)

(application of pyrimidinyl benzenepropanoic acid compds. in preparation of
medical formulations for preventing and/or treating
diabetes mellitus)


IT 1141923-47-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)

(application of pyrimidinyl benzenepropanoic acid compds. in preparation of
medical formulations for preventing and/or treating
diabetes mellitus)

RN 1141923-47-8 HCAPLUS

CN Benzenepropanoic acid, α -methyl- α -phenoxy-4-[[2-phenyl-6-[4-
(phenylmethyl)-1-piperazinyl]-4-pyrimidinyl]oxy]- (CA INDEX NAME)



L52 ANSWER 2 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2008:90956 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:191949

TITLE: Preparation of pyrimidine derivatives and their use as
pesticides

INVENTOR(S): Gauvry, Noelle; Pautrat, Francois; Bouvier, Jacques;
Fruechtel, Joerg; Bapst, Beatrice; Schorderet Weber,
Sandra

PATENT ASSIGNEE(S): Novartis AG, Switz.

SOURCE: PCT Int. Appl., 40pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008009691	A1	20080124	WO 2007-EP57395	20070717 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2007275179	A1	20080124	AU 2007-275179	20070717 <--

CA 2657745 A1 20080124 CA 2007-2657745 20070717 <--
 EP 2091924 A1 20090826 EP 2007-787660 20070717 <--
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
 AL, BA, HR, MK, RS
 IN 2008DN10574 A 20090327 IN 2008-DN10574 20081222 <--
 KR 2009029813 A 20090323 KR 2009-701164 20090120 <--
 MX 2009000802 A 20090203 MX 2009-802 20090121 <--
 CN 101495462 A 20090729 CN 2007-80027769 20090121 <--
 PRIORITY APPLN. INFO.: EP 2006-117639 A 20060721 <--
 WO 2007-EP57395 W 20070717 <--
 OTHER SOURCE(S): CASREACT 148:191949; MARPAT 148:191949
 ED Entered STN: 24 Jan 2008
 GI



AB The title compds. I [X1, X2 = halo; A = substituted Ph or (hetero)aryl], useful in the control of parasites, in particular ectoparasites, in and on warm-blooded animals, were prepared E.g., a 3-step synthesis of 2-(3-dimethylaminophenyl)-4,6-bis-(4-fluoro-3-trifluoromethylphenoxy)pyrimidin-5-ylamine, starting from 4-fluoro-3-trifluoromethylphenol and 4,6-dichloro-5-aminopyrimidine, was given. Exemplified compds. I were tested for antiparasitic activity in various tests (data given).

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 5, 63

IT 1003592-37-7F 1003592-38-8F 1003592-39-9F
1003592-40-2F 1003592-41-3F 1003592-42-4F
1003592-43-5F 1003592-44-6F 1003592-45-7F
1003592-46-8F 1003592-47-9F 1003592-48-0F
1003592-49-1F 1003592-50-4F 1003592-51-5F
1003592-52-6F 1003592-53-7F 1003592-54-8F
1003592-55-9F 1003592-56-0F 1003592-57-1F
1003592-58-2F 1003592-59-3F 1003592-60-6F
1003592-61-7F 1003592-62-8F 1003592-63-9F
1003592-64-0F 1003592-65-1F 1003592-66-2F
1003592-67-3F 1003592-68-4F 1003592-69-5F
1003592-70-8F 1003592-71-9F 1003592-72-0F 1003592-73-1P
 1003592-74-2P 1003592-75-3P 1003592-76-4P 1003592-77-5P
 1003592-78-6P 1003592-79-7P 1003592-80-0P 1003592-81-1P
 1003592-82-2P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); PAC
(Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted pyrimidinamines as pesticides)
 IT 1003592-37-7F 1003592-38-8F 1003592-39-9F
1003592-40-2F 1003592-41-3F 1003592-42-4F
1003592-43-5F 1003592-44-6F 1003592-45-7F


<u>1003592-46-8P</u>	<u>1003592-47-9P</u>	<u>1003592-48-0P</u>
<u>1003592-49-1P</u>	<u>1003592-50-4P</u>	<u>1003592-51-5P</u>
<u>1003592-52-6P</u>	<u>1003592-53-7P</u>	<u>1003592-54-8P</u>
<u>1003592-55-9P</u>	<u>1003592-56-0P</u>	<u>1003592-57-1P</u>
<u>1003592-58-2P</u>	<u>1003592-59-3P</u>	<u>1003592-60-6P</u>
<u>1003592-61-7P</u>	<u>1003592-62-8P</u>	<u>1003592-63-9P</u>
<u>1003592-64-0P</u>	<u>1003592-65-1P</u>	<u>1003592-66-2P</u>
<u>1003592-67-2P</u>	<u>1003592-68-4P</u>	<u>1003592-69-5P</u>
<u>1003592-70-8P</u>		

RL: AGR (Agricultural use); BSU (Biological study, unclassified); PAC
(Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted pyrimidinamines as pesticides)


RN 1003592-37-7 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1003592-38-8 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 1003592-39-9 HCAPLUS

CN 5-Pyrimidinamine, 2-(4-chlorophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-40-2 HCAPLUS

CN 5-Pyrimidinamine, 2-(3-chlorophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-41-3 HCAPLUS

CN 5-Pyrimidinamine, 2-(2-chlorophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-42-4 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 1003592-43-5 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 1003592-44-6 HCAPLUS

CN 5-Pyrimidinamine, 2-(3,5-dichlorophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-45-7 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-(3-methylphenyl)- (CA INDEX NAME)




RN 1003592-46-8 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 1003592-47-9 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(methylthio)phenyl]- (CA INDEX NAME)




RN 1003592-48-0 HCAPLUS

CN 5-Pyrimidinamine, 2-(3,5-dimethoxyphenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-49-1 HCAPLUS

CN 5-Pyrimidinamine, 2-(3-fluorophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-50-4 HCAPLUS

CN Ethanone, 1-[3-[5-amino-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1003592-51-5 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1003592-52-6 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 1003592-53-7 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 1003592-54-8 HCAPLUS

CN Benzenemethanol, 3-[5-amino-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-pyrimidinyl]-α-methyl- (CA INDEX NAME)




RN 1003592-55-9 HCAPLUS

CN Acetamide, N-[3-[5-amino-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1003592-56-0 HCAPLUS

CN Phenol, 3-[5-amino-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-pyrimidinyl]- (CA INDEX NAME)




RN 1003592-57-1 HCAPLUS

CN Methanesulfonamide, N-[3-[5-amino-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1003592-58-2 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-difluorophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-59-3 HCAPLUS

CN 5-Pyrimidinamine, 2-(4-fluoro-3-methylphenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-60-6 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]- (CA INDEX NAME)




RN 1003592-61-7 HCAPLUS

CN 5-Pyrimidinamine, 2-(2-fluoro-5-methoxyphenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-62-8 HCAPLUS

CN 5-Pyrimidinamine, 2-(3-aminophenyl)-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-63-9 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(methoxymethyl)phenyl]- (CA INDEX NAME)




RN 1003592-64-0 HCAPLUS

CN 5-Pyrimidinamine, 2-[3-[(dimethylamino)methyl]phenyl]-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-65-1 HCAPLUS

CN 5-Pyrimidinamine, 2-[3-(dimethylamino)-4-fluorophenyl]-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 1003592-66-2 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 1003592-67-3 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 1003592-68-4 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 1003592-69-5 HCAPLUS

CN 5-Pyrimidinamine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[3-(1-pyrrolidinyl)phenyl]- (CA INDEX NAME)



RN 1003592-70-8 HCAPLUS

CN 5-Pyrimidinamine, 2-[3-(dimethylamino)phenyl]-4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 3 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2007:434909 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:441808

TITLE: Preparation of pyrimidine derivatives for the treatment of cancer

INVENTOR(S): McDonald, Edward; Large, Jonathan M.; Folkes, Adrian; Shuttleworth, Stephen J.; Wan, Nan Chi

PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, Switz.; Cancer

Research Technology Limited; Institute of Cancer
 Research Royal Cancer Hospital; Astellas Pharma Inc.;
 Piramed Limited
 PCT Int. Appl., 71pp.
 CODEN: PIXXD2

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007042806	A1	20070419	WO 2006-GB3776	20061011 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1945627	A1	20080723	EP 2006-794726	20061011 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2009511557	T	20090319	JP 2008-535091	20061011 <--
US 20090156601	A1	20090618	US 2008-89874	20080826 <--
PRIORITY APPLN. INFO.:			GB 2005-20657	A 20051011 <--
			WO 2006-GB3776	W 20061011 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 146:441808

ED Entered SIN: 20 Apr 2007


GI



I



II



III

AB The title compds. I [XR3 is bonded at ring position 2 and YR4 is bonded at ring position 5 or 6; R1 and R2 form, together with the N atom to which they are attached, an (un)substituted morpholine ring; X = a direct bond; R3 = substituted Ph, (un)substituted indazolyl; Y = O(CH₂)_n, NH(CH₂)_n, NHC(O)(CH₂)_n and C(O)NH(CH₂)_n (wherein n = 0-3); R4 = is selected from an (un)substituted unsatd. 5-12 membered carbocyclic or heterocyclic group and a group NR5R6 (wherein R5 and R6 = H, (un)substituted alkyl, cycloalkyl, etc.; or R5 and R6 together form, with the nitrogen atom to which they are attached, an (un)substituted saturated 5-7 membered N-containing heterocyclic group)] that are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurol. disorders, were prepared and formulated. Thus, coupling of II with 3-hydroxyphenylboronic acid afforded 25% III. All of the compds. I tested had an IC50 of 50 µM or less against PI3K. Typically the IC50 against PI3K was 5-500 nM.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 934690-84-3P 934690-85-4P 934690-86-5P
934690-87-6P 934690-88-7P 934690-89-8P
934690-90-1P 934690-91-2P 934690-92-3P
934690-93-4P 934690-94-5P 934690-95-6P
934690-96-7P 934690-97-8P 934690-98-9P 934690-99-0P 934691-00-6P
934691-01-7P 934691-02-8P 934691-03-9P
934691-04-0P 934691-05-1P 934691-06-2P
934691-07-3P 934691-08-4P 934691-09-5P
934691-10-8P 934691-11-9P 934691-12-0P
934691-13-1P 934691-14-2P 934691-15-3P
934691-16-4P 934691-17-5P 934691-18-6P
934691-19-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(preparation of pyrimidinamines for treating cancer)

IT 934690-84-3P 934690-85-4P 934690-86-5P
934690-87-6P 934690-88-7P 934690-89-8P
934690-90-1P 934690-91-2P 934690-92-3P
934690-93-4P 934690-94-5P 934690-95-6P
934691-03-9P 934691-04-0P 934691-05-1P
934691-06-2P 934691-07-3P 934691-08-4P
934691-09-5P 934691-10-8P 934691-11-9P
934691-12-0P 934691-13-1P 934691-14-2P
934691-15-3P 934691-16-4P 934691-17-5P
934691-18-6P 934691-19-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(preparation of pyrimidinamines for treating cancer)


RN 934690-84-3 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[(3-pyridinylmethyl)amino]-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934690-85-4 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934690-86-5 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[(4-pyridinylmethyl)amino]-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934690-87-6 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934690-88-7 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[(2-(3-pyridinyl)ethyl)amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 934690-89-8 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[[2-(4-pyridinyl)ethyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 934690-90-1 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-(2-pyridinylmethoxy)-2-pyrimidinyl]- (CA INDEX NAME)




RN 934690-91-2 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[[2-(4-morpholinyl)ethyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 934690-92-3 HCAPLUS

CN Methanesulfonamide, N-[3-[4-(4-morpholinyl)-6-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 934690-93-4 HCAPLUS

CN Methanesulfonamide, N-[3-[4-(4-morpholinyl)-6-[[2-(3-pyridinyl)ethyl]amino]-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 934690-94-5 HCAPLUS

CN Methanesulfonamide, N-[3-[4-(4-morpholinyl)-6-[[2-(4-pyridinyl)ethyl]amino]-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 934690-95-6 HCAPLUS

CN Methanesulfonamide, N-[3-[4-(4-morpholinyl)-6-(2-pyridinylmethoxy)-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 934691-03-9 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[(phenylmethyl)amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 934691-04-0 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-(phenylamino)-2-pyrimidinyl]- (CA INDEX NAME)




RN 934691-05-1 HCAPLUS

CN Phenol, 3-[4-[(4-methylphenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 934691-06-2 HCAPLUS

CN Phenol, 3-[4-[(3-methylphenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 934691-07-3 HCAPLUS

CN Phenol, 3-[4-[(3-fluorophenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934691-08-4 HCAPLUS

CN Phenol, 3-[4-[(4-fluorophenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934691-09-5 HCAPLUS


CN Phenol, 3-[4-[(2-methylphenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934691-10-8 HCAPLUS

CN Phenol, 3-[4-[(2-fluorophenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)

RN 934691-11-9 HCAPLUS


CN Phenol, 3-[4-[(2-methoxyphenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)

RN 934691-12-0 HCAPLUS

CN Phenol, 3-[4-[(3-methoxyphenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)


RN 934691-13-1 HCAPLUS

CN Phenol, 3-[4-[(4-methoxyphenyl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]-
(CA INDEX NAME)




RN 934691-14-2 HCAPLUS

CN Benzonitrile, 3-[[2-(3-hydroxyphenyl)-6-(4-morpholinyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 934691-15-3 HCAPLUS

CN Benzonitrile, 4-[[2-(3-hydroxyphenyl)-6-(4-morpholinyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 934691-16-4 HCAPLUS

CN Phenol, 3-[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)




RN 934691-17-5 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-[[1,2,3,4-tetrahydro-2-(methylsulfonyl)-7-isoquinolinyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 934691-18-6 HCAPLUS

CN Phenol, 3-[4-[[3-(methylsulfonyl)phenyl]amino]-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 934691-19-7 HCAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-6-phenoxy-2-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 4 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2006:1159256 HCAPLUS [Full-text](#)


DOCUMENT NUMBER: 145:471852

TITLE: Preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists


INVENTOR(S): Caroff, Eva; Fretz, Heinz; Hilpert, Kurt; Houille,

Olivier; Hubler, Francis; Meyer, Emmanuel
 Actelion Pharmaceuticals Ltd, Switz.
 PATENT ASSIGNEE(S): PCT Int. Appl., 381pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114774	A2	20061102	WO 2006-IB51318	20060427 <--
WO 2006114774	A3	20070208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006241260	A1	20061102	AU 2006-241260	20060427 <--
CA 2604967	A1	20061102	CA 2006-2604967	20060427 <--
EP 1893634	A2	20080305	EP 2006-728064	20060427 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
JP 2008539224	T	20081113	JP 2008-508400	20060427 <--
BR 200608089	A2	20091110	BR 2006-8089	20060427 <--
US 20080194576	A1	20080814	US 2007-912545	20071025 <--
MX 2007013436	A	20080116	MX 2007-13436	20071026 <--
CN 101166756	A	20080423	CN 2006-80014374	20071026 <--
KR 2008004608	A	20080109	KR 2007-726652	20071116 <--
NO 2007006094	A	20080125	NO 2007-6094	20071127 <--
IN 2007CN05449	A	20080328	IN 2007-CN5449	20071128 <--
PRIORITY APPLN. INFO.:			WO 2005-EP4578	A 20050428 <--
			WO 2005-IB53711	A 20051110 <--
			WO 2006-IB51318	W 20060427 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 145:471852; MARPAT 145:471852				
ED Entered STN: 03 Nov 2006				
GI				



I



II

AB The invention relates to the preparation of title compds. I [R1 = (un)substituted Ph; W = a bond and R2 = CN, halo/alkoxy/heterocyclyl/cyclo/cycloalkyl/alkyl, hetero/aryl/, heterocyclyl, (partially) saturated heterocyclyl; (un)substituted hydroxyalkyl; W = CH2 and R2 = NR7R8, SR9, SO2R10; W = O, S, and R2 = alkoxy/heterocyclyl/cyclo/ar/heteroaryl/alkyl, hetero/aryl; W = NH and derivs. and R2 = H, dialkylamino/alkoxy/heterocyclyl/hydroxy/alkoxy/cyclo/heterocyclyl/cycloalkyl/aryl/diphenyl/heteroaryl/alkyl, aryl, 2-phenylcyclopropyl, COR11, SO2R12, (un)substituted carboxyalkyl; W = CH:CH and R2 = hydroxy/alkoxy/alkyl alkoxy/heterocyclyl, Ph, or CONR13R14; ; or W = C.tplbond.C and R2 = H, hydroxy/alkoxy/alkyl; or W = CO and R2 = alkyl; W = NR3 and NR2R3 = 4-7 membered heterocyclyl; or W = NR3 and NR2R3 = (un)substituted imidazolyl, pyrazolyl, 1,2,3-triazolyl, etc.; R5a, R5b = independently H, Me; R3 = H, alkyl; R7 aryl/alkyl; or NR7R8 = (un)substituted 4-7 membered heterocyclyl; R9 = cycloalkyl, aryl; R10 = cyclo/alkyl, aryl; R11 = alkoxy/alkyl, hetero/aryl, etc.; R12 = alkyl, aryl; R13, R14 = independently alkyl; X = CO and R6 = cyclo/alkyl, alk(ynyl)oxy, aryloxy, aralkoxy, hetero/aryl, aralkyl or NH2 and derivs.; or X = SO2 and R6 = alkyl; Y = a bond and Z = H, aryl substituted by carboxyalkoxy; or Y = alkoxy/Ph/alkoxyphenyl/alkylene, alkoxyphenylene and Z = H, OH, NH2, CO2H, tetrazolyl, CONH2, COOR17, NHCOR17, NHSO2R17; R17 = alkyl], as P2Y12 receptor antagonists. The invention also relates to the use of pyrimidines I and their stereoisomers, salts, solvent complexes and morphol. forms, in the treatment and/or prevention of peripheral vascular, visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases (no data) or conditions associated with platelet aggregation (no data), particularly thrombosis (no data). Thus, a multi-step synthesis starting from Z-L-Glu(Ot-Bu)-OH (Z = benzyloxycarbonyl) and 1-ethoxycarbonylpiperazine was given for amino acid piperazide II. In a P2Y12 binding assay, II had an IC50 = 117 nM.

IC ICM A61K
CC 34-2 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 28, 63

IT 913946-66-4P 913946-67-5P 913946-68-6P,
4-[(S)-5-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester

913946-71-1P 913946-72-2P,
 4-[(S)-4-Carbamoyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-73-3P 913946-76-6P,
 4-[(S)-2-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-hydroxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-30-5P 913947-34-9P 913948-20-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-21-7P 913948-22-8P,
 4-[(S)-5-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
913948-23-9P, 4-[(S)-2-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-[(ethoxycarbonyl)methoxy]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-24-0P
913948-25-1P 913948-26-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-carboxymethoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-27-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[2-phenyl-6-propoxy-pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-28-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(2-hydroxyethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-29-5P, 4-[(S)-2-[[6-[(Benzyl)oxy]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913948-30-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-(cyclopropylmethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-31-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclohexyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-32-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-isopropoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-33-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-methoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-34-2P,
 4-[2-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-[3-[(ethoxycarbonyl)methoxy]phenyl]propionyl]piperazine-1-carboxylic acid ethyl ester 913948-35-3P,
 4-[2-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-[2-[(ethoxycarbonyl)methoxy]phenyl]propionyl]piperazine-1-carboxylic acid ethyl ester 913948-36-4P,
 4-[(S)-2-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-2-[4-[(ethoxycarbonyl)methoxy]phenyl]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913948-37-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid prop-2-ynyl ester
913948-38-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid butyl ester 913948-39-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isobutyl ester
913948-40-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid 2,2-dimethylpropyl ester 913948-41-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isopropyl ester
913948-42-2P 913948-43-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid phenyl ester

913948-44-4P 913948-45-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid benzyl ester
913948-46-6P 913948-47-7P,
 (S)-4-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxo-5-[4-[(propan-1-yl)sulfonyl]piperazin-1-yl]pentanoic acid tert-butyl ester
913948-48-8P 913948-49-9P 913948-50-2P
913948-51-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-52-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-propylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-53-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-54-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-butylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-55-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isobutylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-56-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-57-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-58-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclohexylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-59-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[[[ethoxycarbonyl]methyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-60-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-hydroxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-61-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-ethoxycarbonyl)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-62-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-hydroxypropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-63-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-tert-butoxycarbonyl)propyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-64-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-dimethylamino)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-65-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-dimethylaminopropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-66-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-morpholin-4-yl)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-67-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-morpholin-4-yl)propyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-68-2P,
 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913948-69-3P 913948-70-6P 913948-71-7P
913948-72-8P 913948-73-9P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-phenethylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913948-74-0P 913948-75-1P 913948-76-2P
913948-77-3P 913948-78-4P 913948-79-5P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(indan-2-yl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-80-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-dimethylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-81-9P,
4-[(S)-2-[[[6-(Azetidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-82-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyrrolidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-83-1P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-84-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(butyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-85-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-phenylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-86-4P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-87-5P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-88-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-89-7P,
4-[4-tert-Butoxycarbonyl-2-[[[6-butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butyl]piperazine-1-carboxylic acid ethyl ester
913948-90-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isobutyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-91-1P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-92-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-93-3P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-94-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(o-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-95-5P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-96-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-97-7P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-98-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-99-9P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-00-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(3-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-01-6P,
4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(2-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913949-02-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(4-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-03-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(3-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-04-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(2-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-05-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methyl-2-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-06-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methyl-2-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-07-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(4-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-08-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(3-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-09-4P
913949-10-7P 913949-11-8P 913949-12-9P
913949-13-0P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[6-(isopropylamino)-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-14-1P,
 4-[(S)-2-[[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-tert-butoxycarbonylpentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-15-2P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-16-3P,
 4-[(S)-5-tert-Butoxycarbonyl-2-[[[6-(cyclopropyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-66-3P 913949-67-4P 913949-68-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(isopropyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-69-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(morpholin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-70-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(thiazolidin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-71-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-hydroxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-72-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-73-2P 913949-74-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(4-hydroxybutyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-75-4P 913949-76-5P
913949-77-6P 913949-78-7P 913949-79-8P
913949-80-1P 913949-81-2P 913949-82-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-83-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-84-5P
913949-85-6P 913949-86-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-87-8P 913949-88-9P
913949-89-0P 913949-90-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-propylsulfonylpyrimidin-4-

yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-91-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-isopropylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-92-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-93-6P 913949-94-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclohexylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-95-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-ethoxycarbonyl)methylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-96-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-ethoxycarbonyl)ethylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-97-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2-phenyl-6-phenylsulfanylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-98-1P, 4-[(S)-2-[[[(6-Benzylsulfanyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-99-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-ethynyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-00-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(3-hydroxyprop-1-ynyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-01-3P 913950-02-4P
913950-03-5
913950-04-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-05-7P 913950-06-8P 913950-07-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(3-hydroxy-3-methylbutyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-08-0P, 4-[(S)-4-Carboxy-2-[[[(6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-09-1P, 4-[(S)-4-Carboxy-2-[[[(6-(4-oxocyclohexyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-10-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-11-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(4-oxocyclohexyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-47-0P 913951-48-1P 913951-49-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(4-methoxypiperidin-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-50-5P 913951-51-6P
913951-52-7P 913951-53-8P 913951-54-9P
913951-55-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-56-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-57-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-

yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-58-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-
 ([1,2,4]triazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-59-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-methylpyrazol-1-yl)-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-60-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-methylpyrazol-1-yl)-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-61-8P,
 4-[(S)-2-[[[6-(4-Butyl-[1,2,3]triazol-1-yl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic
 acid ethyl ester 913951-62-9P,
 4-[(S)-2-[[[6-Amino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-
 butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-63-0P 913951-64-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(ethylsulfonyl)methyl]-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-65-2P 913951-66-3P
913951-67-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-
 [(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-68-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-
 [(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-69-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-
 (pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-70-9P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-71-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-
 (thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-72-1P,
 4-[(S)-2-[[[6-Acetyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-
 butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-73-2P 913951-74-3P 913951-75-4P
913951-76-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-hydroxy-1-
 methyl-ethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-77-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-hydroxyethyl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-78-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-methoxyethyl)-
 2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913951-79-8P 913951-80-1P
913951-81-2P 913951-82-3P 913951-83-4P
913951-84-5P 913951-85-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(tetrahydropyran-4-
 yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-86-7P 913951-87-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-
 4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-88-9P 913951-89-0P 913951-90-3P
913951-91-4P 913951-92-5P 913951-93-6P
913951-94-7P 913951-95-8P 913951-96-9P
913951-97-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-
 trifluoromethylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913951-98-1P,
 4-[(S)-2-[[[6-tert-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-(tert-
 butyloxycarbonyl)butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-99-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-phenoxy-2-

phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-03-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-04-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-05-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913967-11-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazines and their use as P2Y12 receptor antagonists)

- IT 913946-69-7P, 4-[2-[[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester 913946-70-0P, 4-[(S)-2-[[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913946-74-4P, 4-[(S)-6-Amino-2-[[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester 913946-75-5P 913946-77-7P,
 4-[(S)-2-[[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-hydroxypentanoyl]piperazine-1-carboxylic acid ethyl ester 913946-78-8P, 4-[(S)-2-[[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-6-hydroxyhexanoyl]piperazine-1-carboxylic acid ethyl ester 913946-79-9P 913946-80-2P
913946-81-3P 913946-82-4P,
 4-[(S)-4-(Carboxymethoxy)-2-[[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-83-5P 913946-84-6P,
 4-[(S)-2-[[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-(1H-tetrazol-5-yl)butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-85-7P 913946-86-8P 913946-87-9P
913946-88-0P, 4-[(S)-4-Carboxy-2-[[[6-carboxymethoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-89-1P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-propoxypyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-90-4P, 4-[(S)-4-Carboxy-2-[[[6-(2-hydroxyethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-91-5P,
 4-[(S)-2-[[[6-(Benzyl)oxy]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913946-92-6P, 4-[(S)-4-Carboxy-2-[[[6-(cyclopropylmethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-93-7P,
 4-[(S)-4-Carboxy-2-[[[6-cyclohexylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-94-8P, 4-[(S)-4-Carboxy-2-[[[6-isopropoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-95-9P, 4-[(S)-4-Carboxy-2-[[[6-methoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-96-0P, 4-[3-(3-Carboxymethoxyphenyl)-2-[[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester 913946-97-1P,
 4-[3-(2-Carboxymethoxyphenyl)-2-[[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester 913946-98-2P, 4-[(S)-2-(4-Carboxymethoxyphenyl)-2-[[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]ethanoyl]piperazine-1-

carboxylic acid ethyl ester 913946-99-3P,
 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid prop-2-ynyl ester
913947-00-9P, 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid butyl ester 913947-01-0P,
 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isobutyl ester
913947-02-1P, 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid 2,2-dimethylpropyl ester 913947-03-2P,
 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isopropyl ester
913947-04-3P, (S)-4-[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-[4-[(furan-2-yl)carbonyl]piperazin-1-yl]-5-oxopentanoic acid 913947-05-4P,
 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid phenyl ester
913947-06-5P, (S)-5-(4-Benzoylpiperazin-1-yl)-4-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid
913947-07-6P, 4-[(S)-4-Carboxy-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid benzyl ester 913947-08-7P,
 (S)-5-(4-Butyrylpiperazin-1-yl)-4-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid 913947-09-8P,
 (S)-4-[[6-Cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxo-5-[4-(propan-1-yl)sulfonyl]piperazin-1-yl]pentanoic acid
913947-10-1P 913947-11-2P 913947-12-3P
913947-13-4P, 4-[(S)-4-Carboxy-2-[[6-methylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913947-14-5P 913947-15-6P,
 4-[(S)-4-Carboxy-2-[[2-phenyl-6-propylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-16-7P 913947-17-8P,
 4-[(S)-4-Carboxy-2-[[6-isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-18-9P 913947-19-0P,
 4-[(S)-2-[[6-Butylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-20-3P 913947-21-4P,
 4-[(S)-4-Carboxy-2-[[6-isobutylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-22-5P 913947-23-6P,
 4-[(S)-4-Carboxy-2-[[6-cyclopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-24-7P 913947-25-8P,
 4-[(S)-4-Carboxy-2-[[6-cyclopentylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-26-9P 913947-27-0P,
 4-[(S)-4-Carboxy-2-[[6-cyclohexylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-28-1P 913947-29-2P,
 4-[(S)-4-Carboxy-2-[[6-[(ethoxycarbonyl)methyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-31-6P 913947-32-7P 913947-33-8P,
 4-[(S)-4-Carboxy-2-[[6-[(2-ethoxycarbonyl)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-35-0P 913947-36-1P 913947-37-2P,
 4-[(S)-4-Carboxy-2-[[6-[(3-carboxypropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913947-38-3P 913947-39-4P,
 4-[(S)-4-Carboxy-2-[[[6-[(2-dimethylaminoethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-40-7P 913947-41-8P,
 4-[(S)-4-Carboxy-2-[[[6-[(3-dimethylaminopropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-42-9P 913947-43-0P,
 4-[(S)-4-Carboxy-2-[[[6-[[2-(morpholin-4-yl)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-44-1P 913947-45-2P,
 4-[(S)-4-Carboxy-2-[[[6-[[3-(morpholin-4-yl)propyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-46-3P 913947-47-4P,
 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-48-5P 913947-49-6P 913947-50-9P
913947-51-0P 913947-52-1P 913947-53-2P
913947-54-3P 913947-55-4P,
 4-[(S)-4-Carboxy-2-[[[6-phenethylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-56-5P 913947-57-6P 913947-58-7P
913947-59-8P 913947-60-1P 913947-61-2P
913947-62-3P 913947-63-4P 913947-64-5P
913947-65-6P, 4-[(S)-4-Carboxy-2-[[[6-[(indan-2-yl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-66-7P 913947-67-8P,
 4-[(S)-4-Carboxy-2-[[[6-dimethylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-68-9P 913947-69-0P,
 4-[(S)-2-[[[6-(Azetidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-70-3P 913947-71-4P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrrolidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-72-5P 913947-73-6P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-74-7P 913947-75-8P,
 4-[(S)-2-[[[6-(Butyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-76-9P 913947-77-0P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-phenylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-78-1P 913947-79-2P,
 4-[(S)-4-Carboxy-2-[[[6-[(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-80-5P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-81-6P, 4-[(S)-4-Carboxy-2-[[[6-isopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-82-7P, 4-[(S)-2-[[[6-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-83-8P, 4-[(S)-4-Carboxy-2-[[[6-isobutyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-84-9P,
 4-[(S)-4-Carboxy-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-85-0P, 4-[(S)-4-Carboxy-2-[[[6-cyclopentyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-86-1P,

4-[(S)-4-Carboxy-2-[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-87-2E, 4-[(S)-4-Carboxy-2-[[2-phenyl-6-(o-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-89-3E, 4-[(S)-4-Carboxy-2-[[2-phenyl-6-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-89-4E, 4-[(S)-4-Carboxy-2-[[2-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-90-7E, 4-[(S)-4-Carboxy-2-[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-91-8E, 4-[(S)-4-Carboxy-2-[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-92-9E, 4-[(S)-4-Carboxy-2-[[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-93-0E, 4-[(S)-4-Carboxy-2-[[2-(3-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-94-1E, 4-[(S)-4-Carboxy-2-[[2-(2-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-95-2E, 4-[(S)-4-Carboxy-2-[[2-(4-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-96-3E, 4-[(S)-4-Carboxy-2-[[2-(3-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-97-4E, 4-[(S)-4-Carboxy-2-[[2-(2-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-98-5E, 4-[(S)-4-Carboxy-2-[[6-methyl-2-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-99-6E, 4-[(S)-4-Carboxy-2-[[6-methyl-2-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-00-2E, 4-[(S)-4-Carboxy-2-[[2-(4-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-01-3E, 4-[(S)-4-Carboxy-2-[[2-(3-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-02-4E, 4-[2-[[6-Isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
913948-03-5E, 4-[2-[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
913948-04-6E, 4-[2-[[2,6-Diphenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
913948-05-7E, 4-[2-[[6-Cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
913948-06-8E, 4-[(S)-2-[[6-Isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913948-07-9E, 4-[(S)-2-[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913948-08-0E, 4-[(S)-2-[[2,6-Diphenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913948-09-1E 913948-10-4E 913948-11-5E
913948-12-6E 913948-13-7E, 4-[(S)-5-Carboxy-2-[[6-isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
913948-14-8E, 4-[(S)-2-[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-carboxypentanoyl]piperazine-1-carboxylic acid ethyl ester
913948-15-9E, 4-[(S)-5-Carboxy-2-[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic

acid ethyl ester 913948-16-0P,
 4-[(S)-5-Carboxy-2-[[[6-(cyclopropyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
913948-17-1P 913948-18-2P 913948-19-3P
913949-17-4P 913949-18-5P 913949-19-6P,
 4-[(S)-4-Carboxy-2-[[[6-[(isopropyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-20-9P 913949-21-0P,
 4-[(S)-4-Carboxy-2-[[[6-(morpholin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-22-1P 913949-23-2P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazolidin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-24-3P 913949-25-4P 913949-26-5P,
 4-[(S)-4-Carboxy-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 dihydrochloride 913949-27-6P 913949-28-7P,
 4-[(S)-4-Carboxy-2-[[[6-[(4-hydroxybutyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-29-8P 913949-30-1P 913949-31-2P
913949-32-3P 913949-33-4P 913949-34-5P
913949-35-6P 913949-36-7P 913949-37-8P
913949-38-9P, 4-[(S)-4-Carboxy-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-39-0P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-40-3P 913949-41-4P 913949-42-5P,
 4-[(S)-4-Carboxy-2-[[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-43-6P 913949-44-7P
913949-45-8P 913949-46-9P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-propylsulfanylpurimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-47-0P, 4-[(S)-4-Carboxy-2-[[[6-(isopropylsulfanyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-48-1P,
 4-[(S)-4-Carboxy-2-[[[6-(cyclopentylsulfanyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-49-2P 913949-50-5P,
 4-[(S)-4-Carboxy-2-[[[6-(cyclohexylsulfanyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-51-6P, 4-[(S)-4-Carboxy-2-[[[6-[[[6-(ethoxycarbonyl)methyl]sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-52-7P, 4-[(S)-4-Carboxy-2-[[[6-[(2-ethoxycarbonylethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-53-8P
 , 4-[(S)-4-Carboxy-2-[[[6-[(carboxymethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-54-9P, 4-[(S)-4-Carboxy-2-[[[6-[(2-carboxyethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-55-0P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-phenylsulfanylpurimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-56-1P, 4-[(S)-2-[[[6-(Benzylsulfanyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913949-57-2P, 4-[(S)-4-Carboxy-2-[[[6-(ethynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913949-58-3P,
 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxyprop-1-ynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-59-4P, 913949-60-7P, 913949-61-8P,
 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-62-9P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxypropyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-63-0P, 913949-64-1P
913949-65-2P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxy-3-methylbutyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-10-4P, 913950-13-7P
913950-14-8P, 913950-15-9P, 913950-16-0P
913950-17-1P, 4-[(S)-4-Carboxy-2-[[[6-(4-methoxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-18-2P, 913950-19-3P
913950-20-6P, 913950-21-7P, 913950-22-8P
913950-23-9P, 913950-24-0P, 913950-25-1P
913950-26-2P, 913950-27-3P, 913950-28-4P
913950-29-5P, 913950-30-8P, 913950-31-9P,
 4-[(S)-4-Carboxy-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-32-0P, 913950-33-1P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(1,2,4)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-34-2P, 913950-35-3P,
 4-[(S)-4-Carboxy-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-36-4P, 4-[(S)-4-Carboxy-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-37-5P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(1,2,3)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-38-6P, 4-[(S)-2-[[[6-(4-Butyl-[1,2,3]triazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913950-39-7P,
 4-[(S)-2-[[[6-Amino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913950-40-0P, 913950-41-1P,
 4-[(S)-4-Carboxy-2-[[[6-[(cyclohexylcarbonyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-42-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(thien-2-yl)carbonyl]amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-43-3P,
 4-[(S)-4-Carboxy-2-[[[6-[(furan-2-yl)carbonyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-44-4P, 913950-45-5P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(3-phenylpropionyl)amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-46-6P, 4-[(S)-4-Carboxy-2-[[[6-[(2,2-dimethylpropionyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-48-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(2-propylpentanoyl)amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-49-9P,
 4-[(S)-2-[[[6-Benzoylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester

913950-50-2P 913950-51-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 TRU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid
 piperazines and their use as P2Y12 receptor antagonists)

IT 913950-52-4P, 4-[(S)-4-Carboxy-2-[[[6-
 [(cyclobutylcarbonyl)amino]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-53-5P, 4-[(S)-4-Carboxy-2-[[[6-[(cyclopentylcarbonyl)amino]-
 2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913950-54-6P,
 4-[(S)-4-Carboxy-2-[[[6-pentanoylamino-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-55-7P 913950-56-8P,
 4-[(S)-4-Carboxy-2-[[[6-[(cyclopropylcarbonyl)amino]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-57-9P, 4-[(S)-2-[[[6-Acetylamino-2-phenylpyrimidin-4-
 yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl
 ester 913950-58-0P, 4-[(S)-2-[[[6-Butyrylamino-2-
 phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-
 carboxylic acid ethyl ester 913950-59-1P,
 4-[(S)-4-Carboxy-2-[[[6-isobutanoylamino-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-60-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-
 propionylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913950-61-5P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(propan-1-yl)sulfonyl]amino]pyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-62-6P, 4-[(S)-4-Carboxy-2-[[[6-[(ethylsulfonyl)amino]-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913950-63-7P,
 4-[(S)-2-[[[6-[(Phenyl)sulfonyl]amino]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl
 ester 913950-64-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(propan-
 2-yl)sulfonyl]amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913950-65-9P,
 4-[(S)-4-Carboxy-2-[[[6-(4-oxo-4H-pyridin-1-yl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-66-0P, 4-[(S)-4-Carboxy-2-[[[6-(3-methyl-5-oxo-2,5-
 dihydropyrazol-1-yl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-67-1P 913950-68-2P 913950-69-3P,
 4-[(S)-2-[[[6-[(Benzyl)(methyl)amino]methyl]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl
 ester 913950-70-6P, 4-[(S)-4-Carboxy-2-[[[6-[(4-
 ethoxycarbonylpiperidin-1-yl)methyl]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-71-7P 913950-72-8P,
 4-[(S)-4-Carboxy-2-[[[6-[(4-methoxycarbonylpiperidin-1-yl)methyl]-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913950-73-9P 913950-74-0P
913950-75-1P, 4-[(S)-4-Carboxy-2-[[[6-[(morpholin-4-yl)methyl]-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913950-76-2P 913950-77-3P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(piperidin-1-yl)methyl]pyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-78-4P 913950-79-5P,
 4-[(S)-4-Carboxy-2-[[[6-[(ethyl)(methyl)amino]methyl]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913950-80-8P, 4-[(S)-4-Carboxy-2-[[6-(diethylaminomethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-81-9P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(pyrrolidin-1-yl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-82-6P, 4-[(S)-4-Carboxy-2-[[[6-[(ethylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-83-1P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(phenylsulfonyl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-84-2P, 4-[(S)-2-[[[6-[(Phenyl)sulfonyl]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-85-3P,
 4-[(S)-4-Carboxy-2-[[[6-[(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-86-4P, 4-[(S)-4-Carboxy-2-[[[6-[(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-87-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-88-6P,
 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-89-7P, 4-[(S)-4-Carboxy-2-[[[6-(4-methylsulfonylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-90-0P,
 4-[(S)-2-[[[6-(4-Acetylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-91-1P, 4-[(S)-4-Carboxy-2-[[[6-(2-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-92-2P,
 4-[(S)-4-Carboxy-2-[[[6-(3-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-93-3P, 4-[(S)-4-Carboxy-2-[[[6-(3-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-94-4P,
 4-[(S)-4-Carboxy-2-[[[6-(4-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-95-5P, 4-[(S)-4-Carboxy-2-[[[6-(furan-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-96-6P,
 4-[(S)-2-[[[6-(Benzodioxol-5-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-97-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-98-6P,
 4-[(S)-4-Carboxy-2-[[[6-(4-hydroxymethylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-99-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-00-5P,
 4-[(S)-4-Carboxy-2-[[[6-(4-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-01-6P, 4-[(S)-4-Carboxy-2-[[[6-(3-chlorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-02-7P,
 4-[(S)-2-[[[6-(Biphenyl-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-03-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(1H-pyrazol-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913951-04-9P 913951-05-0P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(3-trifluoromethylphenyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-06-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-07-2P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-08-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-09-4P,
 4-[(S)-2-[[[6-Acetyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-10-7P 913951-11-8P 913951-12-9P
913951-13-0P, 4-[(S)-4-Carboxy-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-14-1P,
 4-[(S)-4-(Ethoxycarbonyl)-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-15-2P,
 4-[(S)-4-Carboxy-2-[[[6-(2-hydroxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-16-3P, 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-17-4P 913951-18-5P
913951-19-6P 913951-20-9P 913951-21-0P
913951-22-1P, 4-[(S)-4-Carboxy-2-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913951-23-2P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(tetrahydropyran-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-24-3P 913951-25-4P,
 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-26-5P 913951-27-6P 913951-28-7P
913951-29-8P 913951-30-1P 913951-31-2P
913951-32-3P, 4-[(S)-4-Carboxy-2-[[[6-cyano-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-33-4P 913951-34-5P 913951-35-6P
913951-36-7P 913951-37-8P,
 4-[(S)-4-Carboxy-2-[[[6-ethoxymethyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-38-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-trifluoromethylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-39-0P,
 4-[(S)-2-[[[6-tert-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-40-3P, 4-[(S)-4-Carboxy-2-[[[6-phenoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-41-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(pyridin-3-yl)oxy]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913951-42-5P,
 (S)-5-[4-(tert-Butylcarbamoyl)piperazin-1-yl]-4-[[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid
913951-43-6P, (S)-4-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-[4-(isopropylcarbamoyl)piperazin-1-yl]-5-oxopentanoic
 acid 913951-44-7P, (S)-4-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxo-5-[4-[(thien-2-yl)carbonyl]piperazin-1-yl]pentanoic acid
913951-45-8P,
 (S)-5-[4-(Cyclopentylcarbamoyl)piperazin-1-yl]-4-[[[6-cyclopentyloxy-2-

phenylpyrimidin-4-yl)carbonyl]amino]-5-oxopentanoic acid
913951-46-9P, (S)-4-[[[6-(Cyclopentyloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxo-5-[4-(piperidin-1-yl)carbonyl]piperazin-1-yl]pentanoic acid 913952-00-8P,
 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-01-9P, 4-[(S)-4-Carboxy-2-[[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-02-0P,
 4-[(S)-4-Carboxy-2-[[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]piperazine-1-carboxylic acid ethyl ester
913952-06-4P 913952-07-5P 913952-08-6P
913952-09-7P, 4-[(S)-4-Carboxy-2-[[[6-[(carboxymethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-10-0P,
 4-[(S)-4-Carboxy-2-[[[6-[(2-hydroxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-11-1P, 4-[(S)-4-Carboxy-2-[[[6-[(2-carboxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-12-2P,
 4-[(S)-4-Carboxy-2-[[[6-[(3-hydroxypropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-13-3P 913952-14-4P 913952-15-5P
913952-16-6P, 4-[(S)-4-Carboxy-2-[[[6-(4-hydroxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-17-7P,
 4-[(S)-4-Carboxy-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-18-8P 913952-19-9P,
 4-[(S)-4-Carboxy-2-[[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-20-2P,
 4-[(S)-4-Carboxy-2-[[[6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913953-38-5P 913967-10-9P 913967-12-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y₁₂ receptor antagonists)
 IT 3282-30-2P, Pivaloyl chloride 13514-79-9P,
 6-Methyl-2-phenylpyrimidin-4-ol 13754-38-6P,
 (Phenyl)(piperazin-1-yl)methanone 24779-45-1P,
 trans-2,5-Dimethylpiperazine-1-carboxylic acid ethyl ester 26531-82-8P,
 (S)-(Amino)(4-hydroxyphenyl)ethanoic acid methyl ester 29509-92-0P,
 4-Chloro-6-methyl-2-phenylpyrimidine 50606-33-2P 73955-54-1P
 , 6-Methyl-2-phenylpyrimidine-4-carboxylic acid methyl ester
 81925-29-3P, 3-(Tributylstannanyl)prop-2-en-1-ol 84477-85-0P,
 3-Methylpiperazine-1-carboxylic acid benzyl ester 85815-04-9P,
 6-Methoxy-2-phenylpyrimidine-4-carboxylic acid 89581-58-8P,
 2-Chloro-6-methylpyrimidine-4-carboxylic acid 90152-49-1P,
 3-Methylpiperazine-1-carboxylic acid ethyl ester 120737-73-7P,
 2-Methylpiperazine-1-carboxylic acid ethyl ester 122135-83-5P,
 2-[(Trifluoromethylsulfonyl)oxy]cyclohex-1-ene-1-carboxylic acid ethyl ester 123334-59-8P, 3-(3-Benzyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionic acid 123593-66-8P,
 (S)-(4-Benzyloxyphenyl)-tert-butoxycarbonylaminoethanoic acid 162536-44-9P, 2-Amino-3-(3-hydroxyphenyl)propionic acid methyl ester 170011-47-9P, Trifluoromethanesulfonic acid 1,4-dioxaspiro[4.5]dec-7-en-8-yl ester 179187-31-6P,

2-[(tert-Butoxycarbonyl)amino]-3-(2-hydroxyphenyl)propionic acid methyl ester 188975-30-6P, Trifluoromethanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester 209535-63-7P, 4-Methyl-2-phenyl-6-trifluoromethylpyrimidine 225517-15-7P, (S)-(tert-Butoxycarbonylamino)(4-hydroxyphenyl)ethanoic acid methyl ester 282100-79-2P, 2-[(tert-Butoxycarbonyl)amino]-3-(3-hydroxyphenyl)propionic acid methyl ester 325685-59-4P, 4-Chloro-6-(methoxymethyl)-2-phenylpyrimidine 325685-75-4P, (6-Chloro-2-phenylpyrimidin-4-yl)methanol 339278-89-6P, 6-Methoxymethyl-2-phenylpyrimidin-4-ol 359821-46-8P, 4-(2-Aminoacetyl)piperazine-1-carboxylic acid ethyl ester 361547-56-0P, 3-[(tert-Butyldimethylsilyl)oxy]-2,2-dimethylpropionic acid methyl ester 368424-88-8P, 4-Benzoylpiperazine-1-carboxylic acid benzyl ester 528602-18-8P, 3-[(tert-Butyldimethylsilyl)oxy]-2,2-dimethylpropionic acid 710335-28-7P, 4-[(S)-2-Amino-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 710335-29-8P, 4-[(S)-2-[(Benzoyloxycarbonyl)amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 757168-92-6P, 2-Amino-3-(2-hydroxyphenyl)propionic acid methyl ester 856840-41-0P, 1-(Piperazin-1-yl)butan-1-one hydrochloride 858269-17-7P, 6-Methyl-2-phenylpyrimidine-4-carboxylic acid 859525-60-3P, 1-[(Propan-1-yl)sulfonyl]piperazine hydrochloride 907951-69-3P, (S)-(4-Benzoyloxyphenyl)(tert-butoxycarbonylamino)ethanoic acid methyl ester 913952-21-3P, 4-Cyclopentylloxy-6-(methoxymethyl)-2-phenylpyrimidine 913952-22-4P, (6-Cyclopentylloxy-2-phenylpyrimidin-4-yl)methanol 913952-23-5P, 6-Cyclopentylloxy-2-phenylpyrimidine-4-carboxaldehyde 913952-24-6P, 6-Cyclopentylloxy-2-phenylpyrimidine-4-carboxylic acid 913952-25-7P 913952-26-8P 913952-27-9P, 4-[(S)-2-[(Benzoyloxycarbonyl)amino]-5-tert-butoxycarbonylpentanoyl]piperazine-1-carboxylic acid ethyl ester 913952-28-0P, 4-[(S)-2-Amino-5-tert-butoxycarbonylpentanoyl]piperazine-1-carboxylic acid ethyl ester 913952-29-1P, 4-[2-(Benzoyloxycarbonylamino)acetyl]piperazine-1-carboxylic acid ethyl ester 913952-30-4P, 4-[(S)-2-[(tert-Butoxycarbonyl)amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913952-31-5P, 4-[(S)-2-Amino-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester hydrochloride 913952-32-6P 913952-33-7P 913952-34-8P, 4-[(S)-2-[(tert-Butoxycarbonyl)amino]-4-carbamoylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913952-35-9P, 4-[(S)-2-Amino-4-carbamoylbutanoyl]piperazine-1-carboxylic acid ethyl ester hydrochloride 913952-36-0P 913952-37-1P 913952-38-2P 913952-39-3P, 4-[(S)-6-[(Benzoyloxycarbonyl)amino]-2-[(tert-butoxycarbonyl)amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester 913952-40-6P, 4-[(S)-2-Amino-6-[(benzyloxycarbonyl)amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester hydrochloride 913952-41-7P, 4-[(S)-6-[(Benzoyloxycarbonyl)amino]-2-[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester 913952-42-8P 913952-43-9P 913952-44-6P 913952-45-1P 913952-46-2P, 4-[(S)-4-Cyano-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-47-3P 913952-48-4P 913952-49-5P 913952-50-8P 913952-51-9P 913952-52-0P 913952-53-1P 913952-54-2P 913952-55-3P 913952-56-4P, [(6-Methyl-2-phenylpyrimidin-4-yl)oxy]acetic acid methyl ester 913952-57-5P, 6-[(Methoxycarbonyl)methoxy]-2-phenylpyrimidine-4-carboxylic acid 913952-58-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(methoxycarbonyl)methoxy]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913952-59-7P,
 6-Chloro-2-phenylpyrimidine-4-carboxylic acid 913952-60-0P,
 2-Phenyl-6-propoxypyrimidine-4-carboxylic acid 913952-61-1P,
 6-(2-Hydroxyethoxy)-2-phenylpyrimidine-4-carboxylic acid
913952-62-2P, 6-Benzyloxy-2-phenylpyrimidine-4-carboxylic acid
913952-63-3P, 6-Cyclopropylmethoxy-2-phenylpyrimidine-4-carboxylic
 acid 913952-64-4P, 6-Cyclohexyloxy-2-phenylpyrimidine-4-
 carboxylic acid 913952-65-5P,
 6-Isopropoxy-2-phenylpyrimidine-4-carboxylic acid 913952-66-6P,
 3-(3-Benzyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionic acid methyl
 ester 913952-67-7P, 4-[3-(3-Benzyloxyphenyl)-2-[(tert-
 butoxycarbonyl)amino]propionyl]piperazine-1-carboxylic acid ethyl ester
 913952-68-8P, 4-[2-Amino-3-(3-benzyloxyphenyl)propionyl]piperazine-1-
 carboxylic acid ethyl ester hydrochloride 913952-69-9P,
 4-[3-(3-Benzyloxyphenyl)-2-[(6-cyclopentylloxy-2-phenylpyrimidin-4-
 yl)carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester
913952-70-2P, 4-[2-[(6-Cyclopentylloxy-2-phenylpyrimidin-4-
 yl)carbonyl]amino]-3-(3-hydroxyphenyl)propionyl]piperazine-1-carboxylic
 acid ethyl ester 913952-71-3P, 3-(2-Benzyloxyphenyl)-2-[(tert-
 butoxycarbonyl)amino]propionic acid methyl ester 913952-72-4P,
 3-(2-Benzyloxyphenyl)-2-[(tert-butoxycarbonyl)amino]propionic acid
 913952-73-5P, 4-[3-(2-Benzyloxyphenyl)-2-[(tert-
 butoxycarbonyl)amino]propionyl]piperazine-1-carboxylic acid ethyl ester
 913952-74-6P, 4-[2-Amino-3-(2-benzyloxyphenyl)propionyl]piperazine-1-
 carboxylic acid ethyl ester hydrochloride 913952-75-7P,
913952-76-8P, 4-[2-[(6-Cyclopentylloxy-2-phenylpyrimidin-4-
 yl)carbonyl]amino]-3-(2-hydroxyphenyl)propionyl]piperazine-1-carboxylic
 acid ethyl ester 913952-77-9P, 4-[(S)-2-(4-Benzyloxyphenyl)-2-(tert-
 butoxycarbonylamino)ethanoyl]piperazine-1-carboxylic acid ethyl ester
 913952-78-0P, 4-[(S)-2-Amino-2-(4-benzyloxyphenyl)ethanoyl]piperazine-1-
 carboxylic acid ethyl ester hydrochloride 913952-79-1P,
 4-[(S)-2-(4-Benzyloxyphenyl)-2-[(6-cyclopentylloxy-2-phenylpyrimidin-4-
 yl)carbonyl]amino]ethanoyl]piperazine-1-carboxylic acid ethyl ester
913952-80-4P, 4-[(S)-2-[(6-Cyclopentylloxy-2-phenylpyrimidin-4-
 yl)carbonyl]amino]-2-(4-hydroxyphenyl)ethanoyl]piperazine-1-carboxylic
 acid ethyl ester 913952-81-5P 913952-82-6P
913952-83-7P 913952-84-8P 913952-85-9P,
 4-Butyrylpiperazine-1-carboxylic acid tert-butyl ester 913952-86-0P,
 4-[(Propan-1-yl)sulfonyl]piperazine-1-carboxylic acid tert-butyl ester
 913952-87-1P 913952-88-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[(6-chloro-2-phenylpyrimidin-4-
 yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 913952-89-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[(2-chloro-6-methylpyrimidin-
 4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-90-6P, 4-[2-[(6-Chloro-2-phenylpyrimidin-4-
 yl)carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
913952-91-7P, 4-[(S)-2-[(6-Chloro-2-phenylpyrimidin-4-
 yl)carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl
 ester 913952-92-8P 913952-93-9P,
 4-[(S)-5-tert-Butoxycarbonyl-2-[(6-chloro-2-phenylpyrimidin-4-
 yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
913952-94-0P 913952-95-1P 913952-96-2P
913952-97-3P 913952-98-4P 913952-99-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913953-00-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1,4-dioxaspiro[4.5]decan-8-yl)-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913953-01-2P,
 4-[(S)-4-Carboxy-2-[[[6-chloro-2-phenylpyrimidin-4-

yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913953-02-3P, 4-[(S)-2-[[[6-Azido-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-03-4P 913953-04-5P
913953-05-6P 913953-06-7P,
 6-Formyl-2-phenylpyrimidine-4-carboxylic acid methyl ester
913953-07-8P, 6-Hydroxymethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-08-9P,
 6-Chloromethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester
913953-09-0P, 6-Chloromethyl-2-phenylpyrimidine-4-carboxylic acid 913953-10-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-chloromethyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-11-4P 913953-12-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-vinylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-14-7P 913953-15-8P 913953-16-9P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-oxopropyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-17-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-ethoxycarbonyl)cyclohex-1-enyl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-18-1P 913953-19-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4,5-dihydrofuran-3-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-20-5P,
 6-(1-Hydroxypropyl)-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-21-6P, 6-(1-Hydroxypropyl)-2-phenylpyrimidine-4-carboxylic acid 913953-22-7P, 6-(1-Hydroxybutyl)-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-23-8P,
 6-(1-Hydroxybutyl)-2-phenylpyrimidine-4-carboxylic acid 913953-24-9P, 6-[(Hydroxy)(phenyl)methyl]-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-25-0P,
 6-[(Hydroxy)(phenyl)methyl]-2-phenylpyrimidine-4-carboxylic acid 913953-26-1P, 6-(2-Hydroxy-2-phenylethyl)-2-phenylpyrimidine-4-carboxylic acid 913953-27-2P,
 2-Phenyl-6-trifluoromethylpyrimidine-4-carboxylic acid 913953-28-3P, Acetic acid 5,5-dimethyl-4-oxo-2-hexynyl ester 913953-29-4P, Acetic acid 6-tert-butyl-2-phenylpyrimidin-4-ylmethyl ester 913953-30-7P, (6-tert-Butyl-2-phenylpyrimidin-4-yl)methanol 913953-31-8P, 6-tert-Butyl-2-phenylpyrimidine-4-carboxylic acid 913953-32-9P, Acetic acid 6-[(tert-butyl)dimethylsilyl]oxy]-5,5-dimethyl-4-oxo-2-hexynyl ester 913953-33-0P, Acetic acid [6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-ylmethyl ester 913953-34-1P, [6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-yl)methanol 913953-35-2P, 6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidine-4-carboxylic acid 913953-36-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[2-[(tert-butyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-37-4P, [2-(Tributylstannanyl)cyclopropyl]methanol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazines and their use as P2Y₁₂ receptor antagonists)
 IT 64-04-0, 2-Phenylethylamine 78-81-9, Isobutylamine 78-96-6, 1-Amino-2-propanol 79-03-8, Propionyl chloride 79-30-1, Isobutyryl chloride 96-32-2, Methyl bromoacetate 96-35-5, Methyl glycolate 98-02-2, Furfuryl mercaptan 98-09-9, Benzenesulfonyl chloride 98-80-6, Phenylboronic acid 100-53-8, Benzyl mercaptan 103-67-3,

N-Benzylmethylamine 103-80-0, Phenylacetyl chloride 104-97-2,
 3-Cyclopentylpropionyl chloride 105-36-2, Ethyl bromoacetate 106-94-5,
 1-Bromopropane 107-03-9, 1-Propanethiol 107-10-8, Propylamine,
 reactions 107-19-7, Propargyl alcohol 108-00-9,
 2-Dimethylaminoethylamine 108-12-3, Isovaleryl chloride 108-23-6,
 Isopropyl chloroformate 108-93-0, Cyclohexyl alcohol, reactions
 108-98-5, Thiophenol, reactions 109-00-2, 3-Hydroxypyridine 109-07-9,
 2-Methylpiperazine 109-55-7, (3-Dimethylaminopropan-1-yl)amine
 109-89-7, Diethylamine, reactions 109-98-8, 2-Pyrazole 110-68-9,
 Methyl(butyl)amine 115-19-5, 2-Methyl-3-butyne-2-ol 120-43-4,
 1-Ethoxycarbonylpiperazine 120-92-3, Cyclopentanone 123-00-2,
 4-(3-Aminopropyl)morpholine 124-68-5, 2-Amino-2-methyl-1-propanol
 137-43-9, Bromocyclopentane 140-88-5, Ethyl acrylate 141-75-3, Butyryl
 chloride 141-91-3, 2,6-Dimethylmorpholine 141-97-9, Ethyl acetoacetate
 156-87-6, 3-Aminopropan-1-ol 367-57-7, 1,1,1-Trifluoro-2,4-pentanedione
 371-40-4, 4-Fluoroaniline 501-53-1, Benzyl chloroformate 503-29-7,
 Azetidine 504-78-9, Thiazolidine 513-42-8, 2-Methyl-2-propen-1-ol
 527-69-5, 2-Furoyl chloride 527-72-0, 2-Thiophenecarboxylic acid
 534-26-9, 2-Methyl-2-imidazoline 543-27-1, Isobutyl chloroformate
 582-22-9, β -Methylphenethylamine 592-34-7, Butyl chloroformate
 618-39-3, Benzamide 623-33-6 623-51-8, Ethyl 2-mercaptoacetate
 624-78-2 626-64-2, 4-Pyridinol 627-09-8, Propargyl acetate 627-27-0,
 3-Buten-1-ol 638-29-9, Valeryl chloride 645-45-4, 3-Phenylpropionyl
 chloride 688-73-3, Tributylstannane 693-02-7, 1-Hexyne 765-30-0,
 Cyclopropylamine 768-35-4, 3-Fluorophenylboronic acid 775-06-4
 821-09-0, 4-Penten-1-ol 920-39-8, Isopropylmagnesium bromide
 1003-03-8, Cyclopentylamine 1066-54-2, Trimethylsilylacetylene
 1068-47-9, 1-Mercapto-2-propanol 1122-99-2, Cyclopentylacetyl chloride
 1126-09-6, Ethyl isonipecotatate 1138-80-3 1191-99-7, 2,3-Dihydrofuran
 1423-26-3, [3-(Trifluoromethyl)phenyl]boronic acid 1453-58-3,
 3-Methylpyrazole 1569-69-3, Cyclohexanethiol 1609-86-5, tert-Butyl
 isocyanate 1655-07-8, Ethyl 2-cyclohexanecarboxylate 1670-14-0,
 Benzamide hydrochloride 1679-07-8, Cyclopentyl mercaptan 1679-18-1,
 4-Chlorophenylboronic acid 1692-15-5, Pyridin-4-ylboronic acid
 1692-25-7, Pyridin-3-ylboronic acid 1765-93-1, 4-Fluorophenylboronic
 acid 1795-48-8, Isopropyl isocyanate 1885-14-9, Phenyl chloroformate
 1986-47-6, (trans-2-Phenylcyclopropyl)amine hydrochloride 1993-03-9,
 2-Fluorophenylboronic acid 2028-63-9, 3-Butyn-2-ol 2038-03-1,
 4-(2-Aminoethyl)morpholine 2130-96-3 2304-96-3 2338-18-3,
 2-Aminoindan hydrochloride 2370-61-8 2389-45-9 2516-33-8,
 Cyclopropylmethanol 2627-86-3, (S)-Methylbenzylamine 2680-03-7,
 N,N-Dimethylacrylamide 2719-27-9, Cyclohexanecarbonyl chloride
 2749-11-3, (S)-(+)-2-Amino-1-propanol 2799-21-5,
 (R)-3-Hydroxypyrrolidine 2815-34-1, trans-2,5-Dimethylpiperazine
 2936-08-5, 2,2-Di-n-propylacetyl chloride 2971-79-1, Methyl
 isonipecotatate 3400-45-1, Cyclopentanecarboxylic acid 3433-37-2,
 2-Hydroxymethylpiperidine 3886-08-6 3886-69-9,
 (R)- α -Methylbenzenemethanamine 3900-89-8, 2-Chlorophenylboronic
 acid 4023-34-1, Cyclopropanecarbonyl chloride 4187-86-4,
 Ethylethynylcarbinol 4244-84-2 4344-87-0 4426-47-5, Butylboronic
 acid 4524-93-0, Cyclopentanecarbonyl chloride 4746-97-8,
 1,4-Dioxaspiro[4.5]decan-8-one 4747-21-1, N-Isopropylmethylamine
 4795-29-3, Tetrahydrofurfurylamine 5006-22-4, Cyclobutanecarbonyl
 chloride 5122-94-1, Biphenyl-4-ylboronic acid 5271-67-0,
 2-Thiophenecarbonyl chloride 5382-16-1, 4-Hydroxypiperidine 5456-63-3,
 trans-2-Aminocyclohexanol hydrochloride 5466-06-8, Ethyl
 3-mercaptopropionate 5545-52-8 5720-05-8, 4-Tolylboronic acid
 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic
 acid 6165-68-0, Thien-2-ylboronic acid 6165-69-1, Thien-3-ylboronic
 acid 6168-72-5, 2-Aminopropanol 6783-05-7,

(trans-2-Phenylethenyl)boronic acid 6859-99-0, 3-Hydroxypiperidine 7226-23-5, 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 7554-65-6, 4-Methylpyrazole 10147-36-1, 1-Propanesulfonyl chloride 10147-37-2, 2-Propanesulfonyl chloride 10277-74-4, (R)-1-Aminoindan 10365-98-7, 3-Methoxyphenylboronic acid 13325-10-5, 4-Amino-1-butanol 13726-85-7 13734-41-3 13939-69-0, 1-Piperidinecarbonyl chloride 14002-80-3, Methyl 2,2-dimethyl-3-hydroxypropionate 14047-29-1, 4-Carboxyphenylboronic acid 16419-60-6, 2-Tolylboronic acid 16947-84-5 17933-03-8, 3-Tolylboronic acid 18162-48-6, tert-Butyldimethylsilyl chloride 20412-38-8, Neopentyl chloroformate 23356-96-9, L-Prolinol 23680-31-1 25487-66-5, 3-Carboxyphenylboronic acid 25611-78-3, 1,2-Diphenylethylamine 27489-62-9, trans-4-Aminocyclohexanol 29943-42-8, Tetrahydro-4H-pyran-4-one 31166-44-6, Piperazine-1-carboxylic acid benzyl ester 32462-30-9 33240-34-5, Cyclopentylmagnesium bromide 34698-41-4, 1-Aminoindan 35320-23-1, (R)-(-)-2-Amino-1-propanol 35718-08-2, Propargyl chloroformate 37143-54-7, 2-Amino-1-methoxypropane 38870-89-2, Methoxyacetyl chloride 40172-95-0, 1-(2-Furoyl)piperazine 41051-15-4, Methyl 4-methoxyacetate 53838-27-0 54812-86-1, 3-Mercapto-2-butanol 55552-70-0, Furan-3-ylboronic acid 57260-71-6 58640-01-0 59016-93-2, [4-(Hydroxymethyl)phenyl]boronic acid 63503-60-6, 3-Chlorophenylboronic acid 68832-13-3, D-Prolinol 84110-40-7, Isobutylboronic acid 89793-11-3, 2-Chloro-6-methylpyrimidine-4-carboxylic acid methyl ester 94839-07-3, (3,4-Methylenedioxyphenyl)boronic acid 97674-02-7, (1-Ethoxvinyl)tributylstannane 100243-39-8, (S)-3-Hydroxypyrrolidine 111769-26-7, (R)-3-Aminotetrahydrofuran 120686-18-2, tert-Butyl (3S)-3-amino-3-phenylpropanoate 121359-48-6, 2-(Tributylstannyl)thiazole 126747-14-6, 4-Cyanophenylboronic acid 131724-45-3 149104-88-1, 4-(Methylsulfonyl)phenylboronic acid 149104-90-5, 4-Acetylphenylboronic acid 150255-96-2, 3-Cyanophenylboronic acid 160063-50-3 161671-34-7, tert-Butyl (3R)-3-amino-3-phenylpropanoate 201668-29-3 269410-08-4, 4,4,5,5-Tetramethyl-2-(1H-pyrazol-4-yl)-1,3,2-dioxaborolane 411235-57-9, Cyclopropylboronic acid 913953-13-6, 4-[(S)-2-[[[(6-Phenylsulfonyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-tert-butoxycarbonyl]butanoyl]piperazine-1-carboxylic acid ethyl ester 914069-98-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)

IT 528602-20-2P 1160048-83-8P 1160050-66-7P 1160053-70-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)

IT 913946-66-4P 913946-67-5P 913946-68-6P,

4-[(S)-5-Carboxy-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913946-71-1P 913946-72-2P,

4-[(S)-4-Carbamoyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-73-3P 913946-76-6P,

4-[(S)-2-[[[(6-Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-hydroxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913947-30-5P 913947-34-9P 913948-20-6P,

4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-21-7P 913948-22-8P,

4-[(S)-5-tert-Butoxycarbonyl-2-[[[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913948-23-9P, 4-[(S)-2-[[[(6-Cyclopentyl-2-phenylpyrimidin-4-

yl)carbonyl]amino]-4-[(ethoxycarbonyl)methoxy]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-24-0P
913948-25-1P 913948-26-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-carboxymethoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-27-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2-phenyl-6-propoxypyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-28-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(2-hydroxyethoxy)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-29-5P, 4-[(S)-2-[[[(6-(Benzyl)oxy]-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913948-30-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-(cyclopropylmethoxy)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-31-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclohexyloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-32-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-isopropoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-33-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-methoxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-34-2P,
 4-[2-[[[(6-Cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-[3-[(ethoxycarbonyl)methoxy]phenyl]propionyl]piperazine-1-carboxylic acid ethyl ester 913948-35-3P,
 4-[2-[[[(6-Cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-[2-[(ethoxycarbonyl)methoxy]phenyl]propionyl]piperazine-1-carboxylic acid ethyl ester 913948-36-4P,
 4-[(S)-2-[[[(6-Cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-2-[4-[(ethoxycarbonyl)methoxy]phenyl]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913948-37-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid prop-2-ynyl ester 913948-38-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid butyl ester 913948-39-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isobutyl ester 913948-40-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid 2,2-dimethylpropyl ester 913948-41-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isopropyl ester 913948-42-2P 913948-43-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid phenyl ester 913948-44-4P 913948-45-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid benzyl ester 913948-46-6P 913948-47-7P,
 (S)-4-[[[(6-Cyclopentylloxy-2-phenylpyrimidin-4-yl)carbonyl]amino]-5-oxo-5-[4-[(propan-1-yl)sulfonyl]piperazin-1-yl]pentanoic acid tert-butyl ester 913948-48-8P 913948-49-9P 913948-50-2P
913948-51-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-methylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-52-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(2-phenyl-6-propylaminopyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-53-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[(6-isopropylamino-2-

phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-54-6F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-butylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-55-7F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isobutylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-56-8F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopropylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-57-9F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-58-0F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclohexylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-59-1F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(ethoxycarbonyl)methyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-60-4F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-hydroxyethyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-61-5F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-ethoxycarbonyl)ethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-62-6F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-hydroxypropyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-63-7F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-tert-butoxycarbonyl)propyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-64-8F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-dimethylamino)ethyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-65-9F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(3-dimethylamino)propyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-66-0F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-(morpholin-4-yl)ethyl]amino)-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-67-1F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[[3-(morpholin-4-yl)propyl]amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-68-2F,
 4-[(S)-2-[[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913948-69-3F 913948-70-6F 913948-71-7F
913948-72-8F 913948-73-9F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-phenethylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-74-0F 913948-75-1F 913948-76-2F
913948-77-3F 913948-78-4F 913948-79-5F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(indan-2-yl)amino]-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-80-9F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-dimethylamino-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-81-9F,
 4-[(S)-2-[[[6-(Azetidin-1-yl)-2-phenylpyrimidin-4-yl)carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913948-82-0F, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyrrolidin-1-yl)pyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-83-1F,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(piperidin-1-yl)pyrimidin-4-

yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-84-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-
 [(butyl)(methyl)amino]-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-85-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-
 phenylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913948-86-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(4-fluorophenyl)amino]-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913948-87-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methyl-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-88-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isopropyl-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913948-89-7P,
 4-[4-tert-Butoxycarbonyl-2-[[[6-butyl-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butyl]piperazine-1-carboxylic acid ethyl ester
913948-90-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isobutyl-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913948-91-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-92-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentyl-2-
 phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913948-93-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2,6-diphenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-94-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(o-
 tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913948-95-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(m-tolyl)pyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-96-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(p-
 tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913948-97-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913948-98-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-
 carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-
 carboxylic acid ethyl ester 913948-99-9P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(4-fluorophenyl)-6-methylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-00-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(3-fluorophenyl)-
 6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913949-01-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(2-fluorophenyl)-6-methylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-02-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(4-chlorophenyl)-
 6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913949-03-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(3-chlorophenyl)-6-methylpyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-04-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(2-chlorophenyl)-
 6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic
 acid ethyl ester 913949-05-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methyl-2-(p-tolyl)pyrimidin-4-
 yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-06-1P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-methyl-2-(m-
 tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid
 ethyl ester 913949-07-2P,

4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(4-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-08-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-(3-methoxyphenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-09-4P
913949-10-7P 913949-11-8P 913949-12-9P
913949-13-0P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[6-isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-14-1P,
 4-[(S)-2-[[[6-(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-tert-butoxycarbonylpentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-15-2P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-16-3P,
913949-16-3P, 4-[(S)-5-tert-Butoxycarbonyl-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester 913949-66-3P 913949-67-4P 913949-68-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(isopropyl) (methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-69-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(morpholin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-70-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(thiazolidin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-71-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-hydroxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-72-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-73-2P 913949-74-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-hydroxybutyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-75-4P 913949-76-5P
913949-77-6P 913949-78-7P 913949-79-8P
913949-80-1P 913949-81-2P 913949-82-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-83-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-84-5P
913949-85-6P 913949-86-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-87-8P 913949-88-9P
913949-89-0P 913949-90-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-propylsulfanylpiperazine-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-91-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-isopropylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-92-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclopentylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-93-6P 913949-94-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-cyclohexylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-95-8P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[[ethoxycarbonyl]methyl]sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester

913949-96-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-ethoxycarbonyl)ethyl]sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-97-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-phenylsulfanylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913949-98-1P,
 4-[(S)-2-[[[6-Benzylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913949-99-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-ethynyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-00-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-hydroxyprop-1-ynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-01-3P 913950-02-4P
913950-03-5P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-04-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-hydroxypropyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-05-7P
913950-06-8P 913950-07-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-hydroxy-3-methylbutyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-08-0P,
 4-[(S)-4-Carboxy-2-[[[6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-09-1P,
 4-[(S)-4-Carboxy-2-[[[6-(4-oxocyclohexyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-11-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-oxocyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-12-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-oxocyclohexyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-47-0P 913951-48-1P 913951-49-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-methoxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-50-5P 913951-51-6P
913951-52-7P 913951-53-8P 913951-54-9P
913951-55-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-56-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-57-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-58-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-[[1,2,4-triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-59-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-60-7P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-61-8P,
 4-[(S)-2-[[[6-(4-Butyl-[1,2,3]triazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-62-9P,

4-[(S)-2-[[6-Amino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-63-0P 913951-64-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(ethylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-65-2P 913951-66-3P 913951-67-4P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-68-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-69-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-70-9P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-71-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-72-1P, 4-[(S)-2-[[6-Acetyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-73-2P 913951-74-3P
913951-75-4P 913951-76-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-77-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-hydroxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-78-7P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-methoxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-79-8P 913951-80-1P
913951-81-2P 913951-82-3P 913951-83-4P
913951-84-5P 913951-85-6P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-(tetrahydropyran-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-86-7P 913951-87-8P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-88-9P 913951-89-0P 913951-90-3P
913951-91-4P 913951-92-5P 913951-93-6P
913951-94-7P 913951-95-8P 913951-96-9P
913951-97-0P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-trifluoromethylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-98-1P,
 4-[(S)-2-[[6-tert-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-(tert-butoxycarbonyl)butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-99-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-phenoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-03-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-04-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-05-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913967-11-0P

RL: FAC (Pharmacological activity); RCT (Reactant); SPN


(Synthetic preparation); TRU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid
piperazides and their use as P2Y₁₂ receptor antagonists)

RN 913946-66-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913946-67-5 HCAPLUS

CN 1-Piperazinebutanoic acid, β -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- γ -oxo-, (β S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913946-68-6 HCAPLUS

CN 1-Piperazinehexanoic acid, δ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- ϵ -oxo-, (δ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913946-71-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-4-amino-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1,4-dioxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-72-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-5-amino-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-73-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-amino-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 913946-76-6 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-hydroxy-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-30-5 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-ethoxy-2-oxoethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-29-2

CMF C27 H34 N6 O8

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 913947-34-9 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3-ethoxy-3-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-33-8

CMF C28 H36 N6 O8

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 913948-20-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-

10/595,734

pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-,
1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-21-7 HCAPLUS

CN 1-Piperazinebutanoic acid, β -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- γ -oxo-,
1,1-dimethylethyl ester, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-22-8 HCAPLUS

CN 1-Piperazinehexanoic acid, δ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- ϵ -oxo-,
1,1-dimethylethyl ester, (δS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-23-9 HCAPLUS

CN Acetic acid, 2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[4-(ethoxycarbonyl)-1-piperazinyl]-4-oxobutoxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-24-0 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-25-1 HCAPLUS

CN Acetic acid, 2-[4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]phenoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-26-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(carboxymethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1-(1,1-dimethylethyl) ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-27-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-propoxy-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-28-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-

10/595,734

hydroxyethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-29-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylmethoxy)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-30-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopropylmethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-,
1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-31-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclohexyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-32-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-methylethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-33-1 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-methoxy-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-34-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[3-(2-ethoxy-2-oxoethoxy)phenyl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)



RN 913948-35-3 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[2-(2-ethoxy-2-oxoethoxy)phenyl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)



RN 913948-36-4 HCAPLUS

CN Acetic acid, 2-[4-[(1S)-1-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-2-[4-(ethoxycarbonyl)-1-piperazinyl]-2-oxoethyl]phenoxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-37-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonylamino]-δ-oxo-4-[(2-propyn-1-yloxy)carbonyl]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-38-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(butoxycarbonyl)-γ-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonylamino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-39-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclopentyloxy)-2-phenyl-4-

10/595,734

pyrimidinyl]carbonyl]amino]-4-[(2-methylpropoxy)carbonyl]- δ -oxo-,
1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-40-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[(2,2-dimethylpropoxy)carbonyl]- δ -oxo-,
1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-41-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[(1-methylethoxy)carbonyl]- δ -oxo-,
1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-42-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(2-furanylcarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-43-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(phenoxycarbonyl)-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-44-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-benzoyl- γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-45-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(phenylmethoxycarbonyl)-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-46-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(1-oxobutyl)-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-47-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(propylsulfonyl)-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-48-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-2-methyl- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-49-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-3-methyl- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-50-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-2,5-dimethyl- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-51-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(methylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-52-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(propylamino)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-53-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-54-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(butylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-55-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-methylpropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-56-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclopropylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-57-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclopentylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-58-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclohexylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-59-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-ethoxy-2-oxoethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-60-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-hydroxyethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-61-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3-ethoxy-3-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-62-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3-hydroxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-63-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[4-(1,1-dimethylethoxy)-4-oxobutyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-64-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[2-(dimethylamino)ethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-65-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[3-(dimethylamino)propyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-66-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[[2-(4-morpholinyl)ethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-67-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[3-(4-morpholinyl)propyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-68-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-69-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-70-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-71-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[[[(1S)-3-(1,1-dimethylethoxy)-3-oxo-1-phenylpropyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-72-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[[(1R)-3-(1,1-dimethylethoxy)-3-oxo-1-phenylpropyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-73-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(2-phenylethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-74-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(2-phenylpropyl)amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-75-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(1,2-diphenylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-76-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(2-phenylcyclopropyl)amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-77-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(2,3-dihydro-1H-inden-1-yl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-78-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-79-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[[[(2,3-dihydro-1H-inden-2-yl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-80-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(dimethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-81-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(1-azetidiny)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-82-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1-pyrrolidinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-83-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1-piperidinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-84-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(butylmethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-85-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylamino)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-86-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-fluorophenyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-87-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-methylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-88-6 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-methylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913948-89-7 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[(6-butyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 913948-90-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[(6-(2-methylpropyl)-2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-91-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[(6-cyclopropyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-92-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-93-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[2,6-diphenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-94-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-95-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-96-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-97-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(3-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1-(1,1-dimethylethyl) ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-98-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1-(1,1-dimethylethyl) ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-99-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[2-(4-fluorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-00-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-01-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[2-(2-fluorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-02-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-03-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[2-(3-chlorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-04-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[2-(2-chlorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-05-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-methyl-2-(4-methylphenyl)-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-06-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-methyl-2-(3-methylphenyl)-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-07-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[2-(4-methoxyphenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-08-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[2-(3-methoxyphenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-09-4 HCAPLUS

CN Benzoic acid, 4-[(2S)-3-[4-(ethoxycarbonyl)-1-piperazinyl]-2-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-10-7 HCAPLUS

CN Benzoic acid, 4-[(2S)-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxo-2-[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]propyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-11-8 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[[2,6-diphenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-12-9 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[[6-(cyclopropyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-13-0 HCAPLUS

CN 1-Piperazinehexanoic acid, 4-(ethoxycarbonyl)- δ -[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- ϵ -oxo-, 1,1-dimethylethyl ester, (δ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-14-1 HCAPLUS

CN 1-Piperazinehexanoic acid, 4-(ethoxycarbonyl)- ϵ -oxo- δ -[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (δ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-15-2 HCAPLUS

CN 1-Piperazinehexanoic acid, δ -[[[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (δS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-16-3 HCAPLUS

CN 1-Piperazinehexanoic acid, δ -[[[(6-cyclopropyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (δS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-66-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1Z)-3-hydroxy-1-buten-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 913949-67-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methoxy-1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-68-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[methyl(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-69-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-morpholinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-70-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(3-thiazolidinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-71-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-hydroxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-72-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1-piperazinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-73-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-hydroxy-1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-74-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(4-hydroxybutyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-75-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-hydroxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-76-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[[[tetrahydro-2-furanyl)methyl]amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-77-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-78-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-79-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-80-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-81-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[[[(3R)-tetrahydro-3-furanyl]amino]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-82-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-83-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-84-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[[[1S]-2-hydroxy-1-methylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-85-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(1R)-2-hydroxy-1-methylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-86-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2S)-2-hydroxy-1,1-dimethylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-87-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3S)-3-hydroxy-1-piperidinyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-88-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-(hydroxymethyl)-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-89-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-hydroxycyclohexyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-90-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(propylthio)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-91-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1-methylethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-92-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentylthio)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-93-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-furanylmethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-94-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclohexylthio)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-95-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-ethoxy-2-oxoethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-96-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[3-ethoxy-3-oxopropyl]thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-97-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(phenylthio)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-98-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(phenylmethyl)thio]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-99-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-ethynyl-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-00-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-propyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-01-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-butyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-02-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-pentyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-03-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-3-methyl-1-butyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-04-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-05-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxybutyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-06-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxypentyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-07-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-3-methylbutyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-08-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-(4-oxo-1-cyclohexen-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-09-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-(4-oxocyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-11-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-(4-oxo-1-cyclohexen-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-12-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-(4-oxocyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-47-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-methoxy-1-pyrrolidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

10/595,734

, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-48-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(1S)-2-methoxy-1-methylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-49-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methoxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-50-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3R)-3-methoxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-51-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1R)-2-methoxy-1-methylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-52-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[2-(methoxymethyl)-1-piperidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-53-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-54-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-55-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1,1-dimethylethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-56-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-57-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-58-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-59-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-60-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-61-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4-butyl-1H-1,2,3-triazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-62-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-amino-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-63-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(2,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-64-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(ethylsulfonyl)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-65-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(phenylthio)methyl]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-66-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(phenylsulfonyl)methyl]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-67-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclopentylthio)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-68-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclopentylsulfonyl)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-69-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(3-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-70-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(4-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-71-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(2-thiazolyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-72-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(1-hydroxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-73-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-hydroxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-74-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-methoxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-75-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-ethoxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-76-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-hydroxy-1-methylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-77-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-78-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-methoxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-79-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxycyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-80-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-methoxycyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-81-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxycyclopentyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-82-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-83-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-84-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-85-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(tetrahydro-2H-pyran-4-yl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-86-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-(ethoxycarbonyl)cyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-87-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-3-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-88-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1E)-3-ethoxy-3-oxo-1-propen-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 913951-89-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(tetrahydro-2-furanyl)methyl]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-90-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-2-methylpropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-91-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(tetrahydro-3-furanyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-92-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(1E)-3-(dimethylamino)-3-oxo-1-propen-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 913951-93-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-hydroxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-94-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-hydroxybutyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-95-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(hydroxyphenylmethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-96-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxy-2-phenylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-97-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-98-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(1,1-dimethylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-99-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-phenoxy-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-03-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-oxido-2-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-04-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-oxido-4-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-05-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913967-11-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(trans-4-hydroxycyclohexyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 913946-69-7P, 4-[2-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]acetyl]piperazine-1-carboxylic acid ethyl ester
913946-70-0P, 4-[(S)-2-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913946-74-4P, 4-[(S)-6-Amino-2-[[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester
913946-75-5P 913946-77-7P, 4-[(S)-2-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-hydroxypentanoyl]piperazine-1-carboxylic acid ethyl ester
913946-78-8P, 4-[(S)-2-[[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-6-hydroxyhexanoyl]piperazine-1-carboxylic acid ethyl ester
913946-79-9P 913946-80-2P
913946-81-3P 913946-82-4P, 4-[(S)-4-(Carboxymethoxy)-2-[[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-83-5P 913946-84-6P,

4-[(S)-2-[[6-cyclopentylloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-(1H-tetrazol-5-yl)butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-85-7P 913946-86-8P 913946-87-9P
913946-88-0P, 4-[(S)-4-Carboxy-2-[[6-(carboxymethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-89-1P,
 4-[(S)-4-Carboxy-2-[[2-phenyl-6-propoxy-pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-90-4P, 4-[(S)-4-Carboxy-2-[[6-(2-hydroxyethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-91-5P,
 4-[(S)-2-[[6-(1-(Benzyl)oxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913946-92-6P, 4-[(S)-4-Carboxy-2-[[6-(cyclopropylmethoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913946-93-7P,
 4-[(S)-4-Carboxy-2-[[6-(cyclohexyloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-94-8P, 4-[(S)-4-Carboxy-2-[[6-(isopropoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-95-9P, 4-[(S)-4-Carboxy-2-[[6-(methoxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913946-96-0P, 4-[3-(3-Carboxymethoxyphenyl)-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester 913946-97-1P,
 4-[3-(2-Carboxymethoxyphenyl)-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester
913946-98-2P, 4-[(S)-2-(4-Carboxymethoxyphenyl)-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913946-99-3P,
 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid prop-2-ynyl ester
913947-00-9P, 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid butyl ester 913947-01-0P,
 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isobutyl ester
913947-02-1P, 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid 2,2-dimethylpropyl ester 913947-03-2P,
 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid isopropyl ester
913947-04-3P, (S)-4-[[6-(Cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-[4-((furan-2-yl)carbonyl)piperazin-1-yl]-5-oxopentanoic acid 913947-05-4P,
 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid phenyl ester
913947-06-5P, (S)-5-(4-Benzoylpiperazin-1-yl)-4-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid
913947-07-6P, 4-[(S)-4-Carboxy-2-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid benzyl ester 913947-08-7P,
 (S)-5-(4-Butyrylpiperazin-1-yl)-4-[[6-(cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid 913947-09-8P,
 (S)-4-[[6-(Cyclopentylloxy)-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxo-5-[4-(propan-1-yl)sulfonyl]piperazin-1-yl]pentanoic acid
913947-10-1P 913947-11-2P 913947-12-3P
913947-13-4P, 4-[(S)-4-Carboxy-2-[[6-(methylamino)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913947-14-5P 913947-15-6P,

4-[(S)-4-Carboxy-2-[[2-phenyl-6-propylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-16-7P 913947-17-8P,
 4-[(S)-4-Carboxy-2-[[6-isopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-18-9P 913947-19-0P,
 4-[(S)-2-[[6-Butylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-20-3P 913947-21-4P,
 4-[(S)-4-Carboxy-2-[[6-isobutylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-22-5P 913947-23-6P,
 4-[(S)-4-Carboxy-2-[[6-cyclopropylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-24-7P 913947-25-8P,
 4-[(S)-4-Carboxy-2-[[6-cyclopentylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-26-9P 913947-27-0P,
 4-[(S)-4-Carboxy-2-[[6-cyclohexylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-28-1P 913947-29-2P,
 4-[(S)-4-Carboxy-2-[[6-[(ethoxycarbonyl)methyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-31-6P 913947-32-7P 913947-33-8P,
 4-[(S)-4-Carboxy-2-[[6-[(2-ethoxycarbonyl)ethyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-35-0P 913947-36-1P 913947-37-2P,
 4-[(S)-4-Carboxy-2-[[6-[(3-carboxypropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-38-3P 913947-39-4P,
 4-[(S)-4-Carboxy-2-[[6-[(2-dimethylaminoethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-40-7P 913947-41-8P,
 4-[(S)-4-Carboxy-2-[[6-[(3-dimethylaminopropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-42-9P 913947-43-0P,
 4-[(S)-4-Carboxy-2-[[6-[(2-(morpholin-4-yl)ethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-44-1P 913947-45-2P,
 4-[(S)-4-Carboxy-2-[[6-[(3-(morpholin-4-yl)propyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-46-3P 913947-47-4P,
 4-[(S)-2-[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-48-5P 913947-49-6P 913947-50-9P
913947-51-0P 913947-52-1P 913947-53-2P
913947-54-3P 913947-55-4P,
 4-[(S)-4-Carboxy-2-[[6-phenethylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-56-5P 913947-57-6P 913947-58-7P
913947-59-8P 913947-60-1P 913947-61-2P
913947-62-3P 913947-63-4P 913947-64-5P
913947-65-6P, 4-[(S)-4-Carboxy-2-[[6-1(indan-2-yl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-66-7P 913947-67-8P,
 4-[(S)-4-Carboxy-2-[[6-dimethylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-68-9P 913947-69-0P,
 4-[(S)-2-[[6-(Azetidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester

913947-70-3P 913947-71-4P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrrolidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-72-5P 913947-73-6P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(piperidin-1-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-74-7P 913947-75-8P,
 4-[(S)-2-[[[6-(Butyl)(methyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-76-9P 913947-77-0P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-phenylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-78-1P 913947-79-2P,
 4-[(S)-4-Carboxy-2-[[[6-[(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-80-5P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-81-6P, 4-[(S)-4-Carboxy-2-[[[6-isopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-82-7P, 4-[(S)-2-[[[6-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913947-83-8P, 4-[(S)-4-Carboxy-2-[[[6-isobutyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-84-9P,
 4-[(S)-4-Carboxy-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-85-0P, 4-[(S)-4-Carboxy-2-[[[6-cyclopentyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-86-1P,
 4-[(S)-4-Carboxy-2-[[[2,6-diphenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-87-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(o-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-88-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(m-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-89-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-90-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-91-8P,
 4-[(S)-4-Carboxy-2-[[[6-(4-carboxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-92-9P, 4-[(S)-4-Carboxy-2-[[[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-93-0P,
 4-[(S)-4-Carboxy-2-[[[2-(3-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-94-1P, 4-[(S)-4-Carboxy-2-[[[2-(2-fluorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-95-2P,
 4-[(S)-4-Carboxy-2-[[[2-(4-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-96-3P, 4-[(S)-4-Carboxy-2-[[[2-(3-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-97-4P,
 4-[(S)-4-Carboxy-2-[[[2-(2-chlorophenyl)-6-methylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-98-5P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-(p-tolyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913947-99-6P, 4-[(S)-4-Carboxy-2-[[[6-methyl-2-(m-tolyl)pyrimidin-

4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester
913948-00-2P, 4-[(S)-4-Carboxy-2-[[[2-(4-methoxyphenyl)-6-methylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913948-01-3P,
 4-[(S)-4-Carboxy-2-[[[2-(3-methoxyphenyl)-6-methylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913948-02-4P, 4-[2-[[[6-Isopropylamino-2-phenylpyrimidin-4-yl|carbonyl|amino|acetyl|piperazine-1-carboxylic acid ethyl ester 913948-03-5P, 4-[2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl|carbonyl|amino|acetyl|piperazine-1-carboxylic acid ethyl ester 913948-04-6P, 4-[2-[[[2,6-Diphenylpyrimidin-4-yl|carbonyl|amino|acetyl|piperazine-1-carboxylic acid ethyl ester 913948-05-7P, 4-[2-[[[6-Cyclopropyl-2-phenylpyrimidin-4-yl|carbonyl|amino|acetyl|piperazine-1-carboxylic acid ethyl ester 913948-06-3P, 4-[(S)-2-[[[6-Isopropylamino-2-phenylpyrimidin-4-yl|carbonyl|amino]-3-methylbutanoyl|piperazine-1-carboxylic acid ethyl ester 913948-07-9P, 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl|carbonyl|amino]-3-methylbutanoyl|piperazine-1-carboxylic acid ethyl ester 913948-08-0P,
 4-[(S)-2-[[[2,6-Diphenylpyrimidin-4-yl|carbonyl|amino]-3-methylbutanoyl|piperazine-1-carboxylic acid ethyl ester 913948-09-1P 913948-10-4P 913948-11-5P
913948-12-6P 913948-13-7P,
 4-[(S)-5-Carboxy-2-[[[6-Isopropylamino-2-phenylpyrimidin-4-yl|carbonyl|amino|pentanoyl|piperazine-1-carboxylic acid ethyl ester 913948-14-8P, 4-[(S)-2-[[[6-[(Benzyl)amino]-2-phenylpyrimidin-4-yl|carbonyl|amino]-5-carboxypentanoyl|piperazine-1-carboxylic acid ethyl ester 913948-15-9P, 4-[(S)-5-Carboxy-2-[[[2,6-diphenylpyrimidin-4-yl|carbonyl|amino|pentanoyl|piperazine-1-carboxylic acid ethyl ester 913948-16-0P,
 4-[(S)-5-Carboxy-2-[[[6-cyclopropyl-2-phenylpyrimidin-4-yl|carbonyl|amino|pentanoyl|piperazine-1-carboxylic acid ethyl ester 913948-17-1P 913948-18-2P 913948-19-3P
913949-17-4P 913949-18-5P 913949-19-6P,
 4-[(S)-4-Carboxy-2-[[[6-[(Isopropyl)(methyl)amino]-2-phenylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-20-9P 913949-21-0P,
 4-[(S)-4-Carboxy-2-[[[6-(morpholin-4-yl)-2-phenylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-22-1P 913949-23-2P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazolidin-3-yl)pyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-24-3P 913949-25-4P 913949-26-5P,
 4-[(S)-4-Carboxy-2-[[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester dihydrochloride 913949-27-6P 913949-28-7P,
 4-[(S)-4-Carboxy-2-[[[6-[(4-hydroxybutyl)amino]-2-phenylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-29-8P 913949-30-1P 913949-31-2P
913949-32-3P 913949-33-4P 913949-34-5P
913949-35-6P 913949-36-7P 913949-37-8P
913949-38-9P, 4-[(S)-4-Carboxy-2-[[[6-(imidazol-1-yl)-2-phenylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-39-0P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyrazol-1-yl)pyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-40-3P 913949-41-4P 913949-42-5P,
 4-[(S)-4-Carboxy-2-[[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl|carbonyl|amino|butanoyl|piperazine-1-carboxylic acid ethyl ester 913949-43-6P 913949-44-7P

913949-45-8P 913949-46-9P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-propylsulfanylpiperidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-47-0P, 4-[(S)-4-Carboxy-2-[[[6-isopropylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-48-1P,
 4-[(S)-4-Carboxy-2-[[[6-cyclopentylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-49-2P 913949-50-5P,
 4-[(S)-4-Carboxy-2-[[[6-cyclohexylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-51-6P, 4-[(S)-4-Carboxy-2-[[[6-[[[ethoxycarbonyl)methyl]sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-52-7P, 4-[(S)-4-Carboxy-2-[[[6-(12-ethoxycarbonyl)ethyl]sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-53-8P, 4-[(S)-4-Carboxy-2-[[[6-(1-carboxymethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-54-9P,
 4-[(S)-4-Carboxy-2-[[[6-[(2-carboxyethyl)sulfanyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-55-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-phenylsulfanylpiperidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-56-1P,
 4-[(S)-2-[[[6-Benzylsulfanyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913949-57-2P, 4-[(S)-4-Carboxy-2-[[[6-ethynyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-58-3P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxyprop-1-ynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-59-4P 913949-60-7P
913949-61-8P, 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-62-9P,
 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxypropyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913949-63-0P 913949-64-1P 913949-65-2P,
 4-[(S)-4-Carboxy-2-[[[6-(3-hydroxy-3-methylbutyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-10-4P 913950-13-7P 913950-14-8P
913950-15-9P 913950-16-0P 913950-17-1P,
 4-[(S)-4-Carboxy-2-[[[6-(4-methoxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-18-2P 913950-19-3P 913950-20-6P
913950-21-7P 913950-22-8P 913950-23-9P
913950-24-0P 913950-25-1P 913950-26-2P
913950-27-3P 913950-28-4P 913950-29-5P
913950-30-8P 913950-31-9P
 , 4-[(S)-4-Carboxy-2-[[[6-(2-methyl-4,5-dihydroimidazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-32-0P 913950-33-1P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(1,2,4)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-34-2P 913950-35-3P,
 4-[(S)-4-Carboxy-2-[[[6-(4-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-36-4P, 4-[(S)-4-Carboxy-2-[[[6-(3-methylpyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-37-5P,


4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(1,2,3)triazol-1-yl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-38-6P, 4-[(S)-2-[[[6-(4-Butyl-[1,2,3]triazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-39-7P, 4-[(S)-2-[[[6-Amino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-40-6P 913950-41-1P, 4-[(S)-4-Carboxy-2-[[[6-[(cyclohexylcarbonyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-42-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(thien-2-yl)carbonyl]amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-43-3P, 4-[(S)-4-Carboxy-2-[[[6-[(furan-2-yl)carbonyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-44-4P 913950-45-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(3-phenylpropionyl)amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-46-6P, 4-[(S)-4-Carboxy-2-[[[6-[(3-cyclopentylpropionyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-47-7P, 4-[(S)-4-Carboxy-2-[[[6-[(2,2-dimethylpropionyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-48-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(2-propylpentanoyl)amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-49-9P, 4-[(S)-2-[[[6-Benzoylamino-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-50-2P 913950-51-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazines and their use as P2Y₁₂ receptor antagonists)

RN 913946-69-7 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]acetyl]-, ethyl ester (CA INDEX NAME)



RN 913946-70-0 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-3-methyl-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-74-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-6-amino-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxohexyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-75-5 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-hydroxy-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-77-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-5-hydroxy-1-oxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-78-8 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-6-hydroxy-1-oxohexyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-79-9 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-(acetylamino)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-80-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-(methoxycarbonyl)amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-81-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[(methylsulfonyl)amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-82-4 HCAPLUS

CN Acetic acid, 2-[(3S)-3-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[4-(ethoxycarbonyl)-1-piperazinyl]-4-oxobutoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 913946-83-5 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-(1H-tetrazol-5-yl)propyl]-, ethyl ester

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-84-6 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-4-(1H-tetrazol-5-yl)butyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-85-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-[4-(1H-tetrazol-5-yl)phenyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-86-8 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-87-9 HCAPLUS

CN Acetic acid, 2-[4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-88-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(carboxymethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913946-89-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-propoxy-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-90-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxyethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-91-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylmethoxy)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-92-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopropylmethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-93-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclohexyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-94-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-methylethoxy)-2-phenyl-4-pyrimidinyl]carbonylamino]- δ -oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-95-9 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-methoxy-2-phenyl-4-pyrimidinyl]carbonylamino]- δ -oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913946-96-0 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[3-(carboxymethoxy)phenyl]-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonylamino]-1-oxopropyl]-, 1-ethyl ester (CA INDEX NAME)



RN 913946-97-1 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3-[2-(carboxymethoxy)phenyl]-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, 1-ethyl ester (CA INDEX NAME)



RN 913946-98-2 HCAPLUS

CN Acetic acid, 2-[4-[[[1S]-1-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-2-[4-(ethoxycarbonyl)-1-piperazinyl]-2-oxoethyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913946-99-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-[(2-propyn-1-yloxy)carbonyl]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-00-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(butoxycarbonyl)- γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-01-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[(2-methylpropoxy)carbonyl]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-02-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[(2,2-dimethylpropoxy)carbonyl]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-03-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[(1-methylethoxy)carbonyl]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-04-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(2-furanylcarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-05-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(phenoxycarbonyl)-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-06-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-benzoyl- γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-07-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-[(phenylmethoxy)carbonyl]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-08-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(1-oxobutyl)-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-09-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(propylsulfonyl)-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-10-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-2-methyl- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-11-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-3-methyl- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-12-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-2,5-dimethyl- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-13-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(methylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-14-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(methylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 913947-13-4

CMF C24 H30 N6 O6

Absolute stereochemistry.

10/595,734




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 913947-15-6 HCAPLUS
CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(propylamino)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-16-7 HCAPLUS
CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(propylamino)-4-pyrimidinyl]carbonyl]amino]-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
CM 1
CRN 913947-15-6
CMF C26 H34 N6 O6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 913947-17-8 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-18-9 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 913947-17-8
 CMF C26 H34 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-19-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(butylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 913947-20-3 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-(butylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-19-0

CMF C27 H36 N6 O6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 913947-21-4 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methylpropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-22-5 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methylpropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 913947-21-4
 CMF C27 H36 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-23-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopropylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 913947-24-7 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopropylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-23-6

CMF C26 H32 N6 O6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 913947-25-8 HCAPLUS
 CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclopentylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 913947-26-9 HCAPLUS
 CN 1-Piperazinepentanoic acid, γ-[[[6-(cyclopentylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)-,
 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1
 CRN 913947-25-8
 CMF C28 H36 N6 O6

Absolute stereochemistry.

10/595,734



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-27-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclohexylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-28-1 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclohexylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-27-0

CMF C29 H38 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-29-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-ethoxy-2-oxoethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913947-31-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(carboxymethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, hydrochloride (1:?), (γ S)- (CA INDEX NAME)

Absolute stereochemistry.

10/595,734




●x HCl

RN 913947-32-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-hydroxyethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, hydrochloride (1:?), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 913947-33-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3-ethoxy-3-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913947-35-0 HCAPLUS

10/595,734

CN 1-Piperazinepentanoic acid, γ -[[[6-[(2-carboxyethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, hydrochloride, (γ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 913947-36-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3-hydroxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, hydrochloride (1:?), (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 913947-37-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(3-carboxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.

10/595,734



RN 913947-38-3 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[(3-carboxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-37-2

CMF C27 H34 N6 O8

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-39-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[2-(dimethylamino)ethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-40-7 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[[2-(dimethylamino)ethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-39-4

CMF C27 H37 N7 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-41-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[3-(dimethylamino)propyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-42-9 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[[3-(dimethylamino)propyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-41-8

CMF C28 H39 N7 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-43-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[[2-(4-morpholinyl)ethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-44-1 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[2-(4-morpholinyl)ethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-43-0

CMF C29 H39 N7 O7

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-45-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[3-(4-morpholinyl)propyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-46-3 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[13-(4-morpholinyl)propyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-45-2

CMF C30 H41 N7 O7

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 913947-47-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.

10/595,734



RN 913947-48-5 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-47-4

CMF C30 H34 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-49-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]carbonyl]amino]-, hydrochloride (1:?), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 913947-50-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]carbonyl]amino]-, hydrochloride (1:?), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 913947-51-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[[[(1S)-2-carboxy-1-phenylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-52-1 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[[[(1S)-2-carboxy-1-phenylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-51-0

CMF C32 H36 N6 O8

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913947-53-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[[(1R)-2-carboxy-1-phenylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-54-3 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[[[(1R)-2-carboxy-1-phenylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-53-2

CMF C32 H36 N6 O8

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913947-55-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-phenylethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913947-56-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-phenylethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-55-4
CMF C31 H36 N6 O6

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 913947-57-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-phenylpropyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-58-7 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-phenylpropyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

10/595,734

CRN 913947-57-6
CMF C32 H38 N6 O6

Absolute stereochemistry.



CM 2


CRN 64-18-6
CMF C H2 O2

$\text{C}=\text{CH}-\text{OH}$

RN 913947-59-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(1,2-diphenylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913947-60-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(1,2-diphenylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-59-8
CMF C37 H40 N6 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913947-61-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-phenylcyclopropyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-62-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[(2,3-dihydro-1H-inden-1-yl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, hydrochloride (1:?), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 913947-63-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-64-5 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-63-4

CMF C32 H36 N6 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913947-65-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(2,3-dihydro-1H-inden-2-yl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-66-7 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[(2,3-dihydro-1H-inden-2-yl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913947-65-6

CMF C32 H36 N6 O6

Absolute stereochemistry.



CM 2


CRN 64-18-6
CMF C H2 O2



RN 913947-67-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(dimethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 913947-68-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(dimethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-67-8
CMF C25 H32 N6 O6

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 913947-69-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(1-azetidiny)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 913947-70-3 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-(1-azetidiny)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-69-0

CMF C26 H32 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-71-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1-pyrrolidinyl)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-72-5 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1-pyrrolidinyl)-4-pyrimidinyl]carbonyl]amino]-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-71-4

CMF C27 H34 N6 O6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 913947-75-8 HCAPLUS
 CN 1-Piperazinepentanoic acid, γ -[[[6-(butylmethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-76-9 HCAPLUS
 CN 1-Piperazinepentanoic acid, γ -[[[6-(butylmethylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-,
 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1
 CRN 913947-75-8
 CMF C28 H38 N6 O6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 913947-77-0 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylamino)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-78-1 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylamino)-4-pyrimidinyl]carbonyl]amino]-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1
 CRN 913947-77-0
 CMF C29 H32 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913947-79-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(4-fluorophenyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-80-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-methyl-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-81-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-methylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-82-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[(6-butyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-83-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[(6-(2-methylpropyl)-2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-84-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[(6-cyclopropyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-85-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[(6-cyclopentyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-86-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-87-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[(2-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-88-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-89-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-methylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-90-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-91-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4-carboxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γS)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-92-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[2-(4-fluorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
(γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-93-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-94-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[2-(2-fluorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-95-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-96-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[2-(3-chlorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-97-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[2-(2-chlorophenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913947-98-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-methyl-2-(4-methylphenyl)-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913947-99-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-methyl-2-(3-methylphenyl)-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-00-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[2-(4-methoxyphenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-01-3 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[2-(3-methoxyphenyl)-6-methyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-02-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]acetyl]-, ethyl ester (CA INDEX NAME)




RN 913948-03-5 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]acetyl]-, ethyl ester (CA INDEX NAME)




RN 913948-04-6 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[(2,6-diphenyl-4-pyrimidinyl)carbonyl]amino]acetyl]-, ethyl ester (CA INDEX NAME)



RN 913948-05-7 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[(6-cyclopropyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]acetyl]-, ethyl ester (CA INDEX NAME)



RN 913948-06-8 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-methyl-2-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-07-9 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-methyl-1-oxo-2-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]butyl]-, ethyl ester

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-08-0 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[2,6-diphenyl-4-pyrimidinyl]carbonyl]amino]-3-methyl-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-09-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-(4-carboxyphenyl)-2-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, 1-ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-10-4 HCAPLUS

CN Benzoic acid, 4-[(2S)-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxo-2-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]propyl]- (CA)

INDEX NAME)


Absolute stereochemistry.



RN 913948-11-5 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[[[2,6-diphenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-12-6 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[[[6-cyclopropyl-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 913948-13-7 HCAPLUS

CN 1-Piperazinehexanoic acid, 4-(ethoxycarbonyl)-8-[[[6-[(1-

10/595,734

methylethyl amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-6-oxo-,
(8S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-14-8 HCAPLUS

CN 1-Piperazinehexanoic acid, 4-(ethoxycarbonyl)-6-oxo-δ-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (8S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913948-15-9 HCAPLUS

CN 1-Piperazinehexanoic acid, δ-[[[2,6-diphenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-6-oxo-, (8S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 913948-16-0 HCAPLUS

CN 1-Piperazinehexanoic acid, δ-[[[6-cyclopropyl-2-phenyl-4-

10/595,734

pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)-ε-oxo-, (δS)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913948-17-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-4-amino-1,4-dioxo-2-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]butyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-18-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-1-oxo-2-[[[2-phenyl-6-[(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]-3-(1H-tetrazol-5-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913948-19-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-(4-hydroxyphenyl)-2-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-17-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methoxy-1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-18-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methoxy-1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)


CM 1

CRN 913949-17-4

CMF C27 H36 N6 O7

Absolute stereochemistry.

10/595,734



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913949-19-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[methyl(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-20-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[methyl(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)


CM 1

CRN 913949-19-6

CMF C27 H36 N6 O6

Absolute stereochemistry.

10/595,734



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913949-21-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-morpholinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-22-1 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-morpholinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913949-21-0

CMF C27 H34 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913949-23-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(3-thiazolidinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-24-3 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(3-thiazolidinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913949-23-2

CMF C26 H32 N6 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913949-25-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-hydroxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, hydrochloride (1:?), (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-26-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1-piperazinyl)-4-pyrimidinyl]carbonyl]amino]-, hydrochloride (1:2), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 913949-27-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-hydroxy-1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, hydrochloride (1:?), (γS)- (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 913949-28-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(4-hydroxybutyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913949-29-8 HCAPLUS

10/595,734

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-hydroxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-30-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[[[tetrahydro-2-furanyl)methyl]amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-31-2 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[[[tetrahydro-2-furanyl)methyl]amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913949-30-1

CMF C28 H36 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913949-32-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-33-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-34-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-35-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-36-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[[[(3R)-tetrahydro-3-furanyl]amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913949-37-8 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[[[(3R)-tetrahydro-3-furanyl]amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913949-36-7

CMF C27 H34 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913949-38-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-39-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-40-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[[[1S]-2-hydroxy-1-methylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-41-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[[[(1R)-2-hydroxy-1-methylethyl]amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-42-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-hydroxy-1,1-dimethylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-43-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-44-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[2-(hydroxymethyl)-1-piperidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-45-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-hydroxycyclohexyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-46-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(propylthio)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-47-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1-methylethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-48-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentylthio)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-49-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-furanyl)methyl]thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-50-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclohexylthio)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913949-51-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-ethoxy-2-oxoethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-52-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3-ethoxy-3-oxopropyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-53-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(carboxymethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913949-54-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(2-carboxyethyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913949-55-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylthio)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-56-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(phenylmethyl)thio]-4-pyrimidinyl]carbonylamino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-57-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-ethynyl-2-phenyl-4-pyrimidinyl]carbonylamino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-58-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-propyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonylamino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-59-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-butyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
(γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-60-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-1-pentyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
(γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-61-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-3-methyl-1-butyn-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
(γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-62-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-63-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxybutyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-64-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxypentyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913949-65-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-3-methylbutyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-10-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-hydroxy-1-cyclohexen-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-13-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3S)-3-methoxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-14-8 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3S)-3-methoxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-13-7

CMF C28 H36 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$


RN 913950-15-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1S)-2-

10/595,734

methoxy-1-methylethylamino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-
 δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-16-0 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1S)-2-methoxy-1-methylethylamino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-15-9

CMF C27 H36 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

$\text{C}=\text{CH}-\text{OH}$

RN 913950-17-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methoxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-18-2 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-methoxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-17-1

CMF C29 H38 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 913950-19-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3R)-3-methoxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-20-6 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3R)-3-methoxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (7S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-19-3

CMF C28 H36 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$


RN 913950-21-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(1R)-2-

10/595,734

methoxy-1-methylethylamino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-
δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-22-8 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[[(1R)-2-methoxy-1-methylethylamino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-21-7

CMF C27 H36 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

$\text{C}=\text{CH}-\text{OH}$

RN 913950-23-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[2-(methoxymethyl)-1-piperidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-24-0 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[2-(methoxymethyl)-1-piperidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-23-9

CMF C30 H40 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913950-25-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-26-2 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-25-1

CMF C29 H38 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$

RN 913950-27-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-28-4 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-27-3

CMF C29 H38 N6 O7

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$

RN 913950-29-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, hydrochloride (1:?), (γ S)- (CA INDEX NAME)

RN 913950-32-0 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-31-9

CMF C27 H33 N7 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2



RN 913950-33-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-34-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-

10/595,734


phenyl-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-,
(γ S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 913950-33-1

CMF C25 H28 N8 O6

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$

RN 913950-35-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
(γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-36-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-methyl-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-,
(γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-37-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-1,2,3-triazol-1-yl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-38-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4-butyl-1H-1,2,3-triazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-39-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-amino-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913950-40-0 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-amino-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913950-39-7

CMF C23 H28 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913950-41-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclohexylcarbonyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-42-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-thienylcarbonyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-43-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-furanylcarbonyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-44-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(2-phenylacetyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-45-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-[(1-oxo-3-phenylpropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-46-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[(3-cyclopentyl-1-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-47-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[(2,2-dimethyl-1-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-48-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-
[(1-oxo-2-propylpentyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-,
(γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-49-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(benzoylamino)-2-phenyl-4-
pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913950-50-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[(2-cyclopentylacetyl)amino]-2-
phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-,
(γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-51-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methoxyacetyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 913950-52-4P, 4-[(S)-4-Carboxy-2-[[[6-[(cyclobutylcarbonyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-53-5P, 4-[(S)-4-Carboxy-2-[[[6-[(cyclopentylcarbonyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-54-6P, 4-[(S)-4-Carboxy-2-[[[6-pentanoylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-55-7P 913950-56-8P, 4-[(S)-4-Carboxy-2-[[[6-[(cyclopropylcarbonyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-57-9P, 4-[(S)-2-[[[6-Acetylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913950-58-0P, 4-[(S)-2-[[[6-Butyrylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913950-59-1P, 4-[(S)-4-Carboxy-2-[[[6-isobutanoylamino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-60-4P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-propionylaminopyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-61-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[[[propan-1-yl]sulfonyl]amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913950-62-6P, 4-[(S)-4-Carboxy-2-[[[6-(ethylsulfonyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913950-63-7P,
 4-[(S)-2-[[[6-[(Phenyl)sulfonyl]amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-64-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[[[propan-2-yl)sulfonyl]amino]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-65-9P,
 4-[(S)-4-Carboxy-2-[[[6-(4-oxo-4H-pyridin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-66-0P, 4-[(S)-4-Carboxy-2-[[[6-(3-methyl-5-oxo-2,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-67-1P 913950-68-2P 913950-69-3P,
 4-[(S)-2-[[[6-[(Benzyl)(methyl)amino]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-70-6P, 4-[(S)-4-Carboxy-2-[[[6-[(4-ethoxycarbonylpiperidin-1-yl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-71-7P 913950-72-8P,
 4-[(S)-4-Carboxy-2-[[[6-[(4-methoxycarbonylpiperidin-1-yl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-73-9P 913950-74-0P 913950-75-1P, 4-[(S)-4-Carboxy-2-[[[6-[(morpholin-4-yl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-76-2P 913950-77-3P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(piperidin-1-yl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-78-4P 913950-79-5P,
 4-[(S)-4-Carboxy-2-[[[6-[(ethyl)(methyl)amino]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-80-8P, 4-[(S)-4-Carboxy-2-[[[6-(diethylaminomethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-81-9P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(pyrrolidin-1-yl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-82-0P, 4-[(S)-4-Carboxy-2-[[[6-[(ethylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-83-1P,
 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-[(phenylsulfonyl)methyl]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-84-2P, 4-[(S)-2-[[[6-[(Phenyl)sulfonyl]methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-85-3P,
 4-[(S)-4-Carboxy-2-[[[6-[(cyclopentylsulfonyl)methyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-87-5P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-88-6P,
 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-89-7P, 4-[(S)-4-Carboxy-2-[[[6-(4-methylsulfonylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-90-0P,
 4-[(S)-2-[[[6-(4-Acetylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-91-1P, 4-[(S)-4-Carboxy-2-[[[6-(2-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-92-2P,

4-[(S)-4-Carboxy-2-[[[6-(3-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-93-3P, 4-[(S)-4-Carboxy-2-[[[6-(3-fluorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-94-4P, 4-[(S)-4-Carboxy-2-[[[6-(4-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-95-5P, 4-[(S)-4-Carboxy-2-[[[6-(furan-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-96-6P, 4-[(S)-2-[[[6-(Benzodioxol-5-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913950-97-7P, 4-[(S)-4-Carboxy-2-[[[6-(3-methoxyphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-98-8P, 4-[(S)-4-Carboxy-2-[[[6-(4-hydroxymethylphenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913950-99-9P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiophen-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-00-5P, 4-[(S)-4-Carboxy-2-[[[6-(4-cyanophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-01-6P, 4-[(S)-4-Carboxy-2-[[[6-(3-chlorophenyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-02-7P, 4-[(S)-2-[[[6-(Biphenyl-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-03-8P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(1H-pyrazol-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-04-9P 913951-05-0P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(3-trifluoromethylphenyl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-06-1P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-3-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-07-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(pyridin-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-08-3P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(thiazol-2-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-09-4P, 4-[(S)-2-[[[6-Acetyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester 913951-10-7P 913951-11-8P 913951-12-9P 913951-13-0P, 4-[(S)-4-Carboxy-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-14-1P, 4-[(S)-4-(Ethoxycarbonyl)-2-[[[6-(1-hydroxy-1-methylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-15-2P, 4-[(S)-4-Carboxy-2-[[[6-(2-hydroxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-16-3P, 4-[(S)-4-Carboxy-2-[[[6-(2-methoxyethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-17-4P 913951-18-5P 913951-19-6P 913951-20-9P 913951-21-0P 913951-22-1P, 4-[(S)-4-Carboxy-2-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-23-2P, 4-[(S)-4-Carboxy-2-[[[2-phenyl-6-(tetrahydropyran-4-yl)pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester


913951-24-3P 913951-25-4P,
 4-[(S)-4-Carboxy-2-[[6-(1-oxopyridin-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-26-5P 913951-27-6P 913951-28-7P
913951-29-8P 913951-30-1P 913951-31-2P
913951-32-3P, 4-[(S)-4-Carboxy-2-[[6-cyano-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-33-4P 913951-34-5P 913951-35-6P
913951-36-7P 913951-37-8P,
 4-[(S)-4-Carboxy-2-[[6-ethoxymethyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-38-9P, 4-[(S)-4-Carboxy-2-[[2-phenyl-6-trifluoromethylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-39-0P,
 4-[(S)-2-[[6-tert-Butyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-carboxybutanoyl]piperazine-1-carboxylic acid ethyl ester
913951-40-3P, 4-[(S)-4-Carboxy-2-[[6-phenoxy-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913951-41-4P, 4-[(S)-4-Carboxy-2-[[2-phenyl-6-(pyridin-3-yl)oxy]pyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913951-42-5P,
 (S)-5-[4-(tert-Butylcarbamoyl)piperazin-1-yl]-4-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid
913951-43-6P, (S)-4-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-[4-(isopropylcarbamoyl)piperazin-1-yl]-5-oxopentanoic acid 913951-44-7P, (S)-4-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxo-5-[4-(thien-2-yl)carbonyl]piperazin-1-yl]pentanoic acid 913951-45-8P,
 (S)-5-[4-(Cyclopentylcarbonyl)piperazin-1-yl]-4-[[6-cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxopentanoic acid
913951-46-9P, (S)-4-[[6-Cyclopentyloxy-2-phenylpyrimidin-4-yl]carbonyl]amino]-5-oxo-5-[4-(piperidin-1-yl)carbonyl]piperazin-1-yl]pentanoic acid 913952-00-8P,
 4-[(S)-4-Carboxy-2-[[6-(1-oxopyridin-2-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-01-9P, 4-[(S)-4-Carboxy-2-[[6-(1-oxopyridin-4-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-02-0P,
 4-[(S)-4-Carboxy-2-[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-06-4P 913952-07-5P 913952-08-6P
913952-09-7P, 4-[(S)-4-Carboxy-2-[[6-(1-carboxymethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-10-0P,
 4-[(S)-4-Carboxy-2-[[6-(2-hydroxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-11-1P, 4-[(S)-4-Carboxy-2-[[6-(2-carboxyethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-12-2P,
 4-[(S)-4-Carboxy-2-[[6-(3-hydroxypropyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-13-3P 913952-14-4P 913952-15-5P
913952-16-6P, 4-[(S)-4-Carboxy-2-[[6-(4-hydroxypiperidin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-17-7P,
 4-[(S)-4-Carboxy-2-[[6-(piperazin-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913952-18-8P 913952-19-9P,
 4-[(S)-4-Carboxy-2-[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid

ethyl ester 913952-20-2F,
 4-[(S)-4-Carboxy-2-[[[6-(4,5-dihydropyrazol-1-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
913953-38-5P 913967-10-9P 913967-12-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid
 piperazides and their use as P2Y12 receptor antagonists)

RN 913950-52-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclobutylcarbonyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-,
 (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-53-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclopentylcarbonyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-,
 (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-54-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-[(1-oxopentyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γ S)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-55-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3-methyl-1-oxobutyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-56-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[(cyclopropylcarbonyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-57-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(acetylamino)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-58-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-(1-oxobutyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-59-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(2-methyl-1-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-60-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[6-[(1-oxopropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-61-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(propylsulfonyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-62-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(ethylsulfonyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-63-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(phenylsulfonyl)amino]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-64-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[[[1-(4-phenyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)]]]]


Absolute stereochemistry.



RN 913950-65-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-[[[1-(4-phenyl-2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)]]]]


Absolute stereochemistry.



RN 913950-66-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[[1-(2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)]]]]


Absolute stereochemistry.



RN 913950-67-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxy-1-methylpropyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-68-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxypropyl)thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-69-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[methyl(phenylmethyl)amino]methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-70-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[4-(ethoxycarbonyl)-1-piperidinyl]methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-71-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-72-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[4-(methoxycarbonyl)-1-piperidinyl]methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-73-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(3-hydroxy-1-piperidinyl)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-74-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[2-(hydroxymethyl)-1-piperidinyl]methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-75-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-morpholinylmethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-76-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[[[(3R)-3-hydroxy-1-pyrrolidinylmethyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-77-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1-piperidinylmethyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-78-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[[[(2,6-dimethyl-4-morpholinyl)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-79-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(ethylmethylamino)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-80-8 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-[(diethylamino)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-81-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1-pyrrolidinylmethyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-82-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(ethylsulfonyl)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-83-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(phenylthio)methyl]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-84-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[(phenylsulfonyl)methyl]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-85-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclopentylthio)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-86-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(cyclopentylsulfonyl)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-87-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(3-thienyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-88-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-89-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[4-(methylsulfonyl)phenyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-90-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(4-acetylphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-91-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-fluorophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-92-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3-cyanophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-93-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-fluorophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-94-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-methoxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-95-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-furanyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-96-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(1,3-benzodioxol-5-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-97-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(3-methoxyphenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-98-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(4-(hydroxymethyl)phenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913950-99-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(2-thienyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-00-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4-cyanophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-01-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(3-chlorophenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-02-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-([1,1'-biphenyl]-4-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-03-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(1H-pyrazol-4-yl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-04-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(1E)-2-phenylethenyl]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 913951-05-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-06-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(3-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-07-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(4-pyridinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-08-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(2-thiazolyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-09-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(1-hydroxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-10-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-acetylmethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-11-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-methoxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-12-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-ethoxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-13-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-hydroxy-1-methylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-14-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-hydroxy-1-methylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, ethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-15-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-16-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxyethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-17-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxycyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

(γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-18-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxycyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-19-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxycyclopentyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-20-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-hydroxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-

(γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-21-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-22-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-(3,6-dihydro-2H-pyran-4-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-23-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(tetrahydro-2H-pyran-4-yl)-4-pyrimidinyl]carbonyl]amino]-,

(γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-24-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-(ethoxycarbonyl)cyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-25-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-oxido-3-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-26-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1E)-3-ethoxy-3-oxo-1-propen-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)-

(γS)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 913951-27-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-[(tetrahydro-2-furanyl)methyl]-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-28-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(1E)-4-hydroxy-1-buten-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 913951-29-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(3-hydroxy-2-methylpropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-30-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(tetrahydro-3-furanyl)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913951-31-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(1E)-3-(dimethylamino)-3-oxo-1-propen-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 913951-32-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-cyano-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-33-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-hydroxypropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-34-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-hydroxybutyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-35-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(hydroxyphenylmethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-36-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxy-2-phenylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-37-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(ethoxymethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-38-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]carbonyl]amino]-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-39-0 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(1,1-dimethylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913951-40-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-phenoxy-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-41-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(3-pyridinyloxy)-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-42-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[[[1,1-dimethylethyl]amino]carbonyl]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-43-6 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-[[[1-methylethyl]amino]carbonyl]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-44-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(2-thienylcarbonyl)-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-45-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(cyclopentylcarbonyl)- γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913951-46-9 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-4-(1-piperidinylcarbonyl)-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-00-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-oxido-2-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-01-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(1-oxido-4-pyridinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-02-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-hydroxy-1,1-dimethylethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-06-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[2-(hydroxymethyl)cyclopropyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-07-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[2-(hydroxymethyl)cyclopropyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-08-6 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-amino-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-09-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(carboxymethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913952-10-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-hydroxyethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-11-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(2-carboxyethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-12-2 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(3-hydroxypropyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-13-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-14-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]carbonyl]amino]-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-15-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[(2,3-dihydro-1H-inden-1-yl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-16-6 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(4-hydroxy-1-piperidinyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-17-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(1-piperazinyl)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-18-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-hydroxy-1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-19-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(2-methoxy-1,1-dimethylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-20-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-1H-pyrazol-1-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913953-38-5 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(1E)-3-hydroxy-1-buten-1-yl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 913967-10-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(trans-4-hydroxycyclohexyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913967-12-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(trans-4-hydroxycyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



- IT 73955-54-1P, 6-Methyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 85815-04-9P, 6-Methoxy-2-phenylpyrimidine-4-carboxylic acid 858269-17-7P, 6-Methyl-2-phenylpyrimidine-4-carboxylic acid 913952-21-3P, 4-Cyclopentyl-2-phenylpyrimidine-4-carboxylic acid 913952-22-4P, (6-Cyclopentyl-2-phenylpyrimidin-4-yl)methanol 913952-23-5P, 6-Cyclopentyl-2-phenylpyrimidine-4-carboxaldehyde 913952-24-6P, 6-Cyclopentyl-2-phenylpyrimidine-4-carboxylic acid 913952-38-2P 913952-41-7P, 4-[(S)-2-[(Benzyloxycarbonyl)amino]-2-[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]hexanoyl]piperazine-1-carboxylic acid ethyl ester 913952-44-0P 913952-45-1P 913952-46-2P, 4-[(S)-4-Cyano-2-[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-49-5P 913952-54-2P 913952-55-3P 913952-56-4P, [(6-Methyl-2-phenylpyrimidin-4-yl)oxy]acetic acid methyl ester 913952-57-5P, 6-[(Methoxycarbonyl)methoxy]-2-phenylpyrimidine-4-carboxylic acid 913952-58-6P, 4-[(S)-4-tert-Butoxycarbonyl-2-[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-59-7P, 6-Chloro-2-phenylpyrimidine-4-carboxylic acid 913952-60-0P, 2-Phenyl-6-propoxypyrimidine-4-carboxylic acid 913952-61-1P, 6-(2-Hydroxyethoxy)-2-phenylpyrimidine-4-carboxylic acid 913952-62-2P, 6-Benzoyloxy-2-phenylpyrimidine-4-carboxylic acid 913952-63-3P, 6-Cyclopropylmethoxy-2-phenylpyrimidine-4-carboxylic acid 913952-64-4P, 6-Cyclohexyloxy-2-phenylpyrimidine-4-carboxylic acid 913952-65-5P, 6-Isopropoxy-2-phenylpyrimidine-4-carboxylic acid 913952-69-9P, 4-[3-(3-Benzoyloxyphenyl)-2-[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]propionyl]piperazine-1-carboxylic acid ethyl ester 913952-70-2P, 4-[2-[(6-Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-(3-hydroxyphenyl)propionyl]piperazine-1-carboxylic acid ethyl ester 913952-75-7P 913952-76-8P, 4-[2-[(6-Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-3-(2-hydroxyphenyl)propionyl]piperazine-1-carboxylic acid ethyl ester 913952-79-1P, 4-[(S)-2-(4-Benzoyloxyphenyl)-2-[(6-cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]ethanoyl]piperazine-1-carboxylic acid ethyl ester 913952-80-4P, 4-[(S)-2-[(6-Cyclopentyl-2-phenylpyrimidin-4-yl)carbonyl]amino]-2-(4-hydroxyphenyl)ethanoyl]piperazine-1-carboxylic acid ethyl ester 913952-81-5P 913952-82-6P 913952-83-7P 913952-88-2P, 4-[(S)-4-tert-Butoxycarbonyl-2-[(6-chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913952-90-6P, 4-[2-[(6-Chloro-2-phenylpyrimidin-4-yl)carbonyl]amino]acetyl]piperazine-1-


carboxylic acid ethyl ester 913952-91-7P,
 4-[(S)-2-[[[6-Chloro-2-phenylpyrimidin-4-yl]carbonyl]amino]-3-methylbutanoyl]piperazine-1-carboxylic acid ethyl ester
913952-92-8P 913952-93-9P,
 4-[(S)-5-tert-Butoxycarbonyl-2-[[[6-chloro-2-phenylpyrimidin-4-yl]carbonyl]amino]pentanoyl]piperazine-1-carboxylic acid ethyl ester
913952-94-0P 913952-95-1P 913952-96-2P
913952-97-3P 913952-98-4P 913952-99-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-00-1P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(1,4-dioxaspiro[4.5]decan-8-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-01-2P,
 4-[(S)-4-Carboxy-2-[[[6-chloro-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-02-3P,
 4-[(S)-2-[[[6-Azido-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester 913953-03-4P 913953-04-5P
913953-05-6P 913953-06-7P,
 6-Formyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-07-8P,
 6-Hydroxymethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-08-9P,
 6-Chloromethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-09-0P,
 6-Chloromethyl-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-10-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-chloromethyl-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-11-4P 913953-12-5P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[2-phenyl-6-vinylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-14-7P 913953-15-8P 913953-16-9P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-oxopropyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-17-0P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(2-ethoxycarbonylcyclohex-1-enyl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-18-1P 913953-19-2P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-(4,5-dihydrofuran-3-yl)-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913953-20-5P,
 6-(1-Hydroxypropyl)-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-21-6P,
 6-(1-Hydroxypropyl)-2-phenylpyrimidine-4-carboxylic acid 913953-22-7P,
 6-(1-Hydroxybutyl)-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-23-8P,
 6-(1-Hydroxybutyl)-2-phenylpyrimidine-4-carboxylic acid 913953-24-9P,
 6-[(Hydroxy)(phenyl)methyl]-2-phenylpyrimidine-4-carboxylic acid methyl ester 913953-25-0P,
 6-[(Hydroxy)(phenyl)methyl]-2-phenylpyrimidine-4-carboxylic acid 913953-26-1P,
 6-(2-Hydroxy-2-phenylethyl)-2-phenylpyrimidine-4-carboxylic acid 913953-27-2P,
 2-Phenyl-6-trifluoromethylpyrimidine-4-carboxylic acid 913953-31-8P,
 6-tert-Butyl-2-phenylpyrimidine-4-carboxylic acid 913953-35-2P,
 6-[2-[(tert-Butyldimethylsilyl)oxy]-1,1-dimethylethyl]-2-phenylpyrimidine-4-carboxylic acid 913953-36-3P,
 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[2-[(tert-butyldimethylsilyl)oxy]-1,1-dimethylethyl]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-(4-pyrimidinylcarbonyl) amino acid

piperazides and their use as P2Y12 receptor antagonists)


RN 73955-54-1 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-methyl-2-phenyl-, methyl ester (CA INDEX NAME)




RN 85815-04-9 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-methoxy-2-phenyl- (CA INDEX NAME)




RN 858269-17-7 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-methyl-2-phenyl- (CA INDEX NAME)




RN 913952-21-3 HCAPLUS

CN Pyrimidine, 4-(cyclopentyloxy)-6-(methoxymethyl)-2-phenyl- (CA INDEX NAME)




RN 913952-22-4 HCAPLUS

CN 4-Pyrimidinemethanol, 6-(cyclopentyloxy)-2-phenyl- (CA INDEX NAME)




RN 913952-23-5 HCAPLUS

CN 4-Pyrimidinecarboxaldehyde, 6-(cyclopentyloxy)-2-phenyl- (CA INDEX NAME)



RN 913952-24-6 HCAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-(cyclopentyloxy)-2-phenyl- (CA INDEX NAME)



RN 913952-38-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-[[[1,1-dimethylethoxy]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-41-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-6-[[[phenylmethoxy]carbonyl]amino]hexyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-44-0 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-(phenylmethoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-45-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-cyano-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-46-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-4-cyano-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-49-5 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-(4-cyanophenyl)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-54-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-55-3 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-(4-hydroxyphenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913952-56-4 HCAPLUS

CN Acetic acid, 2-[(6-methyl-2-phenyl-4-pyrimidinyl)oxy]-, methyl ester (CA INDEX NAME)



RN 913952-57-5 HCAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-(2-methoxy-2-oxoethoxy)-2-phenyl- (CA INDEX NAME)



RN 913952-58-6 HCAPLUS


CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(2-methoxy-2-oxoethoxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913952-59-7 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-chloro-2-phenyl- (CA INDEX NAME)




RN 913952-60-0 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-phenyl-6-propoxy- (CA INDEX NAME)




RN 913952-61-1 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(2-hydroxyethoxy)-2-phenyl- (CA INDEX NAME)




RN 913952-62-2 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)




RN 913952-63-3 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(cyclopropylmethoxy)-2-phenyl- (CA INDEX NAME)




RN 913952-64-4 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(cyclohexyloxy)-2-phenyl- (CA INDEX NAME)




RN 913952-65-5 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(1-methylethoxy)-2-phenyl- (CA INDEX NAME)




RN 913952-69-9 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-[3-(phenylmethoxy)phenyl]propyl]-, ethyl ester (CA INDEX NAME)




RN 913952-70-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-(3-hydroxyphenyl)-1-oxopropyl]-, ethyl ester
(CA INDEX NAME)




RN 913952-75-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-[2-(phenylmethoxy)phenyl]propyl]-, ethyl ester (CA INDEX NAME)



RN 913952-76-8 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-3-(2-hydroxyphenyl)-1-oxopropyl]-, ethyl ester
(CA INDEX NAME)



RN 913952-79-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino][4-(phenylmethoxy)phenyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-80-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino][4-(hydroxyphenyl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-81-5 HCAPLUS

CN L-Glutamic acid, N-[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]-, 5-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-82-6 HCAPLUS

CN L-Glutamic acid, N-[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]-, 5-(1,1-dimethylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-83-7 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(cyclopentyloxy)-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-88-2 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-chloro-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913952-90-6 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[(6-chloro-2-phenyl-4-pyrimidinyl)carbonyl]amino]acetyl-, ethyl ester (CA INDEX NAME)



RN 913952-91-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[(6-chloro-2-phenyl-4-pyrimidinyl)carbonyl]amino]-3-methyl-1-oxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-92-8 HCAPLUS

CN Benzoic acid, 4-[(2S)-2-[(6-chloro-2-phenyl-4-pyrimidinyl)carbonyl]amino]-3-[4-(ethoxycarbonyl)-1-piperazinyl]-3-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-93-9 HCAPLUS

CN 1-Piperazinehexanoic acid, 8-[[[(6-chloro-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)-6-oxo-, 1,1-dimethylethyl ester, (8S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-94-0 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-4-amino-2-[[[(6-chloro-2-phenyl-4-pyrimidinyl)carbonyl]amino]-1,4-dioxobutyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913952-95-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-cyano-1-oxo-2-[[[2-phenyl-6-(phenylmethyl)amino]-4-pyrimidinyl]carbonyl]amino]propyl]-, ethyl ester

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-96-2 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-chloro-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-97-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[6-[(1-methylethyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-98-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-[2-(trimethylsilyl)ethynyl]-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913952-99-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-00-1 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(1,4-dioxaspiro[4.5]dec-8-yl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-01-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-chloro-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-02-3 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-azido-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-03-4 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methylpropyl]thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-04-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methylpropyl]thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-05-6 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]thio]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913953-06-7 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-formyl-2-phenyl-, methyl ester (CA INDEX NAME)




RN 913953-07-8 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(hydroxymethyl)-2-phenyl-, methyl ester
(CA INDEX NAME)




RN 913953-08-9 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(chloromethyl)-2-phenyl-, methyl ester (CA
INDEX NAME)



RN 913953-09-0 HCAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-(chloromethyl)-2-phenyl- (CA INDEX NAME)



RN 913953-10-3 HCAPLUS

CN 1-Piperazinepentanoic acid, gamma-[[[6-(chloromethyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-delta-oxo-,
1,1-dimethylethyl ester, (gammaS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-11-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-(1-ethoxyethenyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-12-5 HCAPLUS

CN 1-Piperazinepentanoic acid, γ-[[[6-ethenyl-2-phenyl-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-14-7 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-(2-oxocyclohexyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-15-8 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-(2-oxocyclopentyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-16-9 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[6-(2-oxopropyl)-2-phenyl-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-17-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-(ethoxycarbonyl)-1-cyclohexen-1-yl]-2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913953-18-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-(2-methyl-3-oxopropyl)-2-phenyl-4-pyrimidinyl)carbonyl]amino]- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 913953-19-2 HCAPLUS

CN 1-Piperazinepentanoic acid, γ -[[[6-(4,5-dihydro-3-furanyl)-2-phenyl-4-pyrimidinyl)carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 913953-20-5 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(1-hydroxypropyl)-2-phenyl-, methyl ester
(CA INDEX NAME)

RN 913953-21-6 HCAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-(1-hydroxypropyl)-2-phenyl- (CA INDEX
NAME)

RN 913953-22-7 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(1-hydroxybutyl)-2-phenyl-, methyl ester
(CA INDEX NAME)


RN 913953-23-8 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(1-hydroxybutyl)-2-phenyl- (CA INDEX NAME)




RN 913953-24-9 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(hydroxyphenylmethyl)-2-phenyl-, methyl ester (CA INDEX NAME)




RN 913953-25-0 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(hydroxyphenylmethyl)-2-phenyl- (CA INDEX NAME)




RN 913953-26-1 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(2-hydroxy-2-phenylethyl)-2-phenyl- (CA INDEX NAME)




RN 913953-27-2 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 913953-31-8 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-(1,1-dimethylethyl)-2-phenyl- (CA INDEX NAME)



RN 913953-35-2 HCAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenyl]- (CA INDEX NAME)



RN 913953-36-3 HCAPLUS


CN 1-Piperazinepentanoic acid, γ -[[[6-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,1-dimethylethyl]-2-phenyl]-4-pyrimidinyl]carbonyl]amino]-4-(ethoxycarbonyl)- δ -oxo-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 913953-13-6, 4-[(S)-2-[[6-Phenylsulfonyl-2-phenylpyrimidin-4-yl]carbonyl]amino]-4-tert-butoxycarbonylbutanoyl]piperazine-1-carboxylic acid ethyl ester
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)
 RN 913953-13-6 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- δ -oxo- γ -[[[2-phenyl-6-(phenylsulfonyl)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1160050-66-7F
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)
 RN 1160050-66-7 HCAPLUS
 CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)- γ -[[[6-[(ethylthio)methyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]- δ -oxo-, (γ S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 5 OF 50 HCAPLUS COPYRIGHT 2009 ACS ON STN DUPLICATE 5
 ACCESSION NUMBER: 2006:977650 HCAPLUS Full-text
 DOCUMENT NUMBER: 145:336070
 TITLE: Preparation of 2-phenyl-5-pyrimidinecarboxylic acids
 as cardiovascular agents
 INVENTOR(S): Woltering, Elisabeth; Tuch, Arounarith;
 Dittrich-Wengenroth, Elke; Kretschmer, Axel;
 Baerfacker, Lars; Bauser, Marcus; Ellinghaus, Peter;
 Lustig, Klemens; Pook, Elisabeth; Weber, Olaf
 PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
 SOURCE: PCT Int. Appl., 100pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006097220	A1	20060921	WO 2006-EP2054	20060307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DE 102005027150 A1 20060928 DE 2005-102005027150 20050611 <-- AU 2006224812 A1 20060921 AU 2006-224812 20060307 <-- CA 2600681 A1 20060921 CA 2006-2600681 20060307 <-- EP 1866289 A1 20071219 EP 2006-707442 20060307 <-- R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2008533063 T 20080821 JP 2008-501193 20060307 <-- IN 2007DN06929 A 20070928 IN 2007-DN6929 20070907 <-- MX 2007011070 A 20071107 MX 2007-11070 20070910 <-- KR 2007116876 A 20071211 KR 2007-723311 20071011 <-- CN 101175731 A 20080507 CN 2006-80016168 20071112 <-- US 20080194598 A1 20080814 US 2008-886289 20080310 <-- DE 2005-102005011447A 20050312 <-- DE 2005-102005027150A 20050611 <-- WO 2006-EP2054 W 20060307 <-- OTHER SOURCE(S): CASREACT 145:336070; MARPAT 145:336070 ED Entered STN: 21 Sep 2006 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = CH₂, O; R₁ = halo, CN, alkyl; R₂ = (R₂')_n; R₂' = alkyl, alkoxy, etc.; n = 0-3; R₃ = H, F, Cl; R₄ = H, halo, NO₂, etc.; R₅, R₆ = H, halo, NO₂, etc.; Z = H, alkyl] and their pharmaceutically acceptable salts and formulations were prepared For example, O-arylation of 2-chlorophenol with

chloropyrimidine II afforded claimed phenylpyrimidine III in 99% yield.
 Comps. I are claimed to be useful as cardiovascular agents.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 910053-02-0P, 4-(2-Chlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester 910053-03-1P, 4-(2-Chlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-04-2P, 4-(2-Fluorophenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-05-3P, 4-(2-Methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-06-4P, 4-(2-Bromophenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-07-5P, 4-(2-Chloro-4-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-08-6P, 4-(2-Chloro-4-methoxyphenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-09-7P, 4-(2,5-Dichlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-10-0P, 4-(2,5-Dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester 910053-11-1P, 4-(2,5-Dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-12-2P, 4-(2-Chlorophenoxy)-2-(3-fluorophenyl)pyrimidine-5-carboxylic acid 910053-13-3P, 4-(2-Chlorophenoxy)-2-(4-methylphenyl)pyrimidine-5-carboxylic acid 910053-14-4P, 4-(2-Chlorophenoxy)-2-(4-fluorophenyl)pyrimidine-5-carboxylic acid 910053-15-5P, 4-(2-Chlorophenoxy)-2-(4-methoxyphenyl)pyrimidine-5-carboxylic acid 910053-16-6P, 4-[2-Chloro-5-(trifluoromethyl)phenoxy]-2-phenylpyrimidine-5-carboxylic acid ethyl ester 910053-17-7P, 4-(5-Chloro-2-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester 910053-18-8P, 4-(2-Chlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic acid ethyl ester 910053-19-9P, 4-(2-Chlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic acid 910053-20-2P, 4-(2,5-Dichlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic acid ethyl ester 910053-21-3P, 4-(2,5-Dichlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic acid 910053-22-4P, 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2-chlorophenoxy)pyrimidine-5-carboxylic acid ethyl ester 910053-23-5P, 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2-chlorophenoxy)pyrimidine-5-carboxylic acid 910053-24-6P, 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylic acid ethyl ester 910053-25-7P, 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2,5-dichlorophenoxy)pyrimidine-5-carboxylic acid 910053-26-8P, 4-[2-Chloro-5-(trifluoromethyl)phenoxy]-2-phenylpyrimidine-5-carboxylic acid 910053-27-9P, 4-(5-Chloro-2-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-28-0P, 4-(2-Chlorophenoxy)-2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrimidine-5-carboxylic acid ethyl ester 910053-29-1P, 4-(2-Chlorophenoxy)-2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrimidine-5-carboxylic acid 910053-30-4P, 2-(4-Chloro-3-methylphenyl)-4-(2-chlorophenoxy)pyrimidine-5-carboxylic acid ethyl ester 910053-31-5P, 2-(4-Chloro-3-methylphenyl)-4-(2-chlorophenoxy)pyrimidine-5-carboxylic acid 910053-32-6P, 4-(2-Chlorophenoxy)-2-(3,4-dimethylphenyl)pyrimidine-5-carboxylic acid ethyl ester 910053-33-7P, 4-(2-Chlorophenoxy)-2-(3,4-dimethylphenyl)pyrimidine-5-carboxylic acid 910053-34-8P, 4-(2-Chlorophenoxy)-2-(2-fluorophenyl)pyrimidine-5-carboxylic acid 910053-35-9P, 4-(2,4-Dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid 910053-36-0P,

4-(2,4-Dichloro-3,5-dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-37-1P, 4-(2,3-Dichlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-38-2P, 4-(2,5-Fluorophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-39-3P, 4-(2-Cyanophenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-40-6P, 4-(2-Cyanophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-41-7P, 4-(5-Cyano-2-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-42-8P, 4-(5-Cyano-2-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-43-9P, 4-(2-Chlorophenoxy)-2-(4-methyl-3-nitrophenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-44-0P, 4-(2-Chlorophenoxy)-2-(4-methyl-3-nitrophenyl)pyrimidine-5-carboxylic acid
910053-45-1P, 4-(2-Chlorophenoxy)-2-(4-fluoro-3-methoxyphenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-46-2P, 4-(2-Chlorophenoxy)-2-(4-fluoro-3-methoxyphenyl)pyrimidine-5-carboxylic acid
910053-47-3P, 4-(2-Chlorophenoxy)-2-(3,4,5-trifluorophenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-48-4P, 4-(2-Chlorophenoxy)-2-(3,4,5-trifluorophenyl)pyrimidine-5-carboxylic acid
910053-49-5P, 4-(2-Chlorophenoxy)-2-(3,4-difluorophenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-50-8P, 4-(2-Chlorophenoxy)-2-(3,4-difluorophenyl)pyrimidine-5-carboxylic acid
910053-51-9P, 4-(2-Chlorobenzyl)-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-52-0P, 4-(2-Chlorobenzyl)-2-phenylpyrimidine-5-carboxylic acid
 RL: FAN (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


IT (Preparation of phenylpyrimidinecarboxylic acids as cardiovascular agents)
910053-02-0P, 4-(2-Chlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-03-1P, 4-(2-Chlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-04-2P, 4-(2-Fluorophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-05-3P, 4-(2-Methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-06-4P, 4-(2-Bromophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-07-5P, 4-(2-Chloro-4-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-08-6P, 4-(2-Chloro-4-methoxyphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-09-7P, 4-(2,5-Dichlorophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-10-0P, 4-(2,5-Dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-11-1P, 4-(2,5-Dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-12-2P, 4-(2-Chlorophenoxy)-2-(3-fluorophenyl)pyrimidine-5-carboxylic acid
910053-13-3P, 4-(2-Chlorophenoxy)-2-(4-methylphenyl)pyrimidine-5-carboxylic acid
910053-14-4P, 4-(2-Chlorophenoxy)-2-(4-fluorophenyl)pyrimidine-5-carboxylic acid
910053-15-5P, 4-(2-Chlorophenoxy)-2-(4-methoxyphenyl)pyrimidine-5-carboxylic acid
910053-16-6P, 4-[2-Chloro-5-(trifluoromethyl)phenoxy]-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-17-7P, 4-(5-Chloro-2-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid ethyl ester
910053-18-8P, 4-(2-Chlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-19-9P, 4-(2-Chlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic acid
910053-20-2P, 4-(2,5-Dichlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic

acid ethyl ester 910053-21-3P,
 4-(2,5-Dichlorophenoxy)-2-(3-fluoro-4-methylphenyl)pyrimidine-5-carboxylic
 acid 910053-22-4P, 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2-
 chlorophenoxy)pyrimidine-5-carboxylic acid ethyl ester
910053-23-5P, 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2-
 chlorophenoxy)pyrimidine-5-carboxylic acid 910053-24-6P,
 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2,5-dichlorophenoxy)pyrimidine-5-
 carboxylic acid ethyl ester 910053-25-7P,
 2-[3,5-Di(trifluoromethyl)phenyl]-4-(2,5-dichlorophenoxy)pyrimidine-5-
 carboxylic acid 910053-26-8P,
 4-[2-Chloro-5-(trifluoromethyl)phenoxy]-2-phenylpyrimidine-5-carboxylic
 acid 910053-27-9P, 4-(5-Chloro-2-methylphenoxy)-2-
 phenylpyrimidine-5-carboxylic acid 910053-28-0P,
 4-(2-Chlorophenoxy)-2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrimidine-5-
 carboxylic acid ethyl ester 910053-29-1P,
 4-(2-Chlorophenoxy)-2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrimidine-5-
 carboxylic acid 910053-30-4P,
 2-(4-Chloro-3-methylphenyl)-4-(2-chlorophenoxy)pyrimidine-5-carboxylic
 acid ethyl ester 910053-31-5P,
 2-(4-Chloro-3-methylphenyl)-4-(2-chlorophenoxy)pyrimidine-5-carboxylic
 acid 910053-32-6P, 4-(2-Chlorophenoxy)-2-(3,4-
 dimethylphenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-33-7P, 4-(2-Chlorophenoxy)-2-(3,4-dimethylphenyl)pyrimidine-
 5-carboxylic acid 910053-34-8P,
 4-(2-Chlorophenoxy)-2-(2-fluorophenyl)pyrimidine-5-carboxylic acid
910053-35-9P, 4-(2,4-Dimethylphenoxy)-2-phenylpyrimidine-5-
 carboxylic acid 910053-36-0P,
 4-(2,4-Dichloro-3,5-dimethylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-37-1P, 4-(2,3-Dichlorophenoxy)-2-phenylpyrimidine-5-
 carboxylic acid 910053-38-2P,
 4-(2,5-Fluorophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-39-3P, 4-(2-Cyanophenoxy)-2-phenylpyrimidine-5-carboxylic
 acid ethyl ester 910053-40-6P,
 4-(2-Cyanophenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-41-7P, 4-(5-Cyano-2-methylphenoxy)-2-phenylpyrimidine-5-
 carboxylic acid ethyl ester 910053-42-8P,
 4-(5-Cyano-2-methylphenoxy)-2-phenylpyrimidine-5-carboxylic acid
910053-43-9P, 4-(2-Chlorophenoxy)-2-(4-methyl-3-
 nitrophenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-44-0P, 4-(2-Chlorophenoxy)-2-(4-methyl-3-
 nitrophenyl)pyrimidine-5-carboxylic acid 910053-45-1P,
 4-(2-Chlorophenoxy)-2-(4-fluoro-3-methoxyphenyl)pyrimidine-5-carboxylic
 acid ethyl ester 910053-46-2P,
 4-(2-Chlorophenoxy)-2-(4-fluoro-3-methoxyphenyl)pyrimidine-5-carboxylic
 acid 910053-47-3P, 4-(2-Chlorophenoxy)-2-(3,4,5-
 trifluorophenyl)pyrimidine-5-carboxylic acid ethyl ester
910053-48-4P, 4-(2-Chlorophenoxy)-2-(3,4,5-
 trifluorophenyl)pyrimidine-5-carboxylic acid 910053-49-5P,
 4-(2-Chlorophenoxy)-2-(3,4-difluorophenyl)pyrimidine-5-carboxylic acid
 ethyl ester 910053-50-8P,
 4-(2-Chlorophenoxy)-2-(3,4-difluorophenyl)pyrimidine-5-carboxylic acid
910053-51-9P, 4-(2-Chlorobenzyl)-2-phenylpyrimidine-5-carboxylic
 acid ethyl ester 910053-52-0P,
 4-(2-Chlorobenzyl)-2-phenylpyrimidine-5-carboxylic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of phenylpyrimidinecarboxylic acids as cardiovascular agents)

RN 910053-02-0 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-phenyl-, ethyl ester

(CA INDEX NAME)




RN 910053-03-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-04-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-fluorophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-05-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-methylphenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-06-4 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-07-5 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-methylphenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-08-6 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-methoxyphenoxy)-2-phenyl- (CA INDEX NAME)



RN 910053-09-7 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(2,5-dichlorophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-10-0 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(2,5-dimethylphenoxy)-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 910053-11-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,5-dimethylphenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-12-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 910053-13-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 910053-14-4 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 910053-15-5 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 910053-16-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-chloro-5-(trifluoromethyl)phenoxy]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 910053-17-7 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(5-chloro-2-methylphenoxy)-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 910053-18-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3-fluoro-4-methylphenyl)-, ethyl ester (CA INDEX NAME)




RN 910053-19-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 910053-20-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,5-dichlorophenoxy)-2-(3-fluoro-4-methylphenyl)-, ethyl ester (CA INDEX NAME)




RN 910053-21-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,5-dichlorophenoxy)-2-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)




RN 910053-22-4 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[3,5-bis(trifluoromethyl)phenyl]-4-(2-chlorophenoxy)-, ethyl ester (CA INDEX NAME)




RN 910053-23-5 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[3,5-bis(trifluoromethyl)phenyl]-4-(2-chlorophenoxy)- (CA INDEX NAME)




RN 910053-24-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[3,5-bis(trifluoromethyl)phenyl]-4-(2,5-dichlorophenoxy)-, ethyl ester (CA INDEX NAME)




RN 910053-25-7 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[3,5-bis(trifluoromethyl)phenyl]-4-(2,5-dichlorophenoxy)- (CA INDEX NAME)




RN 910053-26-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-chloro-5-(trifluoromethyl)phenoxy]-2-phenyl- (CA INDEX NAME)



RN 910053-27-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(5-chloro-2-methylphenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-28-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-[3-fluoro-4-(2-chlorophenoxy)phenyl]-


10/595,734

(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 910053-29-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-[3-fluoro-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 910053-30-4 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-chloro-3-methylphenyl)-4-(2-chlorophenoxy)-, ethyl ester (CA INDEX NAME)




RN 910053-31-5 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-chloro-3-methylphenyl)-4-(2-chlorophenoxy)- (CA INDEX NAME)




RN 910053-32-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3,4-dimethylphenyl)-, ethyl ester (CA INDEX NAME)




RN 910053-33-7 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3,4-dimethylphenyl)-
(CA INDEX NAME)




RN 910053-34-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(2-fluorophenyl)-
(CA INDEX NAME)




RN 910053-35-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dimethylphenoxy)-2-phenyl-
(CA INDEX NAME)




RN 910053-36-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichloro-3,5-dimethylphenoxy)-2-phenyl-
(CA INDEX NAME)




RN 910053-37-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,3-dichlorophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-38-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,5-difluorophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-39-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-cyanophenoxy)-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 910053-40-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-cyanophenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-41-7 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(5-cyano-2-methylphenoxy)-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 910053-42-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(5-cyano-2-methylphenoxy)-2-phenyl- (CA INDEX NAME)




RN 910053-43-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-methyl-3-nitrophenyl)-, ethyl ester (CA INDEX NAME)




RN 910053-44-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-methyl-3-nitrophenyl)- (CA INDEX NAME)




RN 910053-45-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-fluoro-3-methoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 910053-46-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(4-fluoro-3-methoxyphenyl)- (CA INDEX NAME)




RN 910053-47-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3,4,5-trifluorophenyl)-, ethyl ester (CA INDEX NAME)




RN 910053-48-4 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3,4,5-trifluorophenyl)- (CA INDEX NAME)




RN 910053-49-5 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3,4-difluorophenyl)-ethyl ester (CA INDEX NAME)




RN 910053-50-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenoxy)-2-(3,4-difluorophenyl)-(CA INDEX NAME)




RN 910053-51-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(2-chlorophenyl)methyl]-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 910053-52-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(2-chlorophenyl)methyl]-2-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 6 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2006:232088 HCAPLUS Full-text
DOCUMENT NUMBER: 144:312100
TITLE: Preparation of substituted pyridines and pyrimidines
as vanilloid receptor ligands
INVENTOR(S): Norman, Mark H.; Pettus, Liping H.; Wang, Xianghong;
Zhu, Jiawang
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 96 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060058308	A1	20060316	US 2005-226844	20050913 <--
US 7335672	B2	20080226		
AU 2005284904	A1	20060323	AU 2005-284904	20050913 <--
CA 2579143	A1	20060323	CA 2005-2579143	20050913 <--
WO 2006031852	A1	20060323	WO 2005-US32660	20050913 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1789413	A1	20070530	EP 2005-796132	20050913 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			


PRIORITY APPLN. INFO.: US 2004-609718P P 20040913 <--
WO 2005-US32660 W 20050913 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:312100; MARPAT 144:312100

ED Entered STN: 16 Mar 2006

GI



II

AB Title compds. I [J = NH, O or S; X = N or CR₂; Y = N or CR₂, wherein at least one of X and Y = N; R¹ = (un)saturated or partially saturated 5-7 membered monocyclic or 6-11 membered bicyclic ring containing 0-4 heteroatoms, wherein the available carbon atoms are substituted by 0-2 oxo or thioxo groups, the ring may contain addnl. substituents; R² = halo, (un)substituted alkyl, benzyl, etc.; R³ = CN, alkoxy, (un)substituted alkyl, etc.; R⁴ = 6-11 membered bicyclic ring containing 0-4 atoms selected from N, O and S, wherein the available carbon atoms are substituted by 0-2 oxo or thioxo groups, the ring may contain addnl. substituents], and their pharmaceutically acceptable salts, are prepared and disclosed as vanilloid receptor ligands. Thus, e.g., II was prepared by coupling of 4-tert-butylphenylboronic acid with 2,4,6-trichloropyrimidine followed by subsequent substitutions with 1,4-benzodioxane-6-amine and 4-methylpiperazine. Selected compds. of the invention exhibited IC₅₀ values of less than 10 nM in the human VR1 capsaicin antagonist assay. I should prove useful in treating pain and inflammatory conditions.

INCL 514249000; 514256000; 544295000; 544323000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT	879596-23-3P	879596-30-2P	879596-36-8P	879596-43-7P	879596-49-3P
	879596-55-1P	879596-63-1P	879596-71-1P	879596-78-8P	879596-84-6P
	879596-90-4P	879596-97-1P	879596-98-2P	879597-05-4P	879597-06-5P
	879597-13-4P	879597-20-3P	879597-27-0P	879597-35-0P	879597-42-9P
	879597-49-6P	879597-57-6P	879597-63-4P	879597-69-0P	879597-77-0P
	879597-84-9P	879597-96-3P	879597-97-4P	879598-14-8P	879598-15-9P
	879598-22-8P	879598-23-9P	879598-30-8P	879598-36-4P	879598-43-3P
	879598-58-0P	879598-59-1P	879598-66-0P	879598-67-1P	879598-73-9P
	879598-79-5P	879598-86-4P	879598-94-4P	879599-00-5P	879599-07-2P
	879599-14-1P	879599-22-1P	879599-29-8P	879599-35-6P	879599-43-6P
	879599-50-5P	879599-56-1P	879599-63-0P	879599-68-5P	879599-74-3P
	879599-80-1P	879599-88-9P	879599-94-7P	879600-00-7P	879600-06-3P
	879600-12-1P	879600-18-7P	879600-23-4P	879600-28-9P	879600-33-6P
	879600-38-1P	879600-45-0P	879600-52-9P	879600-58-5P	879600-63-2P
	879600-70-1P	879600-75-6P	879600-80-3P	879600-87-0P	879600-94-9P
	879600-95-0P	879601-02-2P	879601-03-3P	879601-10-2P	879601-17-9P
	879601-24-8P	879601-30-6P	879601-35-1P	879601-41-9P	879601-57-7P
	879601-63-5P	879601-69-1P	879601-75-9P	879601-80-6P	879601-85-1P
	879601-90-8P	879601-96-4P	879602-02-5P	879602-07-0P	879602-12-7P
	879602-18-3P	879602-24-1P	879602-30-9P	879602-36-5P	879602-43-4P

879602-49-0P	879602-61-6P	879602-62-7P	879602-68-3P	879602-75-2P
879602-76-3P	879602-82-1P	879602-88-7P	879602-89-8P	879602-96-7P
879603-01-7P	879603-07-3P	879603-20-0P	879603-26-6P	879603-32-4P
879603-38-0P	879603-44-8P	879603-48-2P	879603-52-8P	879603-58-4P
879603-63-1P	879603-68-6P	879603-75-5P	879603-81-3P	879603-82-4P
879603-87-9P	879603-99-3P	879604-00-9P	879604-06-5P	879604-11-2P
879604-17-8P	879604-22-5P	879604-34-9P	879604-39-4P	879604-45-2P
879604-49-6P	879604-54-3P	879604-64-5P		
879604-74-7P	879604-77-0P	879604-81-6P	879604-85-0P	879604-90-7P
879604-91-8P	879604-96-3P	879604-97-4P	879605-03-5P	879605-08-0P
879605-25-1P	879605-30-8P	879605-35-3P	879605-43-3P	879605-68-2P
879605-74-0P	879605-77-3P	879605-80-8P	879605-84-2P	879605-91-1P
879605-95-5P	879606-00-5P	879606-04-9P	879606-08-3P	879606-77-6P
879606-82-3P	879606-87-8P	879606-92-5P	879607-35-9P	879607-40-6P
879607-45-1P	879607-52-0P	879607-57-5P	879607-62-2P	879607-71-3P
879607-76-8P	879607-81-5P	879607-84-8P	879607-89-3P	879607-95-1P
879608-15-8P	879608-43-2P	879608-46-5P	879608-51-2P	879608-54-5P
879608-57-8P	879608-64-7P	879610-15-8P	879610-18-1P	879610-25-0P
879610-44-3P	879610-47-6P	879610-51-2P	879610-55-6P	879610-74-9P
879610-79-4P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands)

IT ~~879604-49-6P~~ ~~879604-54-3P~~

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands)


RN 879604-49-6 HCAPLUS

CN Carbamic acid, [4-[4-[(3-amino-1,2-dihydro-2-oxo-5-quinoxalinyloxy)-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 879604-54-3 HCAPLUS

CN 2(1H)-Quinoxalinone, 3-amino-5-[[2-(4-amino-3-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 7 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2005:1241187 HCAPLUS Full-text
DOCUMENT NUMBER: 144:6804
TITLE: Preparation of 4,5-disubstituted-2-aryl pyrimidines as
C5a receptor ligands
INVENTOR(S): Maynard, George D.; Ghosh, Manuka; Yuan, Jun; Currie,
Kevin S.; Mitchell, Scott; Guo, Qin; Zhao, He
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110416	A2	20051124	WO 2005-US15897	20050506 <--
WO 2005110416	A3	20060413		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005244104	A1	20051124	AU 2005-244104	20050506 <--
CA 2563607	A1	20051124	CA 2005-2563607	20050506 <--
US 20050277654	A1	20051215	US 2005-123755	20050506 <--
US 7482350	B2	20090127		
EP 1745033	A2	20070124	EP 2005-746687	20050506 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1976918	A	20070606	CN 2005-80021315	20050506 <--
JP 2007536263	T	20071213	JP 2007-511645	20050506 <--


IN 2006DN07409 A 20070824 IN 2006-DN7409 20061207 <--
 PRIORITY APPLN. INFO.: US 2004-569222P 20040508 <--
 US 2005-649973P 20050204 <--
 WO 2005-US15897 W 20050506 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:6804; MARPAT 144:6804

ED Entered STN: 24 Nov 2005

GI



AB Title compds. I [Ar = mono-, di-, or tri-substituted Ph, (un)substituted naphthyl or heteroaryl; R¹ = H, (un)substituted alkyl, alkenyl, alkynyl, etc.; R² = OH, CHO, (un)substituted alkyl, etc.; R³ = (un)substituted aryl, cycloalkyl, arylalkyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as C5a receptor ligands. Thus, e.g., II was prepared by substitution of 2,4-dichloro-5-chloromethyl-6- methylpyrimidine (preparation given) with (1S)-methyl-(1,2,3,4-tetrahydronaphthalen-1-yl)amine followed by substitution of the 4-chloro group with methanol and coupling with 2,6-diethylphenylboronic acid. Preferred compds. of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. I exhibited IC₅₀ values of 2 μ M or less in calcium immobilization assays. The present invention also relates to pharmaceutical compds. comprising such compds., and to the use of such compds. in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2- arylpyrimidines, which are useful as probes for the localization of C5a receptors.

IC ICM A61K031-505

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 869887-83-2P 869888-24-4P 869888-46-0P 869888-60-8P
869888-90-4P 869889-09-8P 869890-15-3P 869890-17-5P 869890-33-5P
869890-36-8P 869891-14-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of disubstituted arylpyrimidines as C5a receptor ligands)

IT 869887-00-3P 869887-01-4P 869887-02-5P
869887-03-6P 869887-04-7P 869887-05-8P 869887-06-9P
869887-08-1P 869887-10-5P 869887-12-7P
869887-14-9P 869887-16-1P 869887-18-3P
869887-22-9P 869887-25-2P 869887-27-4P 869887-29-6P
869887-31-0P 869887-33-2P 869887-35-4P 869887-37-6P
869887-39-8P 869887-41-2P 869887-42-3P

<u>869887-43-4P</u>	<u>869887-44-5P</u>	<u>869887-45-6P</u>		
<u>869887-46-7P</u>	<u>869887-47-8P</u>	<u>869887-48-9P</u>		
<u>869887-49-0P</u>	<u>869887-50-3P</u>	<u>869887-51-4P</u>		
<u>869887-52-5P</u>	<u>869887-53-6P</u>	<u>869887-54-7P</u>		
<u>869887-55-8P</u>	<u>869887-56-9P</u>	<u>869887-57-0P</u>		
<u>869887-58-1P</u>	<u>869887-59-2P</u>	<u>869887-60-5P</u>		
<u>869887-61-6P</u>	<u>869887-62-7P</u>	<u>869887-63-8P</u>		
<u>869887-64-9P</u>	<u>869887-65-0P</u>	<u>869887-66-1P</u>		
<u>869887-67-2P</u>	<u>869887-68-3P</u>	<u>869887-69-4P</u>		
<u>869887-70-7P</u>	<u>869887-71-8P</u>	<u>869887-72-9P</u>		
<u>869887-72-0P</u>	<u>869887-74-1P</u>	<u>869887-75-2P</u>		
<u>869887-76-3P</u>	<u>869887-77-4P</u>	<u>869887-78-5P</u>		
<u>869887-79-6P</u>	<u>869887-80-9P</u>	<u>869887-81-0P</u>		
<u>869887-82-1P</u>	<u>869887-84-3P</u>	<u>869887-85-4P</u>		
<u>869887-86-5P</u>	<u>869887-87-6P</u>	<u>869887-88-7P</u>		
<u>869887-90-1P</u>	<u>869887-91-2P</u>	<u>869887-92-3P</u>		
<u>869887-93-4P</u>	<u>869887-94-5P</u>	<u>869887-95-6P</u>		
<u>869887-96-7P</u>	<u>869887-97-8P</u>	<u>869887-98-9P</u>	869887-99-0P	
<u>869888-00-6P</u>	<u>869888-01-7P</u>	<u>869888-02-8P</u>		
<u>869888-03-9P</u>	<u>869888-04-0P</u>	<u>869888-05-1P</u>		
<u>869888-06-2P</u>	<u>869888-07-3P</u>	<u>869888-08-4P</u>	869888-09-5P	869888-10-8P
<u>869888-11-9P</u>	<u>869888-12-0P</u>	<u>869888-14-2P</u>		
<u>869888-16-4P</u>	<u>869888-18-6P</u>	<u>869888-20-0P</u>		
<u>869888-22-2P</u>	<u>869888-26-6P</u>	<u>869888-28-8P</u>	869888-30-2P	
<u>869888-31-3P</u>	<u>869888-32-4P</u>	<u>869888-33-5P</u>	869888-34-6P	869888-35-7P
<u>869888-36-8P</u>	<u>869888-37-9P</u>	<u>869888-38-0P</u>	869888-39-1P	869888-40-4P
<u>869888-41-5P</u>	<u>869888-42-6P</u>	<u>869888-43-7P</u>	869888-44-8P	869888-45-9P
<u>869888-47-1P</u>	<u>869888-48-2P</u>	<u>869888-49-3P</u>	869888-50-6P	869888-51-7P
<u>869888-52-8P</u>	<u>869888-53-9P</u>	<u>869888-54-0P</u>		
<u>869888-55-1P</u>	<u>869888-56-2P</u>	<u>869888-57-3P</u>		
<u>869888-58-4P</u>	<u>869888-59-5P</u>	<u>869888-61-9P</u>	<u>869888-62-0P</u>	
<u>869888-63-1P</u>	<u>869888-64-2P</u>	<u>869888-65-3P</u>		
<u>869888-66-4P</u>	<u>869888-67-5P</u>	<u>869888-68-6P</u>	<u>869888-69-7P</u>	
<u>869888-70-0P</u>	<u>869888-71-1P</u>	<u>869888-72-2P</u>		
<u>869888-73-3P</u>	<u>869888-74-4P</u>	<u>869888-75-5P</u>		
<u>869888-76-6P</u>	<u>869888-77-7P</u>	<u>869888-78-8P</u>		
<u>869888-79-9P</u>	<u>869888-80-2P</u>	<u>869888-81-3P</u>		
<u>869888-82-4P</u>	<u>869888-83-5P</u>	<u>869888-84-6P</u>		
<u>869888-85-7P</u>	<u>869888-86-8P</u>	<u>869888-87-9P</u>		
<u>869888-88-0P</u>	<u>869888-89-1P</u>	<u>869888-91-5P</u>	869888-92-6P	869888-93-7P
<u>869888-94-8P</u>	<u>869888-95-9P</u>	<u>869888-96-0P</u>	869888-97-1P	869888-98-2P
<u>869888-99-3P</u>	<u>869889-00-9P</u>	<u>869889-01-0P</u>	<u>869889-02-1P</u>	
<u>869889-04-3P</u>	<u>869889-05-4P</u>	<u>869889-06-5P</u>		
<u>869889-07-6P</u>	<u>869889-08-7P</u>	<u>869889-11-2P</u>	869889-13-4P	869889-15-6P
<u>869889-16-7P</u>	<u>869889-18-9P</u>	<u>869889-20-3P</u>	869889-21-4P	869889-22-5P
<u>869889-24-7P</u>	<u>869889-27-0P</u>	<u>869889-29-2P</u>	869889-32-7P	869889-33-8P
<u>869889-34-9P</u>	<u>869889-36-1P</u>	<u>869889-38-3P</u>	869889-39-4P	
<u>869889-40-7P</u>	<u>869889-42-9P</u>	<u>869889-43-0P</u>	869889-44-1P	869889-45-2P
<u>869889-46-3P</u>	<u>869889-47-4P</u>	<u>869889-48-5P</u>	869889-49-6P	
<u>869889-50-9P</u>	<u>869889-51-0P</u>	<u>869889-52-1P</u>		
<u>869889-53-2P</u>	<u>869889-54-3P</u>	<u>869889-55-4P</u>	869889-56-5P	869889-57-6P
<u>869889-58-7P</u>	<u>869889-59-8P</u>	<u>869889-60-1P</u>	869889-61-2P	869889-62-3P
<u>869889-63-4P</u>	<u>869889-64-5P</u>	<u>869889-65-6P</u>	869889-66-7P	869889-67-8P
<u>869889-68-9P</u>	<u>869889-69-0P</u>	<u>869889-70-3P</u>	869889-71-4P	869889-72-5P
<u>869889-73-6P</u>	<u>869889-74-7P</u>	<u>869889-75-8P</u>	869889-76-9P	869889-77-0P
<u>869889-78-1P</u>	<u>869889-79-2P</u>	<u>869889-80-5P</u>	869889-81-6P	869889-82-7P
<u>869889-83-8P</u>				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(preparation of disubstituted arylpyrimidines as C5a receptor ligands)					
IT	869889-84-9P	869889-85-0P	869889-86-1P	869889-87-2P	869889-88-3P
	869889-89-4P	869889-90-7P	869889-91-8P	869889-92-9P	869889-93-0P
	869889-94-1P	869889-95-2P	869889-96-3P	869889-97-4P	869889-98-5P
	869889-99-6P	869890-00-6P	869890-01-7P	869890-02-8P	869890-03-9P
	<u>869890-04-0P</u>	869890-05-1P	869890-06-2P	869890-07-3P	
	869890-08-4P	869890-09-5P	869890-10-8P	<u>869890-11-9P</u>	
	869890-12-0P	<u>869890-13-1P</u>	<u>869890-14-2P</u>		
	869890-16-4P	869890-18-6P	869890-19-7P	869890-20-0P	869890-21-1P
	869890-22-2P	869890-23-3P	869890-24-4P	869890-25-5P	869890-26-6P
	869890-27-7P	869890-28-8P	869890-29-9P	869890-30-2P	869890-31-3P
	869890-32-4P	869890-34-6P	869890-35-7P	869890-37-9P	869890-38-0P
	869890-39-1P	869890-40-4P	869890-41-5P	869890-42-6P	869890-43-7P
	869890-44-8P	869890-45-9P	869890-46-0P	869890-47-1P	869890-48-2P
	869890-49-3P	869890-50-6P	869890-51-7P	869890-52-8P	869890-53-9P
	869890-54-0P	869890-55-1P	869890-56-2P	869890-57-3P	869890-58-4P
	869890-59-5P	869890-60-8P	869890-61-9P	869890-62-0P	869890-63-1P
	869890-64-2P	869890-65-3P	869890-66-4P	869890-67-5P	869890-68-6P
	869890-69-7P	869890-70-0P	869890-71-1P	869890-72-2P	869890-73-3P
	869890-74-4P	869890-75-5P	869890-76-6P	869890-77-7P	869890-78-8P
	869890-79-9P	869890-80-2P	869890-81-3P	869890-82-4P	869890-83-5P
	869890-84-6P	869890-85-7P	869890-86-8P	869890-87-9P	869890-89-1P
	869890-90-4P	869890-92-6P	869890-93-7P	869890-95-9P	869890-96-0P
	869890-98-2P	869890-99-3P	869891-01-0P	869891-02-1P	
	<u>869891-04-3P</u>	<u>869891-05-4P</u>	869891-07-6P		
	<u>869891-08-7P</u>	<u>869891-10-1P</u>	<u>869891-11-2P</u>		
	<u>869891-13-4P</u>				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of disubstituted arylpyrimidines as C5a receptor ligands)					
IT	108-95-2, Phenol, reactions	177-11-7, 1,4-Dioxo-8-azaspiro[4.5]decane			
	499-75-2, Carvacrol	576-22-7, 2-Bromo-m-xylene	626-48-2	1068-55-9,	
	Isopropylmagnesium chloride	1073-06-9, 3-Bromofluorobenzene	2234-82-4,		
	n-Propylmagnesium chloride	6094-60-6,			
	1-Benzyl-4-hydroxypiperidine-4-carbonitrile	14205-39-1, Methyl			
	3-aminocrotonate	19617-43-7	23357-52-0	57260-71-6	65232-56-6
	65232-57-7	75336-86-6	100379-00-8	286961-14-6	693286-55-4
	693286-67-8	<u>869891-49-6</u>	936020-25-6		

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of disubstituted arylpyrimidines as C5a receptor ligands)					
IT	147-61-5P	16768-43-7P	23453-90-9P	27771-25-1P	36745-93-4P
	49681-43-8P	60956-25-4P	360575-28-6P	610286-39-0P	610794-15-5P
	610796-21-9P	693285-59-5P	693285-60-8P	693285-65-3P	693285-66-4P
	693285-67-5P	693285-69-7P	693285-70-0P	693285-71-1P	869891-30-5P
	869891-31-6P	869891-32-7P	869891-33-8P	869891-34-9P	869891-35-0P
	869891-36-1P	869891-37-2P	869891-39-4P	869891-40-7P	869891-41-8P
	869891-42-9P	<u>869891-43-0P</u>	<u>869891-44-1P</u>		
	869891-45-2P	<u>869891-46-3P</u>	869891-47-4P	869891-48-5P	
	936020-16-5P	1063613-39-7P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of disubstituted arylpyrimidines as C5a receptor ligands)					
IT	<u>869887-83-2P</u>	<u>869891-14-5P</u>			
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN				
	(Synthetic preparation); THU (Therapeutic use); BIOL (Biological				
	study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of disubstituted arylpyrimidines as C5a receptor ligands)				

RN 869887-83-2 HCAPLUS


CN 5-Pyrimidinemethanol, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-

α, α -dipropyl- (CA INDEX NAME)

RN 869891-14-5 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-4-methoxy-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT	<u>869887-00-3P</u>	<u>869887-01-4P</u>	<u>869887-02-5P</u>
	<u>869887-03-6P</u>	<u>869887-06-9P</u>	<u>869887-08-1P</u>
	<u>869887-12-7P</u>	<u>869887-14-9P</u>	<u>869887-16-1P</u>
	<u>869887-18-3P</u>	<u>869887-22-9P</u>	<u>869887-29-6P</u>
	<u>869887-31-0P</u>	<u>869887-39-8P</u>	<u>869887-41-2P</u>
	<u>869887-42-3P</u>	<u>869887-43-4P</u>	<u>869887-44-5P</u>
	<u>869887-45-6P</u>	<u>869887-46-7P</u>	<u>869887-47-8P</u>
	<u>869887-48-9P</u>	<u>869887-49-0P</u>	<u>869887-50-3P</u>
	<u>869887-51-4P</u>	<u>869887-52-5P</u>	<u>869887-53-6P</u>
	<u>869887-54-7P</u>	<u>869887-55-8P</u>	<u>869887-56-9P</u>
	<u>869887-57-0P</u>	<u>869887-58-1P</u>	<u>869887-59-2P</u>
	<u>869887-60-5P</u>	<u>869887-61-6P</u>	<u>869887-63-8P</u>
	<u>869887-64-9P</u>	<u>869887-65-0P</u>	<u>869887-67-2P</u>
	<u>869887-68-3P</u>	<u>869887-70-7P</u>	<u>869887-71-8P</u>
	<u>869887-72-9P</u>	<u>869887-73-0P</u>	<u>869887-74-1P</u>
	<u>869887-75-2P</u>	<u>869887-76-3P</u>	<u>869887-77-4P</u>
	<u>869887-78-5P</u>	<u>869887-79-6P</u>	<u>869887-80-9P</u>
	<u>869887-81-0P</u>	<u>869887-82-1P</u>	<u>869887-84-3P</u>
	<u>869887-85-4P</u>	<u>869887-86-5P</u>	<u>869887-87-6P</u>
	<u>869887-88-7P</u>	<u>869887-91-2P</u>	<u>869887-92-3P</u>
	<u>869887-94-5P</u>	<u>869887-95-6P</u>	<u>869887-98-9P</u>
	<u>869888-01-7P</u>	<u>869888-02-8P</u>	<u>869888-03-9P</u>

869888-04-0P	869888-05-1P	869888-14-2P
869888-16-4P	869888-18-6P	869888-20-0P
869888-22-2P	869888-52-8P	869888-53-9P
869888-54-0P	869888-56-2P	869888-57-3P
869888-58-4P	869888-62-0P	869888-63-1P
869888-64-2P	869888-65-3P	869888-66-4P
869888-69-7P	869888-70-0P	869888-72-2P
869888-74-4P	869888-76-6P	869888-77-7P
869888-80-2P	869888-81-3P	869888-82-4P
869888-84-6P	869888-85-7P	869888-86-8P
869889-02-1P	869889-04-3P	869889-05-4P
869889-06-5P	869889-38-3P	869889-48-5P
869889-50-9P	869889-51-0P	869889-52-1P
869890-04-0P	869890-11-9P	869890-13-1P
869890-14-2P	869891-04-3P	869891-05-4P
869891-10-1P	869891-11-2P	869891-13-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of disubstituted arylpyrimidines as C5a receptor ligands)


RN 869887-00-3 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-methoxy-6-methyl-N,N-dipropyl-
(CA INDEX NAME)




RN 869887-01-4 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-(2-fluorophenyl)-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-02-5 HCAPLUS


CN 5-Pyrimidinamine, 4-(2,6-difluorophenyl)-2-(2,6-dimethylphenyl)-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-03-6 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-methyl-6-phenyl-N,N-dipropyl-
(CA INDEX NAME)

RN 869887-06-9 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-(3-methoxyphenyl)-6-methyl-N,N-dipropyl-
(CA INDEX NAME)

RN 869887-08-1 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-methyl-6-(3-methylphenyl)-N,N-dipropyl-
(CA INDEX NAME)


RN 869887-12-7 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-methyl-N,N-dipropyl-6-[3-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)




RN 869887-14-9 HCAPLUS

CN 5-Pyrimidinamine, 4-(3-chlorophenyl)-2-(2,6-dimethylphenyl)-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-16-1 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dimethylphenyl)-4-(3-ethoxyphenyl)-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-18-3 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-dichlorophenyl)-4-methoxy-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-22-9 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-29-6 HCAPLUS

CN Phenol, 3-[5-(dipropylamino)-4-methoxy-6-methyl-2-pyrimidinyl]-2,4-dimethyl- (CA INDEX NAME)




RN 869887-31-0 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-difluorophenyl)-4-methoxy-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-39-8 HCAPLUS

CN 2-Butanol, 4-[[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]-2-methyl- (CA INDEX NAME)





RN 869887-41-2 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[2-(1-methylethoxy)ethoxy]-N,N-dipropyl- (CA INDEX NAME)





RN 869887-42-3 HCAPLUS

CN Benzonitrile, 4-[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 869887-43-4 HCAPLUS

CN 5-Pyrimidinamine, 2-[2-(2,6-diethylphenyl)-4-(4-ethoxyphenyl)-6-methyl-N,N-dipropyl]- (CA INDEX NAME)




RN 869887-44-5 HCAPLUS

CN 1-Propanol, 3-[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]- (CA INDEX NAME)




RN 869887-45-6 HCAPLUS

CN 2-Propanol, 1-[[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]- (CA INDEX NAME)




RN 869887-46-7 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[2-(4-morpholinyl)ethoxy]-N,N-dipropyl- (CA INDEX NAME)




RN 869887-47-8 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-N,N-dipropyl-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 869887-48-9 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-[3-(dimethylamino)propoxy]-6-methyl-N,N-dipropyl- (CA INDEX NAME)




RN 869887-49-0 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[[4-(methylthio)phenyl]methoxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-50-3 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[[4-(methylsulfonyl)phenyl]methoxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-51-4 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propoxy]-6-methyl-N,N-dipropyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 869887-52-5 HCAPLUS

CN 4,5-Pyrimidinediamine, 2-(2,6-diethylphenyl)-6-methyl-N4-[2-(4-morpholinyl)ethyl]-N5,N5-dipropyl- (CA INDEX NAME)




RN 869887-53-6 HCAPLUS

CN 4,5-Pyrimidinediamine, 2-(2,6-diethylphenyl)-6-methyl-N4-[2-(1-piperidinyl)ethyl]-N5,N5-dipropyl- (CA INDEX NAME)




RN 869887-54-7 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-[[1-(phenylmethyl)-4-piperidinyl]oxy]-N,N-dipropyl- (CA INDEX NAME)




RN 869887-55-8 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[(3-methyl-3-oxetanyl)methoxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-56-9 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[(1-methyl-3-piperidinyl)oxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-57-0 HCAPLUS


CN 2-Butanol, 3-[[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 869887-58-1 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-59-2 HCAPLUS



CN 2-Butanol, 3-[[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]-, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 869887-60-5 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[(1-methyl-4-piperidinyl)oxy]-N,N-dipropyl- (CA INDEX NAME)




RN 869887-61-6 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-(4-piperidinyl)oxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-63-8 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[2-(dimethylamino)ethoxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-64-9 HCAPLUS

CN 2-Butanol, 3-[[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]-, (2R,3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869887-65-0 HCAPLUS


CN Cyclopentanol, 2-[[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 869887-67-2 HCAPLUS

CN Acetamide, N-[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]-2-hydroxy-N-methyl- (CA INDEX NAME)




RN 869887-68-3 HCAPLUS

CN Propanoic acid, 3-[2-(2,6-diethylphenyl)-5-(dipropylamino)-6-methyl-4-pyrimidinyl]oxy]-2,2-dimethyl- (CA INDEX NAME)




RN 869887-70-7 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[(1-methyl-3-pyrrolidinyl)oxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-71-8 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-N,N-dipropyl-6-(3-pyridinyloxy)- (CA INDEX NAME)



RN 869887-72-9 HCAPLUS


CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[2-(4-oxido-4-

morpholinyl)ethoxy]-N,N-dipropyl- (CA INDEX NAME)




RN 869887-73-0 HCAPLUS

CN 5-Pyrimidinamine, 2-(2,6-diethylphenyl)-4-methyl-6-[(4-methylphenyl)methoxy]-N,N-dipropyl- (CA INDEX NAME)



RN 869887-74-1 HCAPLUS


CN 4,5-Pyrimidinediamine, 2-(2,6-diethylphenyl)-N4-[3-(dimethylamino)-2,2-dimethylpropyl]-6-methyl-N5,N5-dipropyl- (CA INDEX NAME)



RN 869887-75-2 HCAPLUS


CN 5-Pyrimidinmethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-[2-(1-methylethoxy)ethoxy]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 869887-76-3 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N-(diphenylmethyl)-4-methoxy-N,6-dimethyl- (CA INDEX NAME)




RN 869887-77-4 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-4-methoxy-N,6-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




RN 869887-78-5 HCAPLUS

CN Benzoic acid, 4-[[[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]methyl]methylamino]methyl]-, methyl ester (CA INDEX NAME)




RN 869887-79-6 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N-[(3-ethoxyphenyl)methyl]-4-methoxy-N,6-dimethyl- (CA INDEX NAME)




RN 869887-80-9 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-(1-propylbutyl)- (CA INDEX NAME)



RN 869887-81-0 HCAPLUS


CN Pyrimidine, 2-(2,6-diethylphenyl)-5-(1-ethoxybutyl)-4-methoxy-6-methyl- (CA INDEX NAME)



RN 869887-82-1 HCAPLUS


CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-4-ethoxy-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 869887-84-3 HCAPLUS


CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-[2-(1-methylethoxy)ethoxy]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 869887-85-4 HCAPLUS


CN 5-Pyrimidinemethanamine, 4-methoxy-2-[3-(methoxymethyl)phenyl]-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 869887-86-5 HCAPLUS


CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-4-[(2-methoxyethyl)methylamino]-N,6-dimethyl-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)]



RN 869887-87-6 HCAPLUS

CN 5-Pyrimidinemethanamine, 4-(cyclobutyloxy)-2-(2,6-diethylphenyl)-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869887-88-7 HCAPLUS

CN 5-Pyrimidinemethanamine, 4-(cyclopentyloxy)-2-(2,6-diethylphenyl)-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869887-91-2 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-(1-methylethoxy)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869887-92-3 HCAPLUS


CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-(2-methylpropoxy)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 869887-94-5 HCAPLUS

CN 3-Quinolinemethanamine, N-[[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl)methyl]-N-methyl- (CA INDEX NAME)



RN 869887-95-6 HCAPLUS


CN Imidazo[1,2-a]pyridine-2-methanamine, N-[[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl)methyl]-N,8-dimethyl- (CA INDEX NAME)



RN 869887-98-9 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-4-[(1S)-2-methoxy-1-methylethoxy]-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-01-7 HCAPLUS

CN 5-Pyrimidinemethanamine, 4-(butylmethylamino)-2-(2,6-diethylphenyl)-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-02-8 HCAPLUS

CN Ethanol, 2-[[2-(2,6-diethylphenyl)-6-methyl-5-[[methyl(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]methyl]-4-pyrimidinyl]methylamino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-03-9 HCAPLUS

CN 5-Pyrimidinethanamine, 2-(2,6-diethylphenyl)-4-[(2-methoxyethyl)amino]-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-04-0 HCAPLUS

CN 5-Pyrimidinethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-(propylamino)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-05-1 HCAPLUS

CN 5-Pyrimidinethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-(methylpropylamino)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-14-2 HCAPLUS

CN 5-Pyrimidinethanamine, 2-(2,6-diethylphenyl)-4-[(2-methoxy-1-methylethyl)amino]-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-16-4 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-[[[(2S)-tetrahydro-2-furanyl)methyl]amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-18-6 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-[[[(2R)-tetrahydro-2-furanyl)methyl]amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-20-0 HCAPLUS

CN 2-Propanol, 1-[(2-(2,6-diethylphenyl)-6-methyl-5-[(methyl(1S)-1,2,3,4-tetrahydro-1-naphthalenyl)amino)methyl]-4-pyrimidinyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-22-2 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-N,4-dimethyl-6-phenoxy-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869888-52-8 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,6-diethylphenyl)-6-methyl-5-
[[methyl (1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]methyl]- (CA INDEX
NAME)


Absolute stereochemistry.



RN 869888-53-9 HCAPLUS

CN 4-Pyrimidineethanol, 2-(2,6-diethylphenyl)-6-methyl-5-[(methyl (1S)-
1,2,3,4-tetrahydro-1-naphthalenyl]amino]methyl]- α -phenyl- (CA INDEX
NAME)


Absolute stereochemistry.



RN 869888-54-0 HCAPLUS


CN 4-Pyrimidinecarboxamide, 2-(2,6-diethylphenyl)-6-methyl-5-[(methyl[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 869888-56-2 HCAPLUS

CN Ethanone, 1-[4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]-1-piperazinyl]- (CA INDEX NAME)




RN 869888-57-3 HCAPLUS

CN 4-Piperidineethanol, 1-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]- (CA INDEX NAME)




RN 869888-58-4 HCAPLUS

CN 4-Piperidineethanol, 1-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]- (CA INDEX NAME)




RN 869888-62-0 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-5-[1-(4-ethyl-1-piperazinyl)butyl]-4-methoxy-6-methyl- (CA INDEX NAME)




RN 869888-63-1 HCAPLUS

CN Pyrimidine, 5-[1-(4-cyclopentyl-1-piperazinyl)butyl]-2-(2,6-diethylphenyl)-4-methoxy-6-methyl- (CA INDEX NAME)




RN 869888-64-2 HCAPLUS

CN 1-Piperazineethanol, 4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]- (CA INDEX NAME)



RN 869888-65-3 HCAPLUS


CN Morpholine, 4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]- (CA INDEX NAME)



RN 869888-66-4 HCAPLUS


CN Morpholine, 4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]-2,6-dimethyl-, (2R,6S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 869888-69-7 HCAPLUS

CN Ethanamine, 2-[1-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 869888-70-0 HCAPLUS

CN Morpholine, 4-[1-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]ethyl]- (CA INDEX NAME)




RN 869888-72-2 HCAPLUS

CN 1-Piperazineacetic acid, 4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]-, ethyl ester (CA INDEX NAME)




RN 869888-74-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]-, ethyl ester (CA INDEX NAME)




RN 869888-76-6 HCAPLUS

CN Ethanone, 1-[4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]-3-methyl-1-piperazinyl]- (CA INDEX NAME)




RN 869888-77-7 HCAPLUS

CN Ethanone, 1-[4-[1-[2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-pyrimidinyl]butyl]-3,5-dimethyl-1-piperazinyl]- (CA INDEX NAME)




RN 869888-80-2 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-[1-[4-[(1-methylethyl)sulfonyl]-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 869888-81-3 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-4-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 869888-82-4 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-4-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 869888-84-6 HCAPLUS

CN Morpholine, 4-[2-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]propyl]- (CA INDEX NAME)



RN 869888-85-7 HCAPLUS

CN Morpholine, 4-[3-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]propyl]- (CA INDEX NAME)




RN 869888-86-8 HCAPLUS

CN 1-Propanamine, 2-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-

10/595,734


methylethyl)phenoxy)methyl]-4-pyrimidinyl]oxy]-N,N-diethyl- (CA INDEX NAME)



RN 869889-02-1 HCAPLUS

CN Benzamide, 4-[[2-(2,6-diethylphenyl)-6-methyl-5-[[methyl[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]methyl]-4-pyrimidinyl]oxy]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 869889-04-3 HCAPLUS


CN Benzamide, 4-[[2-(2,6-diethylphenyl)-6-methyl-5-[[methyl[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]methyl]-4-pyrimidinyl]oxy]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 869889-05-4 HCAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]-, ethenyl ester
(CA INDEX NAME)



RN 869889-06-5 HCAPLUS


CN Pyrimidine, 4-(3-azetidinylloxy)-2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]- (CA INDEX NAME)



RN 869889-38-3 HCAPLUS

CN 5-Pyrimidinemethanamine, 2-(2,6-diethylphenyl)-4-(dimethylamino)-N,6-dimethyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869889-48-5 HCAPLUS


CN 1-Propanol, 2-([2-(2,6-diethylphenyl)-6-methyl-5-([methyl(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino)methyl]-4-pyrimidinyl]amino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 869889-50-9 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-4-(1-methylethoxy)-5-(1-propylbutyl)- (CA INDEX NAME)




RN 869889-51-0 HCAPLUS

CN Benzamide, 4-[[2-(2,6-diethylphenyl)-5-(1-propylbutyl)-4-pyrimidinyl]amino]-2-hydroxy- (CA INDEX NAME)




RN 869889-52-1 HCAPLUS

CN 4-Pyrimidinamine, 2-(2,6-diethylphenyl)-N,N-dimethyl-5-(1-propylbutyl)- (CA INDEX NAME)




RN 869890-04-0 HCAPLUS

CN Pyrimidine, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]- (CA INDEX NAME)



RN 869890-11-9 HCAPLUS


CN Glycine, N-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)



RN 869890-13-1 HCAPLUS

CN D-Valine, N-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 869890-14-2 HCAPLUS

CN D-Valine, N-[2-(2,6-diethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 869891-04-3 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-[[2-(2,6-dimethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]methylamino]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869891-05-4 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-[[2-(2,6-dimethylphenyl)-6-methyl-5-[(2-methyl-5-(1-methylethyl)phenoxy)methyl]-4-pyrimidinyl]methylamino]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869891-10-1 HCAPLUS

CN 1-Pyrrolidineacetamide, 3-[[2-(2,6-dimethylphenyl)-6-methyl-5-[(2-methyl-5-(1-methylethyl)phenoxy)methyl]-4-pyrimidinyl]oxy]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 869891-11-2 HCAPLUS


CN 1-Pyrrolidineacetamide, 3-[[2-(2,6-dimethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 869891-13-4 HCAPLUS

CN 1-Azetidineacetamide, 3-[[2-(2,6-dimethylphenyl)-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]-4-pyrimidinyl]oxy]- (CA INDEX NAME)



IT 869891-49-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of disubstituted arylpyrimidines as C5a receptor ligands)


RN 869891-49-6 HCAPLUS

CN 5-Pyrimidinemethanol, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-α-


propyl- (CA INDEX NAME)




IT 869891-43-0P 869891-44-1P 869891-46-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of disubstituted arylpyrimidines as C5a receptor ligands)
 RN 869891-43-0 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-,
 methyl ester (CA INDEX NAME)



RN 869891-44-1 HCAPLUS
 CN Pyrimidine, 2-(2,6-diethylphenyl)-4-methoxy-6-methyl-5-(1-propyl-1-buten-1-yl)-
 (CA INDEX NAME)



RN 869891-46-3 HCAPLUS
 CN Pyrimidine, 2-(2,6-dimethylphenyl)-4-methoxy-6-methyl-5-[[2-methyl-5-(1-methylethyl)phenoxy]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L52 ANSWER 8 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 8
ACCESSION NUMBER: 2002:888719 HCAPLUS [Full-text](#)
DOCUMENT NUMBER: 137:384854
TITLE: Preparation of diaryl ureas as antiinflammatory agents
INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach,
Abdelhakim; Moss, Neil; Regan, John Robinson
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092576	A1	20021121	WO 2002-US14733	20020508 <--
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2445003	A1	20021121	CA 2002-2445003	20020508 <--
AU 2002305500	A1	20021125	AU 2002-305500	20020508 <--
EP 1392661	A1	20040303	EP 2002-734324	20020508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2004530690	T	20041007	JP 2002-589462	20020508 <--
US 20030008868	A1	20030109	US 2002-143322	20020510 <--
US 6852717	B2	20050208		
MX 2003010487	A	20040309	MX 2003-10487	20031114 <--
PRIORITY APPLN. INFO.:			US 2001-291425P	P 20010516 <--
			WO 2002-US14733	W 20020508 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

ED Entered STN: 22 Nov 2002

GI



I

AB The title diaryl ureas, useful in pharmaceutic compns. for treating a cytokine mediated diseases or conditions involving inflammation such as chronic inflammatory diseases, were prepared Thus, treating 4-(2-chloropyrimidin-4-yloxy)naphthalen-1-ylamine with Et₃N in DMF followed by addition of Et₄NCN, and treatment of the resulting nitrile with phosgene, and reacting the intermediate with 5-tert-butyl-o-anisidine afforded the urea I.

IC ICM C07D239-34

ICS A61K031-505; C07D251-42; C07D239-47; C07D417-12; C07D401-12; C07D231-40; A61P029-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT	285983-44-0P	473269-90-8P	473269-96-4P	473271-63-5P	473271-65-7P
	473271-70-4P	473271-82-8P	473271-86-2P	473271-87-3P	473271-90-8P
	473271-91-9P	473271-96-4P	473272-06-9P	473272-08-1P	473272-09-2P
	473272-15-0P	473272-16-1P	476009-04-8P	476009-05-9P	476009-07-1P
	476009-08-2P	476009-10-6P	476009-12-8P	476009-16-2P	476009-18-4P
	476009-19-5P	476009-21-9P	476009-22-0P	476009-23-1P	476009-25-3P
	476009-27-5P	476009-28-6P	476009-30-0P	476009-34-4P	476009-38-8P
	476009-40-2P	476009-42-4P	476009-43-5P	476009-46-8P	476009-48-0P
	476009-49-1P	476009-52-6P	476009-54-8P	476009-56-0P	476009-58-2P
	476009-60-6P	476009-62-8P	476009-63-9P	476009-65-1P	476009-66-2P
	476009-67-3P	476009-68-4P	476009-70-8P	476009-71-9P	476009-72-0P
	476009-74-2P	<u>476009-78-6P</u>	<u>476009-80-0P</u>		
	<u>476009-82-2P</u>	476009-84-4P	476009-87-7P	476009-89-9P	
	476009-91-3P	476009-93-5P	476009-95-7P	476009-97-9P	476010-05-6P
	476010-09-0P	476010-11-4P	476010-14-7P	476010-16-9P	476010-17-0P
	476010-19-2P	476010-20-5P	476010-22-7P	476010-24-9P	476010-26-1P
	476010-28-3P	476010-30-7P	476010-32-9P	476010-34-1P	476010-36-3P
	476010-38-5P	476010-40-9P	476010-42-1P	476010-44-3P	476010-46-5P
	476010-48-7P	476010-50-1P	476010-52-3P	476010-53-4P	476010-54-5P
	476010-56-7P	476010-58-9P	476010-60-3P	476010-62-5P	476010-64-7P
	476010-65-8P	476010-68-1P	476010-72-7P	476010-74-9P	476010-77-2P
	476010-79-4P	476010-81-8P	476010-84-1P	476010-86-3P	476010-88-5P
	476010-90-9P	476010-92-1P	476010-96-5P	476010-98-7P	476010-99-8P
	476011-01-5P	476011-03-7P	476011-05-9P	476011-06-0P	476011-08-2P
	476011-10-6P	476011-12-8P	476011-14-0P	476011-16-2P	476011-18-4P
	476011-20-8P	476011-22-0P	476011-24-2P	476011-26-4P	476011-28-6P
	476011-30-0P	476011-32-2P	476011-34-4P	476011-36-6P	476011-37-7P
	476011-39-9P	476011-41-3P	476011-43-5P	<u>476011-45-7P</u>	
	476011-47-9P	476011-49-1P	476011-51-5P	476011-53-7P	476011-55-9P
	476012-73-4P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(preparation of diaryl ureas as antiinflammatory agents)

IT 476009-78-6P 476009-80-0P 476009-82-2P

476011-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


10/595,734

THD (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)


(preparation of diaryl ureas as antiinflammatory agents)

RN 476009-78-6 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[[2-(2-methoxyphenyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A


RN 476009-80-0 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[[2-(3-methoxyphenyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)





RN 476009-82-2 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[(2-phenyl-4-pyrimidinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 476011-45-7 HCAPLUS

CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(2-methoxyphenyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 9 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 2002:220582 HCAPLUS Full-text

DOCUMENT NUMBER: 136:247582

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Binch, Hayley; Knegetel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 355 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002022606	A1	20020321	WO 2001-US28803	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422378	A1	20020321	CA 2001-2422378	20010914 <--
AU 2001090944	A	20020326	AU 2001-90944	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317448	A1	20030611	EP 2001-971006	20010914 <--
EP 1317448	B1	20050504		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002411	A2	20031128	HU 2003-2411	20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
JP 2004509116	T	20040325	JP 2002-526859	20010914 <--
JP 4105949	B2	20080625		
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
AT 294797	T	20050515	AT 2001-971006	20010914 <--
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--
AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--
AT 327991	T	20060615	AT 2001-973050	20010914 <--
AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--

AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
IN 2003KN00293	A	20050311	IN 2003-KN293	20030310 <--
NO 2003001189	A	20030513	NO 2003-1189	20030314 <--
NO 326850	B1	20090302		
KR 876069	B1	20081226	KR 2003-703800	20030314 <--
MX 2003002293	A	20030606	MX 2003-2293	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
HK 1057890	A1	20051216	HK 2003-108726	20031128 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		

10/595,734


AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90914	A 20010914 <--
			AU 2001-90944	A3 20010914 <--
			AU 2001-91013	A3 20010914 <--
			AU 2001-94558	A3 20010914 <--
			AU 2001-96871	T0 20010914 <--
			AU 2001-96875	T0 20010914 <--
			EP 2001-971082	A3 20010914 <--
			JP 2002-526860	A3 20010914 <--
			US 2001-952671	A3 20010914 <--
			US 2001-953471	A3 20010914 <--
			US 2001-955601	A3 20010914 <--
			WO 2001-US28803	W 20010914 <--
			AU 2002-234047	A3 20011219 <--
			AU 2002-34047	T0 20011219 <--
			EP 2001-273861	A 20011219 <--
			EP 2001-994323	A3 20011219 <--
			JP 2002-551561	A3 20011219 <--
			JP 2002-557938	A3 20011219 <--
			JP 2002-559413	A3 20011219 <--
			JP 2002-563142	A3 20011219 <--
			JP 2002-565976	A3 20011219 <--
			JP 2002-567928	A3 20011219 <--
			US 2001-26966	A1 20011219 <--
			WO 2001-US49139	W 20011219 <--
			WO 2001-US50312	W 20011219 <--
			JP 2002-551562	A3 20011220 <--
			JP 2002-559414	A3 20011220 <--
			US 2001-34019	A3 20011220 <--
			US 2001-34683	A1 20011220 <--
			IN 2003-KN795	A3 20030619 <--
			US 2003-624800	A3 20030722 <--
			US 2004-775699	A1 20040210 <--
			JP 2004-366925	A3 20041217 <--
			AU 2006-201396	A3 20060404 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:247582

ED Entered STN: 22 Mar 2002

GI



- AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring D]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.
- IC ICM C07D403-12
ICS C07D401-14; A61K031-506; A61K031-4155; A61P035-00; C07D403-14;
C07D405-14; C07D521-00; C07D493-04; C07D495-04; C07D471-04;
C07D473-16
- CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
- IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
[4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,

7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
 6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
 404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
 4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
 404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
 4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-trifluoromethylphenyl)pyrimidine 404827-89-0P,
 6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 404827-91-4P,
 4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
 4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
 4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
 4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
 4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
 404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidine 404827-97-0P,
 4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidine 404827-98-1P,
 4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404828-02-0P,
 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-04-2P,
 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-05-3P,
 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-4-one 404828-06-4P,
 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-30-4P,
 (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404829-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404826-28-4P, 2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl(5-Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](1H-indazol-3-yl)amine 404826-30-8P,
 (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404826-32-0P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-33-1P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404826-34-2P,
 (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-35-3P,
 (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-36-4P,

(5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-37-5P,
 (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-38-6P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
 [6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroprido[4,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-41-1P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroprido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-46-6P,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
 [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
 [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
 [2-Biphenyl-2-ylquinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-

pyrazol-3-yl)amine 404826-73-9P,
 [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,
 (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P,
 (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P,
 (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P,
 (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P,
 (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P,
 (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P,
 (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P,
 [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P,
 (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P,
 (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P,
 (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P,
 (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P,
 [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P,
 [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
 (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
 (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P,
 [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P,
 [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-

Difluoro-1H-indazol-3-yl)amine 404827-16-3P,
 (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P,
 (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P,
 (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P,
 [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P,
 (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P,
 (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-32-3P,
 [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-41-4P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404827-43-6P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-44-7P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-45-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-46-9P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-48-1P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P,
 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine

404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P,
 (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-08-6P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P,
 (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P,
 (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P,
 [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
 [2-(4-Ethylsulfonylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P,
 [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P,
 [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
 [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P,
 [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P,
 [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine 404828-38-2P,
 [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P,
 [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P,

(2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P,
 (2H-Pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P,
 (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P,
 (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P,
 (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine
 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-52-0P,
 (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-53-1P,
 (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-55-3P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-59-7P,
 [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-63-3P,
 (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-65-5P,
 (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-68-8P,
 [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine
 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-71-3P,
 (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-73-5P, [5-(3S)-3-Methoxymethylpyrrolidine-1-carbonyl]-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-74-6P,
 (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine
 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine
 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-77-9P,
 [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-79-1P,
 [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-84-8P,
 (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P,
 (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine
 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine
 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-88-2P,
 [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine
 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-91-7P,
 [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine
 404828-94-0P,
 [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine

4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P,
 [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P,
 (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P,
 (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P,
 (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P,
 (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P,
 [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P,
 [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P,
 [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P,
 [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-22-7P,
 [2-Imidazol-1-ylquinazolin-4-yl] (1H-indazol-3-yl)amine 404829-25-0P,
 (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P,
 [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P,

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P,
 [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P,
 [2-Imidazol-1-ylquinazolin-4-yl] (1H-indazol-3-yl)amine 404829-25-0P,
 (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P,
 [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P,

[5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl)amine 404829-41-0P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P, (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P, [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P, (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P, [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P, (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P, (5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amine 404829-63-6P, (1H-Indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinoline-1-yl]amine 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P, (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine 404829-67-0P, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-68-1P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P, [2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P, (1H-[1,2,4]Triazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine

404829-77-2P, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine
 404829-78-3P, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404829-82-9P 404829-83-0P 404845-75-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404827-83-4 HCAPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-84-5 HCAPLUS

CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-86-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-87-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)


RN 404828-02-0 HCAPLUS

CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404829-31-8 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-

Methyl-2H-pyrazol-3-yl)amine 404826-46-6P,

(1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine

404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-

trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,

(1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-


yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 (6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-82-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer,
 diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404826-51-3 HCAPLUS


CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)


pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-
(CA INDEX NAME)

RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-7-fluoro-
(CA INDEX NAME)


RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5,7-difluoro-
(CA INDEX NAME)

RN 404826-56-8 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-

difluoro- (CA INDEX NAME)




RN 404826-57-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)



RN 404826-59-1 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 404827-32-3 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-

(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-34-5 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS

CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl]-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-37-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl- (CA INDEX NAME)




RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 404829-45-4 HCAPLUS


CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(CA INDEX NAME)


RN 404829-48-7 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(CA INDEX NAME)


RN 404829-49-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(CA INDEX NAME)


RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)


RN 404829-51-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)


RN 404829-52-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)


RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA
INDEX NAME)

RN 404829-79-4 HCAPLUS
 CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404829-82-9 HCAPLUS
 CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 10 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 10
 ACCESSION NUMBER: 2000:401654 HCAPLUS Full-text
 DOCUMENT NUMBER: 133:43533
 TITLE: Preparation of aryl and heterocyclyl substituted
 pyrimidines as anti-coagulants
 INVENTOR(S): Davey, David D.; Phillips, Gary B.
 PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033844	A1	20000615	WO 1999-US28537	19991203 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6127376	A	20001003	US 1998-205498	19981204 <--
CA 2354040	A1	20000615	CA 1999-2354040	19991203 <--
BR 9915938	A	20010821	BR 1999-15938	19991203 <--
EP 1135131	A1	20010926	EP 1999-965087	19991203 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
SI 20637	A	20020228	SI 1999-20090	19991203 <--
HU 2001004508	A2	20020529	HU 2001-4508	19991203 <--
HU 2001004508	A3	20020729		
JP 2002531506	T	20020924	JP 2000-586336	19991203 <--
EE 200100298	A	20021216	EE 2001-298	19991203 <--
AU 760370	B2	20030515	AU 2000-31075	19991203 <--
NZ 512104	A	20031031	NZ 1999-512104	19991203 <--
RO 120971	B1	20061030	RO 2001-606	19991203 <--
IL 143347	A	20061210	IL 1999-143347	19991203 <--
US 6372751	B1	20020416	US 2000-539812	20000330 <--
ZA 2001004235	A	20020823	ZA 2001-4235	20010523 <--
NO 2001002701	A	20010725	NO 2001-2701	20010601 <--
BG 105557	A	20011231	BG 2001-105557	20010601 <--
IN 2001MN00631	A	20050304	IN 2001-MN631	20010601 <--
MX 2001005656	A	20020424	MX 2001-5656	20010604 <--
LT 4912	B	20020425	LT 2001-61	20010612 <--
LV 12783	B	20021020	LV 2001-100	20010704 <--
HR 2001000499	A1	20030430	HR 2001-499	20010704 <--

PRIORITY APPLN. INFO.:

US 1998-205498	A	19981204 <--
WO 1999-US28537	W	19991203 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:43533

ED Entered SIN: 16 Jun 2000

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-III; Z1 = O, NR7, CH2O, SOn (n = 0-2); Z2 = O, NR7, OCH2, SOn (n = 0-2); R1, R4 = H, halo, alkyl, etc.; R2 = C(NH)NH2, C(NH)NHOR7, C(NH)NHCOR7, etc.; R3 = H, halo, alkyl, etc.; R5 = H, halo, alkyl, etc.; R6 = (un)substituted aryl, aralkyl, heterocyclyl, etc.] which inhibit the enzyme, factor Xa and therefore are useful as anti-coagulants, were prepared and formulated. E.g., a multi-step synthesis of I.F3CCO2H [Z1 = Z2 = O; R1 = 2-OH; R2 = 5-C(NH)NH2; R3 = 3-(1-methylimidazolin-2-yl); R4, R5 = H; R6 = Ph] was given. Compds. I demonstrated the selective ability to inhibit human factor Xa and human thrombin, and are effective in treating a 70 kg person at 100-500 mg/day.

IC ICM A61K031-495

ICS C07D239-24

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 1100594-48-6 1100594-49-7 1100594-50-01100594-52-2 1100594-53-3 1100594-54-41100594-55-5 1100594-57-7 1100594-60-21100594-61-3 1100594-63-5 1100594-64-6 1100594-65-7 1100594-66-8

1100594-67-9 1100594-68-0 1100594-69-1 1100594-70-4 1100594-71-5
 1100594-72-6 1100594-73-7 1100594-74-8 1100594-75-9 1100594-76-0
 1100594-77-1 1100594-78-2 1100594-79-3 1100594-80-6

RL: PRPH (Prophetic)

(Preparation of aryl and heterocyclyl substituted pyrimidines as anti-coagulants)

IT 274673-39-1P 274673-40-4P 274673-41-5P
 274673-42-6P 274673-43-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl and heterocyclyl substituted pyrimidines as anti-coagulants)

IT 3740-92-9P 13345-09-0P 13566-71-7P, 4,6-Dihydroxy-2-phenylpyrimidine
 26032-72-4P 36822-11-4P 274673-44-8P 274673-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryl and heterocyclyl substituted pyrimidines as anti-coagulants)


IT 1100594-48-6 1100594-50-0 1100594-52-2
1100594-53-3 1100594-54-4 1100594-55-5
1100594-57-7 1100594-60-2 1100594-80-6

RL: PRPH (Prophetic)

(Preparation of aryl and heterocyclyl substituted pyrimidines as anti-coagulants)


RN 1100594-48-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1100594-50-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1100594-52-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1100594-53-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1100594-54-4 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1100594-55-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1100594-57-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1100594-60-2 HCAPLUS
CN Benzamide, 4-[4-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-2-pyrimidinyl]- (CA INDEX NAME)



RN 1100594-80-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 274673-39-1P 274673-40-4P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); TRU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of aryl and heterocyclyl substituted pyrimidines as
 anti-coagulants)
 RN 274673-39-1 HCAPLUS
 CN Benzenecarboximidamide, 3-[[6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-
 yl)phenoxy]-2-phenyl-4-pyrimidinyl]oxy]-4-hydroxy- (CA INDEX NAME)



RN 274673-40-4 HCAPLUS
 CN Benzenecarboximidamide, 3-[[6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-
 yl)phenoxy]-2-phenyl-4-pyrimidinyl]oxy]-4-hydroxy-, 2,2,2-trifluoroacetate
 (1:1) (CA INDEX NAME)

CM 1

CRN 274673-39-1
 CMF C27 H24 N6 O3




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



IT 274673-44-8P 274673-45-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aryl and heterocyclcyl substituted pyrimidines as
 anti-coagulants)
 RN 274673-44-8 HCAPLUS
 CN Benzonitrile, 3-[(6-chloro-2-phenyl-4-pyrimidinyl)oxy]-4-(phenylmethoxy)-
 (CA INDEX NAME)



RN 274673-45-9 HCAPLUS
 CN Benzonitrile, 3-[[6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-2-
 phenyl-4-pyrimidinyl]oxy]-4-(phenylmethoxy)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (11 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 11 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:552164 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 150:494855

TITLE: Preparation of N-hydroxybenzamide and
 N-hydroxyheterocyclecarboxamide derivatives as
 inhibitors of histone deacetylase (HDAC)

INVENTOR(S): Mallais, Tammy; Moradei, Oscar; Ajamian, Alain;
 Tessier, Pierre; Smil, David; Frechette, Sylvie;
 Machaalani, Roger; Leit, Silvana; Beaulieu, Patrick;
 Deziel, Robert; Mancuso, John



PATENT ASSIGNEE(S): Methylgene Inc., Can.

SOURCE: PCT Int. Appl., 164pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009055917	A1	20090507	WO 2008-CA1911	20081103 <--
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				

PRIORITY APPLN. INFO.: US 2007-985060P P 20071102 <--
 OTHER SOURCE(S): MARPAT 150:494855
 ED Entered STN: 07 May 2009
 GI



AB The title compds. [I; ring X = each (un)substituted aryl, heteroaryl, cycloalkyl, or heterocyclyl; W = N-C:, C(R1); M = C(O)N(R1)OR2, C(O)NR1R2, CO2H, C(O)OR1, -C(O)-C1-C3 alkyl-SR1, NHC(O)-C1-C3 alkyl-SR1, NHC(O)-C1-C3alkyl-OR1, C(O)CH2-S(acetyl), C(O)-heteroaryl, C(O)-heterocyclyl, C(NOH)NR1R2, C(O)-C1-C3 alkyl-OR1, C(O)-C1-C3 alkyl-NR1R2, C(O)CF3, C(O)C(O)OR1, C(O)C(O)NR1R2, C(O)-C1-C4 alkyl, N(OH)C(O)H, N(OR1)C(O)R2, NR1SO2NR1R2, SO2NR1OR2, N(OH)C(O)NR1R2, NRC(O)N(OH)R2, OC(O)N(OH)R2, C(NOH)NR1R2, Zn-chelating group; R1, R2 = H, alkyl, aryl, arylaryl, heteroaryl, heteroarylaryl, heteroarylheteroaryl, alkylheteroaryl, alkylaryl, etc.; R = H, alkyl, halo, HO, NO2, C1-4 alkyl, NR1R2, OR1, aryl, heteroaryl, alkyloxy, CF3; n = 0, 1; L = aryl, heteroaryl, cycloalkyl, heterocyclyl, fused aryl, fused heterocyclyl, fused cycloalkyl, alkenylaryl, arylheteroaryl, heteroarylaryl, alkynylaryl, O-CO-4 alkylaryl, alkylaryl, SO2NR1-CO-4 alkylaryl, etc.; Y = H, halo, arylheterocyclyl, -aryl-O-CO-C4alkylaryl, arylaryl, C1-4 alkyl, heteroalkyl, alkenyl, alkynyl, each (un)substituted NH2, HO, or SH, -CO-3 alkylaryl, -CO-3 alkylheteroaryl, -CO-3 alkylheterocyclyl, -CO-3 alkylcycloalkyl, -C2-4 alkenylaryl, etc.] N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixts., tautomers, diastereomers and enantiomers thereof. There are also disclosed a method for the inhibition of HDAC enzymic activity and a method for treating a disease responsive to an inhibitor of HDAC activity,


more specifically an inhibitor of one or more of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, and HDAC11. The compds. I including benzohydroxamic acid, thiazolecarbohydroxamic acid, thiophenecarbohydroxamic acid, pyrazolecarbohydroxamic acid, pyrimidinecarbohydroxamic acid, and benzothiophenecarbohydroxamic acid derivs. are useful for treating cell proliferative diseases and conditions. Thus, a solution of 420 mg Me 2,4-diphenylthiazole-5-carboxylate in 2.84 mL MeOH and 2.84 mL THF was cooled to 0°, treated with a 50% aqueous solution of hydroxylamine (4,697 mg) and 0.427 mL 4 M aqueous KOH solution, and the resulting mixture was warmed to room temperature and stirred at room temperature for 18 h to give 72% N-hydroxy-2,4-diphenylthiazole-5-carboxamide (II). II showed IC50 of <250 nM against one or more of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, and HDAC11.

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 25


IT 20885-72-7P, N-Hydroxy-2-(phenylamino)benzamide 36828-13-4P,
 N-Hydroxybiphenyl-2-carboxamide 65765-03-9P,
 N-Hydroxy-2-phenoxybenzamide 213012-69-2P,
 2-(N-Benzylsulfonyl)-N-hydroxybenzamide 256643-99-9P,
 N-Hydroxy-2-phenethylbenzamide 858490-34-3P,
 N-Hydroxy-5-methyl-3-phenylisoxazole-4-carboxamide 886574-64-7P,
 2-Benzyl-N-hydroxybenzamide 1148157-38-3P,
 N-Hydroxydibenzofuran-4-carboxamide 1148157-39-4P,
 2-(Benzyloxy)-N-hydroxybenzamide 1148157-40-7P,
 N-Hydroxy-5-methoxy-2-(thiophen-2-yl)benzamide 1148157-42-9P,
 N-Hydroxy-2-(thiophen-2-yl)benzamide 1148157-43-0P,
 N-Hydroxy-3'-phenylbiphenyl-2-carboxamide 1148157-44-1P,
 N-Hydroxy-4'-phenylbiphenyl-2-carboxamide 1148157-45-2P,
 4'-Fluoro-N-hydroxy-2'-methylbiphenyl-2-carboxamide 1148157-46-3P,
 N-Hydroxy-2',3'-dimethoxybiphenyl-2-carboxamide 1148157-47-4P,
 N-Hydroxy-5-phenylbiphenyl-2-carboxamide 1148157-48-5P,
 2-(Benzo[1,3]dioxol-5-yl)-N-hydroxybenzamide 1148157-49-6P,
 N-Hydroxy-3'-methoxybiphenyl-2-carboxamide 1148157-50-9P,
 4'-Fluoro-N-hydroxybiphenyl-2-carboxamide 1148157-51-0P,
 N-Hydroxy-2-(1H-pyrrol-1-yl)benzamide 1148157-52-1P,
 2-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-hydroxybenzamide 1148157-53-2P,
 N-Hydroxy-2'-methoxybiphenyl-2-carboxamide 1148157-54-3P,
 N-Hydroxy-2-[4-(methyl)thiophen-3-yl]benzamide 1148157-55-4P,
 N-Hydroxy-2-(2-methylbenzo[d]thiazol-5-yl)benzamide 1148157-56-5P,
 N-Hydroxy-3'-nitrobiphenyl-2-carboxamide 1148157-57-6P,
 3'-Fluoro-N-hydroxybiphenyl-2-carboxamide 1148157-58-7P,
 N-Hydroxy-3'-(1H-pyrrol-1-yl)biphenyl-2-carboxamide 1148157-59-8P,
 N-Hydroxy-3'-[4-(methyl)thiophen-3-yl]biphenyl-2-carboxamide
 1148157-60-1P, N-Hydroxy-2-(2-methoxy-5-pyridin-3-yl)benzamide
 1148157-61-2P, N-Hydroxy-1,3-diphenyl-1H-pyrazole-4-carboxamide
 1148157-62-3P, N-Hydroxy-3'-methoxy-5-methylbiphenyl-2-carboxamide
 1148157-63-4P, N-Hydroxy-2-(5-phenylthiophen-2-yl)benzamide
 1148157-64-5P, N-Hydroxy-2'-phenylbiphenyl-2-carboxamide 1148157-65-6P,
 5-Fluoro-N-hydroxy-3'-methoxybiphenyl-2-carboxamide 1148157-67-8P,
 2-[(4-Fluoro-3-methylphenyl)ethynyl]-N-hydroxybenzamide 1148157-68-9P,
 N-Hydroxy-5-phenyl-3-[(phenylsulfonyl)amino]thiophene-2-carboxamide
 1148157-71-4P 1148157-72-5P, N-Hydroxy-2,4-bis[4-(methyl)thiophen-3-yl]benzamide
 1148157-76-9P, N'-[2-Amino-5-(thiophen-2-yl)phenyl]-N-hydroxybiphenyl-2,3'-dicarboxamide
 1148157-78-1P,
 3-(4-Bromophenyl)-N-hydroxy-1-(4-methoxyphenyl)-1H-pyrazole-4-carboxamide
 1148157-79-2P, N-Hydroxy-2,5-diphenylthiophene-3-carboxamide
 1148157-80-5P, N-Hydroxy-2,4-diphenylthiazole-5-carboxamide
 1148157-82-7P, 4-(4-Fluorophenyl)-N-hydroxy-2-(4-methoxyphenyl)thiazole-5-carboxamide
 1148157-84-9P, 2-(Benzo[d][1,3]dioxol-5-yl)-N-hydroxy-4-phenylthiazole-5-carboxamide
 1148157-85-0P,
 N-Hydroxy-3,5-diphenylthiophene-2-carboxamide 1148157-88-3P,

N-Hydroxy-3-phenylbenzo[b]thiophene-2-carboxamide 1148157-89-4P,
 N-Hydroxy-2-(1-acetylpiperidin-4-yl)-4-phenylthiazole-5-carboxamide
 1148157-92-9P, N-Hydroxy-3,6-diphenylimidazo[2,1-b]thiazole-2-carboxamide
 1148157-94-1P, 5-(Dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybiphenyl-2-
 carboxamide 1148157-98-5P, N-Hydroxy-N'-(2-phenoxyphenyl)biphenyl-2,5-
 dicarboxamide 1148157-99-6P, 1-Benzyl-N-hydroxy-3-phenyl-1H-pyrazole-4-
 carboxamide 1148158-00-2P, 1-[4-(Benzyloxy)phenyl]-N-hydroxy-3-phenyl-1H-
 pyrazole-4-carboxamide 1148158-01-3P,
 3-(4-Fluorophenyl)-N-hydroxy-1-phenyl-1H-pyrazole-4-carboxamide
 1148158-02-4P, N-Hydroxy-2-(4-morpholinophenyl)-4-phenylthiazole-5-
 carboxamide 1148158-03-5P, 2-(Benzo[b]thiophen-3-yl)-N-hydroxy-4-
 phenylthiazole-5-carboxamide 1148158-04-6P,
 N-Hydroxy-3-phenyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxamide
 1148158-05-7P, N-Hydroxy-2,5-diphenyloxazole-4-carboxamide
 1148158-06-8P, N-Hydroxy-2,5-diphenylthiazole-4-carboxamide
 1148158-07-9P, N-Hydroxy-4-phenyl-2-(2-phenylacetamido)thiazole-5-
 carboxamide 1148158-08-0P, N-Hydroxy-3-phenylbenzofuran-2-carboxamide
 1148158-09-1P, 5-(4-Dimethylaminophenyl)-N-hydroxybiphenyl-2-carboxamide
 1148158-10-4P, N-Hydroxy-4-phenyl-2-(piperidin-1-yl)thiazole-5-carboxamide
 1148158-11-5P, N-Hydroxy-N'-phenylbiphenyl-2,5-dicarboxamide
 1148158-12-6P, N-Hydroxy-2-phenylbenzofuran-3-carboxamide 1148158-13-7P,
 N-Hydroxy-4-phenyl-2-(pyridin-3-yl)thiazole-5-carboxamide 1148158-14-8P,
 2-(3,4-Dihydroquinolin-1(2H)-yl)-N-hydroxy-4-phenylthiazole-5-carboxamide
 1148158-15-9P, N-Hydroxy-4-phenyl-2-(pyridin-4-yl)thiazole-5-carboxamide
 1148158-16-0P, N'-(2-Aminophenyl)-N-hydroxybiphenyl-2,5-dicarboxamide
 1148158-17-1P, 5-(1H-Benzimidazol-2-yl)-N-hydroxybiphenyl-2-carboxamide
 1148158-18-2P, N-Hydroxy-5-(phenoxyethyl)-3-phenylthiophene-2-carboxamide
 1148158-19-3P, N-Hydroxy-3-phenyl-5-
 [(phenylsulfonyl)amino]benzo[b]thiophene-2-carboxamide 1148158-20-6P,
 N-Hydroxy-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
 1148158-21-7P, 3-Chloro-N-hydroxy-5-phenylthiophene-2-carboxamide
 1148158-22-8P, 5-Benzyl-N-hydroxy-3-phenylthiophene-2-carboxamide
 1148158-23-9P, Benzyl [2-(hydroxycarbonyl)-3-phenylbenzo[b]thiophen-5-
 yl]carbamate 1148158-24-0P, 2-(1-Benzylpiperidin-4-yl)-N-hydroxy-4-
 phenylthiazole-5-carboxamide 1148158-25-1P,
 2-(1-Benzoylpiperidin-4-yl)-N-hydroxy-4-phenylthiazole-5-carboxamide
 1148158-26-2P, N-Hydroxy-4'-methoxybiphenyl-2-carboxamide 1148158-27-3P,
 2-(6-Fluoropyridin-3-yl)-N-hydroxybenzamide 1148158-28-4P,
 N-Hydroxy-2-(pyridin-3-yl)benzamide 1148158-29-5P,
 3'-Amino-N-hydroxybiphenyl-2-carboxamide 1148158-30-8P,
 2-Benzoylamino-N-hydroxy-4-phenylthiazole-5-carboxamide 1148158-31-9P,
 2-(2,3-Dihydrobenzofuran-5-yl)-N-hydroxy-4-phenylthiazole-5-carboxamide
 1148158-32-0P, N-Hydroxy-4-phenyl-2-(thiophen-2-yl)thiazole-5-carboxamide
 1148158-33-1P, N-Hydroxy-2,4-diphenylpyrimidine-5-carboxamide
 1148158-34-2P, N-Hydroxy-2-(4-methoxyphenyl)-4-phenylthiazole-5-
 carboxamide 1148158-35-3P,
 4-(3-Fluorophenyl)-N-hydroxy-2-phenylpyrimidine-5-carboxamide
 1148158-36-4P, N-Hydroxy-4-phenyl-2-[1-(pyridin-4-yl)methyl]piperidin-4-
 yl]thiazole-5-carboxamide 1148158-37-5P,
 N-Hydroxy-4-phenyl-2-[1-(pyrrolidin-1-yl)carbonyl]piperidin-4-yl]thiazole-
 5-carboxamide 1148158-38-6P, N-Hydroxy-2-[4-(2-morpholinoethoxy)phenyl]-
 4-phenylthiazole-5-carboxamide 1148158-39-7P, Ethyl
 4-[5-(hydroxycarbonyl)-4-phenylthiazol-2-yl]piperidine-1-carboxylate
 1148158-40-0P, N-Hydroxy-2-[1-(methylsulfonyl)piperidin-4-yl]-4-
 phenylthiazole-5-carboxamide 1148158-41-1P,
 N-Hydroxy-2-phenyl-4-(pyridin-4-yl)pyrimidine-5-carboxamide
 1148158-42-2P, 2-Benzhydryl-N-hydroxy-4-phenylthiazole-5-carboxamide
 1148158-43-3P, N-Hydroxy-4-phenyl-2-[1-(phenylsulfonyl)piperidin-4-
 yl]thiazole-5-carboxamide 1148158-44-4P,
 2-[1-[2-(1H-Indol-3-yl)ethyl]piperidin-4-yl]-N-hydroxy-4-phenylthiazole-5-


carboxamide 1148158-45-5P, N-Hydroxy-4-phenyl-2-(pyridin-2-yl)thiazole-5-carboxamide 1148158-46-6P, N-Hydroxy-5-[[4-methoxyphenyl)sulfonyl]amino]-3-phenylbenzo[b]thiophene-2-carboxamide 1148158-47-7P, N-Hydroxy-5-[2-(4-(trifluoromethyl)phenyl)acetamido]biphenyl-2-carboxamide 1148158-48-8P, N-Hydroxy-2,5-diphenyl-1H-pyrrole-3-carboxamide 1148158-49-9P, N-Hydroxy-3-phenyl-5-[(phenylmethyl)sulfonyl]amino]benzo[b]thiophene-2-carboxamide 1148158-50-2P, 2-[1-(4-Acetamidophenyl)sulfonyl]piperidin-4-yl]-N-hydroxy-4-phenylthiazole-5-carboxamide 1148158-51-3P, 5-[(3,4-Dimethoxyphenyl)sulfonyl]amino]-N-hydroxybiphenyl-2-carboxamide 1148158-52-4P, 5-[(Benzyl)amino]-N-hydroxybiphenyl-2-carboxamide 1148158-53-5P, N-Hydroxy-3-phenyl-5-[(thien-2-yl)sulfonyl]amino]benzo[b]thiophene-2-carboxamide 1148158-54-6P, N-Hydroxy-2-phenyl-4-(phenylthio)pyrimidine-5-carboxamide 1148158-55-7P, 1148158-56-8P, 2-(4-Benzylpiperidin-1-yl)-N-hydroxy-4-phenylpyrimidine-5-carboxamide 1148158-57-9P, N-Hydroxy-1,4-diphenyl-1H-pyrrole-3-carboxamide 1148158-58-0P, [5-(Hydroxycarbamoyl)-4-phenylthiophen-2-yl]methyl benzylcarbamate 1148158-59-1P, [5-(Hydroxycarbamoyl)-4-phenylthiophen-2-yl]methyl N-(benzyl)-N-(methyl)carbamate 1148158-60-4P, 5-[(Benzyl(methyl)amino)methyl]-N-hydroxy-3-phenylthiophene-2-carboxamide 1148158-61-5P, N-Hydroxy-N'-phenyl-3-phenylthiophene-2,5-dicarboxamide 1148158-68-2P, Methyl 3-phenyl-5-(phenylcarbamoyl)thiophene-2-carboxylate 1148158-69-3P, 5-(Dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxy-3-phenylthiophene-2-carboxamide 1148158-81-9P, 1-Benzyl-5-(3-bromophenyl)-N-hydroxy-1H-pyrazole-3-carboxamide 1148158-82-0P, 5-(3-Bromophenyl)-1-tert-butyl-N-hydroxy-1H-pyrazole-3-carboxamide 1148158-83-1P, 1-Benzyl-N-hydroxy-5-(3-morpholinophenyl)-1H-pyrazole-3-carboxamide 1148158-84-2P, N-Hydroxy-5-(3-morpholinophenyl)-1-phenyl-1H-pyrazole-3-carboxamide 1148158-85-3P, 1-(2,4-Dichlorophenyl)-N-hydroxy-5-(3-morpholinophenyl)-1H-pyrazole-3-carboxamide 1148158-86-4P, 1-(2,4-Dichlorophenyl)-N-hydroxy-5-[3-(indolin-1-yl)phenyl]-1H-pyrazole-3-carboxamide 1148158-87-5P, N-Hydroxy-5-(3-morpholinophenyl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide 1148158-88-6P, 5-[3'-(Trifluoromethyl)biphenyl-3-yl]-1H-pyrazole-3-carboxamide 1148158-91-1P, N-Hydroxy-5-[3'-(trifluoromethyl)biphenyl-3-yl]-1H-pyrazole-3-carboxamide 1148158-92-2P, 5-[3'-(Trifluoromethyl)biphenyl-4-yl]-1H-pyrazole-3-carboxamide 1148158-93-3P, 2-(2,4-Diphenylthiazol-5-yl)-N-hydroxyacetamide 1148158-94-4P, 3-[1-(4-Bromophenyl)-3-phenyl-1H-pyrazol-4-yl]-N-hydroxypropanamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-hydroxybenzamide and N-hydroxyheterocyclecarboxamide derivs. as inhibitors of histone deacetylase (HDAC) for treating cell proliferative diseases and conditions)
 IT 1148158-33-1P, N-Hydroxy-2,4-diphenylpyrimidine-5-carboxamide 1148158-35-3P, 4-(3-Fluorophenyl)-N-hydroxy-2-phenylpyrimidine-5-carboxamide 1148158-54-6P, N-Hydroxy-2-phenyl-4-(phenylthio)pyrimidine-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-hydroxybenzamide and N-hydroxyheterocyclecarboxamide derivs. as inhibitors of histone deacetylase (HDAC) for treating cell proliferative diseases and conditions)
 RN 1148158-33-1 HCAPLUS
 CN 5-Pyrimidinecarboxamide, N-hydroxy-2,4-diphenyl- (CA INDEX NAME)



RN 1148158-35-3 HCAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(3-fluorophenyl)-N-hydroxy-2-phenyl- (CA INDEX NAME)





RN 1148158-54-6 HCAPLUS
 CN 5-Pyrimidinecarboxamide, N-hydroxy-2-phenyl-4-(phenylthio)- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L52 ANSWER 12 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:452497 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 150:423213
 TITLE: Preparation of pyrimidinyl-propionic acid derivatives as PPAR agonists
 INVENTOR(S): Shen, Jianhua; Mei, Changlin; Jiang, Hualiang; Dai, Bin; Ye, Yangliang; Xiong, Xishan; Tang, Jing; Fu, Lili
 PATENT ASSIGNEE(S): Shanghai Institute of Materia Medica, Cas, Peop. Rep. China; Changzhen Hospital, Shanghai
 SOURCE: PCT Int. Appl., 65pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009046606	A1	20090416	WO 2007-CN70874	20071011 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			WO 2007-CN70874	20071011 <--
OTHER SOURCE(S):			CASREACT 150:423213; MARPAT 150:423213	
ED Entered STN: 16 Apr 2009				
GI				



- AB Title compds. I [X = CH₂, CH(OH), C(O) O, NH, S, or SO₂; Y = (un)substituted phenyl; n = 0, 2, 3, or 4; R₁ = alkyl, alkoxy, mercapto, CN, NO₂, OH, CF₃, etc.; R₂ = H, Ph, alkyl, alkoxy, amino, mercapto, CN, etc.; R₃ = H, alkoxy, halo, mercapto, CN, NO₂, OH, etc.; R₄ = H, alkyl, alkoxy, mercapto, OH, CF₃, etc.; R₅ = H, alkyl or (un)substituted phenyl; R₆ = H or alkyl], and their pharmaceutically acceptable salts, solvates, or hydrates, are prepared. The compds. are useful as PPAR_γ agonist, through activating PPAR-RXR heterodimers that interacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer. Thus, e.g., II was prepared in 8 steps starting from phenol and ethyl 2-bromopropionate. As PPAR_γ agonist, II exhibited EC₅₀ value of 6.76 μM in transient transfection and transcription assay.
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

- IT 956223-18-0P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-methoxypropion-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-47-8P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-phenylpyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-48-9P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-methylpyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-49-0P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-ethylpyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-58-1P, 3-[4-[[2-Amino-6-[4-(2-iodobenzyl)piperazin-1-yl]pyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-59-2P, 3-[4-[[2-Amino-6-[4-(2-methoxybenzyl)piperazin-1-yl]pyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-65-0P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-ethoxypropion-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-69-4P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-methylaminopyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-83-2P, 3-[4-[[2-Phenylamino-6-(4-benzylpiperazin-1-yl)pyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-84-3P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-(piperazin-1-yl)pyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid 1141923-85-4P, 3-[4-[[2,6-Bis(4-benzylpiperazin-1-yl)pyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid
- RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinyl-propionic acid derivs. as PPAR agonists useful in treatment and prevention of polycystic kidney and cancer)
- IT 1141923-47-8P, 3-[4-[[6-(4-Benzylpiperazin-1-yl)-2-phenylpyrimidin-4-yl]oxy]phenyl]-2-methyl-2-phenoxypropionic acid
- RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinyl-propionic acid derivs. as PPAR agonists useful in treatment and prevention of polycystic kidney and cancer)
- RN 1141923-47-8 HCAPLUS
- CN Benzenepropanoic acid, α -methyl- α -phenoxy-4-[[2-phenyl-6-[4-(phenylmethyl)-1-piperazinyl]-4-pyrimidinyl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 13 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:769551 HCAPLUS Full-text

DOCUMENT NUMBER: 151:70320

TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds

INVENTOR(S): Goldfarb, David Scott

PATENT ASSIGNEE(S): University of Rochester, USA

SOURCE: U.S. Pat. Appl. Publ., 57pp.

DOCUMENT TYPE: CODEN: USXXCO
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222 <--
WO 2009086303	A2	20090709	WO 2008-US88016	20081222 <--
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-16362P	P 20071221 <--
			US 2008-23801P	P 20080125
ED	Entered STN: 26 Jun 2009			
AB	The invention discloses a method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan-altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the Dead assay. [This abstract record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]			
INCL	514312000; 514688000; 514641000			
CC	1-12 (Pharmacology)			
IT	69-52-3	133-10-8	389-08-2, Nalidixic acid	614-52-8 737-31-5
	807-02-3	893-10-7	934-83-8 959-00-2	1240-04-6 1504-24-1
	1572-11-8	1614-25-1	1755-15-3	1774-19-2 1922-79-8 1992-25-2
	2187-27-1	2607-56-9	2627-54-5	2627-55-6 2627-56-7 2736-21-2
	3575-61-9	3781-69-9	4029-54-3	4497-03-4 4497-77-2 4514-43-6
	4593-19-5	4612-90-2	4906-03-0	4937-76-2 5276-05-1 5301-25-7
	5310-26-9	5353-54-8	5520-88-7	5955-43-1 6134-99-2 6161-19-9
	6361-93-9	6484-28-2	6501-31-1	6866-57-5 6930-96-7 7015-77-2
	7230-57-1	7458-01-7	7762-93-8	10177-10-3 10222-81-8 13225-84-8
	13272-19-0	14195-09-6	14210-78-7	15045-48-4 15088-35-4
	15863-23-7	15970-42-0	16151-47-6	16182-01-7 16317-89-8
	16583-28-1	16690-04-3	16980-89-5	17153-59-2 17823-28-8
	17837-54-6	17947-48-7	18006-57-0	19012-01-2 19064-04-1
	19069-76-2	19077-65-7	19209-73-5	19404-34-3 19532-95-7
	19714-15-9	19837-75-3	19903-48-1	20133-32-8 20366-86-3
	20954-77-2	21141-02-6	21258-31-1	21263-59-2 21301-78-0
	21398-73-2	21599-37-1	21631-55-0	21871-49-8 22361-65-5
	22521-40-0	22771-66-0	22812-29-9	23269-55-8 23563-24-8
	23656-72-6	23659-87-2	23767-27-3	23842-78-6 23890-08-6
	23905-56-8	24127-58-0	24132-83-0	24522-51-8 24924-68-3
	25233-47-0	25888-03-3	26180-33-6	26281-30-1 26487-14-9
	26513-80-4	26921-17-5	27161-16-6	27472-15-7 27726-95-0
	28565-98-2	29134-16-5	29178-65-2	30034-03-8 30042-63-8
	30186-36-8	30426-97-2	30487-69-5	30742-62-2 31075-70-4
	31465-35-7	31914-90-6	32121-50-9	32219-17-3 32585-86-7

32599-69-2	32869-90-2	32946-83-1	33493-50-4	33564-30-6
33676-64-1	33720-91-1	33866-44-3	34064-69-2	34233-73-3
34779-73-2	34844-83-2	35212-85-2	35640-07-4	35929-93-2
37425-49-3	37488-43-0	37652-48-5	37737-57-8	37962-09-7
38781-86-1	39884-12-3	40003-44-9	40358-30-3	40536-84-3
40636-81-5	40654-26-0	40722-02-9	40801-11-4	40812-73-5
40918-47-6	41270-65-9	41387-91-1,	2-Benzothiazolebutanoic acid	
41712-53-2	41821-62-9	41957-23-7	42268-36-0	42468-46-2
43077-51-6	46739-60-0	50333-45-4	50451-12-2	50499-83-7
50891-30-0	50970-61-1	51129-65-8	51192-89-3	51411-98-4
51425-79-7	51482-97-4	51486-17-0	51626-34-7	51837-55-9
52068-68-5	52098-22-3	52726-60-0	52900-87-5	53151-52-3
53239-58-0	53452-95-2	53601-32-4	53688-38-3	53957-89-4
54347-53-4	54681-85-5	55296-17-8	55338-29-9	55383-82-9
55790-17-5	55842-08-5	55865-51-5	55901-47-8	56086-43-2
56383-11-0	56796-39-5	57006-40-3	57009-74-2	57037-02-2
57056-24-3	57117-57-4	57338-58-6	57463-71-5	57696-08-9
57736-71-7	57736-89-7	58473-97-5	58490-02-1	58758-09-1
58835-42-0	59048-75-8	59119-48-1	59145-20-9	59676-75-4
59703-84-3	59828-07-8	60072-31-3	60420-73-7	60560-56-7
61080-29-3	61080-36-2	61554-96-9	61654-35-1	61810-48-8
61860-47-7	62237-51-8			

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (method using lifespan-altering comps. for altering lifespan of
 eukaryotic organisms, and screening for such comps.)

IT	63379-21-5	63674-63-5	63703-02-6	63703-30-0	64352-55-2
	64500-72-7	65143-40-0	65322-03-4	65413-58-3	65764-51-4
	66041-93-8	66248-07-5	66346-53-0	66421-41-8	66433-86-1
	67031-58-7	67071-69-6	67304-96-5	67447-98-7	67618-23-9
	67749-21-7	68217-91-4	69066-17-7	69259-39-8	69268-39-9
	69671-78-9	70027-01-9	70839-33-7	71136-18-0	71442-73-4
	71541-04-3	72310-66-8	72461-72-4	72758-86-2	73029-69-3
	73109-30-5	73148-11-5	73373-02-1	74377-50-7	74466-86-7
	74717-21-8	75160-54-2	75160-55-3	75191-40-1	75208-40-1
	75541-71-8	75792-03-9	75843-19-5	76321-81-8	76656-06-9
	76920-97-3	76965-50-9	77905-46-5	77905-47-6	77989-02-7
	78058-51-2	78194-77-1	78394-59-9	78510-05-1	78648-36-9
	78972-84-6	79306-73-3	79317-59-2	80641-18-5	81510-49-8
	81890-59-7	81964-72-9	82649-28-3	82723-00-0	83089-06-9
	83516-65-8	83516-66-9	84096-05-9	85236-70-0	85297-29-6
	85980-47-8	85980-48-9	85980-49-0	86759-30-0	86872-92-6
	86979-00-2	87470-28-8	87537-22-2	87947-59-9	87981-19-9
	88311-80-2	88353-18-8	88722-37-6	88796-07-0	89488-92-6
	90151-22-7	90349-63-6	90871-40-2	91348-51-5	91405-74-2
	91419-48-6	91959-66-9	92152-04-0	92539-89-4	92565-06-5
	92856-34-3	92916-82-0	92971-05-6	93072-34-5	93147-03-6
	93214-86-9	93258-09-4	93439-79-3	93464-05-2	93501-51-0
	93727-72-1	93903-70-9	94258-80-7	94460-27-2	94864-75-2
	95059-40-8	95059-44-2	95318-05-1	96134-52-0	96592-30-2
	96601-26-2	96714-77-1	98281-54-0	98935-12-7	98986-41-5
	99422-01-2	99541-12-5	100361-54-4	100872-69-3	100987-89-1
	101068-29-5	101068-35-3	101072-14-4	101444-59-1	102174-92-5
	102689-49-6	102804-44-4	103492-26-8	103975-55-9	103986-36-3
	104099-23-2	104560-67-0	104582-18-5	104728-84-9	105491-55-2
	105891-72-3	105900-60-5	106135-27-7	106437-84-7	106775-66-0
	106898-36-6	106898-44-6	107235-67-6	107249-98-9	107463-29-6
	107463-65-0	108273-33-2	108540-63-2	108611-69-4	108656-71-9
	108982-96-3	108993-84-6	109813-02-7	110345-33-0	110521-15-8
	111371-16-5	111750-56-2	112507-98-9	112674-06-3	112806-37-8
	113248-79-6	113676-35-0	113849-84-6	113858-98-3	113875-04-0

113896-95-0	113904-77-1	113906-54-0	116530-20-2	117918-56-6
118464-19-0	118644-66-9	118946-58-0	119022-82-1	
121507-66-2	121746-08-5	122005-16-7	122125-51-3	122456-44-4
123403-83-8	125069-22-9	125103-47-1	125488-07-5	126145-44-6
126277-86-9	126801-25-0	127876-86-2	128042-46-6	128991-36-6
129224-65-3	129227-36-7	129768-70-3	130260-37-6	130603-53-1
131028-18-7	132017-68-6	132906-04-8	133636-10-9	134074-28-5
134480-37-8	134538-23-1	135298-44-1	135587-01-8	135627-78-0
136616-58-5	137247-86-0	137522-83-9	138536-34-2	138972-20-0
138972-54-0	139057-04-8	139057-06-0	139158-24-0	140885-44-5
141070-23-7	141210-63-1	141681-59-6	142827-15-4	144106-19-4
145181-85-7	145352-94-9	145938-41-6	146801-24-3	147169-22-0
147992-92-5	148066-35-7	148729-40-2	149837-72-9	

RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of
eukaryotic organisms, and screening for such compds.)

IT	149837-80-9	150016-19-6	150195-43-0	150513-41-0	152449-34-8
	152868-76-3	152894-72-9	153391-28-7	153947-63-8	154054-84-9
	155857-90-2	155857-96-8	159046-21-6	160534-23-6	160591-34-4
	162933-77-9	164355-88-8	164356-03-0	165617-91-4	165824-82-8
	167029-12-1	168200-18-8	169158-28-5	172699-38-6	172758-08-6
	172869-39-5	173258-20-3	173258-21-4	173276-49-8	173281-01-1
	173681-63-5	175432-87-8	175654-36-1	175836-64-3	176242-83-4
	177915-46-7	178307-10-3	178497-04-6	180597-82-4	180799-32-0
	182198-89-6	182563-66-2	184530-26-5	185380-81-8	186263-45-6
	187097-50-3	187393-31-3	187393-32-4	188688-89-3	189149-69-7
	190511-45-6	191085-62-8	191154-23-1	191539-33-0	191539-34-1
	194801-39-3	196713-18-5	196803-97-1	199291-94-6	199392-23-9
	200879-78-3	201541-21-1	201542-11-2	201989-47-1	202057-06-5
	202328-29-8	203506-59-6	204773-00-2	204775-52-0	205173-21-3
	206761-70-8	206982-69-6	206982-87-8	208396-16-1	209109-63-7
	209741-48-0	210221-95-7	211685-70-0	213994-13-9	215591-16-5
	216880-46-5	217460-52-1	217490-20-5	219538-69-9	219719-67-2
	221238-91-1	223110-97-2	224618-98-8	224961-80-2	226259-36-5
	230308-39-1	247583-86-4	250121-99-4	250714-60-4	250722-21-5
	252059-88-4	252059-98-6	252059-99-7	252060-01-8	256340-90-6
	256385-64-5	256954-72-0	259085-53-5	260047-23-2	262603-88-3
	263413-41-8	263699-97-4	263890-27-3	264254-95-7	266303-87-1
	266360-45-6	272437-85-1	275360-54-8	280561-00-4	286956-16-9
	288087-92-3	288312-08-3	288861-05-2	289498-77-7	289498-81-3
	289656-77-5	289661-57-0	289905-34-6	290839-26-8	292622-90-3
	292855-45-9	293765-32-9	293766-53-7	294649-08-4	294654-79-8
	294854-19-6	295360-99-5	296245-38-0	296263-89-3	296271-75-5
	296771-25-0	296773-82-5	296798-60-2	296800-01-6	296800-95-8
	297147-80-9	297744-07-1	298192-55-9	298682-16-3	298684-70-5
	299405-58-6	299450-22-9	299450-55-8	299452-78-1	299897-44-2
	299949-72-7	299951-81-8	300359-10-8	300392-18-1	
	300392-24-9	300392-32-9	300574-25-8	300586-27-0	300589-21-3
	300589-76-8	300589-99-5	300591-67-7	300689-87-6	300695-52-7
	300698-80-0	300698-81-1	300702-83-4	300703-56-4	300703-92-8
	300712-59-8	300713-49-9	300731-75-3	300805-53-2	300815-11-6
	300819-48-1	300829-41-8	300834-40-6	300834-43-9	300834-80-4
	300835-08-9	300835-30-7	300836-45-7	300836-64-0	300838-35-1
	300850-84-4	300852-24-8	301158-87-2	301172-06-5	301173-36-4
	301175-03-1	301201-64-9	301223-05-2	301226-65-3	301306-89-8
	301307-06-2	301330-45-0	301331-47-5	301332-63-8	301341-08-2
	301350-69-6	301353-90-2	301357-41-5	301524-70-9	301643-92-5
	301681-84-5	301807-86-3	301808-38-8	301810-80-0	301813-74-1
	301815-10-1	301815-46-3	301816-56-8	301860-21-9	302344-54-3
	302354-29-6	302551-62-8	302796-42-5	302800-49-3	302800-75-5

302801-08-7	302802-17-1	302805-11-4	302930-64-9	302953-30-6
302956-25-8	303017-20-1	303019-60-5	303062-91-1	303093-54-1
303095-47-8	303120-90-3	303126-78-5	303135-39-9	303137-67-9
<u>303145-54-2</u>	303149-24-8	303149-29-3	303150-92-7	

RL: FAC (Pharmacological activity); BIOL (Biological study)

(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)

IT	303151-41-9	303151-81-7	303172-73-8	303172-75-0	303179-66-0
	303206-08-8	303755-18-2	303775-24-8	303795-94-0	303796-12-5
	303953-17-5	303966-32-7	303983-84-8	303987-50-0	303987-59-9
	304481-35-4	304650-79-1	304661-79-8	304665-33-6	304672-27-3
	304693-19-4	304869-85-0	304870-85-7	304871-85-0	304872-15-9
	304876-36-6	304880-90-8	304888-62-8	304888-78-6	304906-52-3
	305346-29-6	305356-06-3	305375-57-9	305807-17-4	305865-14-9
	305865-84-3	306288-67-5	306304-57-4	306315-55-9	306319-54-0
	306752-43-2	306766-53-0	306954-19-8	306954-97-2	306957-05-1
	306979-95-3	306979-99-7	307327-45-3	307333-65-9	307338-73-4
	307340-24-5	307508-53-8	307511-18-8	307512-34-1	307528-73-0
	307535-30-4	308300-17-6	309273-56-1	309282-36-8	309720-86-3
	309731-36-0	309731-47-3	309733-00-4	309733-65-1	309733-92-4
	309921-93-5	309923-90-8	309926-94-1	309942-78-7	309952-81-6
	309953-57-9	310418-00-9	310437-59-3	310438-47-2	310446-71-0
	310449-07-1	310454-77-4	311315-65-8	311320-41-9	311330-96-8
	311333-10-5	311333-36-5	311333-60-5	311763-22-1	311765-41-0
	311781-06-3	311792-03-7	311813-71-5	312271-48-0	
	<u>312271-56-0</u>	312287-67-5	312311-26-5	312317-91-2	
	312501-01-2	312509-75-4	312521-78-1	312526-88-8	312590-91-3
	312593-03-6	312594-32-4	312594-48-2	312598-56-4	312607-20-8
	312615-88-6	312617-78-0	312620-30-7	312625-66-4	312704-44-2
	312749-65-8	312938-80-0	312939-56-3	312940-70-8	312943-48-9
	312950-92-8	312950-93-9	312950-96-2	313223-80-2	313226-53-8
	313241-59-7	313248-76-9	313254-97-6	313261-26-6	313267-51-5
	313267-54-8	313267-89-9	313272-48-9	313343-42-9	313376-69-1
	313389-11-6	313392-95-9	313393-48-5	313394-11-5	313395-10-7
	313402-96-9	313496-72-9	313506-28-4	313518-12-6	313532-02-4
	313535-25-0	313548-61-7	313552-58-8	313554-48-2	313660-62-7
	313668-40-5	313688-29-8	313702-98-6	313704-08-4	313705-13-4
	313956-68-2	313958-24-6	313965-00-3	313968-32-0	313981-99-6
	314033-56-2	314034-15-6	314042-78-9	314046-81-6	314262-02-7
	315198-88-0	315209-89-3	315216-53-6	315224-95-4	315238-32-5
	315246-54-9	315675-72-0	315676-68-7	315677-77-1	315678-91-2
	315679-71-1	315684-40-3	315694-38-3	315694-65-6	315704-83-7
	315709-80-9	316129-94-9	316132-14-6	316159-24-7	316361-36-1
	316365-59-0	316374-45-5	316381-88-1	317324-39-3	317325-23-9
	317326-24-2	317328-93-1	317329-88-7	317330-70-4	317821-89-8
	317843-57-5	317854-20-9	318238-01-6	318238-10-7	318256-05-2
	318265-14-4	318958-88-2	320419-21-4	<u>320421-36-1</u>	
	320421-73-6	321533-67-9	321533-84-0	321574-13-4	321580-83-0
	321715-17-7	321720-03-0	321972-37-6	321999-03-5	324009-10-1
	324013-58-3	324058-60-8	324067-56-3	324067-81-4	324542-72-5
	324577-32-4	324581-26-2	324772-43-2	324773-80-0	324779-09-1
	324779-70-6	325725-67-5	325729-86-0	325730-01-6	325731-22-4
	325735-83-9	325739-00-2	325739-62-6	325746-44-9	325765-25-1
	325765-57-9	325779-62-2	325798-52-5	325809-76-5	325816-68-0
	325818-05-1	325852-70-8	325854-66-8	325962-59-2	325977-06-8
	325992-20-9				

RL: FAC (Pharmacological activity); BIOL (Biological study)

(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)

IT	448915-63-7	449177-21-3	449767-83-3	450348-88-6	450351-60-7
----	-------------	-------------	-------------	-------------	-------------

450383-36-5	451460-17-6	451463-19-7	451464-61-2	451496-38-1
451512-31-5	451513-50-1	451516-15-7	452055-40-2	452074-13-4
452078-96-5	452299-88-6	452326-47-5	452362-69-5	452934-64-4
452968-47-7	453513-66-1	453532-96-2	454201-83-3	454216-80-9
454243-69-7	454687-91-3	454691-37-3	455299-39-5	457607-36-2
457921-25-4	458551-69-4	459152-96-6	459434-91-4	459436-91-0
459442-41-2	459802-84-7	459821-82-0	459823-43-9	459846-14-1
459852-21-2	459858-28-7	460063-69-8	460071-00-5	460314-70-9
460319-49-7	460320-14-3	460320-36-9	460330-08-9	460338-27-6
460360-85-4	460361-20-0	460362-08-7	460364-99-2	460714-57-2
460715-53-1	460716-28-3	460723-94-8	460725-90-0	460732-92-7
460737-45-5	460993-41-3	460994-35-8	460996-76-3	461013-18-3
461396-00-9	461400-18-0	461407-54-5	461418-98-4	461431-74-3
461437-39-8	461437-59-2	461448-20-4	461454-85-3	461455-35-6
461455-36-7	461455-45-8	461455-94-7	461456-26-8	461681-42-5
462097-52-5	462604-56-4	463308-55-6	464154-19-6	464154-60-7
464155-52-0	464876-54-8	464877-73-4	464877-74-5	464877-75-6
464921-23-1	465535-01-7	466683-99-8	467241-99-2	467444-41-3
467448-93-7	467450-26-6	468093-55-2	468713-12-4	469883-34-9
470468-91-8	471259-90-2	471271-47-3	471914-80-4	472981-93-4
472983-70-3	472984-08-0	472985-07-2	473264-96-9	473265-01-9
473267-32-2	473274-72-5	473443-86-6	473584-42-8	473672-38-7
473709-44-3	473709-57-8	473804-26-1	473881-10-6	473905-40-7
474002-33-0	474003-74-2	474003-98-0	474278-08-5	474298-62-9
474376-23-3	474493-79-3	474515-48-5	474895-79-9	475055-38-0
475283-12-6	475484-59-4	476367-75-6	476448-29-0	476466-11-2
476480-28-1	476642-70-3	477294-89-6	477709-62-9	477711-04-9
477713-11-4	477762-68-8	477845-17-3	477845-47-9	477845-48-0
477845-52-6	477846-09-6	477846-18-7	477846-38-1	477854-95-8
477857-61-7	477857-74-2	477857-75-3	477868-81-8	477886-73-0
477887-34-6	477887-40-4	477888-96-3	477890-07-6	
478029-12-8	478029-68-4	478030-53-4	478031-76-4	
478033-22-6	478033-58-8	478040-38-9	478041-53-1	478041-59-7
478044-98-3	478045-64-6	478045-76-0	478046-27-4	478046-29-6
478047-38-0	478047-41-5	478047-61-9	478048-39-4	478064-41-4
478078-94-3	478258-83-2	478259-58-4	478283-97-5	479403-25-3
479505-79-8	479603-00-4	481718-53-0	481720-32-5	482283-80-7
482301-57-5	482632-53-1	482637-83-2	482653-72-5	483288-18-2
483298-54-0	483321-21-7	483326-63-2	483327-49-7	483335-78-0
483335-80-4	483336-91-0	483349-32-2	483349-94-6	483352-16-5
483357-62-6	483359-13-3	483966-17-2	483970-73-6	483977-84-0
484025-27-6	484025-33-4	484048-62-6	484645-50-3	484645-79-6
484658-23-3	484682-15-7	485317-27-9	485317-35-9	485319-11-7
485328-24-3	485352-59-8	485355-91-7	485388-49-6	485388-50-9
485770-20-5	485771-21-9	485772-85-8	486398-98-5	486457-96-9
487035-36-9	487038-46-0	488119-34-2	488707-18-2	488715-34-0
488725-92-4	488785-58-6	488795-84-2	489396-31-8	489396-98-7

RL: **FAC (Pharmacological activity)**; BIOL (Biological study)
 (method using lifespan-altering compds. for altering lifespan of
 eukaryotic organisms, and screening for such compds.)

IT	1036287-05-4	1036301-23-1	1036303-72-6	1036303-97-5	1036307-91-1
	1036707-02-4	1036707-13-7	1036708-32-3	1036708-58-3	1036708-60-7
	1039727-03-1	1039727-04-2	1041859-60-2	1042905-84-9	1047642-67-0
	1047981-87-2	1047984-61-1	1048375-55-8	1048375-61-6	1049686-03-4
	1049719-91-6	1049722-34-0	1049723-86-5	1049724-00-6	1049724-13-1
	1049724-19-7	1049724-23-3	1049724-24-4	1049724-35-7	1049724-49-3
	1049724-62-0	1049725-19-0	1049725-27-0	1049725-43-0	1049725-53-2
	1049727-57-2	1049727-76-5	1049728-01-9	1049728-22-4	1049741-92-5
	1049741-97-0	1049742-18-8	1049742-19-9	1049747-05-8	1049787-93-0
	1051381-68-0	1051909-19-3	1051909-84-2	1051919-04-0	1052402-95-5

1052412-47-1	1052412-49-3	1052414-20-6	1052414-67-1	1052415-22-1
1052419-44-9	1052421-14-3	1052509-94-0	1052510-73-2	1052510-74-3
1052513-53-7	1052520-20-3	1052523-21-3	1052523-32-6	1052526-25-6
1052526-40-5	1052526-79-0	1052526-92-7	1052527-06-6	1052527-20-4
1052527-52-2	1052527-66-8	1052528-57-0	1052529-05-1	1052529-34-6
1052529-40-4	1052529-53-9	1052529-56-2	1052530-65-0	1052530-69-4
1052530-93-4	1052530-99-0	1052531-26-6	1052531-37-9	1052531-46-0
1052531-52-8	1052531-68-6	1052531-97-1	1052532-75-8	1052533-78-4
1052535-37-1	1052535-55-3	1052535-72-4	1052536-04-5	1052536-07-8
1052536-66-9	1052536-93-2	1052537-07-1	1052537-23-1	1052537-89-9
1052538-88-1	1052541-49-7	1052542-15-0	1052543-12-0	1053064-27-9
1056013-43-4	1061623-23-1	1089303-70-7	1089677-09-7	1095821-43-4
1096159-20-4	1101735-11-8	1103502-88-0	1107060-71-8	1107062-99-6
1137829-95-8	1162656-15-6	1162656-16-7	1162656-17-8	1162656-18-9
1162656-19-0	1162656-20-3	1162656-21-4	1162656-22-5	1162656-23-6
1162656-24-7	1162656-25-8	1162656-26-9	1162656-27-0	1162656-28-1
1162656-29-2				


RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of
eukaryotic organisms, and screening for such compds.)

IT 20954-77-2 118644-66-9 300359-10-8
303145-54-2 312271-56-0 320421-36-1
477888-96-3 478029-68-4

RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of
eukaryotic organisms, and screening for such compds.)


RN 20954-77-2 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2,6-diphenyl- (CA INDEX NAME)




RN 118644-66-9 HCAPLUS

CN Morpholine, 4-(2,6-diphenyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 300359-10-8 HCAPLUS

CN Pyrimidine, 4-methyl-6-phenoxy-2-phenyl- (CA INDEX NAME)




RN 303145-54-2 HCAPLUS

CN Pyrimidine, 4-[3-[[(4-chlorophenyl)sulfonyl]methyl]-4-nitrophenyl]-2-(4-methylphenyl)- (CA INDEX NAME)




RN 312271-56-0 HCAPLUS

CN Ethanone, 1-[4-(methylthio)-2-phenyl-6-(1-pyrrolidinyl)-5-pyrimidinyl]- (CA INDEX NAME)




RN 320421-36-1 HCAPLUS

CN Pyrimidine, 2-phenyl-4-[(phenylsulfinyl)methyl]-6-(phenylthio)- (CA INDEX NAME)




RN 477888-96-3 HCAPLUS

CN Pyrimidine, 4-[4-(3-fluoropropoxy)phenyl]-2-phenyl- (CA INDEX NAME)



RN 478029-68-4 HCAPLUS

CN Pyrimidine, 5-methoxy-4-(3-methylphenoxy)-2-phenyl- (CA INDEX NAME)



L52 ANSWER 14 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:743719 HCAPLUS Full-text

DOCUMENT NUMBER: 149:79639

TITLE: O-linked pyrimidin-4-amine-based compounds, preparation, compositions comprising them, and methods of their use to treat cancer

INVENTOR(S): Augeri, David J.; Carlsen, Marianne; Carson, Kenneth G.; Fu, Qinghong; Healy, Jason P.; Heim-Riether, Alexander; Jessop, Theodore C.; Keyes, Philip E.; Shen, Min; Tarver, James E.; Taylor, Jerry A.; Xu, Xiaolian

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 52pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080146571	A1	20080619	US 2007-954433	20071212 <--
AU 2007334017	A1	20080626	AU 2007-334017	20071213 <--
CA 2672673	A1	20080626	CA 2007-2672673	20071213 <--
WO 2008076779	A2	20080626	WO 2007-US87332	20071213 <--
WO 2008076779	A3	20080828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 2104672	A2	20090930	EP 2007-869192	20071213 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2006-874882P	P 20061214 <--
			WO 2007-US87332	W 20071213 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:79639

ED Entered STN: 20 Jun 2008

GI



AB O-linked pyrimidin-4-amine-based compds. of formula I, pharmaceutical compns. comprising them, and methods of their use are described. Compds. of formula I wherein X is (CH₂)₁₋₃; L1 is a bond, CO, SO_w and (un)substituted methylene; A is (un)substituted alkyl, aryl and heterocyclyl; R1 and R2 are independently H, halo, OH, NH₂, NO₂, CN, CO₂H and derivs., and (un)substituted alkyl; each R3 are independently =O and (un)substituted lower alkyl; m is 0 - 3 if X is CH₂; m is 0 - 4 if X is CH₂CH₂; and m is 0 - 5 if X is (CH₂)₃; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their deoxycytidine kinase inhibitory activity.

INCL 51423800; 544317000; 544296000; 544250000; 544212000; 544123000; 514274000; 514267000; 514241000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT	1033833-23-6P	1033833-24-7P	1033833-26-9P	1033833-27-0P
	1033833-28-1P	1033833-29-2P	1033833-30-5P	1033833-31-6P
	1033833-32-7P	1033833-33-8P	1033833-34-9P	1033833-35-0P
	1033833-36-1P	1033833-37-2P	1033833-38-3P	1033833-39-4P
	1033833-40-7P	1033833-41-8P	1033833-42-9P	1033833-43-0P
	1033833-44-1P	1033833-45-2P	1033833-46-3P	1033833-47-4P
	1033833-48-5P	1033833-49-6P	1033833-50-9P	1033833-51-0P
	1033833-52-1P	1033833-53-2P	1033833-54-3P	1033833-55-4P
	1033833-56-5P	1033833-57-6P	1033833-58-7P	1033833-59-8P
	1033833-60-1P	1033833-61-2P	1033833-62-3P	1033833-63-4P
	1033833-64-5P	1033833-65-6P	1033833-66-7P	1033833-67-8P
	1033833-68-9P	1033833-69-0P	1033833-70-3P	1033833-71-4P
	1033833-72-5P	1033833-73-6P	1033833-74-7P	1033833-75-8P
	1033833-76-9P	1033833-77-0P	1033833-78-1P	1033833-79-2P
	1033833-80-5P	1033833-81-6P	1033833-82-7P	1033833-83-8P
	1033833-84-9P	1033833-85-0P	1033833-86-1P	1033833-87-2P
	1033833-88-3P	1033833-89-4P	1033833-90-7P	1033833-91-8P
	1033833-92-9P	1033833-93-0P	1033833-94-1P	1033833-95-2P
	1033833-96-3P	1033833-97-4P	1033833-98-5P	1033833-99-6P
	1033834-00-2P	1033834-01-3P	1033834-02-4P	1033834-03-5P
	1033834-04-6P	1033834-05-7P	1033834-06-8P	1033834-07-9P
	1033834-08-0P	1033834-09-1P	1033834-10-4P	1033834-12-6P
	1033834-13-7P	1033834-14-8P	1033834-15-9P	1033834-16-0P
	1033834-17-1P	1033834-18-2P	1033834-19-3P	1033834-20-6P
	1033834-21-7P	1033834-22-8P	1033834-23-9P	1033834-24-0P
	1033834-25-1P	1033834-26-2P	1033834-27-3P	1033834-28-4P
	1033834-29-5P	1033834-30-8P	1033834-31-9P	1033834-32-0P
	1033834-33-1P	1033834-34-2P	1033834-35-3P	1033834-36-4P
	1033834-37-5P	1033834-38-6P	1033834-39-7P	1033834-40-0P

1033834-41-1P	1033834-42-2P	1033834-43-3P	1033834-44-4P
1033834-45-5P	1033834-46-6P	1033834-47-7P	1033834-48-8P
1033834-49-9P	1033834-50-2P	1033834-51-3P	1033834-52-4P
1033834-53-5P	1033834-54-6P	1033834-55-7P	1033834-56-8P
1033834-57-9P	1033834-58-0P	1033834-59-1P	1033834-60-4P
1033834-61-5P	1033834-62-6P	1033834-63-7P	1033834-64-8P
1033834-65-9P	1033834-66-0P	1033834-67-1P	1033834-68-2P
1033834-69-3P	1033834-70-6P	1033834-71-7P	1033834-72-8P
1033834-73-9P	1033834-74-0P	1033834-75-1P	1033834-76-2P
1033834-77-3P	1033834-78-4P	1033834-79-5P	1033834-80-8P
1033834-81-9P	1033834-82-0P	1033834-83-1P	1033834-84-2P
1033834-85-3P	1033834-86-4P	1033834-87-5P	1033834-88-6P
1033834-89-7P	1033834-90-0P	1033834-91-1P	1033834-92-2P
1033834-93-3P	1033834-94-4P	1033834-95-5P	1033834-96-6P
1033834-97-7P	1033834-98-8P	1033834-99-9P	1033835-00-5P
1033835-01-6P	1033835-02-7P	1033835-03-8P	1033835-04-9P
1033835-05-0P	1033835-06-1P	1033835-07-2P	1033835-08-3P
1033835-09-4P	1033835-10-7P	1033835-11-8P	1033835-12-9P
1033835-13-0P	1033835-14-1P	1033835-15-2P	1033835-16-3P
1033835-17-4P	1033835-18-5P	1033835-19-6P	1033835-20-9P
1033835-21-0P	1033835-22-1P	1033835-23-2P	1033835-24-3P
1033835-25-4P	1033835-26-5P	1033835-27-6P	1033835-28-7P
1033835-30-1P	1033835-31-2P	1033835-32-3P	1033835-33-4P
1033835-34-5P	1033835-35-6P	1033835-36-7P	1033835-37-8P
1033835-38-9P	1033835-39-0P	1033835-40-3P	1033835-41-4P
1033835-42-5P	1033835-43-6P	1033835-44-7P	1033835-45-8P
1033835-46-9P	1033835-47-0P	1033835-48-1P	1033835-49-2P
1033835-50-5P	1033835-51-6P	1033835-52-7P	1033835-53-8P
1033835-54-9P	1033835-55-0P	1033835-56-1P	1033835-57-2P
1033835-58-3P	1033835-59-4P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP (Preparation)
; USES (Uses)

(drug candidate; preparation of O-linked pyrimidinamine-based compds. as deoxycytidine kinase inhibitors useful in the treatment of cancer)


IT ~~1033834-46-6P~~

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(drug candidate; preparation of O-linked pyrimidinamine-based compds. as deoxycytidine kinase inhibitors useful in the treatment of cancer)

RN 1033834-46-6 HCAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[[1-[6-(2-methoxyphenoxy)-2-phenyl-4-pyrimidinyl]-4-piperidinyl]oxy]- (CA INDEX NAME)



L52 ANSWER 15 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:484949 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:475681

TITLE: Immunomodulatory heterocyclic compounds that target and inhibit the pY binding site of tyrosine kinase p56lck SH2 domain

INVENTOR(S): Mackerell, Alexander; Hayashi, Jun

PATENT ASSIGNEE(S): University of Maryland, Baltimore, USA

SOURCE: U.S. Pat. Appl. Publ., 90 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070099970	A1	20070503	US 2006-507038	20060821 <--
WO 2008024759	A2	20080228	WO 2007-US76402	20070821 <--
WO 2008024759	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-709972P P 20050819 <--
US 2006-507038 A 20060821 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:475681

ED Entered STN: 04 May 2007

AB Small mol.-weight non-peptidic compds. block lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.

INCL 514369000

CC 1-7 (Pharmacology)

IT 4021-27-6 5694-37-1 7084-12-0 17332-48-8 18472-03-2 19336-92-6

19368-17-3 19368-18-4 21926-67-0 24245-01-0 37600-45-6

68620-29-1 69517-61-9 76475-63-3 78648-34-7 84165-49-1

94640-07-0 108540-96-1 129256-38-8 187028-76-8 198219-92-0

198276-05-0 201137-71-5 201137-72-6 201137-73-7 201741-53-9

219793-66-5 219793-68-7 219793-71-2 289485-75-2 292870-58-7

294652-29-2 294656-85-2 301208-13-9 311317-57-4 311327-67-0

311331-92-7 311765-61-4 312319-33-8 313225-00-2 313226-44-7

313229-96-8 313231-87-7 313239-17-7 313663-33-1 323176-64-3

324779-95-5 324780-15-6 325472-35-3 328030-21-3 329712-98-3

329921-76-8 329921-81-5 329936-62-1 330634-96-3 330663-11-1

330861-00-2 331246-28-7 331254-90-1 331837-65-1 332130-07-1

338422-73-4 340225-60-7 340302-19-4 346458-86-4 346638-80-0

350012-60-1 350243-89-9 350503-95-6 351465-66-2 351983-79-4

352225-72-0 352345-64-3 352346-88-4 352346-92-0 352347-18-3

352347-28-5 352451-79-7 352452-15-4 352452-21-2 352682-04-3

353257-86-0 353266-41-8 353280-56-5 353507-20-7 353507-73-0

353510-36-8 354122-00-2 354125-58-9 354125-62-5 357303-67-4

357303-70-9 361174-66-5 364383-87-9 365985-51-9 370870-70-5

392246-86-5	400065-69-2	400868-85-1	400870-63-5	401610-60-4
401629-43-4	401641-69-8	406172-99-4	406173-01-1	406184-59-6
406184-60-9	406184-61-0	415721-99-2	416874-07-2	420105-65-3
422540-99-6	422541-57-9	422541-58-0	422542-68-5	422542-81-2
423135-74-4	423146-74-1	423147-07-3	423147-20-0	423147-26-6
423147-28-8	423147-42-6	425374-68-1	425403-71-0	430463-00-6
430463-69-7	430465-81-9	430467-64-4	430468-36-3	430470-21-6
430471-43-5	430471-60-6	431054-19-2	431068-69-8	431072-65-0
431075-18-2	431075-21-7	431883-68-0	431883-95-3	431884-57-0
431885-49-3	431914-42-0	431917-30-5	431920-02-4	431930-21-1
431938-97-5	431979-88-3	431982-96-6	431986-75-3	432017-78-2
432503-76-9	434318-15-7	434323-03-2	434323-05-4	434323-86-1
434324-43-3	434324-58-0	434324-60-4	434324-73-9	434324-86-4
434324-90-0	434325-23-2	434325-24-3	434325-25-4	434325-27-6
434325-28-7	434325-31-2	434325-44-7	434325-45-8	434325-53-8
434325-67-4	434921-22-9	439107-37-6	439128-26-4	439939-23-8
439939-24-9	441731-18-6	441731-42-6	442641-37-4	442655-61-0
442665-36-3	442665-42-1	442674-70-6	442674-72-8	442675-13-0
442676-39-3	442676-48-4	442676-49-5	442676-50-8	442676-52-0
442676-54-2	442676-56-4	442676-58-6	442676-59-7	442676-69-9
442676-75-7	442676-83-7	442676-95-1	442676-99-5	442677-00-1
442677-15-8	442677-17-0	443105-32-6	443317-81-5	443317-87-1
443317-90-6	443875-07-8	443875-25-0	443875-52-3	443875-86-3
445218-64-4	445406-35-9	445412-35-1	447410-19-7	450385-26-9
450385-27-0	451459-41-9	452059-81-3	452080-23-8	452080-29-4
452080-39-6	452086-00-9	452086-56-5	460736-50-9	461663-18-3
477859-41-9	489455-77-8	497836-20-1	503561-80-6	
503562-00-3	503562-90-1	503562-91-2	505063-23-0	519042-29-6
531496-65-8				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunomodulatory heterocyclic compound inhibitors of pY binding site of tyrosine kinase p56lck SH2 domain)


IT ~~477859-41-9~~

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunomodulatory heterocyclic compound inhibitors of pY binding site of tyrosine kinase p56lck SH2 domain)

RN 477859-41-9 HCAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(4-chlorophenyl)thio]-2-phenyl-N-(phenylmethyl)- (CA INDEX NAME)



L52 ANSWER 16 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:408655 HCAPLUS Full-text

DOCUMENT NUMBER: 137:6189


TITLE: Preparation of pyrimidine derivatives as NK1

antagonists
 INVENTOR(S): Stadler, Heinz
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042280	A2	20020530	WO 2001-EP13084	20011113 <--
WO 2002042280	A3	20020822		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20020099207	A1	20020725	US 2001-977586	20011015 <--
US 6787539	B2	20040907		
CA 2429570	A1	20020530	CA 2001-2429570	20011113 <--
AU 2002027921	A	20020603	AU 2002-27921	20011113 <--
EP 1339698	A2	20030903	EP 2001-989463	20011113 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001015480	A	20031021	BR 2001-15480	20011113 <--
HU 2003003045	A2	20031229	HU 2003-3045	20011113 <--
HU 2003003045	A3	20040329		
JP 2004514673	T	20040520	JP 2002-544415	20011113 <--
JP 3993100	B2	20071017		
NZ 525555	A	20041029	NZ 2001-525555	20011113 <--
CN 1628103	A	20050615	CN 2001-819116	20011113 <--
CN 1309710	C	20070411		
AU 2002227921	B2	20060216	AU 2002-227921	20011113 <--
RU 2284997	C2	20061010	RU 2003-117481	20011113 <--
IL 155705	A	20081126	IL 2001-155705	20011113 <--
ZA 2003003517	A	20040810	ZA 2003-3517	20030507 <--
MX 2003004453	A	20030819	MX 2003-4453	20030520 <--
NO 2003002291	A	20030521	NO 2003-2291	20030521 <--
NO 324865	B1	20071217		
IN 2003CN00786	A	20050415	IN 2003-CN786	20030521 <--
BG 107840	A	20040130	BG 2003-107840	20030522 <--
HK 1078079	A1	20070622	HK 2005-110085	20051111 <--
PRIORITY APPLN. INFO.:			EP 2000-125529	A 20001122 <--
			WO 2001-EP13084	W 20011113 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:6189
 ED Entered STN: 31 May 2002
 GI



AB The title compds. [I; R1 = alkyl, alkoxy, pyridinyl, pyrimidinyl, etc.; R2 = H, alkyl, alkoxy, halo, CF3; R3, R33 = H, alkyl; R4 = halo, CF3, alkoxy; R5 = H, alkyl; X = CONR, NRCO; Y = O, S, SO2, NR; m = 0-2] which have a good affinity to the NK1 receptor and therefore are suitable in the treatment of diseases, related to this receptor, were prepared and formulated. Thus, reacting 4-chloro-2-methylsulfanylpurimidine-5- carboxylic acid Et ester with o-cresol in the presence of Cs2CO3 in MeCN (99%) followed by saponification (47%), and amidation of the resulting acid with [3,5-bis(trifluoromethyl)benzyl]methylamine (96%) afforded I [R1 = SMe; R2 = 2-Me; R3, R33 = H; R4 = 3,5-(CF3)2; Y = O; X = CONMe] which showed pKi of 7.38 against NK-1 receptor binding.

IC ICM C07D239-56

ICS C07D239-46; C07D239-52; A61K031-505; A61P025-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT 432520-79-1P 432520-80-4P 432520-81-5P 432520-82-6P 432520-83-7P
 432520-84-8P 432520-85-9P 432520-87-1P 432520-88-2P 432520-89-3P
 432520-90-6P 432520-91-7P 432520-92-8P 432520-93-9P 432520-94-0P
 432520-95-1P 432520-96-2P 432520-97-3P 432520-98-4P 432520-99-5P
 432521-00-1P 432521-01-2P 432521-02-3P 432521-03-4P 432521-04-5P
 432521-05-6P 432521-06-7P 432521-07-8P 432521-08-9P 432521-09-0P
 432521-10-3P 432521-11-4P 432521-13-6P 432521-14-7P 432521-15-8P
 432521-16-9P 432521-17-0P 432521-18-1P 432521-19-2P
 432521-21-6P 432521-23-8P 432521-24-9P 432521-25-0P 432521-26-1P
 432521-27-2P 432521-28-3P 432521-29-4P 432521-30-7P 432521-32-9P
 432521-33-0P 432521-34-1P 432521-35-2P 432521-36-3P 432521-37-4P
 432521-38-5P 432521-39-6P 432521-41-0P 432521-42-1P 432521-43-2P
 432521-44-3P 432521-45-4P 432521-46-5P 432521-47-6P 432521-48-7P
432521-49-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of pyrimidine derivs. as NK1 antagonists)

IT 75-65-0, tert-Butanol, reactions 87-13-8, Diethyl
 ethoxymethylenemalonate 95-48-7, o-Cresol, reactions 108-00-9,
 2-Dimethylaminoethylamine 108-01-0, 2-Dimethylaminoethanol 109-01-3,
 1-Methylpiperazine 110-85-0, Piperazine, reactions 110-91-8,
 Morpholine, reactions 123-90-0, Thiomorpholine 622-40-2,
 N-(2-Hydroxyethyl)morpholine 5909-24-0,
 4-Chloro-2-methanesulfanylpurimidine-5-carboxylic acid ethyl ester
 15400-46-1 15521-18-3, 2-Dimethylaminopropanol 39989-43-0,
 3,5-Dichlorobenzylamine 56406-44-1 77775-71-4 138588-40-6
 148452-35-1 159820-24-3 289686-69-7 432521-64-7 432521-65-8
 432521-66-9 432521-67-0 432521-68-1 432521-69-2
 432521-70-5 432521-71-6 432521-72-7 432521-73-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as NK1 antagonists)

IT 432521-18-1P 432521-49-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


TBU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of pyrimidine derivs. as NK1 antagonists)


RN 432521-18-1 HCAPLUS

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-phenyl- (CA INDEX NAME)



RN 432521-49-8 HCAPLUS

CN Benzeneacetamide, N,α,α-trimethyl-N-[4-(2-methylphenoxy)-2-phenyl-5-pyrimidinyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




IT 432521-69-2 432521-73-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of pyrimidine derivs. as NK1 antagonists)

RN 432521-69-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-methylphenoxy)-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 432521-73-8 HCAPLUS
 CN 5-Pyrimidinamine, N-methyl-4-(2-methylphenoxy)-2-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 17 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:220584 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:247584

TITLE: Preparation of pyrazolamines and analogs as protein
 kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegetel, Ronald; Golec, Julian M.
 C.; Li, Pan; Davies, Robert; Charrier, Jean-Damien
 Vertex Pharmaceuticals Incorporated, USA

PATENT ASSIGNEE(S): PCT Int. Appl., 356 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022608	A1	20020321	WO 2001-US42152	20010914 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2422380	A1	20020321	CA 2001-2422380	20010914 <--
CA 2422380	C	20090324		
AU 2001096871	A	20020326	AU 2001-96871	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		

US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317452	A1	20030611	EP 2001-977779	20010914 <--
EP 1317452	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
JP 2004509118	T	20040325	JP 2002-526861	20010914 <--
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
HU 2004001819	A2	20041228	HU 2004-1819	20010914 <--
HU 2004001819	A3	20090629		
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--
AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--
AT 327991	T	20060615	AT 2001-973050	20010914 <--
AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--

IN 2003KN00294	A	20050311	IN 2003-KN294	20030310	<--	
NO 2003001188	A	20030513	NO 2003-1188	20030314	<--	
MX 2003002299	A	20030606	MX 2003-2299	20030317	<--	
ZA 2003004468	A	20040624	ZA 2003-4468	20030609	<--	
ZA 2003004471	A	20040624	ZA 2003-4471	20030609	<--	
ZA 2003004473	A	20040624	ZA 2003-4473	20030609	<--	
ZA 2003004472	A	20040625	ZA 2003-4472	20030609	<--	
ZA 2003004474	A	20040625	ZA 2003-4474	20030609	<--	
NO 2003002704	A	20030821	NO 2003-2704	20030613	<--	
MX 2003005609	A	20031006	MX 2003-5609	20030620	<--	
MX 2003005610	A	20031006	MX 2003-5610	20030620	<--	
US 20040224944	A1	20041111	US 2003-624800	20030722	<--	
US 7008948	B2	20060307				
US 20040116454	A1	20040617	US 2003-692355	20031023	<--	
US 7390815	B2	20080624				
US 20040157893	A1	20040812	US 2003-722374	20031125	<--	
HK 1057888	A1	20061124	HK 2003-108639	20031126	<--	
US 20040132781	A1	20040708	US 2003-736426	20031215	<--	
US 7087603	B2	20060808				
US 20040167141	A1	20040826	US 2004-775699	20040210	<--	
US 7427681	B2	20080923				
HK 1060347	A1	20061201	HK 2004-101883	20040315	<--	
HK 1062565	A1	20090731	HK 2004-105510	20040727	<--	
JP 2005097322	A	20050414	JP 2004-366925	20041217	<--	
US 20070270444	A1	20071122	US 2006-369220	20060306	<--	
AU 2006201228	A1	20060413	AU 2006-201228	20060321	<--	
AU 2006201229	A1	20060413	AU 2006-201229	20060321	<--	
AU 2006201229	B2	20081120				
AU 2006201230	A1	20060413	AU 2006-201230	20060321	<--	
AU 2006201230	B2	20080911				
AU 2006201262	A1	20060427	AU 2006-201262	20060321	<--	
AU 2006201262	B2	20080904				
AU 2006201263	A1	20060427	AU 2006-201263	20060321	<--	
AU 2006201263	B2	20081030				
AU 2006201264	A1	20060427	AU 2006-201264	20060321	<--	
AU 2006201265	A1	20060427	AU 2006-201265	20060321	<--	
AU 2006201265	B2	20080904				
US 20060258658	A1	20061116	US 2006-492450	20060725	<--	
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723	<--	
JP 2008115195	A	20080522	JP 2008-15681	20080125	<--	
JP 2008189682	A	20080821	JP 2008-95581	20080401	<--	
JP 2008260767	A	20081030	JP 2008-95584	20080401	<--	
JP 2008222719	A	20080925	JP 2008-97620	20080403	<--	
JP 2008189687	A	20080821	JP 2008-98506	20080404	<--	
US 20080287444	A1	20081120	US 2008-109598	20080425	<--	
JP 2008201808	A	20080904	JP 2008-121723	20080507	<--	
JP 2008247920	A	20081016	JP 2008-121724	20080507	<--	
JP 2008247921	A	20081016	JP 2008-121727	20080507	<--	
AU 2008252044	A1	20090122	AU 2008-252044	20081203	<--	
JP 2009155352	A	20090716	JP 2009-101481	20090417	<--	
PRIORITY APPLN. INFO.:			US 2000-232795P	P	20000915	<--
			US 2000-257887P	P	20001221	<--
			US 2001-286949P	P	20010427	<--
			AU 2001-296871	A3	20010914	<--
			AU 2001-296875	A3	20010914	<--
			AU 2001-90914	A	20010914	<--
			AU 2001-90944	A3	20010914	<--
			AU 2001-91013	A3	20010914	<--
			AU 2001-94558	A3	20010914	<--
			AU 2001-96871	T0	20010914	<--



AU	2001-96875	T0	20010914	<--
EP	2001-971082	A3	20010914	<--
JP	2002-526860	A3	20010914	<--
US	2001-952671	A3	20010914	<--
US	2001-953471	A3	20010914	<--
US	2001-955601	A3	20010914	<--
WO	2001-US42152	W	20010914	<--
AU	2002-234047	A3	20011219	<--
AU	2002-34047	T0	20011219	<--
EP	2001-273861	A	20011219	<--
EP	2001-994323	A3	20011219	<--
JP	2002-551561	A3	20011219	<--
JP	2002-557938	A3	20011219	<--
JP	2002-559413	A3	20011219	<--
JP	2002-563142	A3	20011219	<--
JP	2002-565976	A3	20011219	<--
JP	2002-567928	A3	20011219	<--
US	2001-26966	A1	20011219	<--
WO	2001-US49139	W	20011219	<--
WO	2001-US50312	W	20011219	<--
JP	2002-551562	A3	20011220	<--
JP	2002-559414	A3	20011220	<--
US	2001-34019	A3	20011220	<--
US	2001-34683	A1	20011220	<--
IN	2003-KN795	A3	20030619	<--
US	2003-624800	A3	20030722	<--
US	2004-775699	A1	20040210	<--
JP	2004-366925	A3	20041217	<--
AU	2006-201396	A3	20060404	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:247584

ED Entered STN: 22 Mar 2002

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRY; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W =

C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocycl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocycl ring or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocycl ring or heteroaryl; or N(R7)2 = heterocycl ring or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 = CR9; Z2 and Z3 = N; Z4 = CR9]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IC ICM C07D403-12
ICS C07D401-14; A61K031-506; A61K031-53; A61P035-00; C07D403-14;
C07D405-14; C07D521-00

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
[4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl]-5-methyl-2H-pyrazol-3-ylamine
404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-
trifluoromethylphenyl)pyrimidine 404827-84-5P,
4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-
trifluoromethylphenyl)pyrimidine 404827-87-8P,
4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-
trifluoromethylphenyl)pyrimidine 404827-89-0P,
6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidine 404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 404827-91-4P,
4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-
cycloheptapyrimidine 404827-97-0P,
4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
hexahydrocyclooctapyrimidine 404827-98-1P,

4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-
 pyrimidin-4-one 404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-
 quinazolin-4-one 404828-04-2P, 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-
 quinazolin-4-one 404828-05-3P, 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-
 4-one 404828-06-4P, 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-
 one 404828-30-4P, (2-Chloroquinazolin-4-yl) (5-methyl-1H-pyrazol-3-
 yl)amine 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
 404829-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of heterocyclypyrazolamines and analogs as
 protein kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease)

IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-
 Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (1H-
 indazol-3-yl)amine 404826-30-8P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (7-
 fluoro-1H-indazol-3-yl)amine 404826-32-0P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5-
 fluoro-1H-indazol-3-yl)amine 404826-33-1P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5,7-
 difluoro-1H-indazol-3-yl)amine 404826-34-2P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-35-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-36-4P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-37-5P,
 (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-38-6P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-
 tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
 [6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-
 d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-
 cycloheptapyrimidin-4-yl]amine 404826-41-1P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-
 5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-
 5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-
 4-yl]amine 404826-46-6P,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-
 yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-
 yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-
 3-yl)amine 404826-51-3P,

[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
 [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
 [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
 (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P,
 [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,
 (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P,
 (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P,
 (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P,
 (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P,
 (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P,
 (4-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P,
 [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine

404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine ~~404827-32-3P~~, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine ~~404827-33-4P~~, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine ~~404827-34-5P~~, [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-

yl)amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-41-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-43-6P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-44-7P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-45-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-46-9P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](1H-indazol-3-yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-48-1P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-52-7P, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404827-53-8P, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[(2-(2-Trifluoromethylphenyl)quinazolin-4-yl)amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P, (1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-08-6P, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P, (2-Cyclohexylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P,

[2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P, [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, [2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine

404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-94-0P, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl [2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-

yl)amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P, [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P, [5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P, (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P, (6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P, (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine

404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine
 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine
 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine
 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine
 404829-60-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P,
 (5-Fluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amine 404829-63-6P,
 (1H-Indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinoline-1-yl]amine
 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine 404829-67-0P,
 (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine
 404829-68-1P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine
 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-yl)amine
 404829-71-6P, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-yl)amine
 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine
 404829-77-2P, (2-Phenylquinolin-4-yl) (1H-1,2,4-triazol-3-yl)amine
 404829-78-3P, (1H-[1,2,4]Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404845-75-6P 404870-11-7P 404870-12-8P 404870-14-0P 404870-16-2P
 404870-18-4P 404870-20-8P 404870-22-0P 404870-24-2P 404870-26-4P
 404870-27-5P 404870-28-6P 404870-29-7P 404870-30-0P 404870-31-1P
 404870-32-2P 404870-33-3P 404870-34-4P 404870-35-5P 404870-36-6P
 404870-37-7P 404870-38-8P 404870-39-9P 404870-40-2P 404870-41-3P
 404870-42-4P 404870-43-5P 404870-44-6P 404870-45-7P 404870-46-8P
 404870-47-9P 404870-48-0P 404870-49-1P 404870-50-4P 404870-51-5P
 404870-52-6P

RL: FAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclic pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

II 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-

pyrimidin-4-one 404829-31-8P,


(6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404827-83-4 HCAPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-84-5 HCAPLUS

CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-86-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-87-8 HCAPLUS


CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404828-02-0 HCAPLUS
 CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404829-31-8 HCAPLUS
 CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-46-6P, (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P, (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P, (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-Fluoro-1H-indazol-3-yl)amine 404826-55-7P, (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-

yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] [6-methyl-2-phenylpyrimidin-4-yl]amine 404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-51-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)



RN 404826-56-8 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)



RN 404826-57-9 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-

fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-59-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 404827-32-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-


10/595,734

(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-34-5 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS

CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-37-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl-
(CA INDEX NAME)


RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS


CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(CA INDEX NAME)

RN 404829-48-7 HCAPLUS


CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)

RN 404829-49-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)


RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)




RN 404829-51-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)




RN 404829-52-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)




RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA
INDEX NAME)



RN 404829-79-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(10 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 18 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:220583 HCAPLUS Full-text
DOCUMENT NUMBER: 136:247583
TITLE: Preparation of pyrazolamines and analogs as protein
kinase inhibitors for treatment of cancer, diabetes,
and Alzheimer's disease
INVENTOR(S): Davies, Robert; Bebbington, David; Knegetel, Ronald;
Wannamaker, Marion; Li, Pan; Forester, Cornelia;
Pierce, Albert; Kay, David
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 373 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022607	A1	20020321	WO 2001-US28940	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422379	A1	20020321	CA 2001-2422379	20010914 <--
CA 2422379	C	20081118		
AU 2001091013	A	20020326	AU 2001-91013	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--

US 6610677	B2	20030826		
BR 2001014088	A	20030617	BR 2001-14088	20010914 <--
EP 1318997	A1	20030618	EP 2001-971082	20010914 <--
EP 1318997	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002173	A2	20030929	HU 2003-2173	20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
JP 2004509117	T	20040325	JP 2002-526860	20010914 <--
JP 4170752	B2	20081022		
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
NZ 525008	A	20041224	NZ 2001-525008	20010914 <--
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--
AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--
AT 327991	T	20060615	AT 2001-973050	20010914 <--
AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
CN 1926132	A	20070307	CN 2001-817434	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
RU 2340611	C2	20081210	RU 2003-110575	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--



ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
IN 2003KN00295	A	20060922	IN 2003-KN295	20030310 <--
NO 2003001191	A	20030513	NO 2003-1191	20030314 <--
NO 327708	B1	20090914		
KR 896664	B1	20090514	KR 2003-703787	20030314 <--
MX 2003002291	A	20030606	MX 2003-2291	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--
US 7087603	B2	20060808		
HK 1058356	A1	20061201	HK 2003-109140	20031215 <--
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--

AU 2001-90914	A 20010914 <--
AU 2001-90944	A3 20010914 <--
AU 2001-91013	A3 20010914 <--
AU 2001-94558	A3 20010914 <--
AU 2001-96871	T0 20010914 <--
AU 2001-96875	T0 20010914 <--
EP 2001-971082	A3 20010914 <--
JP 2002-526860	A3 20010914 <--
US 2001-952671	A3 20010914 <--
US 2001-953471	A3 20010914 <--
US 2001-955601	A3 20010914 <--
WO 2001-US28940	W 20010914 <--
AU 2002-234047	A3 20011219 <--
AU 2002-34047	T0 20011219 <--
EP 2001-273861	A 20011219 <--
EP 2001-994323	A3 20011219 <--
JP 2002-551561	A3 20011219 <--
JP 2002-557938	A3 20011219 <--
JP 2002-559413	A3 20011219 <--
JP 2002-563142	A3 20011219 <--
JP 2002-565976	A3 20011219 <--
JP 2002-567928	A3 20011219 <--
US 2001-26966	A1 20011219 <--
WO 2001-US49139	W 20011219 <--
WO 2001-US50312	W 20011219 <--
JP 2002-551562	A3 20011220 <--
JP 2002-559414	A3 20011220 <--
US 2001-34019	A3 20011220 <--
US 2001-34683	A1 20011220 <--
IN 2003-KN795	A3 20030619 <--
US 2003-624800	A3 20030722 <--
US 2004-775699	A1 20040210 <--
JP 2004-366925	A3 20041217 <--
AU 2006-201396	A3 20060404 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:247583

ED Entered STN: 22 Mar 2002

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their

intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6CONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6NNR6, CR6NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring C]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-3 β , Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IC ICM C07D403-12

ICS C07D401-14; A61K031-506; A61K031-4155; A61P035-00; C07D403-14;
C07D405-14; C07D409-14; C07D471-04; C07D487-04; C07D401-12;
C07D493-04; C07D498-04; C07D513-04

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
[4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-84-5P,
4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-87-8P,
4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-trifluoromethylphenyl)pyrimidine
404827-89-0P,
6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine
404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine
404827-91-4P,
4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine

404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidine 404827-97-0P,
 4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidine 404827-98-1P,
 4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzotrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
~~404828-02-0P~~, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404828-03-1P,
 2-(2-Chloro-5-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-04-2P,
 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-05-3P,
 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-4-one 404828-06-4P,
 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-30-4P,
 (2-Chloroquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine
~~404829-31-3P~~, (6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclypyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT ~~404826-28-4P~~, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-30-8P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-32-0P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-33-1P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-34-2P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-35-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-36-4P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-37-5P,
 (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-38-6P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
 [6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-41-1P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine ~~404826-46-6P~~,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
~~404826-47-7P~~, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine ~~404826-48-8P~~,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine ~~404826-49-9P~~,

(1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 [5,7-Difluoro-1H-indazol-3-yl] [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
 [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
 [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
 (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P,
 [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,
 (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P,
 (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P,
 (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P,
 (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P,
 (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P,
 (4-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,

yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P, (5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,

[6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-41-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404827-43-6P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-44-7P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-45-8P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-46-9P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-48-1P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine ~~404827-52-7P~~, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine ~~404827-53-8P~~, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-08-6P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P, (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine

404828-14-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P, [2-(4-Ethylsulfonylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine
 404828-24-6P, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl]amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl]amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl]amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine

404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-(4-(2-Hydroxyethyl)piperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-94-0P, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P,

(5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P,
 (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P,
 [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P,
 [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P,
 [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P,
 [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine
 RL: FAC (Pharmacological activity); SPN (Synthetic preparation);
TNU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P,
 [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P,
 (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine 404829-25-0P,
 (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine
 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine
 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine
404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P,
 [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P,
 [5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P,
 [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine
404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P,
 [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P,
 [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine

404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine
 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P,
 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine
 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P,
 (5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amine 404829-63-6P,
 (1H-Indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine
 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine 404829-67-0P,
 (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine
 404829-68-1P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine
 404829-77-2P, (2-Phenylquinolin-4-yl) (1H-1,2,4-triazol-3-yl)amine
 404829-78-3P, (1H-[1,2,4]Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404845-75-6P 404872-66-8P 404872-67-9P 404872-68-0P
 404872-69-1P 404872-70-4P 404872-71-5P 404872-72-6P 404872-73-7P
 404872-74-8P 404872-75-9P 404872-76-0P 404872-77-1P 404872-78-2P
404872-79-3P 404872-80-6P 404872-81-7P
404872-82-8P 404872-83-9P 404872-84-0P
404872-85-1P 404872-86-2P 404872-87-3P
 404872-88-4P 404872-89-5P 404872-90-8P 404872-91-9P 404872-92-0P
 404872-93-1P 404872-94-2P 404872-95-3P 404872-96-4P 404872-97-5P
 404872-98-6P 404872-99-7P 404873-00-3P 404873-01-4P 404873-02-5P
 404873-03-6P 404873-04-7P 404873-05-8P 404873-06-9P
404873-07-0P 404873-08-1P 404873-09-2P
404873-10-5P 404873-11-6P 404873-12-7P
404873-13-8P 404873-14-9P 404873-15-0P
404873-16-1P 404873-17-2P 404873-18-3P
404873-19-4P 404873-20-7P 404873-21-8P
404873-22-9P 404873-23-0P 404873-24-1P
404873-25-2P 404873-26-3P 404873-27-4P
404873-28-5P 404873-29-6P 404873-30-9P

404873-31-0P 404873-32-1P 404873-33-2P
 404873-34-3P 404873-35-4P 404873-36-5P
 404873-37-6P 404873-38-7P 404873-39-8P
 404873-40-1P 404873-41-2P 404873-42-3P 404873-43-4P 404873-44-5P
 404873-45-6P 404873-46-7P 404873-47-8P 404873-48-9P 404873-49-0P
 404873-50-3P 404873-51-4P 404873-52-5P 404873-53-6P 404873-54-7P
 404873-55-8P 404873-56-9P 404873-57-0P 404873-58-1P 404873-59-2P
 404873-60-5P 404873-61-6P 404873-62-7P 404873-63-8P 404873-64-9P
 404873-65-0P 404873-66-1P 404873-67-2P 404873-68-3P 404873-69-4P
 404873-70-7P 404873-71-8P 404873-72-9P 404873-73-0P 404873-74-1P
 404873-75-2P 404873-76-3P 404873-77-4P 404873-78-5P 404873-79-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


IT 404827-63-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404827-83-4 HCAPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA
 INDEX NAME)




RN 404827-84-5 HCAPLUS


CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA
 INDEX NAME)




RN 404827-86-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)


RN 404827-87-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)

RN 404828-02-0 HCAPLUS

CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX
NAME)

RN 404829-31-8 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-

Methyl-2H-pyrazol-3-yl)amine 404826-46-6P,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-
 yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-
 yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-
 3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-
 yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-
 indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine
404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-
 yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-
 yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-
 yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-
 yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine
404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-
 yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-
 trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-
 yl)amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-
 yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-
 3-yl)amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine
404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-
 yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine
404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-
 2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine
404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-44-3P, [6-Methyl-2-phenylpyrimidin-4-yl] (5-phenyl-2H-
 pyrazol-3-yl)amine 404829-45-4P,
 [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-
 yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-
 yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-
 pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-
 2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine


404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-
tolylpyrimidin-4-yl)amine 404829-53-4P,
(1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine
404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-
trifluoromethylphenyl)pyrimidin-4-yl]amine 404872-66-8P
404872-79-3P 404872-80-6P 404872-81-7P
404872-82-8P 404872-83-9P 404872-84-0P
404872-85-1P 404872-86-2P 404872-87-3P
404873-06-9P 404873-07-0P 404873-08-1P
404873-09-2P 404873-10-5P 404873-11-6P
404873-12-7P 404873-13-8P 404873-14-9P
404873-15-0P 404873-16-1P 404873-17-2P
404873-18-3P 404873-19-4P 404873-20-7P
404873-21-8P 404873-22-9P 404873-23-0P
404873-24-1P 404873-25-2P 404873-26-3P
404873-27-4P 404873-28-5P 404873-29-6P
404873-30-9P 404873-31-0P 404873-32-1P
404873-33-2P 404873-34-3P 404873-36-5P
404873-37-6P 404873-38-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and
analogs as protein kinase inhibitors for treatment of cancer,
diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-
yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-
pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-
pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404826-50-2 HCAPLUS


CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404826-51-3 HCAPLUS


CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

pyrimidinyl)- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-56-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-57-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)



RN 404826-58-0 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)



RN 404826-59-1 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-

(CA INDEX NAME)




RN 404827-32-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-34-5 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS


CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-37-4 HCAPLUS


CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-
(CA INDEX NAME)

RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl-
(CA INDEX NAME)


RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-


10/595,734

(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-48-7 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-49-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-51-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-52-3 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-53-4 HCAPLUS
 CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-79-4 HCAPLUS
 CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404872-66-8 HCAPLUS
 CN 1H-Indazol-3-amine, N-[5-chloro-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404872-79-3 HCAPLUS
 CN 1H-Indazol-3-amine, N-[6-(4-aminocyclohexyl)-5-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404872-80-6 HCAPLUS

CN Acetamide, N-[4-[6-(1H-indazol-3-ylamino)-5-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl]- (CA INDEX NAME)




RN 404872-81-7 HCAPLUS

CN Methanesulfonamide, N-[4-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl-4-pyrimidinyl]cyclohexyl]- (CA INDEX NAME)




RN 404872-82-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5-methyl-6-(4-morpholinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 404872-83-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5-methyl-6-(1-piperazinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 404872-84-0 HCAPLUS

CN Ethanone, 1-[4-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl-4-pyrimidinyl]-1-piperazinyl]- (CA INDEX NAME)




RN 404872-85-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl-4-pyrimidinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 404872-86-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5-methyl-6-[4-(methylsulfonyl)-1-piperazinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404872-87-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-methyl-1-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-06-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 404873-07-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-[1-(methylsulfonyl)-2-piperidinyl]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-08-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 3-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-methyl-, phenylmethyl ester (CA INDEX NAME)




RN 404873-09-2 HCAPLUS

CN Ethanone, 1-[3-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-1-piperazinyl]- (CA INDEX NAME)




RN 404873-10-5 HCAPLUS

CN 1H-indazol-3-amine, N-[6-(2-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-11-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(1-methyl-2-piperazinyl)-2-(trifluoromethyl)phenyl]-4-pyrimidinyl- (CA INDEX NAME)




RN 404873-12-7 HCAPLUS

CN Acetamide, N-[2-[6-(1H-indazol-3-ylamino)-2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl- (CA INDEX NAME)




RN 404873-13-8 HCAPLUS

CN Methanesulfonamide, N-[2-[6-(1H-indazol-3-ylamino)-2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl- (CA INDEX NAME)




RN 404873-14-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-aminocyclohexyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-15-0 HCAPLUS

CN Carbamic acid, [2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 404873-16-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-aminoethyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-17-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-piperidinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-18-3 HCAPLUS

CN Acetamide, N-[2-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]ethyl]- (CA INDEX NAME)




RN 404873-19-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 404873-20-7 HCAPLUS

CN Ethanone, 1-[4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-1-piperidinyl]- (CA INDEX NAME)




RN 404873-21-8 HCAPLUS

CN Methanesulfonamide, N-[2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]ethyl]- (CA INDEX NAME)




RN 404873-22-9 HCAPLUS

CN Ethanone, 1-[2-[2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-4-pyrimidinyl]-1-piperidinyl]- (CA INDEX NAME)




RN 404873-23-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-6-[1-(methylsulfonyl)-2-piperidinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-24-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-25-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(1-piperazinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-26-3 HCAPLUS

CN Ethanone, 1-[4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-1-piperazinyl]- (CA INDEX NAME)



RN 404873-27-4 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-(1H-indazol-3-ylamino)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (CA INDEX NAME)



RN 404873-28-5 HCAPLUS


CN 1H-Indazol-3-amine, N-[6-[4-(methylsulfonyl)-1-piperazinyl]-2-[2-

(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-29-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-methyl-1-piperazinyl)-2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-30-9 HCAPLUS

CN 4-Pyrimidinecarbonitrile, 6-(1H-indazol-3-ylamino)-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404873-31-0 HCAPLUS


CN 4,5-Pyrimidinediamine, N4-1H-indazol-3-yl-N5-methyl-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404873-32-1 HCAPLUS


CN 1H-Indazol-3-amine, N-[6-(1H-imidazol-5-yl)-2-(trifluoromethyl)phenyl]-

4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-33-2 HCAPLUS

CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N4-1H-indazol-3-yl-N6-(phenylmethyl)- (CA INDEX NAME)




RN 404873-34-3 HCAPLUS

CN Acetamide, N-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-[2-(trifluoromethyl)phenyl]-5-pyrimidinyl]- (CA INDEX NAME)




RN 404873-36-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenoxy-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404873-37-6 HCAPLUS

CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N6-(5,7-difluoro-1H-indazol-3-yl)-N4,N4-dimethyl- (CA INDEX NAME)



RN 404873-38-7 HCAPLUS

CN 4-Pyrimidinesulfonamide, 2-(2-chlorophenyl)-6-(1H-indazol-3-ylamino)-5-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 19 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:220581 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:247581

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Golec, Julian M. C.; Charrier, Jean-Damien; Knegt, Ronald; Bebbington, David; Davies, Robert; Li, Pan
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022605	A1	20020321	WO 2001-US28793	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				

US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2422377 A1 20020321 CA 2001-2422377 20010914 <--
 AU 2001092670 A 20020326 AU 2001-92670 20010914 <--
 US 20030055044 A1 20030320 US 2001-953505 20010914 <--
 US 6638926 B2 20031028
 US 20030064981 A1 20030403 US 2001-952836 20010914 <--
 US 6613776 B2 20030902
 US 20030064982 A1 20030403 US 2001-952875 20010914 <--
 US 7473691 B2 20090106
 US 20030073687 A1 20030417 US 2001-952671 20010914 <--
 US 6660731 B2 20031209
 US 20030078166 A1 20030424 US 2001-955601 20010914 <--
 US 6696452 B2 20040224
 US 20030083327 A1 20030501 US 2001-952833 20010914 <--
 US 6610677 B2 20030826
 EP 1317449 A1 20030611 EP 2001-973050 20010914 <--
 EP 1317449 B1 20060531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

ZA 2003001701 A 20040301 ZA 2003-1701 20010914 <--
 ZA 2003001703 A 20040302 ZA 2003-1703 20010914 <--
 JP 2004509115 T 20040325 JP 2002-526858 20010914 <--
 US 20040097501 A1 20040520 US 2001-953471 20010914 <--
 US 7115739 B2 20061003
 US 20050004110 A1 20050106 US 2001-952878 20010914 <--
 US 7098330 B2 20060829
 NZ 525014 A 20050930 NZ 2001-525014 20010914 <--
 ES 2242771 T3 20051116 ES 2001-971006 20010914 <--
 AT 326458 T 20060615 AT 2001-970969 20010914 <--
 AT 327990 T 20060615 AT 2001-970971 20010914 <--
 AT 327992 T 20060615 AT 2001-971082 20010914 <--
 AT 327991 T 20060615 AT 2001-973050 20010914 <--
 AT 326459 T 20060615 AT 2001-977779 20010914 <--
 EP 1698627 A1 20060906 EP 2006-10798 20010914 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AT 346064 T 20061215 AT 2001-975210 20010914 <--
 ES 2266258 T3 20070301 ES 2001-970971 20010914 <--
 ES 2266259 T3 20070301 ES 2001-971082 20010914 <--
 AT 363284 T 20070615 AT 2001-977783 20010914 <--
 NZ 545284 A 20070629 NZ 1984-5452 20010914 <--
 CN 100355750 C 20071219 CN 2001-817427 20010914 <--
 CA 2432303 A1 20020829 CA 2001-2432303 20011219 <--
 AU 2002255452 A1 20020904 AU 2002-255452 20011219 <--
 AU 2002255452 B2 20060608
 CA 2432223 A1 20020906 CA 2001-2432223 20011219 <--
 CA 2432223 C 20080520
 AU 2001297619 A1 20020912 AU 2001-297619 20011219 <--
 AU 2001297619 B2 20060608
 EP 1345922 A1 20030924 EP 2001-271061 20011219 <--
 EP 1345922 B1 20060531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1355905 A1 20031029 EP 2001-273861 20011219 <--
 EP 1355905 B1 20070221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
MX 2003002289	A	20030606	MX 2003-2289	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
HK 1057887	A1	20061215	HK 2003-108524	20031121 <--
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--

10/595,734



JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90914	A 20010914 <--
			AU 2001-90944	A3 20010914 <--
			AU 2001-91013	A3 20010914 <--
			AU 2001-94558	A3 20010914 <--
			AU 2001-96871	T0 20010914 <--
			AU 2001-96875	T0 20010914 <--
			EP 2001-971082	A3 20010914 <--
			JP 2002-526860	A3 20010914 <--
			US 2001-952671	A3 20010914 <--
			US 2001-953471	A3 20010914 <--
			US 2001-955601	A3 20010914 <--
			WO 2001-US28793	W 20010914 <--
			AU 2002-234047	A3 20011219 <--
			AU 2002-34047	T0 20011219 <--
			EP 2001-273861	A 20011219 <--
			EP 2001-994323	A3 20011219 <--
			JP 2002-551561	A3 20011219 <--
			JP 2002-557938	A3 20011219 <--
			JP 2002-559413	A3 20011219 <--
			JP 2002-563142	A3 20011219 <--
			JP 2002-565976	A3 20011219 <--
			JP 2002-567928	A3 20011219 <--
			US 2001-26966	A1 20011219 <--
			WO 2001-US49139	W 20011219 <--
			WO 2001-US50312	W 20011219 <--
			JP 2002-551562	A3 20011220 <--
			JP 2002-559414	A3 20011220 <--
			US 2001-34019	A3 20011220 <--
			US 2001-34683	A1 20011220 <--
			IN 2003-KN795	A3 20030619 <--
			US 2003-624800	A3 20030722 <--
			US 2004-775699	A1 20040210 <--
			JP 2004-366925	A3 20041217 <--
			AU 2006-201396	A3 20060404 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:247581

ED Entered STN: 22 Mar 2002

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover pyrazolamines and indazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N; at least one of Z1 or Z3 = N]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IC ICM C07D403-12
ICS C07D401-14; C07D409-14; A61K031-497; A61K031-53; A61P035-00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
[4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine

404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
 404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
 4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-trifluoromethylphenyl)pyrimidine 404827-89-0P,
 6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 404827-91-4P,
 4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
 4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
 4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
 4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
 4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
 404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidine 404827-97-0P,
 4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidine 404827-98-1P,
 4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-04-2P, 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-05-3P, 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-4-one 404828-06-4P, 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-30-4P, (2-Chloroquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
 404829-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-30-8P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-32-0P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-33-1P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-34-2P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-35-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-36-4P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-37-5P,
 (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-38-6P,

(5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
 [6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-41-1P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-45-6P,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
 [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
 [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
 (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P,
 [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,

(4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-

4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P,
 (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-
 indazol-3-yl)amine 404827-26-5P,
 [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-
 yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P,
 (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-
 yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P,
 (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-32-3P,
 [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-
 3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-
 trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-
 yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-
 methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-
 yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine
 bis(trifluoroacetate) 404827-41-4P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5-fluoro-1H-
 indazol-3-yl)amine 404827-43-6P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl]amine 404827-44-7P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl]amine 404827-45-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl]amine 404827-46-9P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (1H-indazol-3-
 yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-48-1P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5,7-difluoro-
 1H-indazol-3-yl)amine 404827-49-2P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidin-4-yl]amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-
 yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-
 3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P,
 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-
 carboxylic acid methyl ester 404827-56-1P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine
 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-
 indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-
 yl)amine bis(trifluoroacetate) 404827-64-1P,

[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P,
 (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-08-6P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P,
 (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P,
 (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P,
 [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
 [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P,
 [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P,
 [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
 [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P,
 [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P,
 [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-ylquinazolin-4-yl)amine 404828-38-2P,
 [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P,
 [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P,
 (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P,
 (2H-Pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P,
 (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P,
 (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P,

(5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine
 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine
 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-74-6P, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine
 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine
 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine
 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine
 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine
 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine
 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine
 404828-94-0P, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-

yl)quinazolin-4-yl]amine 404828-98-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P,
 (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P,
 (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P,
 (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P,
 [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P,
 [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P,
 [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P,
 [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine
 RL: FAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P,
 [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P,
 (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P,
 [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P,
 [5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P

, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P,
 [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P,
 [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P,
 [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 (6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P,
 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P,
 (5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amine 404829-63-6P,
 (1H-Indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinoline-1-yl]amine 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine 404829-67-0P, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-68-1P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-77-2P, (2-Phenylquinolin-4-yl) (1H-1,2,4-triazol-3-yl)amine 404829-78-3P, (1H-[1,2,4]Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-79-4P,

(1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404845-75-6P 404867-38-5P 404867-39-6P 404867-40-9P 404867-41-0P
 404867-42-1P 404867-43-2P 404867-44-3P 404867-45-4P 404867-46-5P
 404867-47-6P 404867-48-7P 404867-49-8P 404867-50-1P 404867-51-2P
 404867-52-3P 404867-53-4P 404867-54-5P 404867-55-6P 404867-56-7P
 404867-57-8P 404867-58-9P 404867-59-0P 404867-60-3P 404867-61-4P
 404867-62-5P 404867-63-6P 404867-64-7P 404867-65-8P 404867-67-0P
 404867-68-1P 404867-69-2P 404867-70-5P 404867-71-6P 404867-72-7P
 404867-73-8P 404867-74-9P 404867-75-0P 404867-76-1P 404867-77-2P
 404867-78-3P 404867-79-4P 404867-80-7P 404867-81-8P 404867-82-9P
 404867-83-0P 404867-84-1P 404867-85-2P 404867-86-3P 404867-87-4P
 404867-88-5P 404867-89-6P 404867-94-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


IT 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404827-83-4 HCAPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-84-5 HCAPLUS


CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-86-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)


RN 404827-87-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)

RN 404828-02-0 HCAPLUS

CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX
NAME)

RN 404829-31-8 HCAPLUS


CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)

IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-46-6P, (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P, (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P, (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-Fluoro-1H-indazol-3-yl)amine 404826-55-7P, (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P, [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P, [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-52-7P, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404829-29-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] [6-methyl-2-phenylpyrimidin-4-yl]amine 404829-39-6P 404829-40-9P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P, [6-Ethyl-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P, [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P, (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-

2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-
 tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine
404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer,
 diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-51-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-56-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-57-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-59-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-32-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-34-5 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS

CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl]-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-37-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl- (CA INDEX NAME)




RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-48-7 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-49-8 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-51-2 HCAPLUS


CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-52-3 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)


RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]-
(CA INDEX NAME)



RN 404829-79-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 20 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:220580 HCAPLUS Full-text

DOCUMENT NUMBER: 136:247606

TITLE: Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease.

INVENTOR(S): Davies, Robert; Bebbington, David; Binch, Haley; Knegetel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022604	A1	20020321	WO 2001-US28792	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				


	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
CA 2422371	A1	20020321	CA 2001-2422371 20010914 <--
AU 2001094558	A	20020326	AU 2001-94558 20010914 <--
US 20030055044	A1	20030320	US 2001-953505 20010914 <--
US 6638926	B2	20031028	
US 20030064981	A1	20030403	US 2001-952836 20010914 <--
US 6613776	B2	20030902	
US 20030064982	A1	20030403	US 2001-952875 20010914 <--
US 7473691	B2	20090106	
US 20030073687	A1	20030417	US 2001-952671 20010914 <--
US 6660731	B2	20031209	
US 20030078166	A1	20030424	US 2001-955601 20010914 <--
US 6696452	B2	20040224	
US 20030083327	A1	20030501	US 2001-952833 20010914 <--
US 6610677	B2	20030826	
EP 1317450	A1	20030611	EP 2001-975210 20010914 <--
EP 1317450	B1	20061122	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 2003002172	A2	20030929	HU 2003-2172 20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701 20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703 20010914 <--
JP 2004512277	T	20040422	JP 2002-526857 20010914 <--
JP 4105948	B2	20080625	
US 20040097501	A1	20040520	US 2001-953471 20010914 <--
US 7115739	B2	20061003	
US 20050004110	A1	20050106	US 2001-952878 20010914 <--
US 7098330	B2	20060829	
NZ 525009	A	20050527	NZ 2001-525009 20010914 <--
ES 2242771	T3	20051116	ES 2001-971006 20010914 <--
AT 326458	T	20060615	AT 2001-970969 20010914 <--
AT 327990	T	20060615	AT 2001-970971 20010914 <--
AT 327992	T	20060615	AT 2001-971082 20010914 <--
AT 327991	T	20060615	AT 2001-973050 20010914 <--
AT 326459	T	20060615	AT 2001-977779 20010914 <--
EP 1698627	A1	20060906	EP 2006-10798 20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
AT 346064	T	20061215	AT 2001-975210 20010914 <--
ES 2266258	T3	20070301	ES 2001-970971 20010914 <--
ES 2266259	T3	20070301	ES 2001-971082 20010914 <--
AT 363284	T	20070615	AT 2001-977783 20010914 <--
NZ 545284	A	20070629	NZ 1984-5452 20010914 <--
CN 100355750	C	20071219	CN 2001-817427 20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303 20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452 20011219 <--
AU 2002255452	B2	20060608	
CA 2432223	A1	20020906	CA 2001-2432223 20011219 <--
CA 2432223	C	20080520	
AU 2001297619	A1	20020912	AU 2001-297619 20011219 <--
AU 2001297619	B2	20060608	
EP 1345922	A1	20030924	EP 2001-271061 20011219 <--
EP 1345922	B1	20060531	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1355905	A1	20031029	EP 2001-273861 20011219 <--
EP 1355905	B1	20070221	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
IN 2003KN00289	A	20050311	IN 2003-KN289	20030307 <--
NO 2003001190	A	20030513	NO 2003-1190	20030314 <--
MX 2003002292	A	20030606	MX 2003-2292	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
HK 1057748	A1	20070615	HK 2003-108588	20031125 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--


10/595,734

JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90914	A 20010914 <--
			AU 2001-90944	A3 20010914 <--
			AU 2001-91013	A3 20010914 <--
			AU 2001-94558	A3 20010914 <--
			AU 2001-96871	T0 20010914 <--
			AU 2001-96875	T0 20010914 <--
			EP 2001-971082	A3 20010914 <--
			JP 2002-526860	A3 20010914 <--
			US 2001-952671	A3 20010914 <--
			US 2001-953471	A3 20010914 <--
			US 2001-955601	A3 20010914 <--
			WO 2001-US28792	W 20010914 <--
			AU 2002-234047	A3 20011219 <--
			AU 2002-34047	T0 20011219 <--
			EP 2001-273861	A 20011219 <--
			EP 2001-994323	A3 20011219 <--
			JP 2002-551561	A3 20011219 <--
			JP 2002-557938	A3 20011219 <--
			JP 2002-559413	A3 20011219 <--
			JP 2002-563142	A3 20011219 <--
			JP 2002-565976	A3 20011219 <--
			JP 2002-567928	A3 20011219 <--
			US 2001-26966	A1 20011219 <--
			WO 2001-US49139	W 20011219 <--
			WO 2001-US50312	W 20011219 <--
			JP 2002-551562	A3 20011220 <--
			JP 2002-559414	A3 20011220 <--
			US 2001-34019	A3 20011220 <--
			US 2001-34683	A1 20011220 <--
			IN 2003-KN795	A3 20030619 <--
			US 2003-624800	A3 20030722 <--
			US 2004-775699	A1 20040210 <--
			JP 2004-366925	A3 20041217 <--
			AU 2006-201396	A3 20060404 <--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:247606
 ED Entered STN: 22 Mar 2002
 GI



I



II



III

AB The preparation of title compds. I and their pharmaceutically acceptable salts or prodrugs is described [wherein: R1, R2 = dependently form (un)substituted fused, unsatd. or partially unsatd., 5-8 membered carbocyclo ring; R3, R4 = independently H, aliphatic, aryl, heteroaryl, heterocyclyl, or wide variety of functionalized sidechains; or dependently form a fused, 5-8 membered, unsatd. or partially unsatd. ring having 0-3 ring heteroatoms (N, S, O); R5 = fused, (un)substituted 5-7 membered monocyclic ring or 8-10 membered bicyclic ring (aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms (N, S, O))]. For example, chlorination of quinazolinone II with phosphorus oxychloride, followed by condensation with 3-amino-5-methylpyrazole afforded claimed compound III. Compds. I are inhibitors of GSK-3 and Aurora-2 protein kinases. The invention also relates to methods of treating diseases associated with these protein kinases, such as diabetes, cancer and Alzheimer's disease. In bioassays, compds. I inhibited the following kinases with Kis reported < 100 nM: GSK-3 β (163 compds.), AURORA-2 (65 compds.), CDK-2 (no data), ERK2 (8 compds.), AKT (no data), and Human Src kinase (21 compds.). Claims included 146 specific compds., and 188 examples were given. The syntheses of 6 compds. and 46 intermediates are described.

IC ICM C07D403-12

ICS C07D401-14; A61K031-506; A61K031-4155; A61P035-00; C07D403-14;
C07D405-14; C07D521-00; C07D409-14; C07D471-04; C07D487-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT	404826-20-6P	404826-22-8P	404826-23-9P	404826-24-0P	404826-25-1P
	404826-26-2P	404826-28-4P	404826-29-5P	404826-30-8P	
	404826-31-9P	404826-32-0P	404826-33-1P	404826-34-2P	404826-35-3P
	404826-36-4P	404826-37-5P	404826-38-6P	404826-39-7P	404826-40-0P
	404826-41-1P	404826-42-2P	404826-43-3P	404826-44-4P	
	<u>404826-46-6P</u>	<u>404826-47-7P</u>	<u>404826-48-8P</u>		
	<u>404826-49-9P</u>	<u>404826-50-2P</u>	<u>404826-51-3P</u>		
	<u>404826-52-4P</u>	<u>404826-53-5P</u>	<u>404826-54-6P</u>		
	<u>404826-55-7P</u>	<u>404826-56-8P</u>	<u>404826-57-9P</u>		
	<u>404826-58-0P</u>	<u>404826-59-1P</u>	404826-60-4P		
	404826-61-5P	404826-63-7P	404826-64-8P	404826-65-9P	404826-66-0P
	404826-67-1P	404826-68-2P	404826-69-3P	404826-70-6P	404826-71-7P
	404826-72-8P	404826-73-9P	404826-74-0P	404826-75-1P	404826-76-2P
	404826-77-3P	404826-78-4P	404826-79-5P	404826-80-8P	404826-81-9P

404826-82-0P	404826-83-1P	404826-84-2P	404826-85-3P	404826-86-4P
404826-87-5P	404826-88-6P	404826-89-7P	404826-90-0P	404826-91-1P
404826-92-2P	404826-93-3P	404826-94-4P	404826-95-5P	404826-96-6P
404826-97-7P	404826-98-8P	404826-99-9P	404827-01-6P	404827-01-6P
404827-02-7P	404827-03-8P	404827-04-9P	404827-05-0P	404827-07-2P
404827-08-3P	404827-09-4P	404827-10-7P	404827-11-8P	404827-12-9P
404827-14-1P	404827-15-2P	404827-16-3P	404827-24-3P	404827-26-5P
404827-27-6P	404827-28-7P	404827-29-8P	404827-31-2P	404827-35-6P
404827-36-7P	404827-37-8P	404827-38-9P	404827-40-3P	404827-42-5P
404827-43-6P	404827-44-7P	404827-45-8P	404827-46-9P	404827-47-0P
404827-48-1P	404827-49-2P	404827-50-5P	404827-52-7P	
404827-53-8P	404827-54-9P	404827-55-0P	404827-56-1P	
404827-58-3P	404827-62-9P	404827-64-1P	404827-67-4P	404827-70-9P
404827-72-1P	404827-74-3P	404828-07-5P	404828-08-6P	404828-09-7P
404828-10-0P	404828-11-1P	404828-12-2P	404828-13-3P	404828-14-4P
404828-15-5P	404828-16-6P	404828-17-7P	404828-18-8P	404828-19-9P
404828-20-2P	404828-21-3P	404828-22-4P	404828-23-5P	404828-24-6P
404828-25-7P	404828-26-8P	404828-27-9P	404828-28-0P	404828-29-1P
404828-31-5P	404828-32-6P	404828-34-8P	404828-35-9P	404828-36-0P
404828-37-1P	404828-38-2P	404828-39-3P	404828-40-6P	404828-41-7P
404828-42-8P	404828-43-9P	404828-44-0P	404828-45-1P	404828-46-2P
404828-47-3P	404828-48-4P	404828-49-5P	404828-50-8P	404828-51-9P
404828-52-0P	404828-53-1P	404828-55-3P	404828-56-4P	404828-57-5P
404828-59-7P	404828-60-0P	404828-62-2P	404828-63-3P	404828-64-4P
404828-65-5P	404828-66-6P	404828-67-7P	404828-69-9P	404828-71-3P
404828-72-4P	404828-73-5P	404828-74-6P	404828-75-7P	404828-76-8P
404828-77-9P	404828-78-0P	404828-79-1P	404828-80-4P	404828-82-6P
404828-83-7P	404828-84-8P	404828-85-9P	404828-86-0P	404828-88-2P
404828-89-3P	404828-90-6P	404828-91-7P	404828-92-8P	404828-94-0P
404828-96-2P	404828-97-3P	404828-98-4P	404828-99-5P	404829-00-1P
404829-01-2P	404829-02-3P	404829-03-4P	404829-05-6P	404829-06-7P
404829-07-8P	404829-08-9P	404829-16-9P	404829-17-0P	404829-18-1P
404829-19-2P	404829-21-6P	404829-22-7P	404829-23-8P	404829-24-9P
404829-29-4P	404829-30-7P	404829-32-9P		
404829-33-0P	404829-34-1P	404829-35-2P	404829-36-3P	
404829-37-4P	404829-38-5P	404829-39-6P		
404829-40-9P	404829-41-0P	404829-42-1P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

IT	404829-43-2P	404829-44-3P	404829-45-4P		
	404829-46-5P	404829-47-6P	404829-48-7P		
	404829-49-8P	404829-50-1P	404829-51-2P		
	404829-52-3P	404829-53-4P	404829-54-5P		
	404829-55-6P	404829-56-7P	404829-57-8P	404829-60-3P	404829-61-4P,
					(6-Benzyl-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl) (5-fluoro-1H-indazol-3-yl)amine
					404829-62-5P,
					(5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amine
					404829-63-6P 404829-65-8P 404829-66-9P
	404829-67-0P	404829-68-1P	404829-69-2P	404829-70-5P	404829-71-6P
	404829-72-7P	404829-73-8P	404829-74-9P	404829-75-0P	404829-76-1P
	404829-77-2P	404829-78-3P	404829-79-4P	404829-81-8P	
	404844-78-6P	404844-79-7P	404844-80-0P	404844-81-1P	404844-82-2P
	404844-83-3P	404844-84-4P	404844-85-5P	404844-86-6P	404844-87-7P
	404844-88-8P	404844-89-9P	404844-90-2P	404844-91-3P	404844-92-4P
	404844-93-5P	404844-94-6P	404844-95-7P	404844-96-8P	404844-97-9P
	404844-98-0P	404844-99-1P	404845-00-7P	404845-01-8P	404845-02-9P
	404845-03-0P	404845-04-1P	404845-05-2P	404845-06-3P	404845-07-4P

404845-08-5P	404845-09-6P	404845-10-9P	404845-11-0P	404845-12-1P
404845-13-2P	404845-14-3P	404845-15-4P	404845-16-5P	404845-17-6P
404845-18-7P	404845-28-9P	404845-29-0P	404845-30-3P	404845-31-4P
404845-32-5P	404845-33-6P	404845-34-7P	404845-35-8P	404845-36-9P
404845-75-6P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P 61272-71-7P
 61272-72-8P 404826-17-1P, 2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
 2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
 4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404827-60-7P 404827-65-2P
 404827-75-4P 404827-76-5P 404827-77-6P 404827-78-7P 404827-79-8P
 404827-80-1P 404827-81-2P 404827-82-3P 404827-83-4P
404827-84-5P 404827-85-6P 404827-86-7P
404827-87-8P 404827-88-9P 404827-89-0P 404827-90-3P
 404827-91-4P 404827-92-5P 404827-93-6P 404827-94-7P 404827-95-8P
 404827-97-0P 404827-98-1P 404828-00-8P 404828-01-9P
404828-02-0P 404828-03-1P 404828-04-2P 404828-05-3P
 404828-06-4P 404828-30-4P, (2-Chloroquinazolin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine
 404829-59-0P 404845-97-2P, 2-(2-Trifluoromethylphenyl)-3H-pyrido[2,3-d]pyrimidin-4-one 404846-14-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

IT 404826-28-4P 404826-46-6P 404826-47-7P
404826-48-8P 404826-49-9P 404826-50-2P
404826-51-3P 404826-52-4P 404826-53-5P
404826-54-6P 404826-55-7P 404826-56-8P
404826-57-9P 404826-58-0P 404826-59-1P
404827-52-7P 404827-53-8P 404829-29-4P
404829-30-7P 404829-36-3P 404829-37-4P
404829-38-5P 404829-39-6P 404829-40-9P
404829-43-2P 404829-44-3P 404829-45-4P
404829-46-5P 404829-47-6P 404829-48-7P
404829-49-8P 404829-50-1P 404829-51-2P
404829-52-3P 404829-53-4P 404829-79-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-51-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)



RN 404826-56-8 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)



RN 404826-57-9 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-

fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-59-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 404827-52-7 HCAPLUS


CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404827-53-8 HCAPLUS


CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-

pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS

CN Acetamide, N-[4-[(6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-4-pyrimidinyl)thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-37-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl- (CA INDEX NAME)




RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 404829-45-4 HCAPLUS


CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(CA INDEX NAME)


RN 404829-48-7 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)


RN 404829-49-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)


RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)


RN 404829-51-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-52-3 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA
INDEX NAME)

RN 404829-79-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

IT 404827-83-4P 404827-84-5P 404827-86-7P
404827-87-8P 404828-02-0P 404829-31-8P,


(6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-1H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)


RN 404827-83-4 HCAPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-84-5 HCAPLUS

CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-86-7 HCAPLUS


CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-87-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)

RN 404828-02-0 HCAPLUS

CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX
NAME)

RN 404829-31-8 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)

OS.CITING REF COUNT: 9

THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(14 CITINGS)

REFERENCE COUNT: 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib ed abs hitind hitstr 21-38

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, BIOSIS' - CONTINUE? (Y)/N:y

L52 ANSWER 21 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:220579 HCAPLUS Full-text

DOCUMENT NUMBER: 136:247580

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Li, Pan; Golec, Julian; Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 406 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022603	A1	20020321	WO 2001-US28738	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422367	A1	20020321	CA 2001-2422367	20010914 <--
AU 2001090912	A	20020326	AU 2001-90912	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317447	A1	20030611	EP 2001-970969	20010914 <--
EP 1317447	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
JP 2004525075	T	20040819	JP 2002-526856	20010914 <--
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--

AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--
AT 327991	T	20060615	AT 2001-973050	20010914 <--
AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
MX 2003002295	A	20030606	MX 2003-2295	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
HK 1057747	A1	20061201	HK 2003-108474	20031120 <--
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--

US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
AU 2006201391	A1	20060427	AU 2006-201391	20060404 <--
AU 2006201391	B2	20081113		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90912	A3 20010914 <--
			AU 2001-90914	A 20010914 <--
			AU 2001-90944	A3 20010914 <--
			AU 2001-91013	A3 20010914 <--
			AU 2001-94558	A3 20010914 <--
			AU 2001-96871	T0 20010914 <--
			AU 2001-96875	T0 20010914 <--
			EP 2001-971082	A3 20010914 <--
			JP 2002-526860	A3 20010914 <--
			US 2001-952671	A3 20010914 <--
			US 2001-953471	A3 20010914 <--
			US 2001-955601	A3 20010914 <--
			WO 2001-US28738	W 20010914 <--
			AU 2002-234047	A3 20011219 <--
			AU 2002-34047	T0 20011219 <--
			EP 2001-273861	A 20011219 <--
			EP 2001-994323	A3 20011219 <--
			JP 2002-551561	A3 20011219 <--
			JP 2002-557938	A3 20011219 <--
			JP 2002-559413	A3 20011219 <--
			JP 2002-563142	A3 20011219 <--



JP 2002-565976	A3 20011219 <--
JP 2002-567928	A3 20011219 <--
US 2001-26966	A1 20011219 <--
WO 2001-US49139	W 20011219 <--
WO 2001-US50312	W 20011219 <--
JP 2002-551562	A3 20011220 <--
JP 2002-559414	A3 20011220 <--
US 2001-34019	A3 20011220 <--
US 2001-34683	A1 20011220 <--
IN 2003-KN795	A3 20030619 <--
US 2003-624800	A3 20030722 <--
US 2004-775699	A1 20040210 <--
JP 2004-366925	A3 20041217 <--
AU 2006-201396	A3 20060404 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:247580

ED Entered SIN: 22 Mar 2002

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6CONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (triazinyl)pyrazolamines and indazolamines I [wherein Z1, Z2, and Z3 = N; Z4 = CRy]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-

β3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μM for glycogen synthetase kinase 3β (GSK-3β) and 0.1-1.0 μM for Aurora-2.

IC ICM C07D403-12
ICS C07D401-14; C07D409-14; A61K031-497; A61K031-53; A61P035-00;
C07D403-14; C07D405-14; C07D417-14; C07D471-04; C07D487-04

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
[4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-84-5P,
4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-87-8P,
4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-trifluoromethylphenyl)pyrimidine
404827-89-0P,
6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine
404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine
404827-91-4P,
4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidine
404827-97-0P,
4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidine
404827-98-1P,
4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-quinazolin-4-one
404828-04-2P,
2-(4-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-05-3P,
2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-4-one 404828-06-4P,
2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-30-4P,
(2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine
404829-31-8P, (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404829-59-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404826-28-4E, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-30-8P,
(5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-32-0P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-33-1P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-34-2P,
(7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-35-3P,
(5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-36-4P,
(5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-37-5P,
(5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-38-6P,
(5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
[6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
(1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-41-1P,
(7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
(5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
(5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
(1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-46-6P,
(1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
(1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
(1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
[6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
(5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-

yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine
 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
 [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
 [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
 (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P,
 [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,
 (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P,
 (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P,
 (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P,
 (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P,
 (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P,
 (4-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P,
 [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P,
 (4-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-94-4P,
 (1H-Indazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P,
 (5-Amino-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl] (7-fluoro-1H-indazol-3-

yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P, (5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P, [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-41-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-43-6P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-44-7P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-45-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-46-9P,

[2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-48-1P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-52-7P, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, [6-(2-Fluorophenyl)-2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-08-6P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P, (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P, [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, [2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-

dichlorophenyl)quinazolin-4-yl)amine 404828-28-0P,
 [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P,
 [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P,
 [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine 404828-38-2P,
 [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P,
 [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P,
 (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-52-0P,
 (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-59-7P,
 [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P,
 (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P,
 (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P,
 [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P,
 (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-(3S)-3-Methoxymethylpyrrolidine-1-carbonyl]-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P,
 (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P,
 [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P,

[5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-94-0P, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine

RL: FAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P, [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P, [5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P, 404829-40-9P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P, (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P, [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P, (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P, [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P, (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P, (5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-

dJpyrimidin-4-yl)amine 404829-63-6P,
 (1H-Indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinoline-1-yl]amine
 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl) [3-(2-
 trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine 404829-67-0P,
 (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine
 404829-68-1P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-
 yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-
 yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-
 yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-
 phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine
 404829-77-2P, (2-Phenylquinolin-4-yl) (1H-1,2,4-triazol-3-yl)amine
 404829-78-3P, (1H-[1,2,4]Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-
 4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404845-75-6P 404874-28-8P 404874-29-9P 404874-30-2P 404874-31-3P
 404874-32-4P 404874-33-5P 404874-34-6P 404874-35-7P 404874-36-8P
 404874-37-9P 404874-38-0P 404874-39-1P 404874-40-4P 404874-41-5P
 404874-42-6P 404874-43-7P 404874-44-8P 404874-45-9P 404874-46-0P
 404874-47-1P 404874-48-2P 404874-49-3P 404874-50-6P 404874-51-7P
 404874-52-8P 404874-53-9P 404874-54-0P 404874-55-1P 404874-56-2P
 404874-57-3P 404874-58-4P 404874-59-5P 404874-60-8P 404874-61-9P
 404874-62-0P 404874-63-1P 404874-64-2P 404874-65-3P 404874-66-4P
 404874-67-5P 404874-68-6P 404874-69-7P 404874-70-0P 404874-71-1P
 404874-72-2P 404874-73-3P 404874-74-4P 404874-75-5P 404874-76-6P
 404874-77-7P 404874-78-8P 404874-79-9P 404874-80-2P 404874-81-3P
 404874-82-4P 404874-83-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer,
 diabetes, and Alzheimer's disease)


IT 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-
 pyrimidin-4-one 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of heterocyclpyrazolamines and analogs as
 protein kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease)

RN 404827-83-4 HCAPLUS


CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA
 INDEX NAME)




RN 404827-84-5 HCAPLUS
 CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-86-7 HCAPLUS
 CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-87-8 HCAPLUS
 CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404828-02-0 HCAPLUS
 CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404829-31-8 HCAPLUS
 CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
 INDEX NAME)




IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-46-6P,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,

[6-(2-Fluorophenyl)-2-(2-(trifluoromethylphenyl)pyrimidin-4-yl)](1H-indazol-3-yl)amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine
404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine
404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine
404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine
404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer,
 diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-51-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-56-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)



RN 404826-57-9 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-

fluoro- (CA INDEX NAME)




RN 404826-59-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-
(CA INDEX NAME)


RN 404827-32-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 404827-33-4 HCAPLUS


CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 404827-34-5 HCAPLUS


10/595,734

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS

CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-37-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl- (CA INDEX NAME)




RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-48-7 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-49-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 2-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-51-2 HCAPLUS


CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 404829-52-3 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA
INDEX NAME)

RN 404829-79-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
RECORD (13 CITINGS)REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 22 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:220578 HCAPLUS Full-text

DOCUMENT NUMBER: 136:263164

TITLE: Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegetel, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 377 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022602	A2	20020321	WO 2001-US42162	20010914 <--
WO 2002022602	A3	20020627		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2422299	A1	20020321	CA 2001-2422299	20010914 <--
AU 2001096875	A	20020326	AU 2001-96875	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1318814	A2	20030618	EP 2001-977783	20010914 <--
EP 1318814	B1	20070530		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
JP 2004509114	T	20040325	JP 2002-526855	20010914 <--
JP 4105947	B2	20080625		
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--
AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--

AT 327991	T	20060615	AT 2001-973050	20010914 <--
AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	A	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
MX 2003002297	A	20030606	MX 2003-2297	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
HK 1057702	A1	20071102	HK 2003-108682	20031127 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		

HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006021228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006021229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006021229	B2	20081120		
AU 2006021230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006021230	B2	20080911		
AU 2006021262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006021262	B2	20080904		
AU 2006021263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006021263	B2	20081030		
AU 2006021264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006021265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006021265	B2	20080904		
US 20060259658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90914	A 20010914 <--
			AU 2001-90944	A3 20010914 <--
			AU 2001-91013	A3 20010914 <--
			AU 2001-94558	A3 20010914 <--
			AU 2001-96871	T0 20010914 <--
			AU 2001-96875	T0 20010914 <--
			EP 2001-971082	A3 20010914 <--
			JP 2002-526860	A3 20010914 <--
			US 2001-952671	A3 20010914 <--
			US 2001-953471	A3 20010914 <--
			US 2001-955601	A3 20010914 <--
			WO 2001-US42162	W 20010914 <--
			AU 2002-234047	A3 20011219 <--
			AU 2002-34047	T0 20011219 <--
			EP 2001-273861	A 20011219 <--
			EP 2001-994323	A3 20011219 <--
			JP 2002-551561	A3 20011219 <--
			JP 2002-557938	A3 20011219 <--
			JP 2002-559413	A3 20011219 <--
			JP 2002-563142	A3 20011219 <--
			JP 2002-565976	A3 20011219 <--
			JP 2002-567928	A3 20011219 <--
			US 2001-26966	A1 20011219 <--
			WO 2001-US49139	W 20011219 <--
			WO 2001-US50312	W 20011219 <--
			JP 2002-551562	A3 20011220 <--


JP 2002-559414	A3 20011220 <--
US 2001-34019	A3 20011220 <--
US 2001-34683	A1 20011220 <--
IN 2003-KN795	A3 20030619 <--
US 2003-624800	A3 20030722 <--
US 2004-775699	A1 20040210 <--
JP 2004-366925	A3 20041217 <--
AU 2006-201396	A3 20060404 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 136:263164

ED Entered STIN: 22 Mar 2002


GI



I



II



III

AB Triazolamines I and pyrazolamines II [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (heterocyclyl)triazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; R9 is defined above]. Examples include data for approx. 300 invention compds.

prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-quinazolinyl)-1H-1,2,4-triazol-3-amine III was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase β 3 (GSK- β 3) and 1.0-20 μ M for Aurora-2.

IC ICM C07D403-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
 5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
 61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
 2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
 2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
 4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
 [4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
 404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
 5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
 6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
 7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
 6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
 404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
 4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
 404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
 4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-89-0P,
 6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-
 d]pyrimidine 404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-
 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 404827-91-4P,
 4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
 4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
 4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
 4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
 4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
 404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-
 cycloheptapyrimidine 404827-97-0P,
 4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidine 404827-98-1P,
 4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-
 pyrimidin-4-one 404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-
 quinazolin-4-one 404828-04-2P, 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-
 quinazolin-4-one 404828-05-3P, 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-
 4-one 404828-06-4P, 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-
 one 404828-30-4P, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-
 yl)amine 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
 404829-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazolamines, pyrazolamines, and analogs as

protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404826-28-4E, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-1H-pyrazol-3-yl)amine 404826-29-5P, [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-30-8P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P, [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-32-0P, [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-33-1P, [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-34-2P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-35-3P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-36-4P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-37-5P, (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-38-6P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P, [6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-40-0P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-41-1P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-46-6P, (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P, (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P, (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P, [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P, (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,

[2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine
 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine
 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine
 404826-70-6P, [2-Biphenyl-2-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine
 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine
 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-84-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-85-3P, (4-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-86-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-87-5P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-88-6P, (5-Methyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine
 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine
 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine
 404826-94-4P, (1H-Indazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine
 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404827-00-5P, (5-Amino-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl] (7-fluoro-1H-indazol-3-yl)amine
 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-fluoro-1H-

indazol-3-yl)amine 404827-03-8P,
 [2-(2-Chlorophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine
 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-
 indazol-3-yl)amine 404827-05-0P,
 [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404827-07-2P,
 (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-
 yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
 (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-
 difluoro-1H-indazol-3-yl)amine 404827-11-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P,
 [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine
 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P,
 [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine
 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-
 Difluoro-1H-indazol-3-yl)amine 404827-16-3P,
 (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-
 yl]amine 404827-18-5P 404827-20-9P,
 (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-
 4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P,
 (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-
 indazol-3-yl)amine 404827-26-5P,
 [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-
 yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P,
 (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-
 yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P,
 (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404827-32-3P,
 [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-
 3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-
 trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-
 yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-
 methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-
 yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-
 trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine
 bis(trifluoroacetate) 404827-41-4P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5-fluoro-1H-
 indazol-3-yl)amine 404827-43-6P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl]amine 404827-44-7P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl]amine 404827-45-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-
 cyclopentapyrimidin-4-yl]amine 404827-46-9P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (1H-indazol-3-

yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-48-1P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P, (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine ~~404827-52-7P~~, [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine ~~404827-53-8P~~, [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-08-6P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl-amine 404828-11-1P, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P, (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P, [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, [2-Benzo[1,3]dioxol-5-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,

[2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine
 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P,
 [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P,
 [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine 404828-38-2P,
 [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P,
 [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P,
 (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-46-2P,
 (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P,
 (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-52-0P,
 (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-55-3P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-59-7P,
 [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P,
 (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-65-5P,
 (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P,
 [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P,
 (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P,
 (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P,
 [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P,
 [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-

yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-(4-(2-Hydroxyethyl)piperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-94-0P, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P, (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine

RL: FAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P, [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P, [5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P, 404829-40-9P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P, (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P, [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P, (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P, [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P, (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P, (5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-

d]pyrimidin-4-yl)amine 404829-63-6P,
 (1H-Indazol-3-yl)[3-(2-trifluoromethylphenyl)isoquinoline-1-yl]amine
 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl)[3-(2-
 trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl)(2-phenylquinolin-4-yl)amine 404829-67-0P,
 (2-Phenylquinolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine
 404829-68-1P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-
 yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-
 trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-
 yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-
 yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-
 phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl)[3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine
 404829-77-2P, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine
 404829-78-3P, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-
 4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404845-75-6P 404888-97-7P 404888-98-8P 404888-99-9P
 404889-00-5P 404889-01-6P 404889-03-8P 404889-04-9P 404889-05-0P
 404889-06-1P 404889-07-2P 404889-08-3P 404889-09-4P 404889-10-7P
 404889-11-8P 404889-12-9P 404889-13-0P 404889-14-1P 404889-15-2P
404889-16-3P 404889-17-4P 404889-18-5P
404889-19-6P 404889-21-0P 404889-22-1P
404889-23-2P 404889-24-3P 404889-25-4P
404889-26-5P 404889-27-6P 404889-28-7P
 404889-29-8P 404889-30-1P 404889-31-2P 404889-32-3P 404889-33-4P
 404889-34-5P 404889-35-6P 404889-36-7P 404889-37-8P 404889-38-9P
 404889-39-0P 404889-40-3P 404889-41-4P 404889-42-5P 404889-43-6P
 404889-44-7P 404889-45-8P 404889-46-9P 404889-47-0P 404889-48-1P
 404889-49-2P 404889-50-5P 404889-51-6P 404889-52-7P 404889-53-8P
 404889-54-9P 404889-55-0P 404889-56-1P 404889-58-3P 404889-59-4P
 404889-60-7P 404889-61-8P 404889-62-9P 404889-63-0P 404889-64-1P
 404889-65-2P 404889-66-3P 404889-67-4P
404889-68-5P 404889-69-6P 404889-70-9P 404889-71-0P
404889-72-1P 404889-73-2P 404889-74-3P
404889-76-5P 404889-77-6P 404889-78-7P
 404889-79-8P 404889-80-1P 404889-86-7P 404889-96-9P 404890-01-3P
404890-13-7P 404890-14-8P 404890-15-9P
404890-16-0P 404890-17-1P 404890-18-2P
404890-19-3P 404890-22-8P 404890-28-4P
404890-38-6P 404890-43-3P 404890-56-8P
404890-68-2P 404890-77-3P 404890-86-4P
 404890-87-5P 404890-88-6P 404890-89-7P 404890-90-0P 404890-91-1P
 404890-92-2P 404890-94-4P 404891-02-7P 404891-04-9P 404891-05-0P
 404891-06-1P 404891-07-2P 404891-08-3P 404891-09-4P 404891-10-7P
 404891-12-9P 404891-13-0P 404891-14-1P 404891-15-2P 404891-16-3P
 404891-17-4P 404891-18-5P 404891-19-6P 404891-20-9P 404891-21-0P
 404891-23-2P 404891-24-3P 404891-25-4P 404891-26-5P 404891-28-7P
 404891-29-8P 404891-31-2P 404891-32-3P 404891-34-5P 404891-35-6P
 404891-36-7P 404891-38-9P 404891-39-0P 404891-41-4P 404891-42-5P
 404891-43-6P 404891-64-1P 404891-65-2P 404891-69-6P 404891-78-7P
 404891-79-8P 404891-80-1P 404891-81-2P 404891-82-3P 404891-83-4P
 404891-84-5P 404891-85-6P 404891-86-7P 404891-87-8P 404891-88-9P

404891-89-0P 404891-90-3P 404891-91-4P 404891-92-5P 404892-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);TRU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


IT 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P, 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P, 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404829-31-8P, (6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404827-83-4 HCAPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-84-5 HCAPLUS

CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-86-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-87-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)


RN 404828-02-0 HCAPLUS

CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404829-31-8 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-46-6P,
(1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
(1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-

yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 (6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404888-97-7P

<u>404889-16-3P</u>	<u>404889-17-4P</u>	<u>404889-18-5P</u>
<u>404889-19-6P</u>	<u>404889-21-0P</u>	<u>404889-22-1P</u>
<u>404889-23-2P</u>	<u>404889-24-3P</u>	<u>404889-25-4P</u>
<u>404889-26-5P</u>	<u>404889-27-6P</u>	<u>404889-67-4P</u>
<u>404889-69-5P</u>	<u>404889-72-1P</u>	<u>404889-73-2P</u>
<u>404889-74-3P</u>	<u>404889-76-5P</u>	<u>404889-77-6P</u>
<u>404889-78-7P</u>	<u>404890-14-8P</u>	<u>404890-15-9P</u>
<u>404890-16-0P</u>	<u>404890-17-1P</u>	<u>404890-18-2P</u>
<u>404890-19-3P</u>	<u>404890-22-8P</u>	<u>404890-28-4P</u>
<u>404890-38-6P</u>	<u>404890-43-3P</u>	<u>404890-56-8P</u>
<u>404890-68-2P</u>	<u>404890-77-3P</u>	<u>404890-86-4P</u>

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-51-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-53-5 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-4-fluoro- (CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-56-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-57-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-59-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-32-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 404827-34-5 HCAPLUS


CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 404827-52-7 HCAPLUS


CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-

pyrimidinyl)- (CA INDEX NAME)




RN 404827-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS


CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl]-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-37-4 HCAPLUS


CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-
(CA INDEX NAME)

RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl-
(CA INDEX NAME)


RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-


10/595,734

(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-48-7 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-49-8 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-50-1 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-51-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-52-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-79-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404888-97-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)




RN 404889-16-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-17-4 HCAPLUS

CN 4-Pyrimidinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-18-5 HCAPLUS

CN 4-Pyrimidinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-19-6 HCAPLUS

CN 4-Pyrimidinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-21-0 HCAPLUS

CN 4-Pyrimidinamine, 6-(2-chlorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-22-1 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-23-2 HCAPLUS

CN 4-Pyrimidinamine, 5,6-dimethyl-N-[3-(1-methylethyl)-1H-1,2,4-triazol-5-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-24-3 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-[3-(1-methylethyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)




RN 404889-25-4 HCAPLUS

CN Benzonitrile, 2-[4,5-dimethyl-6-[[3-(1-methylethyl)-1H-1,2,4-triazol-5-yl]amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 404889-26-5 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chloro-4-fluorophenyl)-5,6-dimethyl-N-[3-(1-methylethyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)




RN 404889-27-6 HCAPLUS

CN 4-Pyrimidinamine, N-(3-cyclopentyl-1H-1,2,4-triazol-5-yl)-2-(2,4-dichlorophenyl)-5,6-dimethyl- (CA INDEX NAME)




RN 404889-67-4 HCAPLUS

CN 4-Pyrimidinamine, 6-cyclohexyl-N-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-68-5 HCAPLUS

CN 4-Pyrimidinamine, N-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-72-1 HCAPLUS

CN 4-Pyrimidinamine, 6-(4-aminocyclohexyl)-5-methyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404889-73-2 HCAPLUS

CN Acetamide, N-[4-[5-methyl-6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]pyrimidin-2-yl]cyclohexyl]- (CA INDEX NAME)




RN 404889-74-3 HCAPLUS

CN Methanesulfonamide, N-[4-[2-(2-chlorophenyl)-5-methyl-6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-4-pyrimidinyl]cyclohexyl]- (CA INDEX NAME)




RN 404889-76-5 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5-methyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-(4-morpholinyl)- (CA INDEX NAME)




RN 404889-77-6 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5-methyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-(1-piperazinyl)- (CA INDEX NAME)




RN 404889-78-7 HCAPLUS

CN Ethanone, 1-[4-[5-methyl-6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-1-piperazinyl]- (CA INDEX NAME)




RN 404890-14-8 HCAPLUS

CN Acetamide, N-[2-[6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl]- (CA INDEX NAME)




RN 404890-15-9 HCAPLUS

CN Methanesulfonamide, N-[2-[6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]cyclohexyl]- (CA INDEX NAME)




RN 404890-16-0 HCAPLUS

CN 4-Pyrimidinamine, 6-(2-aminocyclohexyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404890-17-1 HCAPLUS

CN Carbamic acid, [2-[6-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]ethyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)




RN 404890-18-2 HCAPLUS

CN 4-Pyrimidineethanamine, 6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404890-19-3 HCAPLUS

CN 4-Pyrimidinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-(4-piperidinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404890-22-8 HCAPLUS

CN Acetamide, N-[2-[6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]ethyl]- (CA INDEX NAME)




RN 404890-28-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 404890-38-6 HCAPLUS

CN Ethanone, 1-[4-[6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-1-piperidinyl]- (CA INDEX NAME)




RN 404890-43-3 HCAPLUS

CN Methanesulfonamide, N-[2-[2-(2-chlorophenyl)-6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-4-pyrimidinyl]ethyl]- (CA INDEX NAME)




RN 404890-56-8 HCAPLUS

CN Ethanone, 1-[2-[2-(2-chlorophenyl)-6-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-4-pyrimidinyl]-1-piperidinyl]- (CA INDEX NAME)




RN 404890-68-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-6-[1-(methylsulfonyl)-2-piperidinyl]-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)




RN 404890-77-3 HCAPLUS

CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N4-(3-methyl-1H-1,2,4-triazol-5-yl)-N6-(phenylmethyl)- (CA INDEX NAME)



RN 404890-86-4 HCAPLUS
 CN Acetamide, N-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-[2-(trifluoromethyl)phenyl]-5-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 23 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:220577 HCAPLUS Full-text

DOCUMENT NUMBER: 136:247579

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Knegetel, Ronald; Bebbington, David; Binch, Hayley; Golec, Julian; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 376 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022601	A1	20020321	WO 2001-US28740	20010914 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2422354	A1	20020321	CA 2001-2422354	20010914 <--
AU 2001090914	A	20020326	AU 2001-90914	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		

US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317444	A1	20030611	EP 2001-970971	20010914 <--
EP 1317444	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
JP 2004509113	T	20040325	JP 2002-526854	20010914 <--
JP 4111824	B2	20080702		
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--
AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--
AT 327991	T	20060615	AT 2001-973050	20010914 <--
AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--

ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
MX 2003002294	A	20050908	MX 2003-2294	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
HK 1057543	A1	20061215	HK 2003-108309	20031114 <--
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
AU 2006201396	A1	20060504	AU 2006-201396	20060404 <--
AU 2006201396	B2	20081002		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008227219	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90914	A3 20010914 <--
			AU 2001-90944	A3 20010914 <--


AU	2001-91013	A3	20010914	<--
AU	2001-94558	A3	20010914	<--
AU	2001-96871	T0	20010914	<--
AU	2001-96875	T0	20010914	<--
EP	2001-971082	A3	20010914	<--
JP	2002-526860	A3	20010914	<--
US	2001-952671	A3	20010914	<--
US	2001-953471	A3	20010914	<--
US	2001-955601	A3	20010914	<--
WO	2001-US28740	W	20010914	<--
AU	2002-234047	A3	20011219	<--
AU	2002-34047	T0	20011219	<--
EP	2001-273861	A	20011219	<--
EP	2001-994323	A3	20011219	<--
JP	2002-551561	A3	20011219	<--
JP	2002-557938	A3	20011219	<--
JP	2002-559413	A3	20011219	<--
JP	2002-563142	A3	20011219	<--
JP	2002-565976	A3	20011219	<--
JP	2002-567928	A3	20011219	<--
US	2001-26966	A1	20011219	<--
WO	2001-US49139	W	20011219	<--
WO	2001-US50312	W	20011219	<--
JP	2002-551562	A3	20011220	<--
JP	2002-559414	A3	20011220	<--
US	2001-34019	A3	20011220	<--
US	2001-34683	A1	20011220	<--
IN	2003-KN795	A3	20030619	<--
US	2003-624800	A3	20030722	<--
US	2004-775699	A1	20040210	<--
JP	2004-366925	A3	20041217	<--
AU	2006-201396	A3	20060404	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 136:247579

ED Entered SIN: 22 Mar 2002

GI



I



II

AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z¹ = N or CR⁹; Z² = N or CH; Z³ = N or CR^x; Z⁴ = N or CR^y; R^x and R^y = independently TR³, or taken together with their

intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, etc.; R and R4 are defined above]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β , Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IC ICM C07D401-14

ICS A61K031-4427; A61K031-4155; A61P035-00; C07D401-12

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
2-(2-Trifluoromethylbenzoylamino)nicotinamide 404826-19-3P,
4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
[4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
404827-79-8P, 4-Pyrryl-1-yl-1H-indazol-3-ylamine 404827-80-1P,
4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-81-2P, 4-Chloro-2-(2-chlorophenyl)-5,6-dimethylpyrimidine
404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-
trifluoromethylphenyl)pyrimidine 404827-84-5P,
4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-
trifluoromethylphenyl)pyrimidine 404827-87-8P,
4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-
trifluoromethylphenyl)pyrimidine 404827-89-0P,
6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidine 404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 404827-91-4P,
4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,

4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
 4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
 404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-
 cycloheptapyrimidine 404827-97-0P,
 4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-
 hexahydrocyclooctapyrimidine 404827-98-1P,
 4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
 404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-
 pyrimidin-4-one 404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-
 quinazolin-4-one 404828-04-2P, 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-
 quinazolin-4-one 404828-05-3P, 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-
 4-one 404828-06-4P, 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-
 one 404828-30-4P, (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-
 yl)amine 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
 404829-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of heterocyclylpyrazolamines and analogs as
 protein kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease)

IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-
 Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](1H-
 indazol-3-yl)amine 404826-30-8P,
 (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](7-
 fluoro-1H-indazol-3-yl)amine 404826-32-0P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](5-
 fluoro-1H-indazol-3-yl)amine 404826-33-1P,
 [2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](5,7-
 difluoro-1H-indazol-3-yl)amine 404826-34-2P,
 (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-35-3P,
 (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-36-4P,
 (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-37-5P,
 (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydroquinazolin-4-yl]amine 404826-38-6P,
 (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-
 tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
 [6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-
 d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
 (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-
 cycloheptapyrimidin-4-yl]amine 404826-41-1P,
 (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-
 5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
 (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-
 5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
 (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-
 tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
 (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-
 4-yl]amine 404826-46-6P,
 (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
 404826-47-7P, (1H-Indazol-3-yl)[6-phenyl-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,

(1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-Fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
 [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
 [2-(2,6-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
 (2-Biphenyl-2-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P,
 [5-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl] [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,
 (4-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P,
 (5-Phenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P,
 (4-Carbamoyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P,
 (5-Hydroxy-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-3P,
 (5-Methoxymethyl-2H-pyrazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P,
 (4-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl) [2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P,
 [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P,
 (4-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404826-94-4P,
 (1H-Indazol-3-yl) [2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P,
 (5-Amino-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404827-03-8P,
 [2-(2-Chlorophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P,
 [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
 (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P,
 [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P,
 [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P,
 (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P,
 (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P,
 (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P,
 [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P,
 (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P,
 (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-32-3P,
 [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,

(5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-41-4P,
 (5-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404827-43-6P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-44-7P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-45-8P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-46-9P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404827-48-1P,
 [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P,
 (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P,
 (7-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P,
 (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P,
 3-[(2-(2-Trifluoromethylphenyl)quinazolin-4-yl)amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P,
 (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P,
 [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P,
 [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P,
 (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-08-6P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl) (2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P,
 (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-

methyl-2H-pyrazol-3-yl)amine 404828-13-3P,
 (2-Cyclohexylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P,
 [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
 [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P,
 [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P,
 [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
 [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P,
 [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P,
 [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-37-1P, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine 404828-38-2P,
 [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P,
 [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P,
 (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine 404828-45-1P,
 (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-46-2P,
 (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-47-3P,
 (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P,
 (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-52-0P,
 (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-53-1P,
 (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-55-3P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-59-7P,
 [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-63-3P,
 (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-

phenylquinazolin-4-yl)amine 404828-65-5P,
 (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine
 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-68-8P,
 [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-71-3P,
 (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-74-6P,
 (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-77-9P,
 [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-79-1P,
 [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-84-8P,
 (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-85-9P, (5-Methyl-2H-pyrazol-3-yl) (2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl) (2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P,
 [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P, [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P,
 (5-Methyl-2H-pyrazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P, [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-94-0P, [2-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-95-1P,
 [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P, [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P,
 (5,7-Difluoro-1H-indazol-3-yl) (2-phenyl-5,6,7,8-tetrahydroquinazolin-4-

yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl) (5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclic pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-26-1P, (1H-Indazol-3-yl) (2-piperidin-1-ylquinazolin-4-yl)amine 404829-27-2P, (1H-Indazol-3-yl) [2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl) [2-(2,6-dimethylmorpholin-4-yl)quinazolin-4-yl]amine 404829-29-4P, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P, [2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-34-1P, [5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P, [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P, (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-42-1P, [2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-43-2P, (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P, [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,

(5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyridin-4-ylthieno[3,2-d]pyrimidin-4-yl)amine 404829-55-6P,
 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P,
 (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(4-methylpiperidin-1-yl)pyrrolo[3,2-d]pyrimidin-4-yl]amine 404829-62-5P,
 (5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amine 404829-63-6P,
 (1H-Indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinoline-1-yl]amine 404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine 404829-67-0P, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-68-1P, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl) [3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-77-2P, (2-Phenylquinolin-4-yl) (1H-1,2,4-triazol-3-yl)amine 404829-78-3P, (1H-[1,2,4]Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
 404845-75-6P 404858-63-5P 404858-64-6P 404858-65-7P 404858-66-8P
 404858-67-9P 404858-68-0P 404858-69-1P 404858-70-4P 404858-71-5P
 404858-72-6P 404858-73-7P 404858-74-8P 404858-75-9P 404858-76-0P
 404858-77-1P 404858-78-2P 404858-79-3P 404858-80-6P 404858-81-7P
 404858-82-8P 404858-83-9P 404858-84-0P 404858-85-1P 404858-86-2P
 404858-87-3P 404858-88-4P 404858-89-5P 404858-90-8P 404858-91-9P
 404858-92-0P 404858-93-1P 404858-94-2P 404858-95-3P 404858-96-4P
 404858-97-5P 404858-98-6P 404858-99-7P 404859-00-3P 404859-01-4P
 404859-02-5P 404859-03-6P 404859-04-7P 404859-05-8P 404859-06-9P
 404859-07-0P 404859-08-1P 404859-09-2P 404859-10-5P 404859-11-6P
 404859-12-7P 404859-13-8P 404859-14-9P 404859-15-0P 404859-16-1P
 404859-17-2P 404860-48-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


- IT 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-84-5P,
4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine 404827-87-8P,
4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404828-82-8P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404829-31-8P,
(6-Chloro-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
- RN 404827-83-4 HCAPLUS
- CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




- RN 404827-84-5 HCAPLUS
- CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



- RN 404827-86-7 HCAPLUS
- CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404827-87-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)


RN 404828-02-0 HCAPLUS

CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404829-31-8 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-Methyl-2H-pyrazol-3-yl)amine 404826-46-6P,
 (1H-Indazol-3-yl) [6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
 404826-47-7P, (1H-Indazol-3-yl) [6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl) [6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
 (1H-Indazol-3-yl) [6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine

404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl) [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404827-52-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl] (1H-indazol-3-yl)amine 404829-29-4P,
 (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl] (5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl] (6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl) (5-phenyl-2H-pyrazol-3-yl)amine 404829-45-4P,
 [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl) [6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl) (6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl) (6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-79-4P, (1H-Indazol-3-yl) [5-methyl-6-morpholin-4-yl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)


RN 404826-28-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-50-2 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-51-3 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404826-52-4 HCAPLUS


CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)



RN 404826-53-5 HCAPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-

(CA INDEX NAME)




RN 404826-54-6 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-56-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-57-9 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-58-0 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)




RN 404826-59-1 HCAPLUS

CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-32-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-34-5 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (CA INDEX NAME)




RN 404827-53-8 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCAPLUS

CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCAPLUS

CN Acetamide, N-[4-[[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-4-pyrimidinyl]thio]phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCAPLUS

CN 4-Pyrimidinamine, 2-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-37-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl- (CA INDEX NAME)




RN 404829-38-5 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl-
(CA INDEX NAME)




RN 404829-39-6 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-43-2 HCAPLUS

CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCAPLUS

CN 4-Pyrimidinamine, N-[5-(2-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)]- (CA INDEX NAME)




RN 404829-46-5 HCAPLUS


CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(CA INDEX NAME)

RN 404829-48-7 HCAPLUS


CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)

RN 404829-49-8 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)

RN 404829-50-1 HCAPLUS


CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)




RN 404829-51-2 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-52-3 HCAPLUS


CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)

RN 404829-53-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA
INDEX NAME)

RN 404829-79-4 HCAPLUS

CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 48 THERE ARE 48 CAPLUS RECORDS THAT CITE THIS RECORD (71 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 24 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:387716 HCAPLUS Full-text
 DOCUMENT NUMBER: 131:78466
 TITLE: Adenosine A3 antagonists
 INVENTOR(S): Sugiura, Yoshihiro; Miwatari, Seiji; Kimura, Hiroyuki; Knzaki, Naoyuki
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11158073	A	19990615	JP 1998-270755	19980925 <--
			JP 1997-262525	A 19970926 <--

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 131:78466
 ED Entered STN: 23 Jun 1999
 AB Adenosine A3 receptor antagonists contain (un)substituted amino-substituted N2-3-containing heterocyclic [5-8 ring-containing] compds. such as 2-chloro-4-ethylamino-6-phenylamino-1,3,5-triazine and 2,4-bis[phenylamino]-6-cyclohexylamino-1,3,5-triazine. Of 6 compds. tested, the IC50 values of adenosine A3 receptor antagonist activities ranged from 0.7 to 285.9 nM as determined in human adenosine A3 receptor-expressing plasmid-transformed CHO (dhfr-) cell cultures. Tablets were formulated containing 2,4-bis[phenylamino]-6-cyclohexylamino-1,3,5-triazine 50, lactose 34, corn starch 10.6, corn starch paste 5, magnesium stearate 0.4 and calcium CM-cellulose 20 mg. The drugs are useful for treating e.g. brain ischemic disease.
 IC ICM A61K031-535
 ICS A61K031-00; A61K031-505; A61K031-53; C07D251-18; C07D251-50; C07D251-70; C07D403-04
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 IT 1973-09-7 6737-62-8 17654-47-6 21665-49-6 50831-60-2 53773-08-3
 53773-09-4 53773-10-7 54589-65-0 61038-64-0 101119-13-5
 107274-03-3 113696-90-5 156126-89-5 189249-05-6 228574-85-4
 228574-86-5 228574-87-6 228574-88-7 228574-89-8 228574-90-1
 228574-91-2 228574-92-3 228574-93-4 228574-94-5 228574-95-6
 228574-96-7 228574-97-8 228574-98-9 228574-99-0 228575-00-6
 228575-01-7 228575-02-8 228575-03-9 228575-04-0 228575-05-1
 228575-06-2 228575-07-3 228575-08-4 228575-09-5

10/595,734

<u>228575-10-8</u>	<u>228575-11-9</u>	<u>228575-12-0</u>	<u>228575-13-1</u>
<u>228575-14-2</u>	<u>228575-15-3</u>	<u>228575-16-4</u>	
<u>228575-17-5</u>	<u>228575-18-6</u>	<u>228575-19-7</u>	
<u>228575-20-0</u>	<u>228575-21-1</u>	<u>228575-22-2</u>	


RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A3 receptor antagonists and pharmaceutical
comps.)

IT	<u>228575-10-8</u>	<u>228575-13-1</u>	<u>228575-14-2</u>
	<u>228575-15-3</u>	<u>228575-16-4</u>	<u>228575-17-5</u>
	<u>228575-18-6</u>	<u>228575-19-7</u>	<u>228575-20-0</u>
	<u>228575-21-1</u>		

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A3 receptor antagonists and pharmaceutical
comps.)


RN 228575-10-8 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N,2-diphenyl- (CA INDEX NAME)




RN 228575-13-1 HCAPLUS

CN 4-Pyrimidinamine, N-cyclohexyl-6-hydrazinyl-2-phenyl- (CA INDEX NAME)




RN 228575-14-2 HCAPLUS

CN 4,6-Pyrimidinediamine, N4-cyclohexyl-N6,2-diphenyl- (CA INDEX NAME)




RN 228575-15-3 HCAPLUS

CN 4,6-Pyrimidinediamine, N4,N6,2-triphenyl- (CA INDEX NAME)




RN 228575-16-4 HCAPLUS

CN 4,6-Pyrimidinediamine, N4,2-diphenyl-N6-(phenylmethyl)- (CA INDEX NAME)




RN 228575-17-5 HCAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N,2-diphenyl- (CA INDEX NAME)




RN 228575-18-6 HCAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 228575-19-7 HCAPLUS


CN Pyrimidine, 4-hydrazinyl-6-phenoxy-2-phenyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 228575-20-0 HCAPLUS

CN 4-Pyrimidinamine, 6-phenoxy-N,2-diphenyl- (CA INDEX NAME)



RN 228575-21-1 HCAPLUS

CN 4-Pyrimidinamine, N-cyclohexyl-6-phenoxy-2-phenyl-, hydrochloride (1:1)
(CA INDEX NAME)

● HCl

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L52 ANSWER 25 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:385479 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:54375

ORIGINAL REFERENCE NO.: 129:11333a,11336a

TITLE: Arthropodocidal and fungicidal cyclic amides
[triazolones] and their preparation, use, and
compositionsINVENTOR(S): Brown, Richard James; Chan, Dominic Ming-Tak; Howard,
Michael Henry, Jr.; Daniel, Dillon Jancey; Clark, David
Alan; Selby, Thomas Paul

PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA

SOURCE: PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9823155	A1	19980604	WO 1996-US18916	19961126 <--
W: JP, KR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9709943	A	19990505	ZA 1997-9943	19971105 <--
IN 1997CA02193	A	20050311	IN 1997-CA2193	19971120 <--
WO 9823156	A1	19980604	WO 1997-US21944	19971125 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854633	A	19980622	AU 1998-54633	19971125 <--
EP 944314	A1	19990929	EP 1997-948597	19971125 <--
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, IE				
BR 9713415	A	20000418	BR 1997-13415	19971125 <--
HU 2000001540	A2	20000828	HU 2000-1540	19971125 <--
JP 2001506984	T	20010529	JP 1998-524889	19971125 <--
MX 9904789	A	20000131	MX 1999-4789	19990524 <--
KR 2000057254	A	20000915	KR 1999-704639	19990526 <--
PRIORITY APPLN. INFO.:			WO 1996-US18916	A 19961126 <--
			US 1996-33614P	P 19961219 <--
			US 1997-48844P	P 19970606 <--
			WO 1997-US21944	W 19971125 <--

OTHER SOURCE(S): MARPAT 129:54375

ED Entered STN: 24 Jun 1998

GI



AB Title compds. I and their N-oxides and agriculturally suitable salts are disclosed [wherein E = (un)substituted 1,2-phenylene, naphthalene or heterocyclyl; A = O, S, N, NR3 or CR4; G = C or N; when G is C, then A is O, S or NR3 and the floating double bond is attached to G; and when G is N, then A is N or CR4 and the floating double bond is attached to A; W = O, S, NH, N(C1-C6 alkyl) or NO(C1-C6 alkyl); X = H, OR1, SOMR1, halo, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, cyano, NH2, NHR1, N(C1-C6 alkyl)R1, NH(C1-C6 alkoxy) or N(C1-C6 alkoxy)R1; R2 = H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C3-C6 cycloalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxy carbonyl, hydroxy, C1-C2 alkoxy, or acetyloxy; R1 = (halo)alkyl, (halo)alkenyl, etc.; R3 = H, (halo)alkyl, etc.; Y = O, CO, SO, etc.; Z = (un)substituted alkyl, alkenyl or alkynyl, R4 = H, halo, alkyl, etc.; m = 0, 1 or 2]. Claims cover methods of

arthropod and fungal control, novel compds., arthropodicidal and fungicidal compns., and novel intermediates. Approx. 1000 invention compds. were prepared. For instance, 5-chloro-2,4-dihydro-4-(2-methoxyphenyl)-2-methyl-3H-1,2,4-triazol-3-one (preparation given) underwent a sequence of cleavage of the Me ether with BBr₃, methoxylation of the chloride with NaOMe, and etherification of the phenolic hydroxy group with 5-chloro-3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-thiadiazole, to give title compound II. Selected I were active in screens against *Erysiphe graminis*, *Pyricularia oryzae*, *Spodoptera frugiperda*, *Tetranychus urticae*, and a variety of other standard pests.

IC ICM A01N043-653

ICS C07D241-08; C07D249-08; C07D249-12; C07D275-02; C07D285-08;
C07D417-04

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 5


IT	186979-56-6P	186979-57-7P	186979-58-8P	186979-59-9P	186979-60-2P
	186979-61-3P	186979-62-4P	186979-63-5P	186979-64-6P	186979-65-7P
	186979-66-8P	186979-67-9P	186979-68-0P	186979-69-1P	186979-70-4P
	186979-71-5P	186979-72-6P	186979-73-7P	186979-74-8P	
	186979-75-9P	186979-76-0P	186979-77-1P	186979-78-2P	
	186979-79-3P	186979-80-6P	186979-81-7P	186979-82-8P	186979-83-9P
	186979-84-0P	186979-85-1P	186979-86-2P	186979-87-3P	186979-88-4P
	186979-89-5P	186979-90-8P	186979-91-9P	186979-92-0P	186979-93-1P
	186979-94-2P	186979-95-3P	186979-96-4P	186979-97-5P	186979-98-6P
	186979-99-7P	186980-00-7P	186980-01-8P	186980-02-9P	186980-03-0P
	186980-04-1P	186980-05-2P	186980-06-3P	186980-07-4P	186980-08-5P
	186980-09-6P	186980-10-9P	186980-11-0P	186980-12-1P	186980-13-2P
	186980-14-3P	186980-15-4P	186980-17-6P	186980-19-8P	186980-20-1P
	186980-21-2P	186980-22-3P	186980-23-4P	186980-24-5P	186980-25-6P
	186980-26-7P	186980-27-8P	186980-28-9P	186980-29-0P	186980-30-3P
	186980-31-4P	186980-32-5P	186980-33-6P	186980-34-7P	186980-35-8P
	186980-36-9P	186980-37-0P	186980-38-1P	186980-39-2P	186980-40-5P
	186980-41-6P	186980-42-7P	186980-43-8P	186980-44-9P	186980-45-0P
	186980-46-1P	186980-47-2P	186980-48-3P	186980-49-4P	186980-50-7P
	186980-51-8P	186980-52-9P	186980-53-0P	186980-54-1P	186980-55-2P
	186980-56-3P	186980-57-4P	186980-58-5P	186980-59-6P	186980-60-9P
	186980-61-0P	186980-63-2P	186980-65-4P	186980-66-5P	186980-67-6P
	186980-68-7P	186980-69-8P	186980-70-1P	186980-71-2P	186980-72-3P
	186980-73-4P	186980-74-5P	186980-75-6P	186980-76-7P	186980-77-8P
	186980-78-9P	186980-79-0P	186980-80-3P	186980-81-4P	186980-82-5P
	186980-83-6P	186980-84-7P	186980-85-8P	186980-86-9P	186980-87-0P
	186980-88-1P	186980-89-2P	186980-90-5P	186980-91-6P	186980-93-8P
	186980-94-9P	186980-95-0P	186980-96-1P	186980-97-2P	186980-98-3P
	186980-99-4P	186981-00-0P	186981-01-1P	186981-02-2P	186981-03-3P
	186981-04-4P	186981-05-5P	186981-06-6P	186981-07-7P	186981-08-8P
	186981-09-9P	186981-10-2P	186981-11-3P	186981-12-4P	186981-13-5P
	186981-14-6P	186981-15-7P	186981-16-8P	186981-17-9P	186981-19-1P
	186981-20-4P	186981-21-5P	186981-22-6P	186981-24-8P	186981-25-9P
	186981-26-0P	186981-27-1P	186981-28-2P	186981-29-3P	186981-30-6P
	186981-31-7P	186981-32-8P	186981-33-9P	186981-40-8P	186981-44-2P
	186981-45-3P	186981-46-4P	186981-47-5P	186981-48-6P	186981-49-7P
	186981-50-0P	186981-51-1P	186981-52-2P	186981-53-3P	186981-54-4P
	186981-55-5P	186981-56-6P	186981-57-7P	186981-58-8P	186981-59-9P
	186981-60-2P	186981-61-3P	186981-62-4P	186981-63-5P	186981-64-6P
	186981-65-7P	186981-66-8P	186981-67-9P	186981-68-0P	186981-69-1P
	186981-70-4P	186981-71-5P	186981-72-6P	186981-73-7P	186981-74-8P
	186981-75-9P	186981-76-0P	186981-77-1P	186981-78-2P	186981-79-3P
	186981-80-6P	186981-81-7P	186981-82-8P	186981-83-9P	186981-84-0P
	186981-85-1P	186981-86-2P	186981-87-3P	186981-88-4P	186981-89-5P
	186981-90-8P	186981-91-9P	186981-92-0P	186981-93-1P	186981-94-2P

186981-95-3P 186981-96-4P 186981-97-5P 186981-98-6P 186981-99-7P
 186982-00-3P 186982-01-4P 186982-02-5P 186982-03-6P 186982-04-7P
 RL: AGR (Agricultural use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as arthropodicide and fungicide)

IT 186979-75-9P
 RL: AGR (Agricultural use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as arthropodicide and fungicide)

RN 186979-75-9 HCAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[2-[[2-(3,5-bis(trifluoromethyl)phenyl)-4-
 pyrimidinyl]oxy]phenyl]-2,4-dihydro-5-methoxy-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
 RECORD (10 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 26 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:323238 HCAPLUS Full-text

DOCUMENT NUMBER: 129:4664

ORIGINAL REFERENCE NO.: 129:1120h,1121a

TITLE: Preparation of fungicidal cyclic amides

INVENTOR(S): Walker, Michael Paul

PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA; Walker, Michael
 Paul

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9820003	A1	19980514	WO 1997-US17608	19971001 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1997CA01788	A	20050311	IN 1997-CA1788	19970924 <--

AU 9746603 A 19980529 AU 1997-46603 19971001 <--
 EP 937051 A1 19990825 EP 1997-945385 19971001 <--
 R: DE, ES, FR, GB, IT
 BR 9712713 A 19991026 BR 1997-12713 19971001 <--
 CN 1242767 A 20000126 CN 1997-181160 19971001 <--
 JP 2001503424 T 20010313 JP 1998-521383 19971001 <--
 ZA 9708958 A 19990407 ZA 1997-8958 19971007 <--
 MX 9904066 A 20000131 MX 1999-4066 19990430 <--
 KR 2000052948 A 20000825 KR 1999-703821 19990430 <--
 PRIORITY APPLN. INFO.: US 1996-29965P P 19961101 <--
 WO 1997-US17608 W 19971001 <--
 OTHER SOURCE(S): MARPAT 129:4664
 ED Entered STN: 30 May 1998
 GI



II

AB The title compds. [I; E = (un)substituted 1,2-phenylene; A = O, S, N, NR5, CR6; G = C, N (provided that when G = C, then A = O, S, NR5 and the floating double bond is attached to G; and when G = N, then A = N, CR6 and the floating double bond is attached to A); W = O, S, NH, N(C1-6 alkyl), NO(C1-6 alkyl); X = OR1, S(O)MR1, halo; Y = O, S(O)n, NR7, etc.; Z = substituted Ph, pyrimidinyl, triazinyl; R1 = C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, etc.; R2 = H, C1-6 alkyl, C1-6 haloalkyl, etc.; R5 = H, C1-6 alkyl, C1-6 haloalkyl, etc.; R6 = H, halo, C1-6 alkyl, etc.], useful for controlling plant diseases caused by fungal plant pathogens, were prepared Thus, 6-step synthesis of the title compound II, which showed 100% control against *Erysiphe graminis* f. sp. tritici and *Puccinia recondita* at 500 g/ha, is described.

IC ICM C07D249-12

ICS A01N043-653; C07D403-12; A01N043-66; A01N043-707


CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 5


IT 207504-17-4P 207504-18-5P 207504-19-6P 207504-23-2P 207504-24-3P
 207504-20-9P 207504-21-0P 207504-22-1P 207504-28-7P 207504-29-8P
 207504-25-4P 207504-26-5P 207504-27-6P 207504-54-9P 207504-55-0P
 207504-30-1P 207504-31-2P 207504-32-3P 207504-59-4P 207504-60-7P
 207504-35-6P 207504-37-8P 207504-38-9P 207504-64-1P 207504-65-2P
 207504-41-4P 207504-42-5P 207504-43-6P 207504-44-7P 207504-45-8P
 207504-46-9P 207504-47-0P 207504-48-1P 207504-49-2P 207504-50-5P
 207504-51-6P 207504-52-7P 207504-53-8P 207504-54-9P 207504-55-0P
 207504-56-1P 207504-57-2P 207504-58-3P 207504-59-4P 207504-60-7P
 207504-61-8P 207504-62-9P 207504-63-0P 207504-64-1P 207504-65-2P
 207504-66-3P 207504-69-6P 207504-70-9P 207504-71-0P 207504-72-1P
 207504-75-4P 207504-76-5P 207504-77-6P 207504-78-7P 207504-80-1P
 207504-82-3P 207504-84-5P 207504-85-6P 207504-86-7P 207504-87-8P
 207504-88-9P 207504-89-0P 207504-90-3P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fungicidal cyclic amides)
 IT 207504-17-4P 207504-18-5P
 RL: AGR (Agricultural use); BAC (Biological activity or effector,
 except adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fungicidal cyclic amides)
 RN 207504-17-4 HCAPLUS
 CN 3H-1,2,4-Triazol-3-one, 4-[2-[[2-(3,5-dichlorophenyl)-4-pyrimidinyl]oxy]-6-
 methylphenyl]-2,4-dihydro-5-methoxy-2-methyl- (CA INDEX NAME)



RN 207504-18-5 HCAPLUS
 CN 3H-1,2,4-Triazol-3-one, 4-[2-[[2-(3,5-dichlorophenyl)-4-
 pyrimidinyl]oxy]phenyl]-2,4-dihydro-5-methoxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 27 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:154790 HCAPLUS Full-text
 DOCUMENT NUMBER: 128:167441
 ORIGINAL REFERENCE NO.: 128:33005a,33008a
 TITLE: Preparation of herbicidal 2,6-disubstituted pyridines
 and 2,4-disubstituted pyrimidines
 INVENTOR(S): Kleemann, Axel; Baltruschat, Helmut Siegfried; Maier,
 Thomas; Scheiblich, Stefan
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: Eur. Pat. Appl., 45 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 823431	A1	19980211	EP 1997-305994	19970806 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
US 5849758	A	19981215	US 1996-693422	19960807 <--
PRIORITY APPLN. INFO.:			US 1996-693422	A 19960807 <--
			US 1995-454044	B2 19950530 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:167441

ED Entered STN: 14 Mar 1998

GI



AB The title compds. [I; A = (un)substituted aryl, 5-6 membered nitrogen-containing heteroaryl, difluorobenzodioxolyl; m = 0-5; n = 0-2; R1 = H, halo, (un)substituted alkyl, etc.; R2 = H, halo, (un)substituted alkyl, etc.; X = O, S; Z = N, CH; with the proviso that if A = 1-methyl-3-trifluoromethyl-pyrazol-5-yl, n = 0, X = O and Z = CH, then R2m does not represent H, 3-CF3, 2,4-Cl2 or 2,4-Me2], useful as herbicides, were prepared. Thus, reaction of 2-bromo-6-phenylpyridine with 1-methyl-3-trifluoromethyl-5-hydroxypyrazole in the presence of K2CO3 in DMF afforded 52% I [A = 1-methyl-3-trifluoromethylpyrazol-5-yl; X = O; Z = CH; R1 = R2 = H]. Compound I [A = 1-methyl-3-trifluoromethylpyrazol-5-yl; X = O; Z = CH; R1 = H; R2 = 3-CF3] showed complete control against Beta vulgaris and Zea mays in preemergence application at 100 g/ha.

IC ICM C07D401-12

ICS C07D213-643; C07D403-14; A01N043-40; A01N043-54; A01N043-56

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 5

IT 202994-52-3P

RL: AGR (Agricultural use); BAC (Biological activity or effector,

except adverse); BSU (Biological study, unclassified); RCT

(Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines)

IT	180606-10-4P	180606-11-5P	180606-12-6P	180606-13-7P	180606-21-7P
	180606-22-8P	180606-23-9P	180606-24-0P	180606-25-1P	180606-26-2P
	180606-27-3P	180606-28-4P	180606-29-5P	180606-30-8P	180606-31-9P
	180606-32-0P	180606-33-1P	180606-34-2P	180606-35-3P	
	180607-16-3P	180607-17-4P	180607-18-5P		
	180607-19-6P	180607-20-9P	180607-21-0P		
	180607-22-1P	180607-23-2P	180607-24-3P		
	180607-25-4P	180607-26-5P	180607-27-6P		
	180607-28-7P	180607-29-8P	180607-30-1P		
	180607-31-2P	180607-32-3P	180607-33-4P		
	180607-34-5P	180607-35-6P	180607-36-7P		

<u>180607-37-8P</u>	<u>180607-39-0P</u>	<u>180607-41-4P</u>		
<u>180607-42-5P</u>	<u>180607-43-6P</u>	<u>180607-44-7P</u>		
<u>180607-45-8P</u>	<u>180607-47-0P</u>	<u>180607-48-1P</u>		
<u>180607-49-2P</u>	<u>180607-50-5P</u>	<u>180607-51-6P</u>		
<u>180607-52-7P</u>	<u>180607-53-8P</u>	<u>180607-54-9P</u>		
<u>180607-55-0P</u>	<u>180607-56-1P</u>	<u>180607-57-2P</u>		
<u>180607-58-3P</u>	<u>180607-59-4P</u>	<u>180607-61-8P</u>		
<u>180607-62-9P</u>	<u>180607-63-0P</u>	<u>180607-64-1P</u>		
<u>180607-65-2P</u>	<u>180607-66-3P</u>	<u>180607-67-4P</u>		
<u>180607-68-5P</u>	<u>180607-69-6P</u>	<u>180607-70-9P</u>		
<u>180607-71-0P</u>	<u>180607-72-1P</u>	<u>180607-73-2P</u>		
<u>180607-74-3P</u>	<u>180607-75-4P</u>	<u>180607-76-5P</u>		
<u>180607-77-6P</u>	<u>180607-78-7P</u>	<u>180607-79-8P</u>		
<u>180607-80-1P</u>	<u>180607-81-2P</u>	<u>180607-82-3P</u>		
<u>180607-83-4P</u>	<u>180607-84-5P</u>	<u>180607-85-6P</u>		
<u>180607-86-7P</u>	<u>180607-87-8P</u>	<u>180607-88-9P</u>		
<u>180607-89-0P</u>	<u>180607-90-3P</u>	<u>180607-92-5P</u>		
<u>180607-94-7P</u>	<u>180607-96-9P</u>	<u>180608-05-3P</u>		
<u>180608-07-5P</u>	<u>180608-08-6P</u>	<u>180608-09-7P</u>		
<u>180608-10-0P</u>	<u>180608-11-1P</u>	<u>180608-12-2P</u>		
<u>180608-13-3P</u>	<u>180608-14-4P</u>	<u>180608-15-5P</u>		
<u>180608-16-6P</u>	<u>180608-17-7P</u>	<u>180608-19-9P</u>		
<u>180608-20-2P</u>	<u>180608-21-3P</u>	<u>180608-24-6P</u>		
<u>180608-27-9P</u>	<u>180608-35-9P</u>	<u>202994-50-1P</u>		
<u>202994-53-4P</u>	<u>202994-54-5P</u>	<u>202994-55-6P</u>	202994-56-7P	202994-57-8P
<u>202994-58-9P</u>	<u>202994-60-3P</u>	<u>202994-62-5P</u>	202994-64-7P	202994-66-9P
<u>202994-68-1P</u>	<u>202994-69-2P</u>	<u>202994-70-5P</u>		
<u>202994-71-6P</u>	<u>202994-72-7P</u>	<u>202994-73-8P</u>		
<u>202994-74-9P</u>	<u>202994-75-0P</u>	<u>202994-76-1P</u>		
<u>202994-77-2P</u>	<u>202994-78-3P</u>	<u>202994-79-4P</u>		
<u>202994-80-7P</u>	<u>202994-81-8P</u>	<u>202994-82-9P</u>		
<u>202994-83-0P</u>	<u>202994-84-1P</u>	<u>202994-85-2P</u>		
<u>202994-86-3P</u>	<u>202994-88-5P</u>	<u>202994-90-9P</u>		
<u>202994-92-1P</u>	<u>202994-94-3P</u>	<u>202994-96-5P</u>		
<u>202994-98-7P</u>	<u>202995-00-4P</u>	<u>202995-01-5P</u>		
<u>202995-02-6P</u>	<u>202995-03-7P</u>	<u>202995-04-8P</u>		
<u>202995-05-9P</u>	<u>202995-06-0P</u>	<u>202995-07-1P</u>		
<u>202995-08-2P</u>	<u>202995-09-3P</u>	<u>202995-10-6P</u>		
<u>202995-11-7P</u>	<u>202995-12-8P</u>	<u>202995-13-9P</u>		
<u>202995-14-0P</u>	<u>202995-15-1P</u>	<u>202995-16-2P</u>		
<u>202995-17-3P</u>	<u>202995-18-4P</u>	<u>202995-19-5P</u>		
<u>202995-20-8P</u>	<u>202995-21-9P</u>	<u>202995-22-0P</u>		
<u>202995-23-1P</u>	<u>202995-24-2P</u>	<u>202995-25-3P</u>		
<u>202995-26-4P</u>	<u>202995-27-5P</u>	<u>202995-28-6P</u>		
<u>202995-29-7P</u>	<u>202995-30-0P</u>	<u>202995-31-1P</u>		
<u>202995-32-2P</u>	<u>202995-33-3P</u>	<u>202995-34-4P</u>		
<u>202995-35-5P</u>	<u>202995-36-6P</u>	<u>202995-37-7P</u>		
<u>202995-38-8P</u>	<u>202995-39-9P</u>	<u>202995-40-2P</u>		
<u>202995-41-3P</u>	<u>202995-42-4P</u>	<u>202995-43-5P</u>		
<u>202995-44-6P</u>	<u>202995-45-7P</u>	<u>202995-46-8P</u>		
<u>202995-47-9P</u>	<u>202995-48-0P</u>	<u>202995-49-1P</u>		
<u>202995-50-4P</u>	<u>202995-51-5P</u>	<u>202995-52-6P</u>		
<u>202995-53-7P</u>				

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines)

IT 456-14-4P, 4-Fluorobenzamidine hydrochloride 879-72-1P,

β -Dimethylaminopropiophenone hydrochloride	2631-60-9P	14401-51-5P
16858-20-1P	19006-82-7P	19927-82-3P
23935-21-9P	24095-60-1P	38980-96-0P
56302-42-2P	62980-03-4P	66744-01-2P
93623-96-2P	97513-47-8P	97603-36-6P
98013-07-1P	107392-33-6P	121219-95-2P
125904-05-4P	125904-06-5P	142220-63-1P
180606-05-7P	180606-06-8P	180606-07-9P
180606-14-8P	180606-15-9P	180606-17-1P
180606-20-6P	180606-36-4P	180606-37-5P
180606-40-0P	180606-41-1P	180606-42-2P
180606-45-5P	180606-46-6P	180606-47-7P
180606-50-2P	180606-51-3P	180606-52-4P
180606-59-1P	180606-61-5P	180606-63-7P
180606-70-6P	180606-72-8P	180606-74-0P
180606-81-9P	180606-84-2P	180606-90-0P
180607-01-6P	180607-03-8P	180607-06-1P
180607-12-9P	180607-13-0P	180607-14-1P
180608-02-0P	180608-04-2P	180608-06-4P
202995-55-9P	202995-56-0P	202995-54-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines)

IT 202994-52-3P


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT

(Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines)

RN 202994-52-3 HCAPLUS

CN Pyrimidine, 4-bromo-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT	<u>180607-16-3P</u>	<u>180607-17-4P</u>	<u>180607-18-5P</u>
	<u>180607-19-6P</u>	<u>180607-20-9P</u>	<u>180607-21-0P</u>
	<u>180607-22-1P</u>	<u>180607-23-2P</u>	<u>180607-24-3P</u>
	<u>180607-25-4P</u>	<u>180607-26-5P</u>	<u>180607-27-6P</u>
	<u>180607-28-7P</u>	<u>180607-29-8P</u>	<u>180607-30-1P</u>
	<u>180607-31-2P</u>	<u>180607-32-3P</u>	<u>180607-33-4P</u>
	<u>180607-34-5P</u>	<u>180607-35-6P</u>	<u>180607-36-7P</u>
	<u>180607-37-8P</u>	<u>180607-39-0P</u>	<u>180607-41-4P</u>
	<u>180607-42-5P</u>	<u>180607-43-6P</u>	<u>180607-44-7P</u>
	<u>180607-45-8P</u>	<u>180607-47-0P</u>	<u>180607-48-1P</u>
	<u>180607-49-2P</u>	<u>180607-50-5P</u>	<u>180607-51-6P</u>


<u>180607-52-7P</u>	<u>180607-53-8P</u>	<u>180607-54-9P</u>
<u>180607-55-0P</u>	<u>180607-56-1P</u>	<u>180607-57-2P</u>
<u>180607-58-3P</u>	<u>180607-59-4P</u>	<u>180607-61-8P</u>
<u>180607-62-9P</u>	<u>180607-63-0P</u>	<u>180607-64-1P</u>
<u>180607-65-2P</u>	<u>180607-66-3P</u>	<u>180607-67-4P</u>
<u>180607-68-5P</u>	<u>180607-69-6P</u>	<u>180607-70-9P</u>
<u>180607-71-0P</u>	<u>180607-72-1P</u>	<u>180607-73-2P</u>
<u>180607-74-3P</u>	<u>180607-75-4P</u>	<u>180607-76-5P</u>
<u>180607-77-6P</u>	<u>180607-78-7P</u>	<u>180607-79-8P</u>
<u>180607-80-1P</u>	<u>180607-81-2P</u>	<u>180607-82-3P</u>
<u>180607-83-4P</u>	<u>180607-84-5P</u>	<u>180607-85-6P</u>
<u>180607-86-7P</u>	<u>180607-87-8P</u>	<u>180607-88-9P</u>
<u>180607-89-0P</u>	<u>180607-90-3P</u>	<u>180607-92-5P</u>
<u>180607-94-7P</u>	<u>180607-96-9P</u>	<u>180608-05-3P</u>
<u>180608-07-5P</u>	<u>180608-08-6P</u>	<u>180608-09-7P</u>
<u>180608-10-0P</u>	<u>180608-11-1P</u>	<u>180608-12-2P</u>
<u>180608-13-3P</u>	<u>180608-14-4P</u>	<u>180608-15-5P</u>
<u>180608-16-6P</u>	<u>180608-17-7P</u>	<u>180608-19-9P</u>
<u>180608-20-2P</u>	<u>180608-21-3P</u>	<u>180608-35-9P</u>
<u>202994-50-1P</u>	<u>202994-70-5P</u>	<u>202994-71-6P</u>
<u>202994-72-7P</u>	<u>202994-73-8P</u>	<u>202994-74-9P</u>
<u>202994-75-0P</u>	<u>202994-76-1P</u>	<u>202994-77-2P</u>
<u>202994-78-3P</u>	<u>202994-79-4P</u>	<u>202994-80-7P</u>
<u>202994-81-8P</u>	<u>202994-82-9P</u>	<u>202994-83-0P</u>
<u>202994-84-1P</u>	<u>202994-85-2P</u>	<u>202994-86-3P</u>
<u>202994-88-5P</u>	<u>202994-90-9P</u>	<u>202994-92-1P</u>
<u>202994-94-3P</u>	<u>202994-96-5P</u>	<u>202994-98-7P</u>
<u>202995-00-4P</u>	<u>202995-01-5P</u>	<u>202995-02-6P</u>
<u>202995-03-7P</u>	<u>202995-04-8P</u>	<u>202995-05-9P</u>
<u>202995-06-0P</u>	<u>202995-07-1P</u>	<u>202995-08-2P</u>
<u>202995-09-3P</u>	<u>202995-10-6P</u>	<u>202995-11-7P</u>
<u>202995-12-8P</u>	<u>202995-13-9P</u>	<u>202995-14-0P</u>
<u>202995-15-1P</u>	<u>202995-16-2P</u>	<u>202995-17-3P</u>
<u>202995-18-4P</u>	<u>202995-19-5P</u>	<u>202995-20-8P</u>
<u>202995-21-9P</u>	<u>202995-22-0P</u>	<u>202995-23-1P</u>
<u>202995-24-2P</u>	<u>202995-25-3P</u>	<u>202995-26-4P</u>
<u>202995-27-5P</u>	<u>202995-28-6P</u>	<u>202995-29-7P</u>
<u>202995-30-0P</u>	<u>202995-31-1P</u>	<u>202995-32-2P</u>
<u>202995-33-3P</u>	<u>202995-34-4P</u>	<u>202995-35-5P</u>
<u>202995-36-6P</u>	<u>202995-37-7P</u>	<u>202995-38-8P</u>
<u>202995-39-9P</u>	<u>202995-40-2P</u>	<u>202995-41-3P</u>
<u>202995-42-4P</u>	<u>202995-43-5P</u>	<u>202995-44-6P</u>
<u>202995-45-7P</u>	<u>202995-46-8P</u>	<u>202995-47-9P</u>
<u>202995-48-0P</u>	<u>202995-49-1P</u>	<u>202995-50-4P</u>
<u>202995-51-5P</u>	<u>202995-52-6P</u>	

RL: AGR (Agricultural use); EAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted
 pyrimidines)


RN 180607-16-3 HCAPLUS

CN Pyrimidine, 2-(4-fluorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
 (CA INDEX NAME)




RN 180607-17-4 HCAPLUS

CN Pyrimidine, 2-(4-fluorophenyl)-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-18-5 HCAPLUS

CN Pyrimidine, 2-(4-fluorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)



RN 180607-19-6 HCAPLUS


CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 180607-20-9 HCAPLUS


CN Pyrimidine, 4-methyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-

(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-21-0 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-22-1 HCAPLUS

CN Pyrimidine, 5-methyl-4-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-23-2 HCAPLUS


CN Pyrimidine, 5-methyl-2-(3-methylphenyl)-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-24-3 HCAPLUS

CN Pyrimidine, 5-methyl-2-(3-methylphenyl)-4-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)

RN 180607-25-4 HCAPLUS


CN Pyrimidine, 4-methyl-2-(3-methylphenyl)-6-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)

RN 180607-26-5 HCAPLUS

CN Pyrimidine, 4-methyl-2-(3-methylphenyl)-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-27-6 HCAPLUS

CN Pyrimidine, 2-(3-chlorophenyl)-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-28-7 HCAPLUS

CN Pyrimidine, 2-(3-chlorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)




RN 180607-29-8 HCAPLUS

CN Pyrimidine, 2-(3-chlorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)



RN 180607-30-1 HCAPLUS


CN Pyrimidine, 2-(2,4-difluorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)



RN 180607-31-2 HCAPLUS


CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(2,4-difluorophenyl)-5-methyl-

(CA INDEX NAME)




RN 180607-32-3 HCAPLUS

CN Pyrimidine, 2-(2,4-difluorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-33-4 HCAPLUS

CN Pyrimidine, 2-(2,4-difluorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-34-5 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(2,4-difluorophenyl)-6-methyl- (CA INDEX NAME)




RN 180607-35-6 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-36-7 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-37-8 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-39-0 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-41-4 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[3-(trifluoromethyl)phenoxy]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-42-5 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-43-6 HCAPLUS

CN Pyrimidine, 4-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-44-7 HCAPLUS

CN Pyrimidine, 4-ethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-45-8 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-ethyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-47-0 HCAPLUS

CN Pyrimidine, 4-(4-fluorophenoxy)-6-methyl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-48-1 HCAPLUS


CN Pyrimidine, 4-ethyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-49-2 HCAPLUS

CN Pyrimidine, 4-(4-fluorophenoxy)-5-methyl-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)

RN 180607-50-5 HCAPLUS


CN Pyrimidine, 2-(4-bromophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)

RN 180607-51-6 HCAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-52-7 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-53-8 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-54-9 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-55-0 HCAPLUS


CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-4-methyl-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-56-1 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-57-2 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-
(CA INDEX NAME)

RN 180607-58-3 HCAPLUS


CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-5,6-dimethyl-
(CA INDEX NAME)

RN 180607-59-4 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4,5-dimethyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-61-8 HCAPLUS

CN Pyrimidine, 2-(3-fluorophenyl)-4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-62-9 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-63-0 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-5-methyl-
(CA INDEX NAME)




RN 180607-64-1 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)




RN 180607-65-2 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-66-3 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-6-methyl-
(CA INDEX NAME)




RN 180607-67-4 HCAPLUS


CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(3,4-difluorophenyl)-5-methyl-
(CA INDEX NAME)

RN 180607-68-5 HCAPLUS


CN Pyrimidine, 2-(3,4-difluorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)



RN 180607-69-6 HCAPLUS


CN Pyrimidine, 2-(3,4-difluorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)

RN 180607-70-9 HCAPLUS

CN Pyrimidine, 4-[(1,3-dimethyl-1H-pyrazol-5-yl)oxy]-2-(3,4-difluorophenyl)-6-methyl-
(CA INDEX NAME)


RN 180607-71-0 HCAPLUS

CN Pyrimidine, 4-[(1,3-dimethyl-1H-pyrazol-5-yl)oxy]-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-72-1 HCAPLUS

CN Pyrimidine, 4-[(1,3-dimethyl-1H-pyrazol-5-yl)oxy]-6-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-73-2 HCAPLUS

CN Pyrimidine, 4-[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]oxy]-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-74-3 HCAPLUS

CN Pyrimidine, 4-[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]oxy]-6-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-75-4 HCAPLUS

CN Pyrimidine, 4-[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]oxy]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-76-5 HCAPLUS

CN Pyrimidine, 4-methyl-2-[4-(trifluoromethoxy)phenyl]-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-77-6 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-78-7 HCAPLUS

CN Pyrimidine, 5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-79-8 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-80-1 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-2-[4-(trifluoromethoxy)phenyl]-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-81-2 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5,6-dimethyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-82-3 HCAPLUS

CN Pyrimidine, 2-(3,4-difluorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-83-4 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-84-5 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-85-6 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-86-7 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-[[2-(4-chlorophenyl)-6-(methoxymethyl)pyridin-4-yl]oxy]-6-methylpyrimidine (CA INDEX NAME)




RN 180607-87-8 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-(methoxymethyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-88-9 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-(methoxymethyl)-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-89-0 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-90-3 HCAPLUS

CN Pyrimidine, 5-methoxy-4-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-92-5 HCAPLUS

CN Pyrimidine, 5-chloro-2-(4-chlorophenyl)-4-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-94-7 HCAPLUS

CN Pyrimidine, 5-chloro-2-(4-chlorophenyl)-4-methoxy-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-96-9 HCAPLUS

CN Pyrimidine, 5-methoxy-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-05-3 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-07-5 HCAPLUS

CN Pyrimidine, 4-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 180608-08-6 HCAPLUS


CN Pyrimidine, 4-methoxy-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 180608-09-7 HCAPLUS


10/595,734

CN Pyrimidine, 4-(methylthio)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-10-0 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-(methylthio)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-11-1 HCAPLUS

CN 4-Pyrimidinamine, N,N-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-12-2 HCAPLUS

CN 4-Pyrimidinamine, N-ethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-13-3 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-14-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-15-5 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N,N-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-16-6 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-17-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-19-9 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-20-2 HCAPLUS

CN Pyrimidine, 4-chloro-2-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-21-3 HCAPLUS

CN Pyrimidine, 4-ethenyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-35-9 HCAPLUS

CN Pyrimidine, 4-fluoro-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-50-1 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-phenyl- (CA INDEX NAME)




RN 202994-70-5 HCAPLUS

CN Pyrimidine, 4-[(6-chloro-4-pyrimidinyl)oxy]-5-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-71-6 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-(methylthio)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 202994-72-7 HCAPLUS

CN Pyrimidine, 4-bromo-6-[(2-chloro-4-pyridinyl)oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-73-8 HCAPLUS

CN Pyrimidine, 4-bromo-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-74-9 HCAPLUS

CN Methanimidamide, N'-[2-(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-pyrimidinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 202994-75-0 HCAPLUS

CN Pyrimidine, 4-ethynyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-76-1 HCAPLUS

CN Pyrimidine, 4-(methoxymethyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-77-2 HCAPLUS

CN Pyrimidine, 4-[4-fluoro-3-(trifluoromethyl)phenoxy]-6-(methoxymethyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-78-3 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-[(methoxymethyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-79-4 HCAPLUS

CN Pyrimidine, 4,5-dichloro-2-(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 202994-80-7 HCAPLUS

CN Pyrimidine, 4-methyl-2-[4-(methylsulfonyl)phenyl]-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 202994-81-8 HCAPLUS

CN Pyrimidine, 4-methyl-2-[4-(methylsulfonyl)phenyl]-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 202994-82-9 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-methyl-2-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 202994-83-0 HCAPLUS

CN Pyrimidine, 4-[(6-chloro-4-pyrimidinyl)oxy]-6-ethyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-84-1 HCAPLUS

CN Pyrimidine, 4-ethyl-6-[[6-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-85-2 HCAPLUS

CN Pyrimidine, 4-[(2,6-dichloro-4-(trifluoromethyl)phenoxy)methyl]-2-ethyl- (CA INDEX NAME)




RN 202994-86-3 HCAPLUS

CN Pyrimidine, 4-ethyl-6-[4-fluoro-3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-88-5 HCAPLUS

CN Pyrimidine, 4-chloro-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-90-9 HCAPLUS

CN Pyrimidine, 4-chloro-6-[(2-chloro-4-pyridinyl)oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-92-1 HCAPLUS

CN Pyrimidine, 4-chloro-6-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-94-3 HCAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[[2-(difluoromethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-96-5 HCAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202994-98-7 HCAPLUS

CN Pyrimidine, 4-ethoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-00-4 HCAPLUS

CN Pyrimidine, 4-(2-fluoroethoxy)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-01-5 HCAPLUS

CN Pyrimidine, 4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-6-(2,2,2-trifluoroethoxy)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-02-6 HCAPLUS

CN Pyrimidine, 4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-6-(2-propen-1-yloxy)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-03-7 HCAPLUS

CN Pyrimidine, 4,5-diethoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-04-8 HCAPLUS

CN Pyrimidine, 4-(methoxymethyl)-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-05-9 HCAPLUS

CN 4-Pyrimidineacetoneitrile, 6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-06-0 HCAPLUS

CN Pyrimidine, 4-hydrazinyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-07-1 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-fluoro-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-08-2 HCAPLUS

CN Pyrimidine, 4-iodo-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-09-3 HCAPLUS

CN Pyrimidine, 2-[4-(dichloromethyl)phenyl]-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 202995-10-6 HCAPLUS

CN Pyrimidine, 4-(difluoromethoxy)-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-11-7 HCAPLUS

CN Pyrimidine, 4-chloro-5-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-12-8 HCAPLUS

CN Pyrimidine, 4-fluoro-5-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-13-9 HCAPLUS

CN Pyrimidine, 4-fluoro-5-methyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-14-0 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-fluoro-5-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-15-1 HCAPLUS

CN Pyrimidine, 4-methyl-2-[4-(trifluoromethyl)phenyl]-6-[2-(trifluoromethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 202995-16-2 HCAPLUS

CN Benzonitrile, 4-[4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-pyrimidinyl]- (CA INDEX NAME)




RN 202995-17-3 HCAPLUS

CN Pyrimidine, 5-chloro-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-18-4 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-19-5 HCAPLUS

CN Pyrimidine, 4-chloro-6-[[2-(difluoromethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-20-8 HCAPLUS

CN Benzonitrile, 3-[[6-methyl-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]- (CA INDEX NAME)




RN 202995-21-9 HCAPLUS

CN Pyrimidine, 5-(1-methylethyl)-4-{3-(trifluoromethyl)phenoxy}-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-22-0 HCAPLUS

CN Pyrimidine, 4-methoxy-2-[4-(trifluoromethyl)phenyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 202995-23-1 HCAPLUS

CN Pyrimidine, 5-methyl-2-[4-(trifluoromethyl)phenyl]-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 202995-24-2 HCAPLUS

CN Pyrimidine, 4-chloro-2-[4-(trifluoromethyl)phenyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 202995-25-3 HCAPLUS

CN Pyrimidine, 2-[3,4-bis(trifluoromethyl)phenyl]-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 202995-26-4 HCAPLUS

CN Pyrimidine, 2-[3,4-bis(trifluoromethyl)phenyl]-4-methyl-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 202995-27-5 HCAPLUS

CN Pyrimidine, 2-[3,4-bis(trifluoromethyl)phenyl]-4-[(2-chloro-4-pyridinyl)oxy]-6-methyl- (CA INDEX NAME)




RN 202995-28-6 HCAPLUS

CN Pyrimidine, 4-(difluoromethoxy)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-29-7 HCAPLUS

CN Pyrimidine, 4-[[2-(difluoromethoxy)-4-pyridinyl]oxy]-6-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-30-0 HCAPLUS

CN Pyrimidine, 4-[[2-(difluoromethoxy)-4-pyridinyl]oxy]-5-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-31-1 HCAPLUS

CN Pyrimidine, 4-chloro-6-[[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-32-2 HCAPLUS

CN Pyrimidine, 4-methoxy-6-[[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-33-3 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-34-4 HCAPLUS

CN Pyrimidine, 5-methyl-4-[3-(trifluoromethoxy)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-35-5 HCAPLUS

CN Pyrimidine, 4-methyl-6-[3-(trifluoromethoxy)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-36-6 HCAPLUS

CN 2-Pyridinecarbonitrile, 4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]- (CA INDEX NAME)




RN 202995-37-7 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[2-(1,1,2,2,2-pentafluoroethyl)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-38-8 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[2-(1,1,2,2,2-pentafluoroethyl)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-39-9 HCAPLUS

CN Pyrimidine, 4-(methoxymethyl)-2-[4-(trifluoromethyl)phenyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 202995-40-2 HCAPLUS

CN Pyrimidine, 4-methoxy-6-[[2-(1,1,2,2,2-pentafluoroethyl)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-41-3 HCAPLUS

CN Pyrimidine, 4-ethyl-2-[4-(trifluoromethyl)phenyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]oxy]- (CA INDEX NAME)




RN 202995-42-4 HCAPLUS

CN Pyrimidine, 4-ethyl-6-[[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-43-5 HCAPLUS

CN Pyrimidine, 4-[[2-(difluoromethoxy)-4-pyridinyl]oxy]-6-ethyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-44-6 HCAPLUS

CN Pyrimidine, 4-[[2-(difluoromethoxy)-4-pyridinyl]oxy]-6-(methoxymethyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-45-7 HCAPLUS

CN Pyrimidine, 4-(methoxymethyl)-6-[[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-46-8 HCAPLUS

CN Pyrimidine, 4-([2-[(difluoromethyl)thio]-4-pyridinyl]oxy)-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-47-9 HCAPLUS

CN Pyrimidine, 4-([2-[(difluoromethyl)thio]-4-pyridinyl]oxy)-5-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-48-0 HCAPLUS

CN Pyrimidine, 4-ethyl-6-([2-(2,2,2-trifluoroethyl)-4-pyridinyl]oxy)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-49-1 HCAPLUS

CN Pyrimidine, 4-(methoxymethyl)-6-[[2-(2,2,2-trifluoroethyl)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-50-4 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[2-(1,1,2,2-tetrafluoroethyl)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-51-5 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[2-(1,1,2,2-tetrafluoroethyl)-4-pyridinyl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 202995-52-6 HCAPLUS

CN Pyrimidine, 4-[[2-[(difluoromethyl)thio]-4-pyridinyl]oxy]-6-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 180608-02-QP
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of herbicidal 2,6-disubstituted pyridines and 2,4-
 disubstituted
 pyrimidines)
 RN 180608-02-0 HCAPLUS
 CN Pyrimidine, 4,6-bis[3-(trifluoromethyl)phenoxy]-2-[4-
 (trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 28 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:544043 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 125:195679
 ORIGINAL REFERENCE NO.: 125:36658h,36659a
 TITLE: Herbicidal 2,6-disubstituted pyridines and
 2,4-disubstituted pyrimidines
 INVENTOR(S): Kleemann, Axel; Baltruschat, Helmut S.; Huelsen,
 Thekla; Maier, Thomas; Scheiblich, Stefan
 PATENT ASSIGNEE(S): American Cyanamid Company, USA; BASF
 Aktiengesellschaft
 SOURCE: Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 723960	A1	19960731	EP 1996-300454	19960123 <--
EP 723960	B1	20030402		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE		
CZ 290330	B6	20020717 CZ 1996-175 19960119 <--
IL 116855	A	20010111 IL 1996-116855 19960122 <--
ZA 9600529	A	19970723 ZA 1996-529 19960123 <--
AT 236124	T	20030415 AT 1996-300454 19960123 <--
CA 2167982	A1	19960727 CA 1996-2167982 19960124 <--
AU 9642164	A	19960801 AU 1996-42164 19960124 <--
AU 710816	B2	19990930
IN 182759	A1	19990710 IN 1996-CA139 19960124 <--
IN 1996CA00127	A	20050304 IN 1996-CA127 19960124 <--
JP 08277268	A	19961022 JP 1996-30101 19960125 <--
JP 4049405	B2	20080220
HU 9600161	A2	19970228 HU 1996-161 19960125 <--
HU 9600161	A3	19970828
HU 221864	B1	20030228
BR 9600222	A	19980106 BR 1996-222 19960125 <--
RU 2134261	C1	19990810 RU 1996-101815 19960125 <--
SK 284993	B6	20060406 SK 1996-109 19960125 <--
CN 1143078	A	19970219 CN 1996-102547 19960126 <--
CN 1135226	C	20040121
US 5824624	A	19981020 US 1996-761479 19961206 <--
CZ 290340	B6	20020717 CZ 2001-1783 20010522 <--

PRIORITY APPLN. INFO.:


EP 1995-101057	A	19950126 <--
US 1995-454044	B1	19950530 <--
CZ 1996-175	A3	19960119 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 125:195679

ED Entered STN: 12 Sep 1996

GI



I



II

AB New pyridine and pyrimidine derivs. are disclosed, specifically I [A = (un)substituted aryl or (un)substituted 5- or 6-membered N-containing heteroarom. group or difluorobenzodioxolyl; m = 0-5; n = 0-2; R1 (or each R1) = H, halo, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, (di)alkoxyalkyl, alkoxyalkoxy, alkylthio, (di)(alkyl)amino, alkoxyamino, formamidino; R2 (or each R2) = H, halo, (un)substituted alk(en/yn)yl, alkoxy, alkylthio, alkylsulfonyl, alkylsulfinyl, NO₂, cyano, haloalkyl, haloalkoxy, haloalkylthio; X = O or S; Z = N or CH; with proviso that if A = 1-methyl-3-trifluoromethylpyrazol-5-yl, n = 0, X = O and Z = CH, then (R2)_m ≠ H or 3-CF₃ or 2,4-di-Cl or 2,4-di-Me]. I can be prepared by conventional methods, and are particularly useful as herbicides. Over 200 synthetic examples, including I and their intermediates, are given. For instance, etherification of 2-(4-fluorophenyl)-4-chloro-6-methylpyridine (preparation given) with 3-HOC₆H₄CF₃ using K₂CO₃ in refluxing DMF gave 56.4% title compound II [R₂ = F]. The similarly prepared compound II [R₂ = CF₃] at 300 g/ha preemergence gave complete (9/9) or nearly complete (8/9) control of 10 weeds including *Echinochloa crus-galli* and *Setaria viridis*.

IC ICM C07D213-00
 ICS C07D401-12; C07D213-66; C07D213-64; C07D213-68; C07D239-34;
 C07D403-12; A01N043-40; A01N043-54; C07D403-14; C07D405-12

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 5

IT 180607-98-1P 180608-18-8P
 RL: AGR (Agricultural use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); RCT
 (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of disubstituted pyridines and pyrimidines as herbicides)


IT 180606-10-4P 180606-11-5P 180606-12-6P 180606-13-7P 180606-21-7P
 180606-22-8P 180606-23-9P 180606-24-0P 180606-25-1P 180606-26-2P
 180606-27-3P 180606-28-4P 180606-29-5P 180606-30-8P 180606-31-9P
 180606-32-0P 180606-33-1P 180606-34-2P 180606-35-3P
180607-16-3P 180607-17-4P 180607-18-5P
180607-19-6P 180607-20-9P 180607-21-0P
180607-22-1P 180607-23-2P 180607-24-3P
180607-25-4P 180607-26-5P 180607-27-6P
180607-28-7P 180607-29-8P 180607-30-1P
180607-31-2P 180607-32-3P 180607-33-4P
180607-34-5P 180607-35-6P 180607-36-7P
180607-37-8P 180607-39-0P 180607-41-4P
180607-42-5P 180607-43-6P 180607-44-7P
180607-45-8P 180607-47-0P 180607-48-1P
180607-49-2P 180607-50-5P 180607-51-6P
180607-52-7P 180607-53-8P 180607-54-9P
180607-55-0P 180607-56-1P 180607-57-2P
180607-58-3P 180607-59-4P 180607-60-7P
180607-61-8P 180607-62-9P 180607-63-0P
180607-64-1P 180607-65-2P 180607-66-3P
180607-67-4P 180607-68-5P 180607-69-6P
180607-70-9P 180607-71-0P 180607-72-1P
180607-73-2P 180607-74-3P 180607-75-4P
180607-76-5P 180607-77-6P 180607-78-7P
180607-79-8P 180607-80-1P 180607-81-2P
180607-82-3P 180607-83-4P 180607-84-5P
180607-85-6P 180607-86-7P 180607-87-8P
180607-88-9P 180607-89-0P 180607-90-3P
180607-92-5P 180607-94-7P 180607-96-9P
180608-00-8P 180608-02-0P 180608-04-2P
180608-05-3P 180608-07-5P 180608-08-6P
180608-09-7P 180608-10-0P 180608-11-1P
180608-12-2P 180608-13-3P 180608-14-4P
180608-15-5P 180608-16-6P 180608-17-7P
180608-19-9P 180608-20-2P 180608-21-3P
180608-22-4P 180608-23-5P 180608-24-6P
 180608-25-7P 180608-26-8P 180608-27-9P 180608-28-0P
 180608-29-1P 180608-30-4P 180608-31-5P
 180608-32-6P 180608-33-7P 180608-34-8P
180608-35-9P
 RL: AGR (Agricultural use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of disubstituted pyridines and pyrimidines as herbicides)

IT 180607-98-1P 180608-18-8P
 RL: AGR (Agricultural use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); RCT
 (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of disubstituted pyridines and pyrimidines as herbicides)


RN 180607-98-1 HCAPLUS

CN Pyrimidine, 4-bis[(2-chloro-4-pyridinyl)oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 180608-18-8 HCAPLUS

CN Pyrimidine, 4-bromo-2-[(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




IT	<u>180607-16-3P</u>	<u>180607-17-4P</u>	<u>180607-18-5P</u>
	<u>180607-19-6P</u>	<u>180607-20-9P</u>	<u>180607-21-0P</u>
	<u>180607-22-1P</u>	<u>180607-23-2P</u>	<u>180607-24-3P</u>
	<u>180607-25-4P</u>	<u>180607-26-5P</u>	<u>180607-27-6P</u>
	<u>180607-28-7P</u>	<u>180607-29-8P</u>	<u>180607-30-1P</u>
	<u>180607-31-2P</u>	<u>180607-32-3P</u>	<u>180607-33-4P</u>
	<u>180607-34-5P</u>	<u>180607-35-6P</u>	<u>180607-36-7P</u>
	<u>180607-37-8P</u>	<u>180607-39-0P</u>	<u>180607-41-4P</u>
	<u>180607-42-5P</u>	<u>180607-43-6P</u>	<u>180607-44-7P</u>
	<u>180607-45-8P</u>	<u>180607-47-0P</u>	<u>180607-48-1P</u>
	<u>180607-49-2P</u>	<u>180607-50-5P</u>	<u>180607-51-6P</u>
	<u>180607-52-7P</u>	<u>180607-53-8P</u>	<u>180607-54-9P</u>
	<u>180607-55-0P</u>	<u>180607-56-1P</u>	<u>180607-57-2P</u>
	<u>180607-58-3P</u>	<u>180607-59-4P</u>	<u>180607-61-8P</u>
	<u>180607-62-9P</u>	<u>180607-63-0P</u>	<u>180607-64-1P</u>
	<u>180607-65-2P</u>	<u>180607-66-3P</u>	<u>180607-67-4P</u>
	<u>180607-68-5P</u>	<u>180607-69-6P</u>	<u>180607-70-9P</u>
	<u>180607-71-0P</u>	<u>180607-72-1P</u>	<u>180607-73-2P</u>
	<u>180607-74-3P</u>	<u>180607-75-4P</u>	<u>180607-76-5P</u>
	<u>180607-77-6P</u>	<u>180607-78-7P</u>	<u>180607-79-8P</u>
	<u>180607-80-1P</u>	<u>180607-81-2P</u>	<u>180607-82-3P</u>
	<u>180607-83-4P</u>	<u>180607-84-5P</u>	<u>180607-85-6P</u>
	<u>180607-86-7P</u>	<u>180607-87-8P</u>	<u>180607-88-9P</u>
	<u>180607-89-0P</u>	<u>180607-90-3P</u>	<u>180607-92-5P</u>
	<u>180607-94-7P</u>	<u>180607-96-9P</u>	<u>180608-00-8P</u>
	<u>180608-02-0P</u>	<u>180608-04-2P</u>	<u>180608-05-3P</u>
	<u>180608-07-5P</u>	<u>180608-08-6P</u>	<u>180608-09-7P</u>

<u>180608-10-0P</u>	<u>180608-11-1P</u>	<u>180608-12-2P</u>
<u>180608-13-3P</u>	<u>180608-14-4P</u>	<u>180608-15-5P</u>
<u>180608-16-6P</u>	<u>180608-17-7P</u>	<u>180608-19-9P</u>
<u>180608-20-2P</u>	<u>180608-21-3P</u>	<u>180608-22-4P</u>
<u>180608-23-5P</u>	<u>180608-29-1P</u>	<u>180608-30-4P</u>
<u>180608-31-5P</u>	<u>180608-32-6P</u>	<u>180608-33-7P</u>
<u>180608-34-8P</u>	<u>180608-35-9P</u>	

RL: AGR (Agricultural use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted pyridines and pyrimidines as herbicides)


RN 180607-16-3 HCAPLUS

CN Pyrimidine, 2-(4-fluorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)




RN 180607-17-4 HCAPLUS

CN Pyrimidine, 2-(4-fluorophenyl)-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)



RN 180607-18-5 HCAPLUS


CN Pyrimidine, 2-(4-fluorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)



RN 180607-19-6 HCAPLUS


CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-

2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-20-9 HCAPLUS

CN Pyrimidine, 4-methyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-21-0 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-22-1 HCAPLUS

CN Pyrimidine, 5-methyl-4-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-23-2 HCAPLUS

CN Pyrimidine, 5-methyl-2-(3-methylphenyl)-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-24-3 HCAPLUS

CN Pyrimidine, 5-methyl-2-(3-methylphenyl)-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-25-4 HCAPLUS

CN Pyrimidine, 4-methyl-2-(3-methylphenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-26-5 HCAPLUS

CN Pyrimidine, 4-methyl-2-(3-methylphenyl)-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-27-6 HCAPLUS

CN Pyrimidine, 2-(3-chlorophenyl)-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-28-7 HCAPLUS

CN Pyrimidine, 2-(3-chlorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 180607-29-8 HCAPLUS


CN Pyrimidine, 2-(3-chlorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-30-1 HCAPLUS

CN Pyrimidine, 2-(2,4-difluorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]-


(CA INDEX NAME)




RN 180607-31-2 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(2,4-difluorophenyl)-5-methyl-
(CA INDEX NAME)


RN 180607-32-3 HCAPLUS

CN Pyrimidine, 2-(2,4-difluorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-
(CA INDEX NAME)

RN 180607-33-4 HCAPLUS


CN Pyrimidine, 2-(2,4-difluorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)

RN 180607-34-5 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(2,4-difluorophenyl)-6-methyl-
(CA INDEX NAME)


RN 180607-35-6 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-36-7 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-37-8 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-39-0 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-41-4 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[3-(trifluoromethyl)phenoxy]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-42-5 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-43-6 HCAPLUS

CN Pyrimidine, 4-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-44-7 HCAPLUS

CN Pyrimidine, 4-ethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-45-8 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-ethyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-47-0 HCAPLUS

CN Pyrimidine, 4-(4-fluorophenoxy)-6-methyl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-48-1 HCAPLUS

CN Pyrimidine, 4-ethyl-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-49-2 HCAPLUS

CN Pyrimidine, 4-(4-fluorophenoxy)-5-methyl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-50-5 HCAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-51-6 HCAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-52-7 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-53-8 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-54-9 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-55-0 HCAPLUS

CN Pyrimidine, 2-[4-(1,1-dimethylethyl)phenyl]-4-methyl-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-56-1 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-57-2 HCAPLUS


CN Pyrimidine, 2-(4-chlorophenyl)-4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)



RN 180607-58-3 HCAPLUS


CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-5,6-dimethyl-
(CA INDEX NAME)

RN 180607-59-4 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4,5-dimethyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-61-8 HCAPLUS

CN Pyrimidine, 2-(3-fluorophenyl)-4,5-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-62-9 HCAPLUS


CN Pyrimidine, 2-(4-chlorophenyl)-5-methyl-4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-63-0 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-5-methyl-
(CA INDEX NAME)


RN 180607-64-1 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-5-methyl-4-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)


RN 180607-65-2 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)


RN 180607-66-3 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-6-methyl-
(CA INDEX NAME)


RN 180607-67-4 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(3,4-difluorophenyl)-5-methyl-
(CA INDEX NAME)


RN 180607-68-5 HCAPLUS

CN Pyrimidine, 2-(3,4-difluorophenyl)-4-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-
(CA INDEX NAME)

RN 180607-69-6 HCAPLUS


CN Pyrimidine, 2-(3,4-difluorophenyl)-4-methyl-6-[3-(trifluoromethyl)phenoxy]-
(CA INDEX NAME)

RN 180607-70-9 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-2-(3,4-difluorophenyl)-6-methyl-
(CA INDEX NAME)


RN 180607-71-0 HCAPLUS

CN Pyrimidine, 4-[(1,3-dimethyl-1H-pyrazol-5-yl)oxy]-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-72-1 HCAPLUS

CN Pyrimidine, 4-[(1,3-dimethyl-1H-pyrazol-5-yl)oxy]-6-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 180607-73-2 HCAPLUS


CN Pyrimidine, 4-[(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)oxy]-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 180607-74-3 HCAPLUS


CN Pyrimidine, 4-[(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)oxy]-6-

methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-75-4 HCAPLUS

CN Pyrimidine, 4-[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]oxy]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-76-5 HCAPLUS

CN Pyrimidine, 4-methyl-2-[4-(trifluoromethoxy)phenyl]-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-77-6 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-78-7 HCAPLUS

CN Pyrimidine, 5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-79-8 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-80-1 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-2-[4-(trifluoromethoxy)phenyl]-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-81-2 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5,6-dimethyl-2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-82-3 HCAPLUS

CN Pyrimidine, 2-(3,4-difluorophenyl)-5-methyl-4-[3-(trifluoromethoxy)phenoxy]-
(CA INDEX NAME)




RN 180607-83-4 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(trifluoromethoxy)-1H-pyrazol-5-yl]oxy]-
2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-84-5 HCAPLUS

CN Pyrimidine, 5-methyl-4-[[1-methyl-3-(trifluoromethoxy)-1H-pyrazol-5-yl]oxy]-
2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-85-6 HCAPLUS

CN Pyrimidine, 4,5-dimethyl-6-[[1-methyl-3-(trifluoromethoxy)-1H-pyrazol-5-yl]oxy]-
2-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 180607-86-7 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-[(2-chloro-4-pyridinyl)oxy]-6-(methoxymethyl)- (CA INDEX NAME)




RN 180607-87-8 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-(methoxymethyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-88-9 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-(methoxymethyl)-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-89-0 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-90-3 HCAPLUS

CN Pyrimidine, 5-methoxy-4-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180607-92-5 HCAPLUS

CN Pyrimidine, 5-chloro-2-(4-chlorophenyl)-4-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180607-94-7 HCAPLUS

CN Pyrimidine, 5-chloro-2-(4-chlorophenyl)-4-methoxy-6-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)




RN 180607-96-9 HCAPLUS

CN Pyrimidine, 5-methoxy-4-([1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-00-8 HCAPLUS

CN Pyrimidine, 4,6-bis([1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-02-0 HCAPLUS

CN Pyrimidine, 4,6-bis[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-04-2 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4,6-bis[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-05-3 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-methoxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-07-5 HCAPLUS

CN Pyrimidine, 4-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-08-6 HCAPLUS

CN Pyrimidine, 4-methoxy-6-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-09-7 HCAPLUS

CN Pyrimidine, 4-(methylthio)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-10-0 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-(methylthio)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-11-1 HCAPLUS

CN 4-Pyrimidinamine, N,N-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-12-2 HCAPLUS

CN 4-Pyrimidinamine, N-ethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-13-3 HCAPLUS

CN Pyrimidine, 2-(4-chlorophenyl)-4-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-14-4 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-methoxy-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-15-5 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N,N-dimethyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-16-6 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-17-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-methyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-19-9 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-chlorophenyl)-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)




RN 180608-20-2 HCAPLUS

CN Pyrimidine, 4-chloro-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-21-3 HCAPLUS

CN Pyrimidine, 4-ethenyl-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-22-4 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-5,6-dimethyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-23-5 HCAPLUS

CN Pyrimidine, 4-[(2-chloro-4-pyridinyl)oxy]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-29-1 HCAPLUS

CN Benzonitrile, 4-[4-methyl-6-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-2-pyrimidinyl]- (CA INDEX NAME)




RN 180608-30-4 HCAPLUS

CN Benzonitrile, 4-[4-methoxy-6-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-2-pyrimidinyl]- (CA INDEX NAME)




RN 180608-31-5 HCAPLUS

CN Pyrimidine, 4-methyl-6-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-2-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 180608-32-6 HCAPLUS

CN Pyrimidine, 4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-6-(2-propyn-1-yl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-33-7 HCAPLUS

CN Pyrimidine, 4-[3-(trifluoromethyl)phenoxy]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 180608-34-8 HCAPLUS

CN Pyrimidine, 4-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 180608-35-9 HCAPLUS

CN Pyrimidine, 4-fluoro-6-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-[(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

L52 ANSWER 29 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:508818 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 121:108818

ORIGINAL REFERENCE NO.: 121:19655a,19658a

TITLE: Pesticidal pyrimidine compounds

INVENTOR(S): Munro, David; Davis, Royston; Day, Janet Anne; Wilkin, Jacqueline Ann; Wood, William Wakefield

PATENT ASSIGNEE(S): Shell Internationale Research Maatschappij B. V., Neth.


SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 121:108818
ED Entered STN: 03 Sep 1994
GI




720

pesticidal activity, were prepared Thus, condensation of 4-chloro-3-trifluoromethylphenol with 4,6-dichloropyrimidine in the presence of K₂CO₃ in DMSO gave 94% title compound, 4,6-bis(4-chloro-3-trifluoromethylphenoxy)pyrimidine. The prepared compds. were tested for acaricidal, insecticidal, and ectoparasitocidal activities (with data).

IC ICM C07D239-52
ICS C07D239-58; C07D239-48; C07D239-60; A01N043-54
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 5
IT 156591-82-1P 156591-83-2P 156591-84-3P 156591-85-4P 156591-86-5P
156591-87-6P 156591-88-7P 156591-89-8P 156591-90-1P 156591-91-2P
156591-92-3P 156591-93-4P 156591-94-5P 156591-95-6P 156591-96-7P
156591-97-8P 156591-98-9P 156591-99-0P 156592-00-6P 156592-01-7P
156592-02-8P 156592-03-9P 156592-04-0P 156592-05-1P 156592-06-2P
156592-07-3P 156592-08-4P 156592-09-5P 156592-10-8P 156592-11-9P
156592-12-0P ~~156592-13-1P~~ 156592-14-2P 156592-15-3P
156592-16-4P ~~156592-17-5P~~ 156592-18-6P 156592-19-7P
~~156592-20-0P~~ 156592-21-1P 156592-22-2P 156592-23-3P
156592-24-4P 156592-25-5P 156592-26-6P 156592-27-7P 156592-28-8P
156592-29-9P 156592-30-2P 156592-31-3P 156592-32-4P 156592-33-5P
156592-34-6P 156592-35-7P 156592-36-8P 156592-37-9P 156592-38-0P
156592-39-1P 156592-40-4P 156592-41-5P 156592-42-6P 156592-43-7P
156592-44-8P 156592-45-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and pesticidal activity of)
IT ~~156592-13-1P~~ ~~156592-20-0P~~
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and pesticidal activity of)
RN 156592-13-1 HCAPLUS
CN Pyrimidine, 2-phenyl-4,6-bis[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 156592-20-0 HCAPLUS
CN Pyrimidine, 4,6-bis[4-fluoro-3-(trifluoromethyl)phenoxy]-2-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 30 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:75794 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 122:55996

ORIGINAL REFERENCE NO.: 122:10851a,10854a

TITLE: Studies of cerebral protective agents. VI. Synthesis of novel 4-(4-nitrobenzoyl)pyrimidine and related compounds with antianoxic activity

AUTHOR(S): Ohkubo, Mitsuru; Kuno, Atsushi; Sakai, Hiroyoshi; Sugiyama, Yoshie; Takasugi, Hisashi

CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharmaceutical Co., Ltd., Osaka, 532, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1994), 42(6), 1279-85


CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 08 Nov 1994

GI



AB Novel pyrimidine derivs., possessing linkages between the aryl group and the pyrimidine nucleus at the C-4 position, were prepared and tested for antianoxic activity in mice. Among them, 5-(4-methylpiperazin-1-ylcarbonyl)-4-(4-nitrobenzoyl)-2-phenylpyrimidine (FR 76659) (I) possessed significant antianoxic activity (10-100 mg/kg, i.p.) with low acute toxicity (LD50 > 1000 mg/kg, i.p.). Structure-activity relationship in regard to antianoxic activity of this series of compds. were examined

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1

IT 103294-21-9DP, analogs and derivs. 116904-25-7P
116904-26-8P 116904-27-9P 116904-28-0P
116904-30-4P 116904-35-9P 116904-53-1P
116904-57-5P 116904-65-5P 116904-66-6P
116904-67-7P 116904-68-8P 116904-69-9P
116924-79-9P 116924-80-2P 159970-99-7P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of antianoxic cerebral protective agent
 [(pyrimidinyl)carbonyl]piperazine)

IT 62088-12-4P 76842-84-7P 116904-36-0P 116904-37-1P
116904-38-2P 116904-39-3P 116904-40-6P
116904-41-7P 116904-43-9P 116904-44-0P
116904-45-1P 116904-47-3P 116904-48-4P
116904-51-9P 116904-52-0P 116904-54-2P
116904-55-3P 116904-61-1P 116904-62-2P
116904-63-3P 116904-64-4P 116904-71-3P
 159971-00-3P 159971-01-4P 159971-02-5P 159971-04-7P
 159971-05-8P 159971-06-9P 159971-07-0P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of antianoxic cerebral protective agent
 [(pyrimidinyl)carbonyl]piperazine)

IT 103294-21-9DP, analogs and derivs. 116904-25-7P
116904-26-8P 116904-27-9P 116904-28-0P
116904-30-4P 116904-35-9P 116904-53-1P
116904-57-5P 116904-65-5P 116904-66-6P
116904-67-7P 116904-68-8P 116904-69-9P
116924-79-9P 116924-80-2P 159970-99-7P


RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of antianoxic cerebral protective agent
 [(pyrimidinyl)carbonyl]piperazine)

RN 103294-21-9 HCAPLUS

CN Methanone, [4-methyl-6-(3-nitrophenyl)-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-25-7 HCAPLUS
 CN Piperazine, 1-methyl-4-[[4-(4-nitrobenzoyl)-2-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 116904-26-8 HCAPLUS

CN Methanone, [4-methyl-6-[(4-nitrophenyl)thio]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 116904-27-9 HCAPLUS


CN Methanone, [4-methyl-6-[(2-nitrophenyl)thio]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 116904-28-0 HCAPLUS


CN Piperazine, 1-methyl-4-[[4-[2-(3-nitrophenyl)ethenyl]-2-phenyl-5-pyrimidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 116904-30-4 HCAPLUS

CN Piperazine, 1-methyl-4-[[4-(3-nitrobenzoyl)-2-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 116904-35-9 HCAPLUS

CN Methanone, (4-methyl-1-piperazinyl) [4-[(4-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]- (CA INDEX NAME)




RN 116904-53-1 HCAPLUS

CN Methanone, [5-[(4-methyl-1-piperazinyl)methyl]-2-phenyl-4-pyrimidinyl] (3-nitrophenyl)- (CA INDEX NAME)




RN 116904-57-5 HCAPLUS

CN Methanone, [4-methyl-6-[(3-nitrophenyl)amino]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-65-5 HCAPLUS

CN Pyrimidine, 5-[(4-methyl-1-piperazinyl)methyl]-4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-66-6 HCAPLUS

CN Pyrimidine, 5-[(4-methyl-1-piperazinyl)methyl]-4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-67-7 HCAPLUS

CN Methanone, [4-[hydroxy(4-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-68-8 HCAPLUS

CN Methanone, [4-[hydroxy(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 116904-69-9 HCAPLUS


CN 4-Pyrimidinemethanol, 5-[(4-methyl-1-piperazinyl)methyl]-α-(3-nitrophenyl)-2-phenyl- (CA INDEX NAME)



RN 116924-79-9 HCAPLUS


CN Piperazine, 1-methyl-4-[[4-[2-(4-nitrophenyl)ethenyl]-2-phenyl-5-pyrimidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 116924-80-2 HCAPLUS

CN Methanone, [5-[(4-methyl-1-piperazinyl)methyl]-2-phenyl-4-pyrimidinyl] (4-nitrophenyl)- (CA INDEX NAME)



RN 159970-99-7 HCAPLUS

CN Methanone, (4-methyl-1-piperazinyl) [4-[(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT	<u>116904-36-0P</u>	<u>116904-37-1P</u>	<u>116904-38-2P</u>
	<u>116904-39-3P</u>	<u>116904-40-6P</u>	<u>116904-41-7P</u>
	<u>116904-43-9P</u>	<u>116904-44-0P</u>	<u>116904-45-1P</u>
	<u>116904-47-3P</u>	<u>116904-48-4P</u>	<u>116904-51-9P</u>
	<u>116904-52-0P</u>	<u>116904-54-2P</u>	<u>116904-55-3P</u>
	<u>116904-61-1P</u>	<u>116904-62-2P</u>	<u>116904-63-3P</u>


116904-64-4P 159971-02-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of antianoxic cerebral protective agent
[(pyrimidinyl)carbonyl]piperazine)


RN 116904-36-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(4-nitrophenyl)methyl]-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 116904-37-1 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3-nitrobenzoyl)-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 116904-38-2 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-(3-nitrophenyl)ethenyl]-2-phenyl-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 116904-39-3 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 116904-40-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-(3-nitrophenyl)ethenyl]-2-phenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 116904-41-7 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-(4-nitrophenyl)ethenyl]-2-phenyl-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 116904-43-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(4-nitrophenyl)thio]-2-phenyl-, (E)- (9CI) (CA INDEX NAME)




RN 116904-44-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(2-nitrophenyl)thio]-2-phenyl-, (E)- (9CI) (CA INDEX NAME)




RN 116904-45-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrobenzoyl)-2-phenyl- (CA INDEX NAME)




RN 116904-47-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 116904-48-4 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3-nitrobenzyl)-2-phenyl- (CA INDEX NAME)




RN 116904-51-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-(4-nitrophenyl)ethenyl]-2-phenyl-, (E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 116904-52-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrobenzoyl)-2-phenyl-, ethyl ester
(CA INDEX NAME)

RN 116904-54-2 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(4-nitrophenyl)thio]-2-phenyl-,
ethyl ester (CA INDEX NAME)

RN 116904-55-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(2-nitrophenyl)thio]-2-phenyl-,
ethyl ester (CA INDEX NAME)


RN 116904-61-1 HCAPLUS

CN 5-Pyrimidinemethanol, 4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-62-2 HCAPLUS

CN 5-Pyrimidinethanol, 4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-63-3 HCAPLUS

CN Pyrimidine, 5-(bromomethyl)-4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-64-4 HCAPLUS

CN Pyrimidine, 5-(bromomethyl)-4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 159971-02-5 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(3-nitrophenyl)methyl]-2-phenyl-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L52 ANSWER 31 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:214528 HCAPLUS [Full-text](#)



DOCUMENT NUMBER: 116:214528

ORIGINAL REFERENCE NO.: 116:36361a,36364a

TITLE: Preparation of
[(pyrimidinyl)oxy]phenylmethoxypropenoates and related
compounds as agrochemical fungicides


INVENTOR(S): Clough, John Martin; Godfrey, Christopher Richard
 Ayles; Streeting, Ian Thomas; Cheetham, Rex; De
 Fraine, Paul John; Bartholomew, David; Eshelby, James
 John
 PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK
 SOURCE: Eur. Pat. Appl., 57 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 468695	A1	19920129	EP 1991-306512	19910717 <--
EP 468695	B1	19960911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 9105512	A	19920429	ZA 1991-5512	19910715 <--
IL 98830	A	19960131	IL 1991-98830	19910715 <--
AU 9180437	A	19920130	AU 1991-80437	19910716 <--
AU 632425	B2	19921224		
AT 142626	T	19960915	AT 1991-306512	19910717 <--
CA 2047510	A1	19920128	CA 1991-2047510	19910722 <--
HU 58299	A2	19920228	HU 1991-2441	19910722 <--
HU 212117	B	19960228		
CN 1060289	A	19920415	CN 1991-105782	19910724 <--
CN 1036519	C	19971126		
BR 9103225	A	19920526	BR 1991-3225	19910726 <--
KR 200936	B1	19990615	KR 1991-12964	19910727 <--
JP 05163249	A	19930629	JP 1991-212941	19910729 <--
JP 3041315	B2	20000515		
US 20030060626	A1	20030327	US 2002-87984	20020305 <--
US 6613773	B2	20030902		
US 20040092746	A1	20040513	US 2003-608698	20030627 <--
US 6777412	B2	20040817		
PRIORITY APPLN. INFO.:				
			GB 1990-16583	A 19900727 <--
			GB 1990-20748	A 19900924 <--
			GB 1991-15480	19910717 <--
			US 1991-736159	B1 19910726 <--
			US 1993-146822	B1 19931101 <--
			US 1995-486060	B1 19950607 <--
			US 2002-87984	A3 20020305 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 116:214528				
ED Entered STN: 31 May 1992				
GI				




- AB Title compds. [I; any 2 of K, L, M = N, the other = CB; T = O, S; Z = (substituted) aryl, heterocyclyl; X = O, S, SO, SO₂, COS, CS₂, NR₄N:CR₁, N(CHO), NR₄, CO, CR₁R₂, CO₂, OCHR₁CHR₂, CR₁:NO, COCO, CONR₄, N:N, SCO, etc.; A, B, E = H, OH, halo, (halo)alkyl, (halo)alkoxy, alkylcarbonyl, alkoxy carbonyl, PhO, NO₂, cyano; R₁, R₂ = H, alkyl, Ph; R₄ = H, alkyl, COR₁], were prepared Thus, formilide was stirred 2 h with NaH in DMF; the mixture was cooled to 0° and Me E-2-[2-(6-methanesulfonylpyrimidin-4-yloxy)phenyl]-3-methoxypropenoate in DMF was added. The mixture was stirred 16 h to give 20% title compound II. II as a 0.05% spray gave complete control of Puccinia recordita, Erysiphe graminis hurdei, Venturia inaequalis, Plasmopara viticola, etc.
- IC ICM C07D239-46
ICS C07D239-52; A01N043-54; C07D239-56; C07D403-04; C07D403-12
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 5
- IT 141189-77-7P 141189-78-8P 141189-79-9P 141189-80-2P 141189-81-3P
141189-82-4P 141189-83-5P 141189-84-6P 141189-85-7P 141189-86-8P
141189-87-9P 141189-88-0P 141189-89-1P 141189-90-4P 141189-91-5P
141189-92-6P 141189-93-7P 141189-94-8P 141189-95-9P 141189-96-0P
141189-97-1P 141189-98-2P 141189-99-3P 141190-00-3P 141190-01-4P
141190-02-5P 141190-03-6P 141190-04-7P 141190-05-8P 141190-06-9P
141190-07-0P 141190-08-1P 141190-09-2P 141190-10-5P 141190-11-6P
141190-12-7P 141190-13-8P 141190-14-9P 141190-15-0P 141190-16-1P
141190-17-2P 141190-18-3P 141190-19-4P 141190-20-7P 141190-21-8P
141190-22-9P 141190-23-0P 141190-24-1P 141190-25-2P 141190-26-3P
141190-27-4P 141190-28-5P 141190-29-6P 141190-30-9P 141190-31-0P
141190-32-1P 141190-33-2P 141190-34-3P 141190-35-4P 141190-36-5P
141190-37-6P 141190-38-7P 141190-39-8P 141190-40-1P 141190-41-2P
141190-42-3P 141190-43-4P 141190-44-5P 141190-45-6P 141190-46-7P
141190-47-8P 141190-48-9P 141190-49-0P 141190-50-3P
141190-51-4P 141190-52-5P 141190-53-6P 141190-54-7P 141190-55-8P
141206-50-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agrochem. fungicide)
- IT 141190-49-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agrochem. fungicide)
- RN 141190-49-0 HCAPLUS
- CN Benzenesacetic acid, α -(methoxymethylene)-2-[(2-phenyl-4-pyrimidinyl)oxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L52 ANSWER 32 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1991:228864 HCAPLUS Full-text
 DOCUMENT NUMBER: 114:228864
 ORIGINAL REFERENCE NO.: 114:38605a,38608a
 TITLE: Synthesis and biological activity of some
 4-substituted pyrimidines and fused pyrimidines
 AUTHOR(S): El-Bahaie, S.; El-Deeb, A.; Assy, M. C.
 CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt
 SOURCE: Pharmazie (1991), 46(1), 26-8
 CODEN: PHARAT; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:228864
 ED Entered STN: 15 Jun 1991
 GI



AB Reaction of acetylpyrimidine I (R = SH) with acrylonitrile and Cl gave I [R = SCH₂CH₂CN (II), Cl (III)] resp. II reacted with N₂H₄ and KMnO₄ in presence of H₂SO₄ to give pyrazolopyrimidine IV and thienopyrimidine V resp. Reaction of III with aromatic amines, PhNHNH₂, urea and NaN₃ gave I (R = NHR₁, NHNHPh, R₁ = substituted Ph), pyrimidopyrimidine VI, and tetrazolopyrimidine VII resp. Other reactions of III are also reported. Most of the prepared compds. were tested for antibacterial activity and most were active.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 10

IT 117831-37-5P 117831-38-6P 133761-03-2P 133761-04-3P
 133761-05-4P 133761-06-5P 133761-08-7P
 133761-20-3P 133782-27-1P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL


(Biological study); PREP (Preparation)
(preparation and antibacterial activity of)

IT 133761-04-3P 133761-06-5P 133761-08-7P
133761-20-3P 133782-27-1P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation and antibacterial activity of)


RN 133761-04-3 HCAPLUS

CN Ethanone, 1-[4-methyl-2-phenyl-6-(phenylamino)-5-pyrimidinyl]- (CA INDEX NAME)




RN 133761-06-5 HCAPLUS

CN Ethanone, 1-(4-ethoxy-6-methyl-2-phenyl-5-pyrimidinyl)- (CA INDEX NAME)




RN 133761-08-7 HCAPLUS

CN Ethanone, 1-[4-(2,4-dinitrophenoxy)-6-methyl-2-phenyl-5-pyrimidinyl]- (CA INDEX NAME)




RN 133761-20-3 HCAPLUS

CN Ethanone, 1-[4-[(4-chlorophenyl)amino]-6-methyl-2-phenyl-5-pyrimidinyl]- (CA INDEX NAME)




RN 133782-27-1 HCAPLUS
 CN Ethanone, 1-[4-methyl-6-[(4-methylphenyl)amino]-2-phenyl-5-pyrimidinyl]-
 (CA INDEX NAME)




OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)

L52 ANSWER 33 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1991:101905 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 114:101905
 ORIGINAL REFERENCE NO.: 114:17373a,17376a
 TITLE: Synthesis of certain mercapto- and aminopyrimidine derivatives as potential antimicrobial agents
 AUTHOR(S): El-Kerdawy, M. M.; Eisa, H. M.; El-Emam, A. A.; Massoud, M. A.; Nasr, M. N.
 CORPORATE SOURCE: Fac. Pharm., Univ. Mansoura, Mansoura, Egypt
 SOURCE: Archives of Pharmacal Research (1990), 13(2), 142-6
 CODEN: APHRDQ; ISSN: 0253-6269
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 23 Mar 1991
 GI




AB Reaction of Et 4-chloro-2-phenylpyrimidine-4-carboxylate (I) with 5-chloro-2-methylthiophenol or 3-aryl-4-phenyl-1,2,4-triazole-5-thiols yielded the corresponding thioethers II and III (R = 4-pyridyl, 2-thienyl). Careful alkaline hydrolysis of II yielded the corresponding carboxylic acid. Reaction of I with p-aminoacetophenone yielded compd.IV (R1 = Me), which reacted with aromatic aldehydes to afford the α,β -unsatd. ketones IV (R1 = CH:CHC6H4R2; R2 = 2-Cl, 4-Cl, 3-Br, 4-Br, 4-NO2) (V). Condensation of I with malononitrile or phenylhydrazine yielded the corresponding 2-amino-3-cyanopyridines or the 2-

- pyrazolines, resp. Seven representative compds. were tested for their in vitro antimicrobial activity against some pathogenic bacteria and fungi.
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 10
- IT 132165-77-6P 132165-78-7P 132165-79-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activities of)
- IT 132165-71-0P 132165-72-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activity of)
- IT 132165-69-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
- IT 132165-70-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, attempted cyclization, and bactericidal and fungicidal activity of)
- IT 132165-77-6P 132165-78-7P 132165-79-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activities of)
- RN 132165-77-6 HCAPLUS
- CN 5-Pyrimidinecarboxylic acid, 4-[[4-[3-(4-bromophenyl)-1-oxo-2-propen-1-yl]phenyl]amino]-2-phenyl-, ethyl ester (CA INDEX NAME)




- RN 132165-78-7 HCAPLUS
- CN 5-Pyrimidinecarboxylic acid, 4-[[4-[6-amino-4-(2-chlorophenyl)-5-cyano-2-pyridinyl]phenyl]amino]-2-phenyl-, ethyl ester (CA INDEX NAME)



- RN 132165-79-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[4-[6-amino-4-(4-chlorophenyl)-5-cyano-2-pyridinyl]phenyl]amino]-2-phenyl-, ethyl ester (CA INDEX NAME)




IT 132165-71-0P 132165-72-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and bactericidal and fungicidal activity of)


RN 132165-71-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-phenyl-4-[[4-phenyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]thio]-, ethyl ester (CA INDEX NAME)



RN 132165-72-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-phenyl-4-[[4-phenyl-5-(2-thienyl)-4H-1,2,4-triazol-3-yl]thio]-, ethyl ester (CA INDEX NAME)




IT 132165-69-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and saponification of)

RN 132165-69-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(5-chloro-2-methylphenyl)thio]-2-phenyl-, ethyl ester (CA INDEX NAME)




IT 132165-70-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, attempted cyclization, and bactericidal and fungicidal activity of)

RN 132165-70-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(5-chloro-2-methylphenyl)thio]-2-phenyl-
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L52 ANSWER 34 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:570451 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 109:170451

ORIGINAL REFERENCE NO.: 109:28279a,28282a

TITLE: Preparation of pyrimidine derivatives as drugs for
treating disease and disorders of cerebral blood
vessels

INVENTOR(S): Takatani, Takao; Takasugi, Hisashi; Kuno, Atsushi;
Sugiyama, Yoshie; Sakai, Hiroyoshi; Okubo, Mitsuru

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63107966	A	19880512	JP 1987-124326	19870520 <--
			JP 1986-117800	A1 19860522 <--

PRIORITY APPLN. INFO.: CASREACT 109:170451; MARPAT 109:170451

OTHER SOURCE(S):


ED Entered STN: 12 Nov 1988

GI




- AB The title compds. [I; Ar = (nitro or haloalkyl)aryl, fused benzene-heterocyclyl containing N or O; X = bond, lower hydroxyalkylene, lower alkenylene, NH, S, CO; R1 = (esterified) CO2H, lower hydroxyalkyl, lower haloalkyl, (N-substituted) CONH2 or lower aminoalkyl; R2 = H, lower alkyl, optionally R1R2 completing (substituted) N-containing heterocycle; R3 = aryl], were prepared as drugs e.g. for treating apoplexy. A mixture of 6-bromomethyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylic acid Me ester and Me2NCH2CHNH2 in iso-PrOH was stirred at 70° for 1 h to give 6-[2-(dimethylamino)ethyl]-4-(3-nitrophenyl)-5-oxo-2-phenyl-6,7-dihydropyrrolo[3,4-d]pyrimidine. The latter at 10 mg/kg i.p. extended the survival time of mice from 28.2 ± 1.1 s (control) to 33.6 ± 2.9 s when the mice were exposed to 100% N atmospheric
- IC ICM C07D239-28
ICS A61K031-505; C07D239-32; C07D239-42; C07D403-06; C07D413-04; C07D487-04
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
- IT 116904-45-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(acid chloride formation and amidation of, with methylpiperazine)
- IT 116904-47-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with methylpiperazine)
- IT 103311-82-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)
- IT 103294-21-9P 116904-11-1P 116904-12-2P 116904-13-3P
116904-14-4P 116904-15-5P 116904-16-6P 116904-17-7P 116904-18-8P
116904-19-9P 116904-20-2P 116904-21-3P 116904-22-4P 116904-23-5P
116904-24-6P 116904-25-7P 116904-26-8P
116904-27-9P 116904-28-0P 116904-29-1P
116904-30-4P 116904-31-5P 116904-32-6P
116904-33-7P 116904-34-8P 116904-35-9P
116904-36-0P 116904-37-1P 116904-38-2P
116904-39-3P 116904-40-6P 116904-41-7P
116904-42-8P 116904-43-9P 116904-44-0P
116904-45-1P 116904-46-2P 116904-47-3P
116904-48-4P 116904-49-5P 116904-50-8P 116904-51-9P
116904-52-0P 116904-53-1P 116904-54-2P
116904-55-3P 116904-56-4P 116904-57-5P
116904-58-6P 116904-59-7P 116904-60-0P 116904-61-1P
116904-62-2P 116904-63-3P 116904-64-4P
116904-65-5P 116904-66-6P 116904-67-7P
116904-68-8P 116904-69-9P 116904-78-0P
116924-79-9P 116924-80-2P 117699-25-9P
- RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as drug for treating apoplexy)
- IT 62088-12-4P 70076-42-5P 116904-71-3P 116904-73-5P
116904-75-7P 116904-76-8P 116904-77-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in preparation of drug for treating apoplexy)


IT 116904-45-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (acid chloride formation and amidation of, with methylpiperazine)
 RN 116904-45-1 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrobenzoyl)-2-phenyl- (CA INDEX NAME)



IT 116904-47-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation of, with methylpiperazine)
 RN 116904-47-3 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



IT 103311-82-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (bromination of)
 RN 103311-82-6 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-ethyl-6-(3-nitrophenyl)-2-phenyl-, methyl ester (CA INDEX NAME)



IT <u>103294-21-9P</u>	<u>116904-25-7P</u>	<u>116904-26-8P</u>
<u>116904-27-9P</u>	<u>116904-28-0P</u>	<u>116904-30-4P</u>
<u>116904-31-5P</u>	<u>116904-34-8P</u>	<u>116904-35-9P</u>
<u>116904-36-0P</u>	<u>116904-37-1P</u>	<u>116904-38-2P</u>
<u>116904-39-3P</u>	<u>116904-40-6P</u>	<u>116904-41-7P</u>
<u>116904-42-8P</u>	<u>116904-43-9P</u>	<u>116904-44-0P</u>
<u>116904-45-1P</u>	<u>116904-47-3P</u>	<u>116904-48-4P</u>
<u>116904-51-9P</u>	<u>116904-52-0P</u>	<u>116904-53-1P</u>
<u>116904-54-2P</u>	<u>116904-55-3P</u>	<u>116904-56-4P</u>
<u>116904-57-5P</u>	<u>116904-61-1P</u>	<u>116904-62-2P</u>
<u>116904-63-3P</u>	<u>116904-64-4P</u>	<u>116904-65-5P</u>
<u>116904-66-6P</u>	<u>116904-67-7P</u>	<u>116904-68-8P</u>

10/595,734

116904-69-9P

116904-78-0P



116924-79-9P

116924-80-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as drug for treating apoplexy)


RN 103294-21-9 HCAPLUS

CN Methanone, [4-methyl-6-(3-nitrophenyl)-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-25-7 HCAPLUS

CN Piperazine, 1-methyl-4-[[4-(4-nitrobenzoyl)-2-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 116904-26-8 HCAPLUS

CN Methanone, [4-methyl-6-[(4-nitrophenyl)thio]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 116904-27-9 HCAPLUS


CN Methanone, [4-methyl-6-[(2-nitrophenyl)thio]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 116904-28-0 HCAPLUS


CN Piperazine, 1-methyl-4-[[4-[2-(3-nitrophenyl)ethenyl]-2-phenyl-5-pyrimidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 116904-30-4 HCAPLUS

CN Piperazine, 1-methyl-4-[[4-(3-nitrobenzoyl)-2-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 116904-31-5 HCAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-(4-nitrobenzoyl)-2-phenyl- (CA INDEX NAME)



RN 116904-34-8 HCAPLUS


CN Methanone, (4-methyl-1-piperazinyl)[4-[(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 116904-35-9 HCAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[4-[(4-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]- (CA INDEX NAME)




RN 116904-36-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(4-nitrophenyl)methyl]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 116904-37-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-nitrobenzoyl)-2-phenyl-, ethyl ester
(CA INDEX NAME)

RN 116904-38-2 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-(3-nitrophenyl)ethenyl]-2-phenyl-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 116904-39-3 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 116904-40-6 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-(3-nitrophenyl)ethenyl]-2-phenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 116904-41-7 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-(4-nitrophenyl)ethenyl]-2-phenyl-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 116904-42-8 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(3-nitrophenyl)amino]-2-phenyl- (CA INDEX NAME)




RN 116904-43-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(4-nitrophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 116904-44-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(2-nitrophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 116904-45-1 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrobenzoyl)-2-phenyl- (CA INDEX NAME)




RN 116904-47-3 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 116904-48-4 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3-nitrobenzoyl)-2-phenyl- (CA INDEX NAME)




RN 116904-51-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-(4-nitrophenyl)ethenyl]-2-phenyl-, (E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 116904-52-0 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrobenzoyl)-2-phenyl-, ethyl ester
(CA INDEX NAME)


RN 116904-53-1 HCAPLUS

CN Methanone, [5-[(4-methyl-1-piperazinyl)methyl]-2-phenyl-4-pyrimidinyl](3-nitrophenyl)- (CA INDEX NAME)




RN 116904-54-2 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(4-nitrophenyl)thio]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 116904-55-3 HCAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(2-nitrophenyl)thio]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 116904-56-4 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[(3-nitrophenyl)amino]-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 116904-57-5 HCAPLUS
 CN Methanone, [4-methyl-6-[(3-nitrophenyl)amino]-2-phenyl-5-pyrimidinyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-61-1 HCAPLUS
 CN 5-Pyrimidinemethanol, 4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 116904-62-2 HCAPLUS
 CN 5-Pyrimidinemethanol, 4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-63-3 HCAPLUS
 CN Pyrimidine, 5-(bromomethyl)-4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-64-4 HCAPLUS

CN Pyrimidine, 5-(bromomethyl)-4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-65-5 HCAPLUS

CN Pyrimidine, 5-[(4-methyl-1-piperazinyl)methyl]-4-[(4-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-66-6 HCAPLUS

CN Pyrimidine, 5-[(4-methyl-1-piperazinyl)methyl]-4-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 116904-67-7 HCAPLUS

CN Methanone, [4-[hydroxy(4-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-68-8 HCAPLUS

CN Methanone, [4-[hydroxy(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 116904-69-9 HCAPLUS

CN 4-Pyrimidinemethanol, 5-[(4-methyl-1-piperazinyl)methyl]-α-(3-nitrophenyl)-2-phenyl- (CA INDEX NAME)



RN 116904-78-0 HCAPLUS


CN Methanone, (4-methyl-1-piperazinyl)[4-[(3-nitrophenyl)methyl]-2-phenyl-5-pyrimidinyl]- (CA INDEX NAME)



RN 116924-79-9 HCAPLUS


CN Piperazine, 1-methyl-4-[[4-[2-(4-nitrophenyl)ethenyl]-2-phenyl-5-pyrimidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 116924-80-2 HCAPLUS

CN Methanone, [5-[(4-methyl-1-piperazinyl)methyl]-2-phenyl-4-pyrimidinyl] (4-nitrophenyl)- (CA INDEX NAME)




IT 116904-73-5P 116904-77-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, in preparation of drug for treating apoplexy)


RN 116904-73-5 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(1-bromoethyl)-6-(3-nitrophenyl)-2-phenyl-, methyl ester (CA INDEX NAME)




RN 116904-77-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-2-phenyl-6-[3-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)



L52 ANSWER 35 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1988:21928 HCAPLUS Full-text
 DOCUMENT NUMBER: 108:21928
 ORIGINAL REFERENCE NO.: 108:3727a,3730a
 TITLE: Preparation of
 azolylaryl(piperazinylphenoxy)dioxolanes as medical
 fungicides
 INVENTOR(S): Kampe, Klaus Dieter; Raether, Wolfgang; Dittmar,
 Walter; Haenel, Heinz
 PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 49 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3609598	A1	19871001	DE 1986-3609598	19860321 <--
EP 237962	A2	19870923	EP 1987-103588	19870312 <--
EP 237962	A3	19890322		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8701206	A	19870922	FI 1987-1206	19870319 <--
ZA 8702021	A	19871028	ZA 1987-2021	19870319 <--
HU 48236	A2	19890529	HU 1987-1220	19870319 <--
US 4859670	A	19890822	US 1987-28193	19870319 <--
DK 8701440	A	19870922	DK 1987-1440	19870320 <--
NO 8701165	A	19870922	NO 1987-1165	19870320 <--
AU 8770422	A	19870924	AU 1987-70422	19870320 <--
AU 590692	B2	19891109		
JP 62230781	A	19871009	JP 1987-64427	19870320 <--
IL 81950	A	19910630	IL 1987-81950	19870320 <--
CA 1294280	C	19920114	CA 1987-532655	19870320 <--
PRIORITY APPLN. INFO.:			DE 1986-3609598	A 19860321 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 108:21928				
ED Entered STN: 23 Jan 1988				
GI				



- AB The title compds. [I; R1 = Cl-3 alkyl, F, Cl; R2 = naphthyl, thienyl, halothienyl, (substituted) Ph; Y = (substituted) phenylpyrimidinyl, phenylpyridyl, quinolyl, isoquinolyl; A = CH, N; n = 0-2] were prepared as medicinal fungicides. cis-2-S(R)-(2,4-Dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-4-R(S)methanesulfonyloxymethyl-1,3-dioxolane in DMF was added to a mixture of 4-[[4-(4-hydroxyphenyl)-1-piperazinyl]methyl]-6-methoxy-2-phenylpyrimidine and NaH in DMF and the mixture was refluxed 4 h to give 66.6% I (R1 = H, R2 = 2,4-Cl2C6H3, R3 = 6-methoxy-2-phenyl-4-pyrimidinyl, A = N). I were up to 60% more effective than terconazole against Trichophyton mentagrophytes.
- IC ICM C07D405-14
ICS C07D239-26; C07D239-28; C07D239-30; C07D239-34; C07D239-36;
C07D213-04; C07D215-02; C07D217-02; A01N043-50; A01N043-54;
A01N043-653
- ICA C07D233-60
- ICI C07D249-08, C07D213-36, C07D213-62, C07D215-12, C07D239-26, C07D239-28,
C07D239-34
- CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
- IT 35252-98-3 111921-72-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(amination of, by hydroxyphenylpiperazine derivative)
- IT 111921-21-2P 111921-22-3P 111921-23-4P 111921-24-5P
111921-25-6P 111921-26-7P 111921-27-8P
111921-28-9P 111921-29-0P 111921-30-3P 111921-31-4P 111921-32-5P
111921-33-6P 111921-34-7P 111921-35-8P 111921-36-9P 111921-37-0P
111921-38-1P 111921-39-2P 111921-40-5P 111921-41-6P 111921-42-7P
111921-43-8P 111921-44-9P 111921-45-0P 111921-46-1P
111921-47-2P 111921-48-3P 111921-49-4P 111921-50-7P
111921-51-8P 111921-52-9P 111921-53-0P 111921-54-1P 111921-55-2P
111921-56-3P 111921-57-4P 111921-58-5P 111921-59-6P 111921-60-9P
111933-28-9P
- RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for medicinal fungicide)
- IT 75050-34-9P 75050-35-0P 75050-36-1P 75050-37-2P 75050-38-3P
111920-67-3P 111920-68-4P
111920-69-5P 111920-70-8P 111920-71-9P 111920-72-0P
111920-73-1P 111920-74-2P 111920-75-3P 111920-76-4P
111920-77-5P 111920-78-6P 111920-79-7P 111920-80-0P 111920-82-2P
111920-83-3P 111920-84-4P 111920-85-5P 111920-86-6P 111920-87-7P
111920-88-8P 111920-89-9P 111920-90-2P 111920-91-3P
111920-92-4P 111920-93-5P 111920-94-6P 111920-95-7P
111920-96-8P 111920-97-9P 111920-98-0P 111920-99-1P 111921-00-7P
111921-01-8P 111921-02-9P 111921-03-0P 111921-04-1P 111921-05-2P
111921-06-3P 111921-07-4P 111921-08-5P 111921-09-6P 111921-10-9P
111921-11-0P 111921-12-1P 111921-13-2P 111921-14-3P 111921-15-4P
111921-16-5P 111921-17-6P 111921-18-7P 111921-19-8P 111921-20-1P

10/595,734

111943-47-6P 111943-48-7P 111943-49-8P 111943-50-1P
111943-51-2P 111943-52-3P 111943-53-4P 111943-53-4P
 111973-80-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as medicinal fungicide)

IT 111921-72-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (amination of, by hydroxyphenylpiperazine derivative)

RN 111921-72-3 HCAPLUS

CN Pyrimidine, 4-(chloromethyl)-6-methoxy-2-phenyl- (CA INDEX NAME)




IT 111921-21-2P 111921-25-6P 111921-26-7P
111921-44-9P 111921-48-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for medicinal fungicide)


RN 111921-21-2 HCAPLUS

CN Phenol, 4-[4-[(6-methoxy-2-phenyl-4-pyrimidinyl)methyl]-1-piperazinyl]-
 (CA INDEX NAME)




RN 111921-25-6 HCAPLUS

CN Phenol, 4-[4-[(6-butoxy-2-phenyl-4-pyrimidinyl)methyl]-1-piperazinyl]-
 (CA INDEX NAME)




RN 111921-26-7 HCAPLUS

CN Phenol, 4-[4-[(6-methoxy-2-phenyl-4-pyrimidinyl)methyl]-1-piperazinyl]-2,6-dimethyl- (CA INDEX NAME)




RN 111921-44-9 HCAPLUS

CN Phenol, 4-[4-[[4-(4-methoxyphenoxy)-2-phenyl-6-propyl-5-pyrimidinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 111921-48-3 HCAPLUS

CN Phenol, 4-[4-[[4-(4-methyl-6-(1-methylethoxy)-2-pyrimidinyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)




IT 111920-67-3P 111920-68-4P 111920-69-5P
111920-75-3P 111920-90-2P 111920-95-7P
111943-51-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as medicinal fungicide)

RN 111920-67-3 HCAPLUS

CN Pyrimidine, 4-[[4-[4-[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]methyl]-6-methoxy-2-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 111920-68-4 HCAPLUS

CN Pyrimidine, 4-butoxy-6-[[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]methyl]-2-phenyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 111920-69-5 HCAPLUS

CN Pyrimidine, 4-butoxy-6-[[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]methyl]-2-phenyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 111920-75-3 HCAPLUS

CN Pyrimidine, 4-[[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-3,5-dimethylphenyl]-1-piperazinyl]methyl]-6-methoxy-2-phenyl-, cis- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 111920-90-2 HCAPLUS

CN Pyrimidine, 5-[[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-3,5-dimethylphenyl]-1-piperazinyl]methyl]-4-methoxy-2-phenyl-6-propyl-, cis- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 111920-95-7 HCAPLUS



CN Pyrimidine, 2-[4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]methyl]phenyl]-4-methyl-6-(1-methylethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 111943-51-2 HCAPLUS
 CN Pyrimidine, 5-[[4-[[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]methyl]-4-(4-methoxyphenoxy)-2-phenyl-6-propyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L52 ANSWER 36 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1985:162193 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 102:162193

ORIGINAL REFERENCE NO.: 102:25429a, 25432a

TITLE: Phenylpyrimidines as antidotes for protecting
cultivated plants against phytotoxic damage caused by
herbicides

INVENTOR(S): Burdeska, Kurt; Kabas, Guglielmo; Brunner, Hans Georg;
Foery, Werner

PATENT ASSIGNEE(S): Ciba-Geigy Corp., USA

SOURCE: U.S., 29 pp. Cont.-in-part of U.S. Ser. No. 331,853,
abandoned.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4493726	A	19850115	US 1983-486651	19830420 <--
ZA 8108852	A	19821229	ZA 1981-8852	19811222 <--
US 4674229	A	19870623	US 1984-667705	19841102 <--
PRIORITY APPLN. INFO.:			CH 1980-9522	A 19801223 <--
			CH 1981-2363	A 19810408 <--
			US 1981-331853	A2 19811217 <--
			US 1983-486651	A3 19830420 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
ED Entered STIN: 18 May 1985				
GI				



AB	The phenylpyrimidines I (R = H, halo, CN, NO ₂ , OH, C1-6 alkyl, alkoxy or alkylthio, etc.; R1 and R2 = halo, CN, OH, SH, C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl, haloalkyl, or Ph; n = 1-5) are herbicide antidotes. The pertinent herbicides are butachlor [23184-66-9], alachlor [15972-60-8], acetochlor [34256-82-1], trifluralin [1582-09-8], and many others. Thus, in pot expts., 2-(p-chlorophenyl)-4,6-dichloropyrimidine [26870-72-4], applied together with pretilachlor [51218-49-6], at 0.25 kg/ha each, protected rice against the phytotoxicity of the latter.				
IC	ICM A01N057-10				
	ICS A01N043-48; C07D239-02				
INCL	071087000				
CC	5-3 (Agrochemical Bioregulators)				
	Section cross-reference(s): 28				
IT	3740-90-7P	3740-91-8P	3740-92-9P	13514-79-9P	14727-23-2P
	15726-40-6P	17077-89-3P	17077-93-9P	20655-14-5P	21139-61-7P
	21139-63-9P	26863-48-9P	26863-54-7P	26870-72-4P	29509-92-0P
	29954-25-4P	72520-17-3P	77232-14-5P		
	77232-18-9P	77232-19-0P	77232-21-4P		
	77232-23-6P	77232-25-8P	79382-42-6P		
	79382-43-7P	79382-44-8P	79382-45-9P		
	79382-46-0P	79382-47-1P	79382-48-2P		
	79382-49-3P	79382-50-6P	79382-51-7P		
	79382-68-6P	79382-77-7P	79382-78-8P	79382-82-4P	
	79396-00-2P	83216-81-3P	83216-82-4P	83216-83-5P	
	83216-84-6P	83216-85-7P	83216-86-8P		
	83216-87-9P	83216-88-0P	83216-89-1P		
	83216-90-4P	83216-91-5P	83216-92-6P		
	83216-93-7P	83216-94-8P	83216-95-9P	83216-96-0P	
	83216-97-1P	83216-98-2P	83216-99-3P		
	83217-00-9P	83217-01-0P	83217-02-1P		
	83217-03-2P	83217-04-3P	83217-05-4P	83217-06-5P	
	83217-07-6P	83217-08-7P	83217-09-8P	83217-10-1P	83217-11-2P
	83217-12-3P	83217-13-4P	83217-14-5P	83217-15-6P	83217-16-7P
	83217-17-8P	83217-18-9P	83217-19-0P	83217-20-3P	83217-21-4P
	83217-22-5P	83217-23-6P	83217-24-7P	83217-25-8P	83217-26-9P
	83217-27-0P	83217-28-1P	83217-29-2P	83217-30-5P	83217-31-6P

83217-32-7P	83217-34-9P	83217-35-0P	83217-36-1P	83217-37-2P
83217-39-4P	83217-40-7P	83217-41-8P	83217-42-9P	83217-43-0P
83217-44-1P	83217-45-2P	83217-46-3P	83217-47-4P	83217-48-5P
83217-49-6P	83217-50-9P	83217-51-0P	83217-52-1P	83217-53-2P
83217-54-3P	83217-55-4P	83217-56-5P	83217-57-6P	83217-58-7P
83217-59-8P	83217-60-1P	83217-61-2P	83217-62-3P	83217-63-4P
83217-64-5P	83217-65-6P	83217-66-7P	83217-67-8P	83217-68-9P
83217-70-3P	83217-72-5P	83217-73-6P	83217-74-7P	83217-75-8P
83217-76-9P	83311-26-6P	95573-52-7P	95573-53-8P	
95573-54-9P	95573-55-0P			


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide antidote)

IT	72520-17-3P	77232-14-5P	77232-18-9P
	77232-19-0P	77232-21-4P	77232-23-6P
	79382-42-6P	79382-43-7P	79382-44-8P
	79382-46-0P	79382-47-1P	79382-48-2P
	79382-49-3P	79382-50-6P	79382-51-7P
	79382-78-8P	79382-82-4P	83216-84-6P
	83216-85-7P	83216-86-8P	83216-87-9P
	83216-88-0P	83216-89-1P	83216-90-4P
	83216-91-5P	83216-92-6P	83216-93-7P
	83216-94-8P	83216-98-2P	83216-99-3P
	83217-00-9P	83217-01-0P	83217-02-1P
	83217-03-2P	83217-04-3P	95573-54-9P
	95573-55-0P		

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide antidote)


RN 72520-17-3 HCAPLUS

CN Pyrimidine, 4-methoxy-6-methyl-2-phenyl- (CA INDEX NAME)




RN 77232-14-5 HCAPLUS

CN Pyrimidine, 4,6-dimethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 77232-18-9 HCAPLUS

CN Pyrimidine, 4,6-diethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 77232-19-0 HCAPLUS

CN Pyrimidine, 2-(4-methylphenyl)-4,6-dipropoxy- (CA INDEX NAME)




RN 77232-21-4 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)




RN 77232-23-6 HCAPLUS

CN Pyrimidine, 4-methoxy-2-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)




RN 79382-42-6 HCAPLUS

CN Pyrimidine, 4,6-bis(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-43-7 HCAPLUS

CN Pyrimidine, 2-(4-methylphenyl)-4,6-diphenoxy- (CA INDEX NAME)




RN 79382-44-8 HCAPLUS

CN Pyrimidine, 4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-46-0 HCAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyethoxy)-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-47-1 HCAPLUS

CN 4-Pyrimidinamine, N,N-diethyl-6-(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-48-2 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-49-3 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-50-6 HCAPLUS

CN Pyrimidine, 4,6-bis(ethylthio)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-51-7 HCAPLUS

CN Pyrimidine, 4,6-dibutoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-78-8 HCAPLUS

CN Pyrimidine, 4-methoxy-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-82-4 HCAPLUS

CN Pyrimidine, 4-methyl-2-(4-methylphenyl)-6-phenoxy- (CA INDEX NAME)




RN 83216-84-6 HCAPLUS

CN Pyrimidine, 4-chloro-6-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-85-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-methoxy-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-86-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-87-9 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-phenoxy- (CA INDEX NAME)




RN 83216-88-0 HCAPLUS

CN 4-Pyrimidinamine, 5-bromo-6-chloro-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-89-1 HCAPLUS

CN Pyrimidine, 4-(2-methoxyethoxy)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 83216-90-4 HCAPLUS

CN Pyrimidine, 4-[2-(2-methoxyethoxy)ethoxy]-6-methyl-2-phenyl- (CA INDEX NAME)




RN 83216-91-5 HCAPLUS

CN Pyrimidine, 4-(2-methoxyethoxy)-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-92-6 HCAPLUS

CN 4-Pyrimidinamine, N,N,6-trimethyl-2-phenyl- (CA INDEX NAME)




RN 83216-93-7 HCAPLUS

CN 4-Pyrimidinamine, N,N,6-trimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-94-8 HCAPLUS

CN 4-Pyrimidinamine, 5-bromo-N,N,6-trimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-98-2 HCAPLUS

CN Pyrimidine, 4,6-dimethoxy-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-99-3 HCAPLUS


CN Pyrimidine, 4,6-dimethoxy-2-(4-methylphenyl)-5-phenyl- (CA INDEX NAME)




RN 83217-00-9 HCAPLUS
 CN Pyrimidine, 5-bromo-4,6-bis(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-01-0 HCAPLUS
 CN Pyrimidine, 4,6-bis(2-methoxyethoxy)-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-02-1 HCAPLUS
 CN Pyrimidine, 5-chloro-4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-03-2 HCAPLUS
 CN Pyrimidine, 5-bromo-4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-04-3 HCAPLUS
 CN 4-Pyrimidinamine, 5-bromo-6-(2-methoxyethoxy)-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)



RN 95573-54-9 HCAPLUS
 CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-(trifluoromethoxy)- (CA INDEX NAME)



RN 95573-55-0 HCAPLUS
 CN 4(3H)-Pyrimidinone, 6-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 37 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1986:47176 HCAPLUS Full-text
 DOCUMENT NUMBER: 104:47176
 ORIGINAL REFERENCE NO.: 104:7553a,7556a
 TITLE: Use of phenylpyrimidines as plant growth regulators
 INVENTOR(S): Seiler, Alfred; Mueller, Urs
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Ger. Dem. Rep.
 SOURCE: Eur. Pat. Appl., 57 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 136976	A2	19850410	EP 1984-810408	19840820 <--
EP 136976	A3	19850515		

R: BE, CH, DE, FR, GB, IT, LI, NL

JP 60072808 A 19850424 JP 1984-175823 19840823 <--
 PRIORITY APPLN. INFO.: CH 1983-4614 A 19830823 <--
 OTHER SOURCE(S): MARPAT 104:47176
 ED Entered STN: 23 Feb 1986
 GI



AB The phenylpyrimidines I (R = H, halo, NO₂, CN, OH, alkyl, etc.; R₁ and R₂ = H, halo, alkyl, alkoxyalkyl, etc.; R₃ = H, halo, alkyl, haloalkyl, or Ph) are plant growth regulators. Thus, 2-phenyl-4,6-dichloropyrimidine [3740-92-9] (500 mg/kg), applied as a seed dressing, increased the length and weight of wheat roots. The synthesis of I is given.

IC ICM A01N043-54

CC 5-3 (Agrochemical Bioregulators)

Section cross-reference(s): 28

IT	3740-90-7P	3740-91-8P	3740-92-9P	13514-79-9P	14727-23-2P
	15726-40-6P	17077-89-3P	17077-93-9P	20655-14-5P	21139-61-7P
	21139-63-9P	26863-48-9P	26863-54-7P	26870-72-4P	29509-92-0P
	29954-25-4P	35252-98-3P	72520-17-3P	77232-12-3P	
	77232-14-5P	77232-18-9P	77232-19-0P		
	77232-21-4P	77232-23-6P	77232-25-8P		
	79382-42-6P	79382-43-7P	79382-44-6P		
	79382-45-9P	79382-46-0P	79382-47-1P		
	79382-48-2P	79382-49-3P	79382-50-6P		
	79382-51-7P	79382-68-6P	79382-77-7P	79382-78-8P	
	79382-82-4P	79396-00-2P	83216-81-3P	83216-82-4P	
	83216-83-5P	83216-84-6P	83216-85-7P		
	83216-86-8P	83216-87-9P	83216-88-0P		
	83216-89-1P	83216-90-4P	83216-91-5P		
	83216-92-6P	83216-93-7P	83216-94-8P		
	83216-95-9P	83216-96-0P	83216-97-1P	83216-98-2P	
	83216-99-3P	83217-00-9P	83217-01-0P		
	83217-02-1P	83217-03-2P	83217-04-3P		
	83217-05-4P	83217-06-5P	83217-07-6P	83217-08-7P	83217-09-8P
	83217-10-1P	83217-11-2P	83217-12-3P	83217-13-4P	83217-14-5P
	83217-15-6P	83217-16-7P	83217-17-8P	83217-18-9P	83217-19-0P
	83217-20-3P	83217-21-4P	83217-22-5P	83217-23-6P	83217-24-7P
	83217-25-8P	83217-26-9P	83217-27-0P	83217-28-1P	83217-29-2P
	83217-30-5P	83217-31-6P	83217-32-7P	83217-34-9P	83217-35-0P
	83217-36-1P	83217-37-2P	83217-38-3P	83217-39-4P	83217-40-7P
	83217-41-8P	83217-42-9P	83217-43-0P	83217-44-1P	83217-45-2P
	83217-46-3P	83217-47-4P	83217-48-5P	83217-49-6P	83217-50-9P
	83217-51-0P	83217-52-1P	83217-53-2P	83217-54-3P	83217-55-4P
	83217-56-5P	83217-57-6P	83217-58-7P	83217-59-8P	83217-60-1P
	83217-61-2P	83217-62-3P	83217-63-4P	83217-64-5P	83217-65-6P
	83217-66-7P	83217-67-8P	83217-68-9P	83217-70-3P	
	83217-71-4P	83217-72-5P	83217-73-6P	83217-74-7P	
	83217-75-8P	83217-76-9P	83217-77-0P		89508-35-0P
	89508-68-9P	97513-33-2P	97513-44-5P	97513-45-6P	97513-46-7P
	97513-47-8P	97513-48-9P	97513-49-0P		

97513-51-4P 97513-52-5P 97513-53-6P 97513-54-7P 97513-55-8P
 97513-56-9P 97702-44-8P 97702-45-9P 97702-46-0P 97702-47-1P
 97702-48-2P


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as plant-growth regulator)

IT ~~72520-17-3P~~ ~~77232-14-5P~~ ~~77232-18-9P~~
~~77232-19-0P~~ ~~77232-21-4P~~ ~~77232-23-6P~~
~~79382-42-6P~~ ~~79382-43-7P~~ ~~79382-44-8P~~
~~79382-46-0P~~ ~~79382-47-1P~~ ~~79382-48-2P~~
~~79382-49-3P~~ ~~79382-50-6P~~ ~~79382-51-7P~~
~~79382-78-8P~~ ~~79382-82-4P~~ ~~83216-84-6P~~
~~83216-85-7P~~ ~~83216-86-8P~~ ~~83216-87-9P~~
~~83216-88-0P~~ ~~83216-89-1P~~ ~~83216-90-4P~~
~~83216-91-5P~~ ~~83216-92-6P~~ ~~83216-93-7P~~
~~83216-94-8P~~ ~~83216-98-2P~~ ~~83216-99-3P~~
~~83217-00-9P~~ ~~83217-01-0P~~ ~~83217-02-1P~~
~~83217-03-2P~~ ~~83217-04-3P~~ ~~83217-71-4P~~
~~97513-49-0P~~

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as plant-growth regulator)


RN 72520-17-3 HCAPLUS

CN Pyrimidine, 4-methoxy-6-methyl-2-phenyl- (CA INDEX NAME)




RN 77232-14-5 HCAPLUS

CN Pyrimidine, 4,6-dimethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 77232-18-9 HCAPLUS

CN Pyrimidine, 4,6-diethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 77232-19-0 HCAPLUS

CN Pyrimidine, 2-(4-methylphenyl)-4,6-dipropoxy- (CA INDEX NAME)




RN 77232-21-4 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)




RN 77232-23-6 HCAPLUS

CN Pyrimidine, 4-methoxy-2-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)




RN 79382-42-6 HCAPLUS

CN Pyrimidine, 4,6-bis(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-43-7 HCAPLUS

CN Pyrimidine, 2-(4-methylphenyl)-4,6-diphenoxy- (CA INDEX NAME)




RN 79382-44-8 HCAPLUS

CN Pyrimidine, 4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-46-0 HCAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyethoxy)-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-47-1 HCAPLUS

CN 4-Pyrimidinamine, N,N-diethyl-6-(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-48-2 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-49-3 HCAPLUS


CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-50-6 HCAPLUS
 CN Pyrimidine, 4,6-bis(ethylthio)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-51-7 HCAPLUS
 CN Pyrimidine, 4,6-dibutoxy-2-(4-methylphenyl)- (CA INDEX NAME)



RN 79382-78-8 HCAPLUS
 CN Pyrimidine, 4-methoxy-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-82-4 HCAPLUS
 CN Pyrimidine, 4-methyl-2-(4-methylphenyl)-6-phenoxy- (CA INDEX NAME)




RN 83216-84-6 HCAPLUS

CN Pyrimidine, 4-chloro-6-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-85-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-methoxy-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-86-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-87-9 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-phenoxy- (CA INDEX NAME)




RN 83216-88-0 HCAPLUS

CN 4-Pyrimidinamine, 5-bromo-6-chloro-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-89-1 HCAPLUS

CN Pyrimidine, 4-(2-methoxyethoxy)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 83216-90-4 HCAPLUS

CN Pyrimidine, 4-[2-(2-methoxyethoxy)ethoxy]-6-methyl-2-phenyl- (CA INDEX NAME)




RN 83216-91-5 HCAPLUS

CN Pyrimidine, 4-(2-methoxyethoxy)-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-92-6 HCAPLUS

CN 4-Pyrimidinamine, N,N,6-trimethyl-2-phenyl- (CA INDEX NAME)




RN 83216-93-7 HCAPLUS

CN 4-Pyrimidinamine, N,N,6-trimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-94-8 HCAPLUS

CN 4-Pyrimidinamine, 5-bromo-N,N,6-trimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-98-2 HCAPLUS

CN Pyrimidine, 4,6-dimethoxy-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-99-3 HCAPLUS


CN Pyrimidine, 4,6-dimethoxy-2-(4-methylphenyl)-5-phenyl- (CA INDEX NAME)




RN 83217-00-9 HCAPLUS
 CN Pyrimidine, 5-bromo-4,6-bis(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-01-0 HCAPLUS
 CN Pyrimidine, 4,6-bis(2-methoxyethoxy)-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-02-1 HCAPLUS
 CN Pyrimidine, 5-chloro-4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)



RN 83217-03-2 HCAPLUS
 CN Pyrimidine, 5-bromo-4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-04-3 HCAPLUS
 CN 4-Pyrimidinamine, 5-bromo-6-(2-methoxyethoxy)-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-71-4 HCAPLUS

CN 4-Pyrimidinol, 6-chloro-2-(4-methylphenyl)-, 4-acetate (CA INDEX NAME)



RN 97513-49-0 HCAPLUS

CN 4-Pyrimidinesulfonic acid, 3,6-dihydro-2-(4-methylphenyl)-6-oxo-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L52 ANSWER 38 OF 50 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1982:558036 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 97:158036

ORIGINAL REFERENCE NO.: 97:26277a,26280a

TITLE: Use of phenylpyrimidines as protecting agents for crop plants against phytotoxic damage caused by herbicides
Burdeska, Kurt; Kabas, Guglielmo; Brunner, Hans Georg; Foery, Werner

INVENTOR(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 98 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 55693	A1	19820707	EP 1981-810505	19811217 <--
EP 55693	B1	19880120		

R: AT, BE, CH, DE, FR, GB, IT, NL

IN 159209	A1	19870411	IN 1981-DE784	19811215 <--
AT 32065	T	19880215	AT 1981-810505	19811217 <--
CA 1220953	A1	19870428	CA 1981-392824	19811221 <--
IL 64612	A	19880930	IL 1981-64612	19811221 <--
DK 8105712	A	19820624	DK 1981-5712	19811222 <--
DK 156687	B	19890925		
DK 156687	C	19900312		
ZA 8108852	A	19821229	ZA 1981-8852	19811222 <--
DD 202798	A5	19831005	DD 1981-236096	19811222 <--
HU 27801	A2	19831128	HU 1981-3912	19811222 <--
HU 191339	B	19870227		
CS 243465	B2	19860612	CS 1981-9672	19811222 <--
SU 1482505	A3	19890523	SU 1981-3369450	19811222 <--
AU 8178840	A	19820701	AU 1981-78840	19811223 <--
AU 558710	B2	19870205		
JP 57131702	A	19820814	JP 1981-208971	19811223 <--
JP 62025641	B	19870604		
BR 8108383	A	19821013	BR 1981-8383	19811223 <--
RO 83451	A1	19840221	RO 1981-106092	19811223 <--
PL 130575	B1	19840831	PL 1981-234418	19811223 <--
JP 61246102	A	19861101	JP 1986-68237	19860326 <--
JP 02053402	B	19901116		


PRIORITY APPLN. INFO.:

CH 1980-9522	A	19801223 <--
CH 1981-2363	A	19810408 <--
EP 1981-810505	A	19811217 <--

OTHER SOURCE(S): MARPAT 97:158036

ED Entered STN: 12 May 1984

GI



AB The phenylpyrimidines I (R = H, alkyl, halo, NO₂, CF₃, etc.; R₁ = H, halo, Some, OMe, etc.; R₂ = H, Me, Ph, NMe, OEt, etc.; R₃ = H, halo, OEt, NHMe, SEt, etc.; n = 1-5) are herbicide antidotes. Thus, post-transplant application of 2-phenyl-4-chloropyrimidine [3740-92-9] (1 kg/ha) protected rice against the phytotoxic activity of pretilachlor [51218-49-6] (1 kg/ha) by 50%. The synthesis of I is given.

IC C07D239-30; A01N025-32; C07D405-10

CC 5-3 (Agrochemical Bioregulators)

Section cross-reference(s): 28

IT	1701-72-0P	3740-90-7P	3740-91-8P	3740-92-9P	13514-79-9P
14727-23-2P	15726-40-6P	17077-89-3P	17077-93-9P	20655-14-5P	
21139-61-7P	21139-63-9P	26863-48-9P	26863-54-7P	26870-72-4P	
29509-92-0P	29954-25-4P	<u>72520-17-3P</u>	<u>77232-14-5P</u>		
<u>77232-18-9P</u>	<u>77232-19-0P</u>	<u>77232-21-4P</u>			
<u>77232-23-6P</u>	<u>77232-25-8P</u>	<u>79382-42-6P</u>			
<u>79382-43-7P</u>	<u>79382-44-8P</u>	<u>79382-45-9P</u>			
<u>79382-46-0P</u>	<u>79382-47-1P</u>	<u>79382-48-2P</u>			
<u>79382-49-3P</u>	<u>79382-50-6P</u>	<u>79382-51-7P</u>			
<u>79382-68-6P</u>	<u>79382-77-7P</u>	<u>79382-78-8P</u>	<u>79382-82-4P</u>		

79396-00-2P	83063-00-7P	83063-01-8P	83216-81-3P	83216-82-4P
83216-83-5P	83216-84-6P	83216-85-7P		
83216-86-8P	83216-87-9P	83216-88-0P		
83216-92-6P	83216-93-7P	83216-94-8P		
83216-95-9P	83216-96-0P	83216-97-1P	83216-98-2P	
83216-99-3P	83217-00-9P	83217-01-0P		
83217-02-1P	83217-03-2P	83217-04-3P		
83217-05-4P	83217-06-5P	83217-07-6P	83217-08-7P	83217-09-8P
83217-10-1P	83217-11-2P	83217-12-3P	83217-13-4P	83217-14-5P
83217-15-6P	83217-16-7P	83217-17-8P	83217-18-9P	83217-19-0P
83217-20-3P	83217-21-4P	83217-22-5P	83217-23-6P	83217-24-7P
83217-25-8P	83217-26-9P	83217-27-0P	83217-28-1P	83217-29-2P
83217-30-5P	83217-31-6P	83217-32-7P	83217-33-8P	
83217-34-9P	83217-35-0P	83217-36-1P	83217-37-2P	83217-38-3P
83217-39-4P	83217-40-7P	83217-41-8P	83217-42-9P	83217-43-0P
83217-44-1P	83217-45-2P	83217-46-3P	83217-47-4P	83217-48-5P
83217-49-6P	83217-50-9P	83217-51-0P	83217-52-1P	83217-53-2P
83217-54-3P	83217-55-4P	83217-56-5P	83217-57-6P	83217-58-7P
83217-59-8P	83217-60-1P	83217-61-2P	83217-62-3P	83217-63-4P
83217-64-5P	83217-65-6P	83217-66-7P	83217-67-8P	83217-68-9P
83217-69-0P	83217-70-3P	83217-71-4P	83217-72-5P	
83217-73-6P	83217-74-7P	83217-75-8P	83217-76-9P	


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and herbicide-antidote activity of)

IT	72520-17-3P	77232-14-5P	77232-18-9P
	77232-19-0P	77232-21-4P	77232-23-6P
	79382-42-6P	79382-43-7P	79382-44-8P
	79382-46-0P	79382-47-1P	79382-48-2P
	79382-49-3P	79382-50-6P	79382-51-7P
	79382-78-8P	79382-82-4P	83216-84-6P
	83216-85-7P	83216-86-8P	83216-87-9P
	83216-88-0P	83216-92-6P	83216-93-7P
	83216-94-8P	83216-98-2P	83216-99-3P
	83217-00-9P	83217-01-0P	83217-02-1P
	83217-03-2P	83217-04-3P	83217-33-8P
	83217-71-4P		

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and herbicide-antidote activity of)


RN 72520-17-3 HCAPLUS

CN Pyrimidine, 4-methoxy-6-methyl-2-phenyl- (CA INDEX NAME)




RN 77232-14-5 HCAPLUS


CN Pyrimidine, 4,6-dimethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 77232-18-9 HCAPLUS
 CN Pyrimidine, 4,6-diethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 77232-19-0 HCAPLUS
 CN Pyrimidine, 2-(4-methylphenyl)-4,6-dipropoxy- (CA INDEX NAME)




RN 77232-21-4 HCAPLUS
 CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)



RN 77232-23-6 HCAPLUS
 CN Pyrimidine, 4-methoxy-2-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)




RN 79382-42-6 HCAPLUS
 CN Pyrimidine, 4,6-bis(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-43-7 HCAPLUS

CN Pyrimidine, 2-(4-methylphenyl)-4,6-diphenoxy- (CA INDEX NAME)




RN 79382-44-8 HCAPLUS

CN Pyrimidine, 4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-46-0 HCAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyethoxy)-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-47-1 HCAPLUS

CN 4-Pyrimidinamine, N,N-diethyl-6-(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-48-2 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-49-3 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-N,N-diethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-50-6 HCAPLUS

CN Pyrimidine, 4,6-bis(ethylthio)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-51-7 HCAPLUS

CN Pyrimidine, 4,6-dibutoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-78-8 HCAPLUS

CN Pyrimidine, 4-methoxy-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 79382-82-4 HCAPLUS

CN Pyrimidine, 4-methyl-2-(4-methylphenyl)-6-phenoxy- (CA INDEX NAME)




RN 83216-84-6 HCAPLUS

CN Pyrimidine, 4-chloro-6-methoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-85-7 HCAPLUS

CN Pyrimidine, 4-chloro-6-methoxy-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-86-8 HCAPLUS

CN Pyrimidine, 4-chloro-6-(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-87-9 HCAPLUS

CN Pyrimidine, 4-chloro-2-(4-methylphenyl)-6-phenoxy- (CA INDEX NAME)




RN 83216-88-0 HCAPLUS

CN 4-Pyrimidinamine, 5-bromo-6-chloro-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-92-6 HCAPLUS

CN 4-Pyrimidinamine, N,N,6-trimethyl-2-phenyl- (CA INDEX NAME)




RN 83216-93-7 HCAPLUS

CN 4-Pyrimidinamine, N,N,6-trimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-94-8 HCAPLUS


CN 4-Pyrimidinamine, 5-bromo-N,N,6-trimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-98-2 HCAPLUS
 CN Pyrimidine, 4,6-dimethoxy-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83216-99-3 HCAPLUS
 CN Pyrimidine, 4,6-dimethoxy-2-(4-methylphenyl)-5-phenyl- (CA INDEX NAME)




RN 83217-00-9 HCAPLUS
 CN Pyrimidine, 5-bromo-4,6-bis(1-methylethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-01-0 HCAPLUS
 CN Pyrimidine, 4,6-bis(2-methoxyethoxy)-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-02-1 HCAPLUS
 CN Pyrimidine, 5-chloro-4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-03-2 HCAPLUS
 CN Pyrimidine, 5-bromo-4,6-bis(2-methoxyethoxy)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 83217-04-3 HCAPLUS
 CN 4-Pyrimidinamine, 5-bromo-6-(2-methoxyethoxy)-N-methyl-2-(4-methylphenyl)- (CA INDEX NAME)



RN 83217-33-8 HCAPLUS
 CN Phenol, 2-bromo-4-[4-chloro-6-(2-propen-1-yloxy)-2-pyrimidinyl]- (CA INDEX NAME)



RN 83217-71-4 HCAPLUS
 CN 4-Pyrimidinol, 6-chloro-2-(4-methylphenyl)-, 4-acetate (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

=> d iall abeq tech abex fraghitstr 39-44
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, BIOSIS' - CONTINUE? (Y)/N:y

L52 ANSWER 39 OF 50 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2007-397098 [38] WPIX
DOC. NO. CPI: C2007-143417 [38]
TITLE: New pyrazole compounds are glycogen synthase kinase-3 activity inhibitors, useful for treating e.g. diabetes, Alzheimer's disease, schizophrenia, Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis B03
DERWENT CLASS: B03
INVENTOR: BEBBINGTON D; BINCH H; CHARRIER J; DAVIES R; FORSTER C; GOLEC J M C; KAY D; KNEGTEL R; LI P; PATEL S; PIERCE A; WANNAMAKER M
PATENT ASSIGNEE: (VERT-N) VERTEX PHARM INC
COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG	MAIN IPC
AU 2006201263	A1 20060427 (200738)*	EN	354	[0]	<--
AU 2006201263	B2 20081030 (200929)	EN			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
AU 2006201263	A1 Div Ex	AU 2001-290944	20010914
AU 2006201263	A1	AU 2006-201263	20060321
AU 2006201263	B2 Div Ex	AU 2001-290944	20010914
AU 2006201263	B2	AU 2006-201263	20060321

PRIORITY APPLN. INFO: AU 2006-201263 20060321
AU 2001-290944 20010914

INT. PATENT CLASSIF.:
IPC ORIGINAL:

A61K0031-4155 [I,A]; A61K0031-506 [I,A]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-14 [I,A]; C07D0403-00 [I,C]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0403-14 [I,A]; C07D0405-00 [I,C]; C07D0405-14 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0473-00 [I,C]; C07D0473-16 [I,A]; C07D0493-00 [I,C]; C07D0493-04 [I,A]; C07D0495-00 [I,C]; C07D0495-04 [I,A]; C07D0521-00 [I,A]; A61K0031-4155 [I,C]; A61K0031-506 [I,C]; A61P0035-00 [I,C]; C07D0401-00 [I,C]; C07D0403-00 [I,C]; C07D0405-00

[I,C]; C07D0471-00 [I,C]; C07D0473-00 [I,C]; C07D0493-00 [I,C]; C07D0495-00 [I,C]; C07D0521-00 [I,C]

BASIC ABSTRACT:

AU 2006201263 A1 UPAB: 20090509

NOVELTY - Pyrazole compounds (I) and their derivatives and prodrugs are new.

DETAILED DESCRIPTION - Pyrazole compounds of formula (I) and their derivatives and prodrugs are new.

Ring D = 5-7 membered monocyclic ring or 8-10 membered bicyclic ring of (hetero)aryl, heterocyclyl (both having 1-4 ring heteroatoms of N, O or S) or carbocyclyl (all substituted at any substitutable ring C by oxo or R5, or at any substitutable ring N by R4);

R-x, R-y = T-R3;

T = a bond or 1-4C alkylidene chain;

R2, R-2a = R or T-W1-R6;

R3 = R, halo, =O, OR, C(=O)R, CO2R, COCOR, COCH2COR, NO2, CN, S(O)R, S(O)2R, SR, N(R4)2, CON(R4)2, SO2N(R4)2, OC(=O)R, N(R4)COR, N(R4)CO2 (optionally substituted 1-6C aliphatic), N(R4)N(R4)2, C=NN(R4)2, C=N-OR, N(R4)CON(R4)2, N(R4)SO2N(R4), N(R4)SO2R or OC(=O)N(R4)2;

R = 1-6C aliphatic, 6-10C aryl, heteroaryl ring of 5-10 ring atoms, heterocyclyl ring of 5-10 ring atoms (all optionally substituted) or H;

R4 = R7, COR7, CO2 (optionally substituted 1-6C aliphatic), CON(R7)2 or SO2R7; or

NR4R4 = 5-8 membered heterocyclyl or heteroaryl ring;

R5 = R, halo, OR, C(=O)R, CO2R, COCOR, NO2, CN, S(O)R, SO2R, SR, N(R4)2, CON(R4)2, SO2N(R4)2, OC(=O)R, N(R4)COR, N(R4)CO2 (optionally substituted 1-6C aliphatic), N(R4)N(R4)2, C=NN(R4)2, C=N-OR, N(R4)CON(R4)2, N(R4)SO2N(R4)2, N(R4)SO2R or OC(=O)N(R4)2;

V1 = O, S, SO, SO2, N(R6)SO2, SO2N(R6), N(R6), CO, CO2, N(R6)CO, N(R6)C(O)O, N-(R6)CON(R6), N(R6)SO2N(R6), N(R6)N(R6), C(O)N(R6), OC(O)N(R6), C(R6)2O, C(R6)2S, C(R6)2SO, C(R6)2SO2, C(R6)2SO2N(R6), C(R6)2N(R6), C(R6)2N(R6)C(O), C(R6)2N(R6)C(O)O, C(R6)=NN(R6), C(R6)=N-O, C(R6)2N(R6)N(R6), C(R6)2N(R6)SO2N(R6) or C(R6)2N(R6)CON(R6);

W1 = C(R6)2O, C(R6)2S, C(R6)2SO, C(R6)2SO2, C(R6)2SO2N(R6), C(R6)2N(R6)CO, CO2, C(R6)OC(O), C(R6)OC(O)N(R6), C(R6)2N(R6)CO, C(R6)2N(R6)C(O)O, C(R6)=NN(R6), C(R6)=N-O, C(R6)2N(R6)N(R6), C(R6)2N(R6)SO2N(R6), C(R6)2N(R6)CON(R6) or CON(R6); either

R6 = H or 1-4C aliphatic group (optionally substituted); or

NR6R6 = 5-6 membered heterocyclyl or heteroaryl ring;

R7 = H or 1-6C aliphatic group (optionally substituted); or

NR7R7 = 5-8 membered heterocyclyl ring or heteroaryl; or

CR-x+CR-y = optionally unsaturated, 5-8 membered ring having 1-3 ring heteroatoms of O, S or N (where any substitutable C on the fused ring is optionally substituted by T-R3 or any substitutable N on the ring is substituted by R4); or

CR-x+CR-y = optionally unsaturated, 5-8 membered ring having 1-3 ring heteroatoms of O, S or N (where any substitutable C on the fused ring is optionally substituted by T-R3 or any substitutable N on the ring is substituted by R4); or

CR-2+CR-2a = optionally unsaturated, 5-8 membered ring having 1-3 ring heteroatoms of O, S or N, where the ring is optionally substituted by up to 3 halo, oxo, CN, NO2, R7, or V1-R6; and

provided that when ring D is a 6 membered (hetero)aryl ring, R5 is H at each ortho C position of ring D.

An INDEPENDENT CLAIM is included for a composition comprising (I) optionally in combination with a second therapeutic agent.

ACTIVITY - Antidiabetic; Neuroprotective; Nootropic; Neuroleptic; Cytostatic; Anticonvulsant; Antiparkinsonian; Anti-HIV; Cardiovascular-Gen.; Vasotropic; Antiangiogenic; Nephrotropic; Virucide; Antipsoriatic;

Antiartherosclerotic; Endocrine-Gen.; Immunosuppressive; Antiarthritic; Antirheumatic; CNS-Gen.; Gastrointestinal-Gen.; Osteopathic.

MECHANISM OF ACTION - Protein kinase inhibitor; Glycogen synthase kinase (GSK)-3 activity inhibitor; Aurora activity inhibitor; Glycogen synthesis enhancer; Hyperphosphorylated Tau protein production inhibitor; beta-catenin phosphorylation inhibitor.

(I) were tested for their GSK-3 inhibitory activity using a standard coupled enzyme system. The results showed that the inhibition constant of (I) was less than 0.1 μ M or less.

USE - For treating a disease that is alleviated by treatment with an glycogen synthase kinase (GSK)-3 inhibitor, where the disease is diabetes, Alzheimer's disease and schizophrenia or by an aurora inhibitor, where the disease is cancer; to enhance glycogen synthesis; to lower blood levels of glucose; and to inhibit the production of hyperphosphorylated Tau protein and the phosphorylation of beta-catenin (claimed). The composition is useful to treat Huntington's disease, Parkinson's disease, AIDS-associated dementia, amyotrophic lateral sclerosis, multiple sclerosis, cardiomyocyte hypertrophy, reperfusion/ischemia, baldness, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis, hypercalcemia, osteoporosis, osteoarthritis, cancer, symptomatic treatment of bone metastasis and Paget's disease. MANUAL CODE: CFI: B06-H; B07-D08; B07-D12; B14-A02A3; B14-A02B1;

B14-C09B; B14-D06C; B14-F01; B14-F02B2; B14-F02D; B14-F02F2; B14-F05; B14-F07; B14-F09; B14-G02D; B14-H01; B14-H01H1; B14-J01; B14-L01; B14-L06; B14-N01A; B14-N10; B14-N16; B14-N17C; B14-R02; B14-S01; B14-S04

TECH

ORGANIC CHEMISTRY - Preparation: Preparation of (I) comprises reaction of 2-methylmalonic acid diethyl ester compounds of formula (1) with amidine compounds of formula (2) to give pyrimidinedione compounds of formula (3); reaction of (3) with phosphoryl chloride and tri-n-propylamine to give dichloropyrimidine compounds of formula (4); reaction of (4) with morpholine and methanol to give mbno-chloropyrimidine compounds of formula (5); and reaction of (5) with 3-aminopyrazole or 3-aminoindazole compounds of formula (6) to give pyrazole compounds of formula (7) (representative of (I)).

ABEX DEFINITIONS - Preferred Definitions: - Ring D = phenyl, pyridinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, azepanyl, morpholinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,3-dihydro-1H-isoindolyl, 2,3-dihydro-1H-indolyl, isoquinolinyl, naphthyl or naphthyl ring (all optionally substituted); - R5 = halo, CN, oxo, -SR, -OR, -N(R4)2, -C(O)R, 5-6 membered heterocyclyl, 6-10C aryl or 1-6C aliphatic (all optionally substituted); - R-2a = H; - W1 = -C(R6)2O-, -C(R6)2N(R6), -CO-, -CO2-, -C(R6)OC(O)-, -C(R6)2N(R6)CO- or -CON(R6)-; and - R = 1-6C aliphatic or phenyl. - R-x and R-y are taken together with their intervening atoms to form a 6-membered optionally unsaturated ring having 1-2 ring nitrogens, optionally substituted with halo, CN, oxo, 1-6C alkyl, 1-6C alkoxy, (1-6C alkyl)carbonyl, (1-6C alkyl)sulfonyl, mono- or dialkylamino, mono- or dialkylaminocarbonyl, mono- or dialkylaminocarbonyloxy, or 5-6 membered heteroaryl; and R2 and R-2a are taken together with their intervening atoms to form an optionally substituted benzo, pyrido, or partially unsaturated 6-membered carbocyclic ring optionally substituted with -halo, oxo, -N(R4)2, -1-4C alkyl, -1-4C haloalkyl, -NO2, -O(1-4C alkyl), -CO2(1-4C alkyl), -CN, -SO2(1-4C alkyl), -SO2NH2, -OC(O)NH2, -NH2SO2(1-4C alkyl), -NHC(O)(1-4C alkyl), -C(O)NH2 or -CO(1-4C alkyl), where the (1-4C alkyl) is a straight, branched or cyclic alkyl.

ADMINISTRATION - Dosage is 0.01-100 mg/kg, administered orally, parenterally (including subcutaneously, intravenously, intramuscularly, intra-articularly, intra-synovially, intrasternally, intrathecally,

intrahepatically, intralesionally or via intracranial injection or infusion), topically, rectally, nasally, buccally, vaginally, via inhalation, spray or an implanted reservoir.


SPECIFIC COMPOUNDS - 31 Compounds (I) are specifically claimed, e.g. (2-(4-methylpiperidin-1-yl)-purin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine of formula (Ia).

EXAMPLE - To a suspension of 2,4-dichloro-purine (2 g) in anhydrous ethanol (10 ml) was added 5-methyl-1H-pyrazol-3-yl amine (2.05 g). The resulting mixture was stirred for 48 hours. The resulting precipitate was collected by filtration, washed with ethanol, and dried under vacuum to give (2-chloro-purin-4-yl)-(5-methyl-1H-pyrazol-3-yl)-amine (A), which was used in the next step without further purification. To a solution of (A) (200 mg) was added 4-methylpiperidine (4 ml) and the reaction mixture heated at reflux overnight. The solvent was evaporated and the residue dissolved in a mixture of ethanol and water (1:3, 4 ml). Potassium carbonate (57 mg) was added and the mixture was stirred for 2 hours. The resulting suspension was filtered, washed with water (twice) and rinsed with ethanol (twice) to give (2-(4-methylpiperidin-1-yl)-purin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine (225 mg, 90%).

AN.S DCR-535398

CN.S N-{4-[6-(5-Methyl-1H-pyrazol-3-ylamino)-2-phenyl-pyrimidin-4-ylsulfanyl]-phenyl}-acetamide

SDCN RA6Y17



L52 ANSWER 40 OF 50

ACCESSION NUMBER:

DOC. NO. CPI:

TITLE:

DERWENT CLASS:

INVENTOR:

PATENT ASSIGNEE:

COUNTRY COUNT:

WPIX COPYRIGHT 2009

THOMSON REUTERS on STN

2003-342586 [32] WPIX

C2003-089955 [32]

Composition useful for controlling weeds in crops e.g. corn, sorghum, rice, soyabean comprises phenyluracil compound and herbicide and/or safener

C02

EVANS R; EVANS R R; LANDES A; LANDES M; NEWSOM L; NEWSOM L J; NEWSOM L J; ORTLIP C; ORTLIP C L; OUAKENBUSH L; OUAKENBUSH L; SIEVERNICH B; WITSCHER M; ZAGAR C (BADI-C) BASF AG; (EVAN-I) EVANS R R; (LAND-I) LANDES A; (LAND-I) LANDES M; (NEWS-I) NEWSOM L J; (ORTL-I) ORTLIP C L; (OUAK-I) OUAKENBUSH L; (SIEV-I) SIEVERNICH B; (WITS-I) WITSCHER M; (ZAGA-I) ZAGAR C; (BADI-C) BASF SE

100

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003024221	A1	20030327	(200332)*	EN	42[0]	<--
EP 1429609	A1	20040623	(200441)	EN		<--
AU 2002342671	A1	20030401	(200452)	EN		<--
KR 2004033314	A	20040421	(200454)	KO		<--
BR 2002012460	A	20041019	(200476)	PT		<--
US 20040235665	A1	20041125	(200478)	EN		<--
MX 2004002087	A1	20040601	(200504)	ES		<--
JP 2005502715	W	20050127	(200510)	JA	152	<--
CN 1555219	A	20041215	(200519)	ZH		<--
HU 2004002256	A2	20050329	(200528)	HU		<--
ZA 2004002791	A	20050629	(200552)	EN	95	<--
NZ 531486	A	20050826	(200560)	EN		<--
IN 2004CN00546	P4	20051223	(200604)	EN		<--
EP 1429609	B1	20070307	(200720)	EN		<--
TW 252078	B1	20060401	(200720)	ZH		<--
DE 60218707	E	20070419	(200729)	DE		<--
AU 2002342671	B2	20070222	(200735)	EN		<--
DE 60218707	T2	20070628	(200742)	DE		<--
ES 2281550	T3	20071001	(200768)	ES		<--
US 7375058	B2	20080520	(200834)	EN		
JP 4237622	B2	20090311	(200920)	JA	67	
MX 255891	B	20080402	(200932)	ES		
CN 100493354	C	20090603	(200970)	ZH		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003024221	A1	WO 2002-EP10136	20020910
US 20040235665	A1 Provisional	US 2001-318834P	20010914
US 20040235665	A1 Provisional	US 2001-333135P	20011127
IN 2004CN00546	P4	WO 2002-EP10136	
AU 2002342671	A1	AU 2002-342671	20020910
AU 2002342671	B2	AU 2002-342671	20020910
BR 2002012460	A	BR 2002-12460	20020910
CN 1555219	A	CN 2002-817977	20020910
DE 60218707	E	DE 2002-60218707	20020910
DE 60218707	T2	DE 2002-60218707	20020910
EP 1429609	A1	EP 2002-779329	20020910
EP 1429609	B1	EP 2002-779329	20020910
DE 60218707	E	EP 2002-779329	20020910
DE 60218707	T2	EP 2002-779329	20020910
ES 2281550	T3	EP 2002-779329	20020910
NZ 531486	A	NZ 2002-531486	20020910
EP 1429609	A1	WO 2002-EP10136	20020910
BR 2002012460	A	WO 2002-EP10136	20020910
US 20040235665	A1	WO 2002-EP10136	20020910
MX 2004002087	A1	WO 2002-EP10136	20020910
JP 2005502715	W	WO 2002-EP10136	20020910
HU 2004002256	A2	WO 2002-EP10136	20020910
NZ 531486	A	WO 2002-EP10136	20020910
EP 1429609	B1	WO 2002-EP10136	20020910
DE 60218707	E	WO 2002-EP10136	20020910
DE 60218707	T2	WO 2002-EP10136	20020910
US 7375058	B2	WO 2002-EP10136	20020910
JP 4237622	B2 PCT Application	WO 2002-EP10136	20020910

MX 255891 B PCT Application	<u>WO 2002-EP10136 20020910</u>
TW 252078 B1	<u>TW 2002-120878 20020912</u>
JP 2005502715 W	<u>JP 2003-528125 20020910</u>
JP 4237622 B2	<u>JP 2003-528125 20020910</u>
HU 2004002256 A2	<u>HU 2004-2256 20020910</u>
MX 2004002087 A1	<u>MX 2004-2087 20040304</u>
MX 255891 B	<u>MX 2004-2087 20040304</u>
US 20040235665 A1	<u>US 2004-488977 20040309</u>
US 7375058 B2	<u>US 2004-488977 20040309</u>
IN 2004CN00546 P4	<u>IN 2004-CN546 20040312</u>
KR 2004033314 A	<u>KR 2004-703761 20040312</u>
ZA 2004002791 A	<u>ZA 2004-2791 20040413</u>
CN 100493354 C	<u>CN 2002-817977 20020910</u>

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
DE 60218707	E	Based on	EP 1429609	A
DE 60218707	T2	Based on	EP 1429609	A
ES 2281550	T3	Based on	EP 1429609	A
JP 4237622	B2	Previous Publ	JP 2005502715	W
EP 1429609	A1	Based on	WO 2003024221	A
AU 2002342671	A1	Based on	WO 2003024221	A
BR 2002012460	A	Based on	WO 2003024221	A
MX 2004002087	A1	Based on	WO 2003024221	A
JP 2005502715	W	Based on	WO 2003024221	A
HU 2004002256	A2	Based on	WO 2003024221	A
NZ 531486	A	Based on	WO 2003024221	A
EP 1429609	B1	Based on	WO 2003024221	A
DE 60218707	E	Based on	WO 2003024221	A
AU 2002342671	B2	Based on	WO 2003024221	A
DE 60218707	T2	Based on	WO 2003024221	A
US 7375058	B2	Based on	WO 2003024221	A
JP 4237622	B2	Based on	WO 2003024221	A
MX 255891	B	Based on	WO 2003024221	A

PRIORITY APPLN. INFO: US 2001-318834P 20010914
US 2001-333135P 20011127
US 2004-488977 20040309

INT. PATENT CLASSIF.:

MAIN: A01N043-54
SECONDARY: A01N033-18; A01N035-10; A01N037-22; A01N037-32;
A01N037-40; A01N039-02; A01N039-04; A01N041-10;
A01N043-10; A01N043-18; A01N043-40; A01N043-50;
A01N043-70; A01N043-76; A01N043-80; A01N043-86;
A01N047-30; A01N047-34; A01N047-36; A01N057-20

IPC ORIGINAL: A01N0025-00 [I,C]; A01N0033-00 [I,C]; A01N0033-00 [I,A]; A01N0033-18 [I,A]; A01N0033-00 [I,C]; A01N0035-00 [I,C]; A01N0035-00 [I,C]; A01N0035-10 [I,A]; A01N0035-10 [I,A]; A01N0037-22 [I,A]; A01N0037-22 [I,A]; A01N0037-22 [I,C]; A01N0037-22 [I,C]; A01N0037-32 [I,A]; A01N0037-32 [I,C]; A01N0037-32 [I,C]; A01N0037-36 [I,C]; A01N0037-36 [I,C]; A01N0037-40 [I,A]; A01N0039-00 [I,C]; A01N0039-00 [I,C]; A01N0039-00 [I,C]; A01N0039-02 [I,A]; A01N0039-02 [I,A]; A01N0039-04 [I,A]; A01N0041-00 [I,C]; A01N0041-00 [I,C]; A01N0041-00 [I,A]; A01N0041-10 [I,A]; A01N0041-10 [I,A]; A01N0043-02 [I,C]; A01N0043-02 [I,C]; A01N0043-02 [I,C]; A01N0043-10 [I,A]; A01N0043-10 [I,A]; A01N0043-18 [I,A];

A01N0043-34 [I,C]; A01N0043-34 [I,C]; A01N0043-40 [I,A];
 A01N0043-48 [I,C]; A01N0043-48 [I,C]; A01N0043-50 [I,A];
 A01N0043-54 [I,A]; A01N0043-54 [I,A]; A01N0043-54 [I,A];
 A01N0043-64 [I,C]; A01N0043-64 [I,C]; A01N0043-70 [I,A];
 A01N0043-72 [I,C]; A01N0043-72 [I,C]; A01N0043-76 [I,A];
 A01N0043-80 [I,A]; A01N0043-86 [I,A]; A01N0047-28 [I,C];
 A01N0047-28 [I,C]; A01N0047-28 [I,C]; A01N0047-30 [I,A];
 A01N0047-30 [I,A]; A01N0047-34 [I,A]; A01N0047-36 [I,A];
 A01N0057-00 [I,C]; A01N0057-00 [I,C]; A01N0057-00 [I,C];
 A01N0057-20 [I,A]; A01N0057-20 [I,A]; A01P0013-00 [I,A];
 A01P0013-00 [I,C]; A01N0025-00 [I,A]; A01N0043-48 [I,C];
 A01N0061-00 [I,A]; A01N0061-00 [I,C];
 IPC RECLASSIF.: A01N0033-00 [I,C]; A01N0033-18 [I,A]; A01N0035-00 [I,C];
 A01N0035-10 [I,A]; A01N0037-22 [I,A]; A01N0037-22 [I,C];
 A01N0037-32 [I,A]; A01N0037-32 [I,C]; A01N0037-36 [I,C];
 A01N0037-40 [I,A]; A01N0039-00 [I,C]; A01N0039-02 [I,A];
 A01N0039-04 [I,A]; A01N0041-00 [I,C]; A01N0041-10 [I,A];
 A01N0043-02 [I,C]; A01N0043-10 [I,A]; A01N0043-18 [I,A];
 A01N0043-34 [I,C]; A01N0043-40 [I,A]; A01N0043-48 [I,C];
 A01N0043-50 [I,A]; A01N0043-54 [I,A]; A01N0043-64 [I,C];
 A01N0043-70 [I,A]; A01N0043-72 [I,C]; A01N0043-76 [I,A];
 A01N0043-80 [I,A]; A01N0043-86 [I,A]; A01N0047-28 [I,C];
 A01N0047-30 [I,A]; A01N0047-34 [I,A]; A01N0047-36 [I,A];
 A01N0057-00 [I,C]; A01N0057-20 [I,A]; A01N [I,S]
 ECLA: A01N0043-54+M
 USCLASS NCLM: 504/116.100; 504/243.000
 JAP. PATENT CLASSIF.:
 MAIN/SEC.: A01N0033-18 B; A01N0035-10; A01N0037-22; A01N0037-32 101;
 A01N0037-40; A01N0039-02 A; A01N0039-04 A; A01N0041-10 A;
 A01N0043-10 B; A01N0043-18 Z; A01N0043-40 101 D;
 A01N0043-40 102; A01N0043-50 Q; A01N0043-54 F;
 A01N0043-70; A01N0043-76 101; A01N0043-80 101;
 A01N0043-86 101; A01N0047-30 B; A01N0047-34 G;
 A01N0047-36 101 E; A01N0057-20 G; A01N0057-20 L;
 A01P0013-00
 A01N0043-54 F
 MAIN:
 SECONDARY: A01N0033-18 B; A01N0035-10; A01N0037-22; A01N0037-32 101;
 A01N0037-40; A01N0039-02 A; A01N0039-04 A; A01N0041-10 A;
 A01N0043-10 B; A01N0043-18 Z; A01N0043-40 101 D;
 A01N0043-40 102; A01N0043-50 Q; A01N0043-70; A01N0043-76
 101; A01N0043-80 101; A01N0043-86 101; A01N0047-30 B;
 A01N0047-34 G; A01N0047-36 101 E; A01N0057-20 G;
 A01N0057-20 L; A01P0013-00
 FTERM CLASSIF.: 4H011; 4H011/AB01; 4H011/BA03; 4H011/BA06; 4H011/BB04;
 4H011/BB05; 4H011/BB06; 4H011/BB07; 4H011/BB08;
 4H011/BB09; 4H011/BB10; 4H011/BB14; 4H011/BB17;
 4H011/DA15; 4H011/DA16; 4H011/DD04; 4H011/DE15;
 4H011/DF04

BASIC ABSTRACT:

WO 2003024221 A1 UPAB: 20090401

NOVELTY - A composition comprises at least one phenyluracil compound (I) and/or its salts and at least one of a herbicide (a1) or a safener (a2) or its salts or derivatives.

DETAILED DESCRIPTION - A composition comprises:

- (1) at least one phenyluracil compound of formula (I) and/or its salts; and
- (2) at least one of a herbicide (a1) or its salts or derivatives having a carboxyl group; and/or
- (3) a safener (a2) or its salts or derivatives having a carboxyl group.

(a1) is a lipid biosynthesis inhibitor, acetolactate synthase (ALS) inhibitor, photosynthesis inhibitor, protoporphyrinogen-IX oxidase inhibitor, bleacher herbicide, enolpyruvyl shikimate 3-phosphate synthase (EPSP) inhibitor, glutamine synthetase inhibitor, 7,8-dihydropteroate synthase (DHP) inhibitor, mitose inhibitor, very long chain fatty acids (VLCFA) synthesis inhibitor, cellulose biosynthesis inhibitor, decoupler herbicide, auxin herbicide, auxin transport inhibitor, benzoylprop, flamprop, flamprop-M, bromobutide, chlorfluorenoil, cinmethylin, methylaldimuron, etobenzanid, fosamine, metam, pyributicarb, oxaziclonofone, dazomet, triaziflam, or methyl bromide. (a2) is benoxacor, cloquintocet, cyometrinil, dichlorimid, dicyclonon, dietholate, fenchlorazole, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen, mefenpyr, mephenate, naphthalic anhydride, 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine, 4-(dichloroacetyl)-1-oxa-4-azaspiro(4.5)decane or oxabtrinil.

R1 = methyl or NH₂;

R2 = 1-2C haloalkyl;

R3 = H or halo;

R4 = halo or cyano;

R5 = benzyl (optionally substituted by halo or alkyl), H, cyano, 1-6C alkyl, 1-6C alkoxy, 1-4C alkoxy-1-4C alkyl, 3-7C cycloalkyl, 3-6C alkynyl or 3-6C alkenyl;

R6, R7 = benzyl, phenyl, 1-6C alkyl, 1-6C alkoxy, 3-7C cycloalkyl, 3-7C cycloalkenyl, 3-6C alkynyl or 3-6C alkenyl (all optionally mono- or hexasubstituted by halo and/or mono- or trisubstituted by T1) or H; or

NR6R7 = 3 - 7 membered optionally saturated nitrogen heterocycle mono- or hexa-substituted by methyl and may further contain 1 or 2 N, S, or O; and

T1 = OH, NH₂, CN, CONH₂, formyl, phenyl, benzyl, 1-4C (halo)alkoxy, 1-4C (halo)alkylthio, 1-4C (halo)alkylsulfonyl, 1-4C alkylamino, di(1-4C)alkylamino, 1-4C alkylcarbonyl, 1-4C alkoxy carbonyl, 1-4C alkylaminocarbonyl, di(1-4C)alkylaminocarbonyl, or 3-7C cycloalkyl.

ACTIVITY - Post-emergence Herbicide; Pre-emergence Herbicide. A composition comprising 5-(3-amino-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)-2-chloro-4-fluoro-(N-methyl-N-isopropylaminosulfonyl)benzamide and sulcotrione in a weight ratio of 1:1 was prepared and applied post emergence to a test plant of *Echinochloa crus-galli* at a rate (g/ha) of 3.91 and 62.5. The damage caused by the composition was evaluated by comparing with the untreated control plants. The composition showed 100% herbicidal action.

MECHANISM OF ACTION - None given.

USE - For controlling weeds in crops e.g. cereals, corn, sorghum, rice, cotton, oilseed rape, soyabean, potatoes, dry beans and groundnuts, perennial crops, forestry, and in crop plants resistant to at least one herbicide or attack by insects owing to genetical engineering and/or breeding; and for desiccation and defoliation of the plants (all claimed). Application is post-emergence or pre-emergence.

ADVANTAGE - The composition exhibits an enhanced herbicidal activity through the synergistic action of different herbicides having specific action. The composition reduces the application rate of the herbicides and prevents damage to the crop plants. (a1) and (a2) improve herbicidal activity of (I) against undesirable plants and also their compatibility with useful plants.

MANUAL CODE: CPl: C02-P02; C05-B01G; C05-B01N; C06-H; C07-H; C10-A08; C10-A10; C10-A11A; C10-A12A; C10-A12C; C10-A13A; C10-A13D; C10-A15; C10-A20; C10-B01A; C10-B02A; C10-B04B; C10-C04C; C10-D03; C10-E02; C10-E04B; C10-G01; C10-G02; C10-G03; C10-H01; C14-D05A; C14-D10; C14-V03A; C14-V03B

TECH

AGRICULTURE - Preferred Composition: The wt. ratio of (I) to (a1) is 10:1 - 1:500; (I) to (a2) is 10:1 - 1:10; and (a1) to (a2) is 50:1 - 1:10. The composition additionally comprises at least one inert liquid and/or solid carrier and optionally at least one surfactant and auxiliaries. Preferred

Components: The bleacher herbicide is a 3-heterocyclyl-substituted benzoyl derivative of formula (II).

R8, R10 = H, halo, 1-6C alkyl, 1-6C haloalkyl, 1-6C haloalkoxy, 1-6C alkylthio, 1-6C alkylsulfinyl or 1-6C alkylsulfonyl;

R9 = thiazol-2-yl, thiazol-3-yl, thiazol-4-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 4,5-dihydroisoxazol-3-yl, 4,5-dihydroisoxazol-4-yl, 4,5-dihydroisoxazol-5-yl (all optionally substituted with one or more halo, 1-4C alkyl, 1-4C alkoxy, 1-4C haloalkyl, 1-4C haloalkoxy or 1-4C alkylthio);

R11 = H, halo, 1-6C alkyl;

R12 = 1-6C alkyl; and

R13 = H or 1-6C alkyl.

ABEX DEFINITIONS - Preferred Definitions: - R2 = trifluoromethyl; - R3 = fluorine; - R4 = chlorine; - R5 = H; and - R6, R7 = 1-6C alkyl; or - NR6R7 = pyrrolidine, piperidine, morpholine, N-methylpiperazine, or perhydroazepine.

ADMINISTRATION - The composition is applied to the leaves of the plants before, during and/or after emergence of the weeds (claimed). The application rate of is 0.001 - 3 (preferably 0.005 - 2, especially 0.01 - 1) kg/ha. The composition is applied by spraying, atomizing, dusting, broadcasting, watering.


SPECIFIC COMPOUNDS - 361 Compounds are specifically claimed as (a1) e.g. clodinafop, cyhalofop, amidosulfuron, azimsulfuron, atrazine, acifluorfen, norflurazon, (2-chloro-3-(4,5-dihydro-3-isoxazolyl)-4-(methylsulfonyl)phenyl)(5-hydroxy-1-methyl-1H-pyrazol-4-yl)methanone, glyphosate, glufosinate, benfluralin, acetochlor, dichlobenil, dichlorprop, diflufenzopyr, mecoprop, cyanazine, fluoroglyphofen, diflufenican, butralin.

EXAMPLE - No relevant example given.

AN.S DCR-338180

CN.S 4-(3-Trifluoromethyl-phenoxy)-2-(4-trifluoromethyl-phenyl)-pyrimidine

SDCN RA2U09



L52 ANSWER 41 OF 50

ACCESSION NUMBER:

DOC. NO. CPI:

TITLE:

WPIX COPYRIGHT 2009

THOMSON REUTERS on STN

2002-304090 [34] WPIX

C2002-088428 [34]

New herbicidal composition comprising a carrier and/or surface active agent and a 2-phenyl-4-(hetero-)arylpyrimidine and an additional herbicide and/or safening agent

DERWENT CLASS:

INVENTOR:

PATENT ASSIGNEE:

COUNTRY COUNT:

C02

BALTRUSCHAT H S; BALTRUSCHAT S; BRANDT A

(BADI-C) BASF AG

96

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
WO 2002015694	A2	20020228	(200234) *	EN	57[0]		<--
US 20020055435	A1	20020509	(200235)	EN			<--
AU 2002010461	A	20020304	(200247)	EN			<--
EP 1313369	A2	20030528	(200336)	EN			<--
CZ 2003000863	A3	20030618	(200347)	CS			<--
SK 2003000350	A3	20030805	(200360)	SK			<--
US 6683027	B2	20040127	(200408)	EN			<--
HU 2003002950	A2	20040128	(200415)	HU			<--
EP 1313369	B1	20050629	(200543)	EN			<--
DE 60111749	E	20050804	(200552)	DE			<--
DE 60111749	T2	20051215	(200582)	DE			<--
AU 2002210461	B2	20061214	(200729)	EN			<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002015694	A2	WO 2001-EP9799	20010824
US 20020055435	A1 Provisional	US 2000-228317P	20000825
US 6683027	B2 Provisional	US 2000-228317P	20000825
DE 60111749	E	DE 2001-611749	20010824
DE 60111749	T2	DE 2001-611749	20010824
EP 1313369	A2	EP 2001-978304	20010824
EP 1313369	B1	EP 2001-978304	20010824
DE 60111749	E	EP 2001-978304	20010824
DE 60111749	T2	EP 2001-978304	20010824
US 20020055435	A1	US 2001-938370	20010824
US 6683027	B2	US 2001-938370	20010824
EP 1313369	A2	WO 2001-EP9799	20010824
CZ 2003000863	A3	WO 2001-EP9799	20010824
SK 2003000350	A3	WO 2001-EP9799	20010824
HU 2003002950	A2	WO 2001-EP9799	20010824
EP 1313369	B1	WO 2001-EP9799	20010824
DE 60111749	E	WO 2001-EP9799	20010824
DE 60111749	T2	WO 2001-EP9799	20010824
AU 2002010461	A	AU 2002-10461	20010824
CZ 2003000863	A3	CZ 2003-863	20010824
HU 2003002950	A2	HU 2003-2950	20010824
SK 2003000350	A3	SK 2003-350	20010824
AU 2002210461	B2	AU 2002-210461	20010824

FILING DETAILS:

PATENT NO	KIND	PATENT NO
DE 60111749	E	Based on EP 1313369 A
DE 60111749	T2	Based on EP 1313369 A
AU 2002010461	A	Based on WO 2002015694 A
EP 1313369	A2	Based on WO 2002015694 A
CZ 2003000863	A3	Based on WO 2002015694 A
SK 2003000350	A3	Based on WO 2002015694 A
HU 2003002950	A2	Based on WO 2002015694 A
EP 1313369	B1	Based on WO 2002015694 A
DE 60111749	E	Based on WO 2002015694 A
DE 60111749	T2	Based on WO 2002015694 A

AU 2002210461 B2 Based on WO 2002015694 A

PRIORITY APPLN. INFO: US 2000-228317P 20000825
US 2001-938370 20010824

INT. PATENT CLASSIF.:

MAIN: A01N043-54
 IPC ORIGINAL: A01N0043-48 [I,C]; A01N0043-54 [I,A]
 IPC RECLASSIF.: A01N0043-48 [I,C]; A01N0043-54 [I,A]
 ECLA: A01N0043-54+M
 USCLASS NCLM: 504/103.000
 NCLS: 504/104.000; 504/105.000; 504/106.000; 504/107.000;
 504/108.000; 504/109.000; 504/110.000; 504/111.000;
 504/112.000

BASIC ABSTRACT:

WO 2002015694 A2 UPAB: 20060202

NOVELTY - A new herbicidal composition comprises a carrier and/or surface active agent and a 2-phenyl-4-(hetero-)arylpurine and an additional herbicide and/or safening agent.

DETAILED DESCRIPTION - A novel herbicidal composition comprises a carrier and/or surface active agent and, as active ingredient:

(a) at least one 2-phenyl-4-(hetero-)aryloxypurine (I) or their salts;

(b) at least one additional herbicidal compound, which is active against broad-leaved weeds and/or annual grasses; and/or

(c) at least one additional safening compound.

A = an optionally substituted phenyl, or an optionally substituted 5- or 6-membered N-containing heteroaromatic group or a difluorobenzo-dioxyl;

m = 0-2;

n = 0-5;

R1 = halo, optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, dialkoxyalkyl, alkoxyalkoxy, alkylthio, amino, alkylamino, dialkylamino, alkoxyamino or formamido;

each R2 = halo, optionally substituted alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, alkylthio, or haloalkylthio or a nitro, cyano, SF5 or alkylsulfonyl or alkylsulfinyl group.

ACTIVITY - Herbicide.

Tests were carried out on the herbicidal performance of the mixed compound (A) (4-(3-trifluoromethylphenoxy)-2-(4-trifluoromethyl-phenyl)-pyrimidine) and isoproturon (IPU) against grass and broadleaf weeds in pre-emergence application. The following weeds were used: grass weeds: Alopecurus myosuroides, Apera spica-venti, Lolium perenne, and Setaria viridis; and broadleaf weeds: Galium aparine, Lamium purpureum, Matricaria inodora, Papaver rhoeas, Stellaria media, and Veronica persica. The different dosage rates/test species were recorded. The observed activity was clearly superior to the expected activity, thus demonstrating that the combination was synergistic.

MECHANISM OF ACTION - None given in the source material.

USE - The compositions can be used for controlling the growth of weeds at a locus before, during or after the emergence of undesired plants (claimed). They can be used for controlling the growth of weeds in cereal crops (claimed). They are used particularly for combating Alopecurus myosuroides, Apera spica-venti, Lolium perenne, Setaria viridis; Galium aparine, Lamium purpureum, Matricaria inodora, Papaver rhoeas, Stellaria media, and/or Veronica persica (claimed). The use offers both foliar and residual activity and may be used to control a broad spectrum of weed species in crops, especially in cereals, e.g. in wheat, barley, rice and maize.

ADVANTAGE - The compositions provide synergistic activity against many broad-leaved weed species and annual grasses. It has been found that injuries on crop plants caused by a compound of group (I) or by a mixture of a compound of group (I) or by a mixture of a compound of group (I) and a compound of group (c) may be reduced by additionally applying a compound of group (c).

MANUAL CODE: CPI: C06-H; C07-H; C10-A13D; C10-A15; C10-B04A; C10-C03;
C14-M01E; C14-M01F; C14-S09; C14-V02B; C14-V03

TECH

AGRICULTURE - (I) are disclosed in e.g. EP0723960. The 2-phenyl-4-(hetero-)aryloxy pyrimidine (I) may be e.g. 4-(3-(trifluoromethylphenoxy)-2-(4-(trifluoromethylphenyl)-pyrimidine. Preferred Inhibitors: the additional herbicidal compound may be lipid biosynthesis inhibitors, acetolactate synthase inhibitors (ALS), photosynthesis inhibitors, protoporphyrinogen-IX-oxidase inhibitors, bleacher herbicides, enolpyruvylshikimate 3-phosphate synthase inhibitors (EPSP), glutamine synthetase inhibitors, dihydropteroate synthase inhibitors (DHP), mitosis inhibitors, cell division inhibitors, cellulose biosynthesis inhibitors, uncoupling herbicides, auxin herbicides, auxin transport inhibitors, or various other herbicides. The lipid biosynthesis inhibitor may be e.g. chlorazifop, clodinafop, clofop, cyhalofop, dichofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluzifop, fluzifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, propaquizafop, quizalofop, quizalofop-P, isoxapyrifop, proppaquizafop, quizalofop, quizalofop-P, trifop, alloxidim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, teptaloxydim, tralkoxydim, butylate, cycloate, di-allate, dimetopate, EPTC, esprocarb, ethiolate, isopollinate, methiobencarb, molinate, orbencarb, pebulate, prosulfocarb, sulfallate, thiobencarb, tiocarbazil, tri-allate, vernolate, bensulide, benfuserate or ethofumesate. The acetolactate synthase inhibitor may be a sulfonyl-urea type herbicide, e.g. amidosulfuron, azimsulfuron, bensulfuron, chlorimuron, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron, ethoxysulfuron, flazasulfuron, fluprimsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron, nicosulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron, thifensulfuron, triazulfuron, tribenuron, trifloxysulfuron, triflusaluron, tritosulfuron, propoxyacarbazon, or flucarbazone; a sulfonamide type herbicide e.g. chloransulam, diclosulam, florasulam, flumetsulam, metoosulam or penoxsulam; an imidazolinone type herbicide e.g. imazamethabenz, imazamox, imazapyr, imazaquin, or imazethapyr; a pyrimidyl ether e.g. bispyribac, pyribenzoxim, pyriftalid, pyriothiobac or pyriminobac. The photosynthesis inhibitor may be a photosynthetic electron transport inhibitor e.g. a triazine type herbicide e.g. ametryn, atraton, atrazine, aziprotyn, chlorazine, cyanatryn, cyanazine, cyprazine, desmetryne, dimethamethryn, dipropetryn, eglazine, ipazine, mesoprazine, methometon, methopetryn, procyzazine, proglazine, prometon, prometryn, propazine, sebuthylazine, seccbumeton, simazine, simeton, simetryn, terbuteton, terbutylazine, terbutryn or trietazine; or a urea type herbicide e.g. anisuron, benzthiazuron, buthiuron, buturon, chlorbromuron, chloreturon, chlortoluron, chloroxuron, difenoxuron, dimefuron, diuron, etidimuron, fenuron, fluometuron, fluothiuuron, isoproturon, isouron, linuron, methabenzthiazuron, methiuron, metobenzuron, metabromuron, metoxuron, monoisouron, monolinuron, monuron, neburon, parafluron, phenobenzuron, siduron, tobuthiuron, tetrafluron, thiadiazuron, or thiazafurion; another photosynthesis inhibitor e.g. a nitrile type herbicide e.g. bromobonil, bromoxynil, chloroxynil, iodonil, or ioxynil; a triazinone type herbicide e.g. atridione, amibuzin, hexazinone, isometiozin, metamitron, or metribuzin; a uracil type herbicide e.g. bromacil, isocil, lenacil or terbacil; a pyridazinone type herbicide e.g. brompyrazon, chloridazon or dimidazon; a phenyl carbamate type herbicide e.g. desmedipham, phenisopham, or phenmedipham; and amide type herbicide, e.g. propanil; a benzothiadiazole type herbicide e.g. bentazone, a phenyl pyridazine type herbicide, e.g. pyridate or pyridaol; a bipyridylum type herbicide e.g. cyperquat, diethamquat, difenzoquat, diquat, morfamquat or paraquat; amicarbazone, bromofenoxim, flumezin, methazole or

pentanochlor. The protoporphyrinogen IX oxidase inhibitor may be a diphenyl ether type herbicide e.g. acifluorfen, bifenox, chlomefenoxifen, chlornitrofen, ethoxyfen, fluorodifen, fluoroglycofen, fluoronitrofen, fomesafen, furolyxyfen, halosafen, lactofen, nitrofen, nitrofluorfen or oxyfluorfen; a N-phenylphthalimide type herbicide e.g. cinidon-ethyl, flumiclorac, flumioxazin, or flumipropyn; a thiaziazole type herbicide e.g. fluthiacet or thidiazimin; an oxadiazole type herbicide e.g. oxadiazon or oxadiargyl; azafenidin, carfentrazone, sulfentrazone, pentoxazone, benfendizone, butafenacil, pyraclozil, proflumazox, flufenpyr, flupropanil, nipyraclufen, etniprodim, fluzoxazole (JV 485) or pyraflufen. The bleacher herbicide may be metflurazon, norflurazon, diflufenican, flufenican, picolinafen, beflubutamide, fluridone, flurochloridone, flurtamone, isoxachlortole, isoxaflutole, mesotrione, sulcotrione, benzofenap, pyrazoxynate, pyrazoxyfenn, benzobicyclon, amitrol, clomazone, acifluorfen, ketospiradox or a 3-heterocyclyl substituted benzoyl derivative (II).

Ra, Rc = H, halo, 1-6C alkyl, 1-6C haloalkyl, 1-6C alkoxy, 1-6C haloalkoxy, 1-6C alkylthio, 1-6C alkylsulfinyl or 1-6C alkylsulfonyl; Rb = a heterocyclic radical selected from thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 4,5-dihydroisoxazol-3-yl, 4,5-dihydroisoxazol-4-yl, and 4,5-dihydroisoxazol-5-yl, it being possible for the 9 radicals methioned to be unsubstituted or mono- or polysubstituted by halogen, 1-4C alkyl, 1-4C alkoxy, 1-4C haloalkyl, 1-4C haloalkoxy or 1-4C alkylthio; Rd = H, halo or 1-6C alkyl; Re = 1-6C alkyl; Rf = H or 1-6C alkyl.

The enolpyruvylshikimate 3-phosphate synthase inhibitor (EPSP) may be glyphosate e.g. a glutamine synthetase inhibitor e.g. bilanaphos or glufosinate. The dihydropteroate synthase inhibitor (DHP) may be asulam. The mitosis inhibitor may be a dinitoaniline type herbicide e.g. benfluralin, butralin, dinitramin, ethalfuralin, fluchloralin, isopropalin, methopropalin, nitratin, oryzalin, pendimethalin, prodiamine, profluralin or trifluralin; a phosphoramidate type herbicide e.g. amiprofos-methyl or buutamifos; a pyridazine type herbicide e.g. dithiopyr or thiazopyr; propyzamid, tebutam, chlorthal, carbetamide, chlorbufam, chlorpropham or propham. The cell division inhibitor may be a chloroacetamide type herbicide e.g. acetochlor, alachlor, allidochlor, butachlor, butenachlor, CDEA, delachlor, diethatyl, dimethachlor, dimethenamid, dimethenamid-P, epronaz, metazachlor, metolachlor, S-metolachlor, pethoxamid, pretilachlor, propachlor, propisochlor, pyrachlor, terbutachlor, thenylchlor or xylachlor; an acetamide type herbicide, diphenamid, napropamide or naproanilide; an oxacetamide type herbicide e.g. flufenacet or mefenacet; fentrazamide, aniliphos, piperophos, cafenstrole, indanofan or tridiphane. The cellulose biosynthesis inhibitor may be dichlobenil, chlorthiamid, isoxaben or flupoxam. The uncoupling herbicide may be dinofenat, dinoprop, dinosam, dinoseb, dinoterb, DNOC, etinofen or medinoterb. The auxin herbicide may be clomeprop, 2,4-D, 2,4-DB, dichlorprop, dichlorprop-P, MCPA, MCPA thioethyl, MCPB, mecoprop, mecoprop-P, 2,4,5-T, chloramben, dicamba, 2,3,6-TBA, tricamba, quinchlorac, quinmerac, clopyralid, fluroxypyr, picloram, trichlopyr, or benazolin. The auxin transport inhibitor may be naptalam or diflufenzopyr. The various other herbicides may be a flurene carboxylic acid e.g. chlorflurenol or flurenol; benzoilprop, flamprop, flamprom-M, bromobutide, cinmethylin, cumyluron, daimuron, methylaldymron, etobenzanid, fosamin, metam, pyributicarb, oxaziclomefone, dazomet, triflufam or methylbromid. The safening compound may be e.g. benoxacor, cloquintocet, cyometrinil, dichlormid, dicyclon, dietholate, fenchlorazole, fenclorim, flurazole, fluxofenim, furilazole, isoxdifen, mefenpyr, mephenate, naphthalic anhydride, oxabenil or R 29148. The weight

ratio of (I) to the additional herbicide may be 1:0.002 to 1:800, preferably 1:1 to 1:100. The weight ratio of (I) to the additional safening compound may be 1:0.002 to 1:800.


ABEX ADMINISTRATION - (I) may be used at rates of 0.1 - 500, preferably 2 - 100g/ha. Component (b) may be used at 0.5 - 4000, preferably 100 - 1500g/ha. Component (c) may be used at 1 - 1500, preferably 5 - 1250g/ha.

EXAMPLE - A preferred emulsion concentrate comprises compound (A): 4-(3-trifluoromethylphenoxy)-2-(4-trifluoromethyl-phenyl)pyrimidine.
Active ingredient: Compound A + isoproturon (1:16) 30 wt.%; Emulsifiers: Altos (RTM) 4856B/Atlox (RTM) 4858 B 5 wt.% (mixture containing calcium alkyl aryl sulfonate, fatty alcohol ethoxylates and light aromatics/mixture containing calcium alkyl aryl sulfonate, fatty alcohol ethoxylates and light aromatics); Solvent: Shellsol (RTM) A (mixture of 9 - 10C aromatic hydrocarbons) to 1000 ml.

AN.S DCR-338180

CN.S 4-(3-Trifluoromethyl-phenoxy)-2-(4-trifluoromethyl-phenyl)-pyrimidine

SDCN RA2U09



L52 ANSWER 42 OF 50 WPIX COPYRIGHT 2009 THOMSON REUTERS ON STN
ACCESSION NUMBER: 2002-163728 [21] WPIX
CROSS REFERENCE: 2001-564353
DOC. NO. CPI: C2002-050498 [21]
TITLE: Production of substituted pyrimidines used in pesticides or in pharmaceuticals, involves reacting amidine compound or its salt, with 3,3-disubstituted vinylcarbonyl compound in inert solvent in the presence of base
DERWENT CLASS: B03; C02
INVENTOR: GUTHEIL D; MEYER O
PATENT ASSIGNEE: (AMCY-C) AMERICAN CYANAMID CO; (BADI-C) BASF AG
COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
US 20020004600	A1	20020110	(200221)*	EN	7[0]		<--
US 6559307	B2	20030506	(200338)	EN			<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20020004600	A1	Provisional	<u>US 1999-129462P 19990415</u>
US 20020004600	A1	Provisional	<u>US 1999-139356P 19990615</u>

US 20020004600 A1 Div Ex
US 20020004600 A1

US 2000-547666 20000412
US 2001-896078 20010629

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 20020004600 A1	Div ex	US 6281358 B

PRIORITY APPLN. INFO: US 2001-896078 20010629
US 1999-129462P 19990415
US 1999-139356P 19990615
US 2000-547666 20000412

INT. PATENT CLASSIF.:

IPC RECLASSIF.: C07D0239-00 [I,C]; C07D0239-32 [I,A]; C07D0239-34 [I,A];
C07D0401-00 [I,C]; C07D0401-14 [I,A]; C07D0403-00 [I,C];
C07D0403-12 [I,A]

ECLA: C07D0239-32; C07D0239-34; C07D0401-14+241B+239B+213;
C07D0403-12+239B+231

ICO: M07D0239:32; M07D0239:34B; M07D0401:14; M07D0403:12
USCLASS NCLM: 544/319.000

BASIC ABSTRACT:

US 20020004600 A1 UPAB: 20050525

NOVELTY - Substituted pyrimidines, i.e. 4-phenoxy-2-arylpyrimidine, are prepared by reacting an amidine compound or its salt, with a 3,3-disubstituted vinylcarbonyl compound in an inert solvent in the presence of a base.

DETAILED DESCRIPTION - Preparation of substituted pyrimidines of formula (I), i.e. 4-phenoxy-2-arylpyrimidine, involves reacting an amidine compound of formula $H_2NC(=NH)R_1$ (II) or its salt with a 3,3-disubstituted vinylcarbonyl compound of formula $L_12C=C(R_3)COR_4$ (III). The process is carried out in an inert solvent in the presence of a base and optionally a compound of formula HXR_2 .

R₁, R₂ = optionally substituted alkyl, cycloalkyl, phenyl, heteroaryl;
R₃, R₄ = H, or optionally substituted alkyl or phenyl;

X = O or S; and

L = halo or group of formula XR_2 .

An INDEPENDENT CLAIM is also included for a compound of formula (Ia).

R'₁ = optionally substituted 3-8C cycloalkyl or pyrazin-2-yl;

R₅ = halo, haloalkyl, or haloalkoxy;

W-V = N-CH, S-CH, N-CH-CH, CH-CH-CH, or N-N(R₆); and

R₆ = 1-4C alkyl.

ACTIVITY - Pesticide; Herbicide.

No biological data given.

MECHANISM OF ACTION - None given in the source material.

USE - For preparing substituted pyrimidines used in pesticides or pharmaceuticals.

ADVANTAGE - The process effectively and efficiently produces

pyrimidines.

MANUAL CODE: CPI: B07-D12; B14-B01; C07-D12; C14-B01; C14-V01

TECH

ORGANIC CHEMISTRY - Preferred Component: The base is alkali hydrogencarbonates, alkali carbonate, or tertiary amines. The inert diluent is acetonitrile, benzene, toluene, xylene, hexane, cyclohexane, dichloromethane, tetrachloromethane, diethylether, diisopropyl ether, tert-butylmethyl ether, 2,2-dimethoxypropane, dimethoxyethane, diethoxyethane, tetrahydrofuran, tetrahydropyran, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide, and/or dioxane. Preferred Process: The molar ratio of (II) to (III) is 1:5-1:0.5. The reaction step also includes stirring a mixture consisting of (II), (III),

inert diluent, base, and optionally substituted alcohol, thioalcohol, phenol, or thiophenol at 0-150degreesC. The reaction is preferably carried out in the presence of 3-trifluoromethylphenol. (III) Is prepared by in situ hydrolysis of 1,1,1,3-tetrachloro-3-alkoxypropane.

ABEX DEFINITIONS - Preferred Definitions: - R2 = phenyl substituted by at least one halo, at least one alkyl, alkoxy, haloalkyl, or haloalkoxy; - R1 = R2, preferably 4-trifluoromethylphenyl; and - X = O.


SPECIFIC COMPOUNDS - (III) Is 3,3-dichloroacrolein.

EXAMPLE - A 10 mmol of 3,3-dichloroacrolein diluted with 50 ml acetonitrile was slowly added to a mixture composed of (mmol) 4-trifluoromethylphenol (11), potassium carbonate (40), and 100 ml acetonitrile, and stirred under reflux. After addition of 3,3-dichloroacrolein was completed, additional 4-trifluoromethylbenzimidine (0.5) was added. The reaction mixture was stirred for 20 hours under reflux and subsequently cooled down, and then filtered through silica. The organic phase was washed with ethyl acetate and concentrated under vacuum. The residue was purified on aluminum oxide, yielding a 3.25 g (85%) of 4-(3-trifluoromethylphenoxy)-2-(4-trifluoromethylphenyl)-pyrimidine.

AN.S DCR-338180

CN.S 4-(3-Trifluoromethyl-phenoxy)-2-(4-trifluoromethyl-phenyl)-pyrimidine

SDCN RA2U09



L52 ANSWER 43 OF 50 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN

ACCESSION NUMBER: 2001-564353 [63] WPIX

CROSS REFERENCE: 2002-163728

DOC. NO. CPI: C2001-167459 [63]

TITLE: Preparation of substituted pyrimidine used in pesticides, involves reacting an amidine and 3,3-di substituted vinylcarbonyl compound in an inert solvent in the presence of a base, halogenated compound

DERWENT CLASS: B03; C02

INVENTOR: GUTHEIL D; MEYER O

PATENT ASSIGNEE: (AMCY-C) AMERICAN CYANAMID CO

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG	MAIN IPC
US 6281358	B1	20010828	(200163)*	EN	6[0]

<--

APPLICATION DETAILS:

their mixture.

ABEX DEFINITIONS - Preferred Definitions: - R1 = phenyl group substituted by at least one H or at least one alkyl, alkoxy, haloalkyl or haloalkoxy group, preferably 4-trifluoromethyl phenyl group


SPECIFIC COMPOUNDS - The 3,3-disubstituted vinylcarbonyl compound is 3,3-dichloroacrolein of formula (IIIa) (claimed). The preparation of 17 examples of (I) is disclosed e.g. 2-(4-chlorophenyl)-4-(3-trifluoromethylphenoxy)pyrimidine of formula (Ia).

EXAMPLE - (In mmoles) 3,3-dichloroacrolein (10) diluted with 50 ml of acetonitrile was slowly added to the mixture of 4-trifluoromethylbenzamide (10), 3-trifluoromethylphenol (11), potassium carbonate (40) and 100 ml of acetonitrile. The mixture was stirred under reflux. Additionally 4-trifluoromethyl benzamide (0.5) was added when the addition of 3,3-dichloroacrolein was completed. The reaction mixture was stirred for 20 hours under reflux and cooled to ambient temperature and filtered through silica. The organic phase was washed with ethyl acetate and concentrated in vacuum. The residue was purified by chromatography on alumina and 3.25 g of pure 4-(3-trifluoromethylphenoxy)-2-(4-trifluoromethyl phenyl)-pyrimidine was obtained at a yield of 85%. The product had melting point at 66-67degreesC.

AN.S DCR-338181

CN.S 2-(4-Chloro-phenyl)-4-(3-trifluoromethyl-phenoxy)-pyrimidine


SDCN RA2UOA



AN.S DCR-338182

CN.S 2-(4-Fluoro-phenyl)-4-(3-trifluoromethyl-phenoxy)-pyrimidine

SDCN RA2UOB



L52 ANSWER 44 OF 50

ACCESSION NUMBER:

DOC. NO. CPI:

TITLE:

WPXI COPYRIGHT 2009

2001-015752 [02] WPXI

C2001-004195 [02]

Preparation of partly new 4-substituted pyrimidines useful as or intermediates for e.g. pesticides, by reacting an amidine with a 3,3-disubstituted

THOMSON REUTERS on STN

10/595,734

vinylcarbonyl compound in the presence of a base and optionally a thiol or alcohol

DERWENT CLASS:

B03; C02

INVENTOR:

GUTHEIL D; MEYER O

PATENT ASSIGNEE:

(AMCY-C) AMERICAN CYANAMID CO; (BADI-C) BASF AG

COUNTRY COUNT:

89

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
WO 2000063183	A1	20001026	(200102)*	EN	23[0]		<--
AU 2000043371	A	20001102	(200107)	EN			<--
CZ 2001003691	A3	20020417	(200231)	CS			<--
EP 1200414	A1	20020502	(200236)	EN			<--
SK 2001001475	A3	20020509	(200239)	SK			<--
KR 2002000167	A	20020104	(200244)	KO			<--
HU 2002000830	A2	20020729	(200258)	HU			<--
CN 1355792	A	20020626	(200263)	ZH			<--
JP 2002542233	W	20021210	(200301)	JA	23		<--
ZA 2001008392	A	20021224	(200309)	EN	32		<--
MX 2001010390	A1	20020401	(200363)	ES			<--
EP 1200414	B1	20050420	(200528)	EN			<--
AU 780907	B2	20050421	(200532)	EN			<--
DE 60019606	E	20050525	(200538)	DE			<--
BR 2000012736	A	20050705	(200545)	PT			<--
DE 60019606	T2	20050818	(200554)	DE			<--
ES 2240093	T3	20051016	(200571)	ES			<--
CN 1161342	C	20040811	(200612)	ZH			<--
MX 228876	B	20050704	(200627)	ES			<--
IL 145888	A	20060820	(200672)	EN			<--
SK 285728	B6	20070706	(200753)	SK			<--
KR 781851	B1	20071203	(200843)	KO			<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000063183 A1		<u>WO 2000-US9522 20000410</u>	
AU 2000043371 A		<u>AU 2000-43371 20000410</u>	
AU 780907 B2		<u>AU 2000-43371 20000410</u>	
BR 2000012736 A		<u>BR 2000-12736 20000410</u>	
CN 1355792 A		<u>CN 2000-807931 20000410</u>	
CN 1161342 C		<u>CN 2000-807931 20000410</u>	
DE 60019606 E		<u>DE 2000-60019606 20000410</u>	
DE 60019606 T2		<u>DE 2000-60019606 20000410</u>	
EP 1200414 A1		<u>EP 2000-923205 20000410</u>	
EP 1200414 B1		<u>EP 2000-923205 20000410</u>	
DE 60019606 E		<u>EP 2000-923205 20000410</u>	
DE 60019606 T2		<u>EP 2000-923205 20000410</u>	
ES 2240093 T3		<u>EP 2000-923205 20000410</u>	
IL 145888 A		<u>IL 2000-145888 20000410</u>	
JP 2002542233 W		<u>JP 2000-612275 20000410</u>	
CZ 2001003691 A3		<u>WO 2000-US9522 20000410</u>	
EP 1200414 A1		<u>WO 2000-US9522 20000410</u>	
SK 2001001475 A3		<u>WO 2000-US9522 20000410</u>	
KR 2002000167 A		<u>WO 2000-US9522 20000410</u>	
HU 2002000830 A2		<u>WO 2000-US9522 20000410</u>	
JP 2002542233 W		<u>WO 2000-US9522 20000410</u>	
MX 2001010390 A1		<u>WO 2000-US9522 20000410</u>	

EP 1200414 B1	WO 2000-US9522 20000410
DE 60019606 E	WO 2000-US9522 20000410
BR 2000012736 A	WO 2000-US9522 20000410
DE 60019606 T2	WO 2000-US9522 20000410
MX 228876 B	WO 2000-US9522 20000410
SK 285728 B6	WO 2000-US9522 20000410
CZ 2001003691 A3	CZ 2001-3691 20000410
SK 2001001475 A3	SK 2001-1475 20000410
SK 285728 B6	SK 2001-1475 20000410
ZA 2001008392 A	ZA 2001-8392 20011012
KR 2002000167 A	KR 2001-713141 20011015
MX 2001010390 A1	MX 2001-10390 20011015
MX 228876 B	MX 2001-10390 20011015
HU 2002000830 A2	HU 2002-830 20000410
KR 781851 B1	WO 2000-US9522 20000410
KR 781851 B1	KR 2001-713141 20011015

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 780907	B2	Previous Publ	AU 2000043371	A
DE 60019606	E	Based on	EP 1200414	A
DE 60019606	T2	Based on	EP 1200414	A
ES 2240093	T3	Based on	EP 1200414	A
SK 285728	B6	Previous Publ	SK 200101475	A
AU 2000043371	A	Based on	WO 2000063183	A
CZ 2001003691	A3	Based on	WO 2000063183	A
EP 1200414	A1	Based on	WO 2000063183	A
SK 2001001475	A3	Based on	WO 2000063183	A
KR 2002000167	A	Based on	WO 2000063183	A
HU 2002000830	A2	Based on	WO 2000063183	A
JP 2002542233	W	Based on	WO 2000063183	A
MX 2001010390	A1	Based on	WO 2000063183	A
EP 1200414	B1	Based on	WO 2000063183	A
AU 780907	B2	Based on	WO 2000063183	A
DE 60019606	E	Based on	WO 2000063183	A
BR 2000012736	A	Based on	WO 2000063183	A
DE 60019606	T2	Based on	WO 2000063183	A
MX 228876	B	Based on	WO 2000063183	A
IL 145888	A	Based on	WO 2000063183	A
SK 285728	B6	Based on	WO 2000063183	A
KR 781851	B1	Previous Publ	KR 2002000167	A
KR 781851	B1	Based on	WO 2000063183	A

PRIORITY APPLN. INFO: US 1999-333528 19990615
US 1999-292442 19990415

INT. PATENT CLASSIF.:

MAIN: C07D239-34; C07D409-12
 SECONDARY: C07D401-14; C07D403-12
 IPC ORIGINAL: C07D0239-00 [I,C]; C07D0239-34 [I,A]; C07D0403-00 [I,C];
 C07D0403-12 [I,A]; C07D0409-00 [I,C]; C07D0409-00 [I,C];
 C07D0409-12 [I,A]; C07D0409-12 [I,A]
 IPC RECLASSIF.: C07D [I,S]; C07D0239-00 [I,C]; C07D0239-00 [I,C];
 C07D0239-34 [I,A]; C07D0239-38 [I,A]; C07D0401-00 [I,C];
 C07D0401-14 [I,A]; C07D0403-00 [I,C]; C07D0403-00 [I,C];
 C07D0403-12 [I,A]; C07D0409-00 [I,C]; C07D0409-00 [I,C];
 C07D0409-12 [I,A]; C07D0521-00 [I,A]; C07D0521-00 [I,C]
 ECLA: C07D0231-12; C07D0233-56; C07D0239-34; C07D0239-34B;
 C07D0239-38; C07D0249-08; C07D0401-14+241B+239B+213;

ICO: C07D0403-12+239B+231; C07D0521-00B2H
M07D0239:34B; M07D0239:38; M07D0401:14; M07D0403:12;
M07D0521:00B2H

JAP. PATENT CLASSIF.:

MAIN/SEC.: C07D0239-34; C07D0401-14; C07D0403-12

FTERM CLASSIF.:

4C020; 4C063; 4C063/AA01; 4C063/AA03; 4C063/BB01;
4C063/BB08; 4C063/CC29; 4C063/CC34; 4C063/DD22;
4C063/DD29; 4C063/EE01

BASIC ABSTRACT:

WO 2000063183 A1 UPAB: 20060116

NOVELTY - Preparation of substituted pyrimidines (I) comprises reacting an amidine (II) with a 3,3-disubstituted vinylcarbonyl compound (III) in an inert solvent and in the presence of a base and optionally a thiol or alcohol derivative (IV).

DETAILED DESCRIPTION - Preparation of substituted pyrimidines of formula (I) comprises reacting an amidine of formula (II) or its salt with a 3,3-disubstituted vinylcarbonyl compound of formula (III) in an inert solvent and in the presence of a base and a compound of formula H-X-R2 (IV) or, if L = -X-R2, in the presence of an inert solvent and base.

R1, R2 = optionally substituted alkyl, cycloalkyl, phenyl or heteroaryl;

R3, R4 = H or optionally substituted alkyl or phenyl;

X = O or S;

L = halo or XR2.

An INDEPENDENT CLAIM is included for compounds of formula (IA).

R1a = optionally substituted 3-8C cycloalkyl or pyrazin-2-yl;

R5 = halo, haloalkyl or haloalkoxy;

W-V = N-CH, S-CH, N-CH-CH, CH-CH-CH or N-NR6;

R6 = 1-4C alkyl.

USE - The process is useful for preparing 4-substituted pyrimidines which are effective as pharmaceuticals or pesticides and especially certain compounds are stated to have herbicidal activity.

ADVANTAGE - The process allows preparation of (I) on a large scale.

MANUAL CODE:

CPI: B07-D12; C07-D12; C14-V01

TECH

ORGANIC CHEMISTRY - Preferred Process: The base is preferably an alkali hydrogen carbonate, an alkali carbonate or a tertiary amine and the ratio of (II) to (III) is preferably 1:5 to 1:0.5. The solvent is preferably acetonitrile, benzene, toluene, xylene, hexane, cyclohexane, dichloromethane, tetrachloromethane, diethylether, diisopropylether, tert-butylmethylether, 2,2-dimethoxypropane, dimethoxyethane, diethoxyethane, tetrahydrofuran, tetrahydropyran, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide or dioxane. The reaction is preferably carried out in the presence of 3-trifluoromethylphenol and the vinylcarbonyl compound is preferably 3,3-dichloroacrolein, preferably prepared in situ by hydrolysis of 1,1,1,3-tetrachloro-3-alkoxypropane.


ABEX DEFINITIONS - Preferred Definitions: - R1 = 4-trifluoromethylphenyl.

EXAMPLE - A solution of 3,3-dichloroacrolein (10 mmoles) in MeCN (50 ml) was added slowly to a mixture of 4-trifluoromethylbenzamidine (10 mmoles), 3-trifluoromethylphenol (11 mmoles), K2CO3 (40 mmoles) and MeCN (100 ml) under reflux. Additional 4-trifluoromethylbenzamidine (0.5 mmoles) was added and the mixture was stirred under reflux for 20 hours. The cooled mixture was filtered through silica and washed (EtOAc) and concentrated. The residue was purified by chromatography to give 3.25 g of 4-(3-trifluoromethylphenoxy)-2-(4-trifluoromethylphenyl)-pyrimidine (m.pt. 66 - 67 degreesC).

AN.S DCR-338180

CN.S 4-(3-Trifluoromethyl-phenoxy)-2-(4-trifluoromethyl-phenyl)-pyrimidine


SDCN RA2U09



AN.S DCR-338181

CN.S 2-(4-Chloro-phenyl)-4-(3-trifluoromethyl-phenoxy)-pyrimidine


SDCN RA2UOA



AN.S DCR-338182

CN.S 2-(4-Fluoro-phenyl)-4-(3-trifluoromethyl-phenoxy)-pyrimidine

SDCN RA2UOB



=> d ibib ed ab ind 45-50

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, BIOSIS' - CONTINUE? (Y)/N:y

L52 ANSWER 45 OF 50 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STNACCESSION NUMBER: 2002:570340 BIOSIS [Full-text](#)

DOCUMENT NUMBER: PREV200200570340

TITLE: Endothelin ETB receptor-mediated mechanisms involved in
oleic acid-induced acute lung injury in mice.

AUTHOR(S): Guimaraes, Claudio L.; Trentin, Patricia G.; Rae, Giles A.
[Reprint author]

CORPORATE SOURCE: Department of Pharmacology, CCB, Universidade Federal de Santa Catarina, Rua Ferreira Lima, 82, Florianopolis, SC, 88015-420, Brazil
garae@farmaco.ufsc.br

SOURCE: Clinical Science (London), (August, 2002) Vol. 103, No. Suppl. 48, pp. 340S-344S. print.
CODEN: CSCIAE. ISSN: 0143-5221.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 7 Nov 2002
Last Updated on STN: 7 Nov 2002

ED Entered STN: 7 Nov 2002
Last Updated on STN: 7 Nov 2002

AB The receptors underlying the endothelin-dependent component of lung plasma extravasation and leucocyte infiltration induced by oleic acid were assessed in mice. Oleic acid (1 mcgntdotkg-1 intravenously), but not endothelin-1 (up to 1 nmolntdotkg-1 intravenously), increased accumulation of Evans blue in the lungs (excluding the trachea and main bronchi) from 11.8+-3.9 to 98.6+-10.7 mug l h after injection. Bosentan, the antagonist of endothelin receptors (ETA and ETB) or the selective ETB receptor antagonists Ro 46-8443 or A-192621 (administered 1 h before oleic acid at doses of 30, 10 and 30 mcgntdotkg-1 respectively) reduced the effect of oleic acid by 71%, 58% and 79% respectively. However, the selective ETA receptor antagonist A-127722.5 (10 mcgntdotkg-1) was inactive. Oleic acid (2 mcgntdotkg-1, intravenously) raised the number of total leucocytes, mononuclear cells and neutrophils in broncho-alveolar lavage fluid 4 h after injection. Bosentan and Ro 46-8443 (at doses of 30 and 10 mcgntdotkg-1 respectively) inhibited the neutrophil infiltration induced by oleic acid by approx. 80%. None of the antagonists modified control (basal) pulmonary microvascular permeability or total and differential cell counts. Thus, endogenous endothelins, acting via ETB receptor-dependent mechanisms, play a major role in oleic acid-induced lung injury in the mouse by promoting infiltration of circulating neutrophils and enhancement of pulmonary microvascular plasma extravasation. These findings suggest that either ETB or mixed ETA/ETB receptor antagonists might be beneficial in the treatment of the adult respiratory distress syndrome.

CC Cytology - Animal 02506
Biochemistry studies - Lipids 10066
Pathology - Therapy 12512
Blood - Blood and lymph studies 15002
Blood - Blood cell studies 15004
Respiratory system - Physiology and biochemistry 16004
Respiratory system - Pathology 16006
Pharmacology - General 22002
Toxicology - General and methods 22501
Immunology - General and methods 34502

IT Major Concepts
Pharmacology; Respiratory System (Respiration); Toxicology

IT Parts, Structures, & Systems of Organisms
leukocyte: blood and lymphatics, immune system; leukocytes: blood and lymphatics, immune system; lung: respiratory system; mononuclear cells: blood and lymphatics, immune system; neutrophils: blood and lymphatics, immune system

IT Diseases
acute lung injury: injury, respiratory system disease, chemically-induced

IT Diseases
respiratory distress syndrome: respiratory system disease
Respiratory Distress Syndrome (MeSH)

IT Chemicals & Biochemicals
 A-127722.5: endothelin A receptor antagonist; A-192621: endothelin B receptor antagonist; Ro 46-8443: endothelin B receptor antagonist; bosentan: endothelin A receptor antagonist, endothelin B receptor antagonist; endothelin A receptor; endothelin B receptor; endothelin-I; oleic acid

ORGN Classifier
 Muridae 86375
 Super Taxa
 Rodentia; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 mouse: male, strain-Swiss
 Taxa Notes
 Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates

RN 195529-54-5 (A-192621)
 175556-12-4 (Ro 46-8443)
 147536-97-8 (bosentan)
 123626-67-5 (endothelin-I)
 112-80-1 (oleic acid)

L52 ANSWER 46 OF 50 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:599495 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200200599495
 TITLE: Function of the endothelinB receptor in cardiovascular physiology and pathophysiology.
 AUTHOR(S): D'Orleans-Juste, P. [Reprint author]; Labonte, J.; Bkaily, G.; Choufani, S.; Plante, M.; Honore, J. C.
 CORPORATE SOURCE: Department of Pharmacology, Institut de Pharmacologie de Sherbrooke, Medical School, Universite de Sherbrooke, 3001 12th Avenue North, Sherbrooke, Quebec, J1H 5N4, Canada labpdj@courrier.usherb.ca
 SOURCE: Pharmacology and Therapeutics, (September, 2002) Vol. 95, No. 3, pp. 221-238. print.
 CODEN: PTHDT. ISSN: 0163-7258.
 DOCUMENT TYPE: Article
 General Review; (Literature Review)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 20 Nov 2002
 Last Updated on STN: 20 Jan 2003

ED Entered STN: 20 Nov 2002
 Last Updated on STN: 20 Jan 2003

CC Cytology - Animal 02506
 Cytology - Human 02508
 Biochemistry studies - General 10060
 Biochemistry studies - Proteins, peptides and amino acids 10064
 Biochemistry studies - Lipids 10066
 Enzymes - General and comparative studies: coenzymes 10802
 Pathology - Therapy 12512
 Digestive system - Physiology and biochemistry 14004
 Cardiovascular system - Physiology and biochemistry 14504
 Cardiovascular system - Heart pathology 14506
 Cardiovascular system - Blood vessel pathology 14508
 Urinary system - Physiology and biochemistry 15504
 Urinary system - Pathology 15506
 Respiratory system - Physiology and biochemistry 16004
 Reproductive system - Physiology and biochemistry 16504
 Endocrine - General 17002
 Muscle - Physiology and biochemistry 17504

Integumentary system - Physiology and biochemistry 18504
 Pharmacology - General 22002
 Pharmacology - Clinical pharmacology 22005
 Development and Embryology - General and descriptive 25502

IT Major Concepts
 Biochemistry and Molecular Biophysics; Cardiovascular System (Transport and Circulation); Urinary System (Chemical Coordination and Homeostasis)

IT Parts, Structures, & Systems of Organisms
 adrenal gland: endocrine system; artery: circulatory system; endothelial cells: circulatory system; heart: circulatory system; kidney: excretory system; liver: digestive system; lung: respiratory system; myometrium: muscular system, reproductive system; saphenous vein: circulatory system; skin: integumentary system; umbilical vein: circulatory system, embryonic structure; vascular smooth muscles: circulatory system, muscular system

IT Diseases
 atherosclerosis: vascular disease
 Arteriosclerosis (MeSH)

IT Diseases
 cardiovascular diseases: heart disease, vascular disease
 Cardiovascular Diseases (MeSH)

IT Diseases
 congestive heart failure: heart disease
 Heart Failure, Congestive (MeSH)

IT Diseases
 primary pulmonary hypertension: vascular disease
 Hypertension, Pulmonary (MeSH)

IT Diseases
 renal failure: urologic disease
 Kidney Failure (MeSH)

IT Diseases
 renal ischemia: urologic disease, vascular disease
 Ischemia (MeSH)

IT Chemicals & Biochemicals
 4-ALA-ET-1: endothelin-BR agonist; BQ-209670:
 endothelin-AR/endothelin-BR antagonist; BQ-238:
 endothelin-AR/endothelin-BR antagonist; BQ-3020: endothelin-BR agonist;
 BQ-928: endothelin-AR/endothelin-BR antagonist; G-protein-coupled
 endothelin-BRS; IRL-1620: endothelin-BR agonist; L-744-753:
 endothelin-AR/endothelin-BR antagonist; PABSA:
 endothelin-AR/endothelin-BR antagonist; PD 145065:
 endothelin-AR/endothelin-BR antagonist; RO-46-2005:
 endothelin-AR/endothelin-BR antagonist; RO-46-8443:
 endothelin-AR/endothelin-BR antagonist; RO-61-0612:
 endothelin-AR/endothelin-BR antagonist; STX-S6c: endothelin-BR agonist;
 TAK-044: endothelin-AR/endothelin-BR antagonist; endothelial-derived
 relaxing factors; endothelin-1: mitogenic properties, vasoactive
 effects; endothelin-A receptors; endothelin-A-G-protein-coupled
 receptor-like proteins; endothelin-B receptor: clearance, function,
 pharmacology; mitogen-activated protein kinase; nitric oxide;
 prostacyclin; tyrosine kinases

IT Miscellaneous Descriptors
 cardiovascular pathophysiology; cardiovascular physiology;
 pharmacological tools; vascular tone

ORGN Classifier
 Canidae 85765
 Super Taxa
 Carnivora; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name

dog
 Taxa Notes
 Animals, Carnivores, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman
 Mammals, Vertebrates
 ORGN Classifier
 Caviidae 86300
 Super Taxa
 Rodentia; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 guinea pig
 Taxa Notes
 Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals,
 Rodents, Vertebrates
 ORGN Classifier
 Felidae 85770
 Super Taxa
 Carnivora; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 cat
 Taxa Notes
 Animals, Carnivores, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman
 Mammals, Vertebrates
 ORGN Classifier
 Hominidae 86215
 Super Taxa
 Primates; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 human
 Taxa Notes
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates
 ORGN Classifier
 Leporidae 86040
 Super Taxa
 Lagomorpha; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 rabbit
 Taxa Notes
 Animals, Chordates, Lagomorphs, Mammals, Nonhuman Vertebrates, Nonhuman
 Mammals, Vertebrates
 ORGN Classifier
 Muridae 86375
 Super Taxa
 Rodentia; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 mouse
 rat
 Taxa Notes
 Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals,
 Rodents, Vertebrates
 ORGN Classifier
 Mustelidae 85780
 Super Taxa
 Carnivora; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 ferret
 Taxa Notes
 Animals, Carnivores, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman
 Mammals, Vertebrates
 ORGN Classifier
 Suidae 85740

Super Taxa

Artiodactyla; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
pig

Taxa Notes

Animals, Artiodactyls, Chordates, Mammals, Nonhuman Vertebrates,
Nonhuman Mammals, Vertebrates

RN 143113-45-5 (BQ-3020)
166735-10-0 (BQ-928)
142569-99-1 (IRL-1620)
151039-37-1 (PD 145065)
150725-87-4 (RO-46-2005)
~~175556-12-4~~ (RO-46-8443)
157380-72-8 (TAK-044)
90880-94-7 (endothelial-derived relaxing factors)
123626-67-5 (endothelin-1)
142243-02-5 (mitogen-activated protein kinase)
10102-43-9 (nitric oxide)
35121-78-9 (prostacyclin)
80449-02-1 (tyrosine kinases)
161253-64-1 (BQ-238)

L52 ANSWER 47 OF 50 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STN

ACCESSION NUMBER: 2000:109768 BIOSIS Full-text

DOCUMENT NUMBER: PREV200000109768

TITLE: Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670.

AUTHOR(S): Burrell, Kylie M.; Molenaar, Peter [Reprint author];
Dawson, Peter J.; Kaumann, Alberto J.

CORPORATE SOURCE: Cardiovascular Research Unit, Department of Medicine,
University of Queensland, Prince Charles Hospital,
Chermside, QLD, 4032, Australia

SOURCE: Journal of Pharmacology and Experimental Therapeutics, (
Jan., 2000) Vol. 292, No. 1, pp. 449-459. print.
CODEN: JPETAB. ISSN: 0022-3565.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 22 Mar 2000

Last Updated on STN: 3 Jan 2002

ED Entered STN: 22 Mar 2000

Last Updated on STN: 3 Jan 2002

AB It is known that binding sites with endothelinA (ET)A and ETB receptor characteristics coexist in human heart but little is known about the receptors that mediate cardiostimulant effects of ET receptor agonists or their consequences. Functional studies were performed on isolated human cardiac tissues. The maximal positive inotropic effects of ET-1 were right atrium > left atrium = right ventricle. The rank order of potencies of agonists in right atrium was sarafotoxin S6c > ET-1 = ET-2 > ET-3. The ETA receptor-selective compounds BQ123 (10 µM) and A-127722 (1 µM) only slightly blocked (<0.5 log-unit shift) the effects of lower concentrations of ET-1, and the ETB receptor antagonist Ro46-8443 (10 µM) did not cause blockade. SB 209670 caused concentration-dependent rightward shifts of ET-1 and sarafotoxin S6c concentration-effect curves with Schild slopes not different from one and affinities (-logM KB) of 7.0 and 7.9, respectively. ET-1 caused arrhythmic contractions in right atrial trabeculae that were prevented by 10 µM SB 209670 but not 10 µM BQ123 or 1 µM A-127722, precluding ETA receptors. ET-1 caused a higher incidence of arrhythmic contractions in tissues taken from patients treated with beta-blockers before surgery than in tissues from non-beta blocker-treated patients. Sarafotoxin S6c produced arrhythmias that were

prevented by SB 209670. The positive inotropic effects of ET-1 in human right atrial myocardium are mediated mostly by a non-ETA, non-ETB receptor. Ventricular inotropic ET receptors differ from atrial inotropic ET receptors. ET-1 induced arrhythmic contractions in human atria do not appear to be mediated by an ETA receptor.

CC Pharmacology - General 22002
 Biochemistry studies - General 10060
 Pathology - Therapy 12512
 Metabolism - General metabolism and metabolic pathways 13002
 Cardiovascular system - General and methods 14501

IT Major Concepts
 Biochemistry and Molecular Biophysics; Pharmacology; Cardiovascular System (Transport and Circulation)

IT Parts, Structures, & Systems of Organisms
 heart: circulatory system

IT Chemicals & Biochemicals
 A-127722: endothelin-A receptor; BQ123: endothelin-A receptor-selective; Ro46-8443: endothelin-B receptor antagonist; SB 209670; endothelin-1; endothelin-A receptor; endothelin-B receptor; sarafotoxin S6c

ORGN Classifier
 Hominidae 86215
 Super Taxa
 Primates; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 human
 Taxa Notes
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 136553-81-6 (BQ123)
 175556-12-4 (Ro46-8443)
 157659-79-5 (SB 209670)
 123626-67-5 (endothelin-1)
 121695-87-2 (sarafotoxin S6c)
 173864-34-1 (A-127722)

L52 ANSWER 48 OF 50 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 1996:160728 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199698732863
 TITLE: Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor.
 AUTHOR(S): Boer, R.; Dichtl, M.; Borchers, C.; Ulrich, W. R.; Marecek, J. F.; Prestwich, G. D.; Glossmann, H.; Striessnig, J. [Reprint author]
 CORPORATE SOURCE: Fak. Chem., Univ. Konstanz, Konstanz, Germany
 SOURCE: Biochemistry, (1996) Vol. 35, No. 5, pp. 1387-1396.
 CODEN: BICHAW. ISSN: 0006-2960.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 11 Apr 1996
 Last Updated on STN: 10 Jun 1997

ED Entered STN: 11 Apr 1996

Last Updated on STN: 10 Jun 1997

AB A photoreactive dihydropyridine (DHP), BZDC-DHP (2,6-dimethyl-4-(2-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid -(3-(4-benzoylphenyl)propionylamino)ethyl) ester ethyl ester), and its tritiated derivative were synthesized as novel probes for human p-glycoprotein (p-gp). (3H)BZDC-DHP specifically photolabeled p-gp in membranes of multidrug-

resistant CCRF-ADR5000 cells. In reversible labeling experiments a saturable, vinblastine-sensitive and high-affinity ($K_d = 16.3$ nM, $B_{max} = 58$ pmol/mg of protein, $k_{+1} = 0.031$ nM $^{-1}$ min $^{-1}$, $k_{-1} = 0.172$ min $^{-1}$) binding component was present in CCRF-ADR5000 membranes but absent in the sensitive parent cell line. Binding was inhibited by cytotoxics and known chemosensitizers with a p-gp characteristic pharmacological profile. For eight chemosensitizers tested, the potency for binding inhibition correlated (r gt 0.94) with the potency for drug transport inhibition (measured using rhodamine 123 accumulation). The DHP niguldipine and a structurally related pyrimidine stereoselectively stimulated reversible (-)-(3H)BZDC-DHP binding, suggesting that more than one DHP molecule can bind to p-gp at the same time. Our data demonstrate that DHPs label multiple chemosensitizer domains on p-gp, distinct from the vinblastine interaction site. (-)-(3H)BZDC-DHP represents a valuable tool to characterize the molecular organization of chemosensitizer binding domains on p-gp by both reversible binding and photoinduced covalent modification. It provides a novel simple screening assay for p-gp active drugs.

- CC Cytology - Human 02508
 Biochemistry methods - General 10050
 Biochemistry studies - General 10060
 Biochemistry studies - Proteins, peptides and amino acids 10064
 Biochemistry studies - Carbohydrates 10068
 Biophysics - Molecular properties and macromolecules 10506
 Biophysics - Membrane phenomena 10508
 Metabolism - General metabolism and metabolic pathways 13002
 Pharmacology - General 22002
 Neoplasms - Therapeutic agents and therapy 24008
- IT Major Concepts
 Biochemistry and Molecular Biophysics; Cell Biology; Membranes (Cell Biology); Metabolism; Oncology (Human Medicine, Medical Sciences); Pharmacology
- IT Chemicals & Biochemicals
 1,4-DIHYDROPYRIDINE; PRENYLAMINE; B9309-012; NIGULDIPINE;
 DEXNIGULDIPINE; VERAPAMIL; QUINIDINE; CICLOSPORIN; ETOPOSIDE;
 COLCHICINE; ACTINOMYCIN D; VINCRISTINE; VINBLASTINE; B9109-012;
 NICARDIPINE
- IT Miscellaneous Descriptors
 (DEXTRO)-2,6-DIMETHYL-4-(2-(TRIFLUOROMETHYL)-PHENYL)-1,4-DIHYDROPYRIDINE-3, 5-DICARBOXYLIC ACID
 (2-(3-(4-BENZOYLPHENYL)PROPIONYLAMINO)ETHYL) ESTER ETHYL ESTER;
 (LEVO)-2,6-DIMETHYL-4-(2-(TRIFLUOROMETHYL)-PHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID (2-(3-(4-BENZOYLPHENYL)PROPIONYLAMINO)ETHYL) ESTER ETHYL ESTER; (RACEMIC)-AZIDOPINE; (RACEMIC)-SADOPINE; ACTINOMYCIN D; ANALYTICAL METHOD; ANTINEOPLASTIC AGENT RESISTANCE; B9109-012; B9309-012; CICLOSPORIN A; COLCHICINE; DEXNIGULDIPINE; ETOPOSIDE; HUMAN CCRF-ADR5000 MULTIDRUG-RESISTANT CELL; NICARDIPINE; NIGULDIPINE; P-GLYCOPROTEIN ACTIVE PHARMACEUTICAL AGENT; P-GLYCOPROTEIN PROBE; PHARMACEUTICAL AGENT TRANSPORT; PRENYLAMINE; QUINIDINE; STRUCTURE-FUNCTION RELATIONSHIP; SYNTHETIC METHOD; TRIITATED (RACEMIC)-2,6-DIMETHYL-4-(2-(TRIFLUOROMETHYL)-PHENYL)-1,4-DIHYDROPYRIDINE-3, 5-DICARBOXYLIC ACID
 (2-(3-(4-BENZOYLPHENYL)PROPIONYLAMINO)ETHYL) ESTER ETHYL ESTER; VERAPAMIL; VINBLASTINE; VINCRISTINE
- ORGN Classifier
 Hominidae 86215
 Super Taxa
 Primates; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 CCRF-CEM: cell line
 Taxa Notes

Animals, Chordates, Humans, Mammals, Primates, Vertebrates
 RN 3337-17-5 (1,4-DIHYDROPYRIDINE)
 390-64-7Q (PRENYLAMINE)
 13822-06-5Q (PRENYLAMINE)
 173220-66-1 (B9309-012)
 113165-32-5 (NIGULDIPINE)
 120054-86-6 (DEXNIGULDIPINE)
 52-53-9 (VERAPAMIL)
 56-54-2 (QUINIDINE)
 59865-13-3 (CICLOSPORIN)
 33419-42-0 (ETOPOSIDE)
 64-86-8 (COLCHICINE)
 50-76-0 (ACTINOMYCIN D)
 57-22-7 (VINCISTINE)
 865-21-4 (VINBLASTINE)
 173268-91-2 (B9109-012)
 55985-32-5 (NICARDIPINE)

L52 ANSWER 49 OF 50 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
 STN

ACCESSION NUMBER: 1996:192585 BIOSIS Full-text

DOCUMENT NUMBER: PREV199698748714

TITLE: The role of ET-B receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ET-B receptor antagonist Ro 46-8443.

AUTHOR(S): Clozel, Martine [Reprint author]; Breu, Volker

CORPORATE SOURCE: Pharma Div., Preclin. Res., c/o F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland

SOURCE: FEBS Letters, (1996) Vol. 383, No. 1-2, pp. 42-45.

CODEN: FEBLAL. ISSN: 0014-5793.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 2 May 1996

Last Updated on STN: 10 Jun 1996

ED Entered STN: 2 May 1996

Last Updated on STN: 10 Jun 1996

AB We used Ro 46-8443, non-peptidic antagonist selective of endothelin ET-B receptors, to study the role of ET-B receptors in rat hypertension models. In normotensive rats, Ro 46-8443 decreased blood pressure, but in SHR and DOCA rats, it induced a pressor effect, due to blockade of ET-B-mediated release of nitric oxide since L-NAME prevented it. In rats rendered hypertensive by chronic L-NAME, Ro 46-8443 did not induce a pressor but depressor effect. Thus, in DOCA rats and SHR, Ro 46-8443 reveals a predominant influence of endothelial 'vasorelaxant' ET-B receptors, while in normotensive rats the prevailing role of ET-B receptors seems to be in mediating a vasoconstrictor tone.

CC Biochemistry studies - General 10060

Biochemistry studies - Proteins, peptides and amino acids 10064

Biophysics - Membrane phenomena 10508

Cardiovascular system - Physiology and biochemistry 14504

Cardiovascular system - Blood vessel pathology 14508

Endocrine - Neuroendocrinology 17020

Pharmacology - Cardiovascular system 22010

IT Major Concepts

Cardiovascular System (Transport and Circulation); Endocrine System (Chemical Coordination and Homeostasis); Membranes (Cell Biology); Pharmacology

IT Chemicals & Biochemicals
 RO 46-8443

IT Miscellaneous Descriptors
 ANTIHYPERTENSIVE-DRUG; CARDIOVASCULAR-DRUG; ENDOTHELIN; RO 46-8443;
 VASOCONSTRICTOR; VASORELAXATION

ORGN Classifier
 Muridae 86375
 Super Taxa
 Rodentia; Mammalia; Vertebrata; Chordata; Animalia
 Organism Name
 Muridae
 Taxa Notes
 Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals,
 Rodents, Vertebrates

RN 175556-12-4 (RO 46-8443)

L52 ANSWER 50 OF 50 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
 STN

ACCESSION NUMBER: 1996:192584 BIOSIS Full-text
 DOCUMENT NUMBER: PREV199698748713

TITLE:
 In vitro characterisation of Ro 46-8443, the first
 non-peptide antagonist selective for the endothelin ET-B
 receptor.

AUTHOR(S): Breu, Volker [Reprint author]; Clozel, Martine; Burri,
 Kaspar; Hirth, Georges; Neidhart, Werner; Ramuz, Henri

CORPORATE SOURCE:
 Pharma Div., Preclin. Res., c/o F.Hoffmann-La Roche Ltd.,
 Grenzacherstrasse 124, CH-4070 Basel, Switzerland

SOURCE:
 FEBS Letters, (1996) Vol. 383, No. 1-2, pp.
 37-41.
 CODEN: FEBLAL. ISSN: 0014-5793.

DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 2 May 1996
 Last Updated on STN: 10 Jun 1996

ED Entered STN: 2 May 1996
 Last Updated on STN: 10 Jun 1996

AB We describe here Ro 46-8443, the first non-peptide endothelin ET-B receptor
 selective antagonist. It displays up to 2000-fold selectivity for ET-B
 receptors both in terms of binding inhibitory potency and functional
 inhibition. The observed parallel rightward shift of concentration-response
 curves with different antagonist concentrations is consistent with a
 competitive binding mode. Since Ro 46-8443 selectively inhibits ET-B receptor
 mediated responses, it is a valuable tool for clarifying the role of ET-B
 receptors in pathology.

CC Biochemistry studies - General 10060
 Biochemistry studies - Proteins, peptides and amino acids 10064
 Biophysics - Membrane phenomena 10508
 Cardiovascular system - Blood vessel pathology 14508
 Endocrine - Neuroendocrinology 17020
 Pharmacology - Cardiovascular system 22010
 In vitro cellular and subcellular studies 32600

IT Major Concepts
 Cardiovascular System (Transport and Circulation); Endocrine System
 (Chemical Coordination and Homeostasis); Membranes (Cell Biology);
 Pharmacology

IT Chemicals & Biochemicals
 RO 46-8443

IT Miscellaneous Descriptors
 CARDIOVASCULAR-DRUG; RO 46-8443; VASOCONSTRICTION

RN 175556-12-4 (RO 46-8443)

```

=> d que nos 129
L7          STR
L9          27538 SEA FILE=REGISTRY SSS FUL L7
L12         STR
L14         1556 SEA FILE=REGISTRY SUB=L9 SSS FUL L12
L15         QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
L16         QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
L17         QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
L18         QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
L21         99 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L14
L22         1883 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L9
L23         515 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L21 OR L22) (L) (THU
OR PKT OR PAC OR DMA OR BAC) /RL
L24         564 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L21 OR L22) AND
PHARM?/SC, SX
L25         178 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L21 OR L22) (L)
(TREAT? OR THERAP? OR REMED? OR MEDIC? OR ?PHARM? OR BIOPHARM?)

L26         656 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25)
L27         55 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L26 AND L21
L29         1 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L27 AND (L15 OR L16
OR L17 OR L18)

```

```

=> d que nos 140
L7          STR
L12         STR
L15         QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
L16         QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
L17         QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
L18         QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
L34         1954 SEA FILE=WPIX SSS FUL L7
L38         116 SEA FILE=WPIX SUB=L34 SSS FUL L12
L39         18 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L38/DCR
L40         1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L39 AND (L15 OR L16 OR
L17 OR L18)

```

```

=> d his 146
(FILE 'MEDLINE, BIOSIS, EMBASE, BIOTECHNO, CABA, AGRICOLA, DRUGU, VETU'
ENTERED AT 09:31:14 ON 24 NOV 2009)
L46         0 S L45 AND L15-L18

```

```

=> d que nos 146
L7          STR
L9          27538 SEA FILE=REGISTRY SSS FUL L7
L15         QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
L16         QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
L17         QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
L18         QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
L44         2 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L9 AND (MEDLINE OR
BIOSIS OR EMBASE OR BIOTECHNO OR CABA OR AGRICOLA OR DRUGU OR
VETU OR CROFU)/LC
L45         6 SEA L44
L46         0 SEA L45 AND (L15 OR L16 OR L17 OR L18)

```

```

=> d his 151

```

(FILE 'MEDLINE, BIOSIS, EMBASE, CABA, CEABA-VTB, PASCAL, JAPIO, LIFESCI, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, AGRICOLA, CROPU, CROPB, FSTA, FROSTI, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 09:33:42 ON 24 NOV 2009)

L51 0 S L50 AND L19

=> d que nos 151

L15 QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
 L16 QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
 L17 QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
 L18 QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
 L19 QUE SPE=ON ABB=ON PLU=ON EXELIXIS/CS,SO,PA
 L49 159573 SEA ?PYRIMIDIN?/IT,TI,CC,CT,ST,STP
 L50 143 SEA L49 AND (L15 OR L16 OR L17 OR L18)
 L51 0 SEA L50 AND L19

=> dup rem 129 140 146 151

L46 HAS NO ANSWERS

L51 HAS NO ANSWERS

DUPLICATE IS NOT AVAILABLE IN 'RDISCLOSURE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 09:47:09 ON 24 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 09:47:09 ON 24 NOV 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

PROCESSING COMPLETED FOR L29

PROCESSING COMPLETED FOR L40

PROCESSING COMPLETED FOR L46

PROCESSING COMPLETED FOR L51

L53 1 DUP REM L29 L40 L46 L51 (1 DUPLICATE REMOVED)

ANSWER '1' FROM FILE HCAPLUS

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:47:21 ON 24 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 20, 2009 (20091120/UP).

=> d ibib ed abs hitind hitstr
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L53 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2005:451367 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:476293
 TITLE: Substituted pyrimidine compositions and methods using
 them for the treatment of NGFI-B-related diseases
 INVENTOR(S): Martin, Richard; Mohan, Raju;
Ordentlich, Peter
 PATENT ASSIGNEE(S): X-Ceptor Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047268	A2	20050526	WO 2004-US37642	20041109
WO 2005047268	A3	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070293464	A1	20071220	US 2007-595734	20070522
PRIORITY APPLN. INFO.:			US 2003-519030P	P 20031110
			WO 2004-US37642	W 20041109
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 142:476293				
ED	Entered STN: 27 May 2005			
AB	Comps. and methods using substituted pyrimidines are provided. The substituted pyrimidines may be used to treat diseases modulated by NGFI-B family activity.			
IC	ICM C07D239-00			
CC	1-12 (Pharmacology)			
	Section cross-reference(s): 63			
IT	50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 53-03-2, Prednisone 53-06-5, Cortisone 58-56-0, Pyridoxine hydrochloride 59-67-6, Nicotinic acid, biological studies 59-92-7, biological studies 65-23-6, Pyridoxine 68-19-9, Vitamin B12 83-46-5, β -Sitosterol 98-92-0, Niacinamide 103-90-2, Acetaminophen 552-94-3, Salicylsalicylic acid 637-07-0, Clofibrate 943-45-3D, Fibric acid, derivs. 1247-42-3, Methylprednisone 1406-18-4, Vitamin E 7235-40-7, β -Carotene 8059-24-3, Vitamin B6 9002-64-6, Parathyroid hormone 9004-54-0D, Dextran, crosslinked, dialkylaminoalkyl derivs., biological studies 11041-12-6, Cholestyramine 14417-88-0, Melinamide 15687-27-1, Ibuprofen 23187-87-3, Choline magnesiumsalicylate			

23288-49-5, Probucol 25812-30-0, Gemfibrozil 41859-67-0, Bezafibrate
 49562-28-9, Fenofibrate 50925-79-6, Colestipol 65789-90-4
 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin
 89048-95-3 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin

299406-55-6 300359-06-2 300359-07-3
 300359-08-4 300719-05-5 300837-31-4
 303147-11-7 303147-12-8 303147-40-2
 303147-41-3 303147-45-7 306980-56-3
 306980-58-5 307332-77-0 307332-78-1
 312499-77-7 312626-14-5 312626-15-6 315194-30-0
 320418-43-7 320418-48-2 320418-49-3
 320421-36-1 329077-60-7 330221-00-6
 330819-79-9 330981-36-7 330981-37-8
 330981-38-9 330981-39-0 330981-41-4
 330981-42-5 330981-45-8 330981-47-0
 330981-49-2 330981-52-7 330981-53-8
 330981-54-9 330981-55-0 330981-59-4
 330981-60-7 330981-61-6 330981-63-0
 330981-64-1 330981-65-2 330981-70-9
 330993-01-6 330993-02-7 331648-43-2
 331648-44-3 331848-81-8 331971-30-3 332374-83-1
 333415-58-0 337488-96-7 338395-36-1
 338960-71-7 338960-72-8 338960-73-9
 338960-74-0 338960-75-1 338960-76-2
 338960-93-3 338960-99-9 338967-63-8
 339279-05-9 339279-06-0 339279-07-1
 339279-08-2 339279-21-9 339279-27-5
 371199-20-1 371199-57-4 380472-88-8
 380571-66-4 381693-04-1 383146-83-6
 415699-44-4 419548-22-4 420104-18-3
 477710-02-4 477886-15-0 477886-16-1
 477886-19-4 478031-54-8 478031-59-3
 478031-64-0 487015-37-2 499975-26-7
 691869-12-2 692738-30-0 692738-31-1 692738-32-2

RL: PAC (Pharmacological activity); TRU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(pyrimidine derivs. for treatment of NGFI-B-related diseases)

IT 65789-90-4 299406-55-6 300359-06-2
 300359-07-3 300359-08-4 300719-05-5
 300837-31-4 303147-11-7 303147-12-8
 303147-40-2 303147-41-3 303147-45-7
 306980-56-3 306980-58-5 307332-77-0
 307332-78-1 312626-15-6 315194-30-0
 320418-43-7 320418-48-2 320418-49-3
 320421-36-1 329077-60-7 330221-00-6
 330819-79-9 330981-36-7 330981-37-8
 330981-38-9 330981-39-0 330981-41-4
 330981-42-5 330981-45-8 330981-47-0
 330981-49-2 330981-52-7 330981-53-8
 330981-54-9 330981-55-0 330981-59-4
 330981-60-7 330981-61-8 330981-63-0
 330981-64-1 330981-65-2 330981-70-9
 330993-01-6 330993-02-7 331648-43-2
 331648-44-3 332374-83-1 333415-58-0
 338395-36-1 338960-71-7 338960-72-8
 338960-73-9 338960-74-0 338960-75-1
 338960-76-2 338960-93-3 338960-99-9
 338967-63-8 339279-05-9 339279-06-0
 339279-07-1 339279-08-2 339279-21-9
 339279-27-5 371199-20-1 371199-57-4


<u>380472-88-8</u>	<u>380571-66-4</u>	<u>381683-04-1</u>
<u>415699-44-4</u>	<u>419548-22-4</u>	<u>420104-18-3</u>
<u>477710-02-4</u>	<u>477886-15-0</u>	<u>477886-16-1</u>
<u>477886-19-4</u>	<u>478031-54-8</u>	<u>478031-59-3</u>
<u>478031-64-0</u>	<u>487015-37-2</u>	<u>499975-26-7</u>

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrimidine derivs. for treatment of NGFI-B-related diseases)


RN 65789-90-4 HCAPLUS

CN Benzoic acid, 4-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]-, ethyl ester
(CA INDEX NAME)




RN 299406-55-6 HCAPLUS

CN Benzoic acid, 4-[(2,6-diphenyl-4-pyrimidinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 300359-06-2 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 300359-07-3 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(2-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 300359-08-4 HCAPLUS

CN 4-Pyrimidinamine, N-(4-methoxyphenyl)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 300719-05-5 HCAPLUS

CN Benzoic acid, 4-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]oxy]- (CA INDEX NAME)




RN 300837-31-4 HCAPLUS

CN Benzoic acid, 4-[[[6-methyl-2-phenyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 303147-11-7 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)thio]methyl]-2-phenyl-6-(phenylthio)- (CA INDEX NAME)




RN 303147-12-8 HCAPLUS

CN Pyrimidine, 4-(4-chlorophenoxy)-6-[[[(4-chlorophenyl)thio]methyl]-2-phenyl- (CA INDEX NAME)




RN 303147-40-2 HCAPLUS

CN Pyrimidine, 2-phenyl-4-[(phenylsulfonyl)methyl]-6-(phenylthio)- (CA INDEX NAME)




RN 303147-41-3 HCAPLUS

CN Pyrimidine, 4-phenoxy-2-phenyl-6-[(phenylsulfonyl)methyl]- (CA INDEX NAME)




RN 303147-45-7 HCAPLUS

CN Pyrimidine, 4-[(4-chlorophenyl)thio]-2-phenyl-6-[(phenylsulfonyl)methyl]- (CA INDEX NAME)




RN 306980-56-3 HCAPLUS

CN Pyrimidine, 4-[(4-chlorophenyl)sulfinylmethyl]-6-phenoxy-2-phenyl- (CA INDEX NAME)




RN 306980-58-5 HCAPLUS

CN Pyrimidine, 4-[[(4-chlorophenyl)sulfinyl]methyl]-6-[(4-chlorophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 307332-77-0 HCAPLUS

CN Benzonitrile, 4-[(2,6-diphenyl-4-pyrimidinyl)oxy]- (CA INDEX NAME)




RN 307332-78-1 HCAPLUS

CN Pyrimidine, 4-(4-butylphenoxy)-2,6-diphenyl- (CA INDEX NAME)




RN 312626-15-6 HCAPLUS

CN Benzoic acid, 4-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)




RN 315194-30-0 HCAPLUS

CN Pyrimidine, 4-([1,1'-biphenyl]-4-yloxy)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 320418-43-7 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 2,4-diphenyl-6-(phenylthio)- (CA INDEX NAME)




RN 320418-48-2 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-2-phenyl-6-(phenylthio)- (CA INDEX NAME)




RN 320418-49-3 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-6-[(4-chlorophenylthio)-2-phenyl- (CA INDEX NAME)




RN 320421-36-1 HCAPLUS

CN Pyrimidine, 2-phenyl-4-[(phenylsulfinyl)methyl]-6-(phenylthio)- (CA INDEX NAME)




RN 329077-80-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-(2,5-dimethylphenyl)-6-phenyl- (CA INDEX NAME)




RN 330221-00-6 HCAPLUS

CN Phenol, 2-[4-({1,1'-biphenyl}-4-yloxy)-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)




RN 330819-79-9 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(4-nitrophenyl)-2-phenyl-5-(2-propen-1-yl)- (CA INDEX NAME)




RN 330981-36-7 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N,6-diphenyl- (CA INDEX NAME)




RN 330981-37-8 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-(4-methylphenyl)-6-phenyl- (CA INDEX NAME)




RN 330981-38-9 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-(4-methoxyphenyl)-6-phenyl- (CA INDEX NAME)




RN 330981-39-0 HCAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-(3-fluorophenyl)-6-phenyl- (CA INDEX NAME)




RN 330981-41-4 HCAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-4-phenoxy-6-phenyl- (CA INDEX NAME)




RN 330981-42-5 HCAPLUS

CN Pyrimidine, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-bromophenyl)-6-phenyl- (CA INDEX NAME)




RN 330981-45-8 HCAPLUS

CN Benzonitrile, 4-([2-(4-bromophenyl)-6-phenyl-4-pyrimidinyl]oxy)- (CA INDEX NAME)




RN 330981-47-0 HCAPLUS

CN 4-Pyrimidinamine, N-(3-fluorophenyl)-2,6-diphenyl- (CA INDEX NAME)




RN 330981-49-2 HCAPLUS

CN Pyrimidine, 4-phenoxy-2,6-diphenyl- (CA INDEX NAME)




RN 330981-52-7 HCAPLUS

CN Pyrimidine, 4-(4-nitrophenoxy)-2,6-diphenyl- (CA INDEX NAME)




RN 330981-53-8 HCAPLUS

CN Benzoic acid, 4-[(2,6-diphenyl-4-pyrimidinyl)oxy]-, methyl ester (CA INDEX NAME)




RN 330981-54-9 HCAPLUS

CN Benzaldehyde, 4-[(2,6-diphenyl-4-pyrimidinyl)oxy]- (CA INDEX NAME)




RN 330981-55-0 HCAPLUS

CN Pyrimidine, 2,4-diphenyl-6-(4-propylphenoxy)- (CA INDEX NAME)




RN 330981-59-4 HCAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-4-methyl-6-phenoxy- (CA INDEX NAME)




RN 330981-60-7 HCAPLUS

CN Ethanone, 1-[4-[[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]oxy]phenyl]-
(CA INDEX NAME)


RN 330981-61-8 HCAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-4-methyl-6-(4-nitrophenoxy)- (CA INDEX NAME)




RN 330981-63-0 HCAPLUS


CN Benzoic acid, 4-[[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]oxy]-, methyl ester (CA INDEX NAME)




RN 330981-64-1 HCAPLUS
 CN Pyrimidine, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-bromophenyl)-6-methyl- (CA INDEX NAME)




RN 330981-65-2 HCAPLUS
 CN Pyrimidine, 2-(4-bromophenyl)-4-methyl-6-(4-propylphenoxy)- (CA INDEX NAME)



RN 330981-70-9 HCAPLUS
 CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-methyl-N-phenyl- (CA INDEX NAME)




RN 330993-01-6 HCAPLUS
 CN 4-Pyrimidinamine, N-(4-methylphenyl)-2,6-diphenyl- (CA INDEX NAME)




RN 330993-02-7 HCAPLUS

CN 4-Pyrimidinamine, N-(2-methylphenyl)-2,6-diphenyl- (CA INDEX NAME)




RN 331648-43-2 HCAPLUS

CN Phenol, 2-[4-[(4-bromophenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)




RN 331648-44-3 HCAPLUS

CN Phenol, 2-[4-[(4-methoxyphenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)




RN 332374-83-1 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(4-nitrophenyl)-2-phenyl- (CA INDEX NAME)




RN 333415-58-0 HCAPLUS


CN Benzoic acid, 3-[[(6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 338395-36-1 HCAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-2-phenyl-6-(phenylthio)-
(CA INDEX NAME)

RN 338960-71-7 HCAPLUS

CN Pyrimidine, 4-[(4-chlorophenyl)thio]-6-(methoxymethyl)-2-phenyl- (CA
INDEX NAME)


RN 338960-72-8 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(4-methylphenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338960-73-9 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(2,6-dichlorophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338960-74-0 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(3-chlorophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338960-75-1 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(2,4-dichlorophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338960-76-2 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(4-methoxyphenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338960-93-3 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(4-chlorophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338960-99-9 HCAPLUS

CN Pyrimidine, 4-[[[(4-chlorophenyl)methyl]thio]methyl]-6-[(4-fluorophenyl)thio]-2-phenyl- (CA INDEX NAME)




RN 338967-63-8 HCAPLUS

CN Pyrimidine, 4-[(4-bromophenyl)thio]-6-[(methylsulfonyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 339279-05-9 HCAPLUS

CN Pyrimidine, 4-[(2,3-dichlorophenyl)thio]-6-(methoxymethyl)-2-phenyl- (CA INDEX NAME)




RN 339279-06-0 HCAPLUS


CN Pyrimidine, 4-[(2,6-dichlorophenyl)thio]-6-(methoxymethyl)-2-phenyl- (CA INDEX NAME)




RN 339279-07-1 HCAPLUS
 CN Pyrimidine, 4-[(2,4-dichlorophenyl)thio]-6-(methoxymethyl)-2-phenyl- (CA INDEX NAME)




RN 339279-08-2 HCAPLUS
 CN Pyrimidine, 4-[(4-bromophenyl)thio]-6-(methoxymethyl)-2-phenyl- (CA INDEX NAME)



RN 339279-21-9 HCAPLUS
 CN Pyrimidine, 4-[(4-methoxyphenyl)thio]-6-[[[(4-chlorophenyl)methyl]thio]methyl]-2-phenyl- (CA INDEX NAME)




RN 339279-27-5 HCAPLUS
 CN Pyrimidine, 4-[(4-bromophenyl)thio]-6-[[[(4-chlorophenyl)methyl]thio]methyl]-2-phenyl- (CA INDEX NAME)




RN 371199-20-1 HCAPLUS

CN Benzoic acid, 4-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 371199-57-4 HCAPLUS

CN Phenol, 2-[4-methyl-6-[(4-nitrophenyl)amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 380472-88-8 HCAPLUS

CN Phenol, 2-[4-[(3,4-dichlorophenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)




RN 380571-66-4 HCAPLUS

CN Benzoic acid, 4-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 381683-04-1 HCAPLUS

CN Phenol, 2-[4-[(3,5-dichlorophenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)




RN 415699-44-4 HCAPLUS

CN 4-Pyrimidinamine, N-(4-butoxyphenyl)-2,6-diphenyl- (CA INDEX NAME)




RN 419548-22-4 HCAPLUS

CN Phenol, 2-[4-methyl-6-[(4-methylphenyl)amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 420104-18-3 HCAPLUS

CN 4-Pyrimidinamine, N-(3-methoxyphenyl)-2-(4-nitrophenyl)-6-phenyl- (CA INDEX NAME)




RN 477710-02-4 HCAPLUS

CN Pyrimidine, 4-phenoxy-2-phenyl-6-[(phenylsulfinyl)methyl]- (CA INDEX NAME)




RN 477886-15-0 HCAPLUS

CN Pyrimidine, 4-[(methylthio)methyl]-2-phenyl-6-(phenylthio)- (CA INDEX NAME)




RN 477886-16-1 HCAPLUS

CN Pyrimidine, 4-[(methylthio)methyl]-2-phenyl-6-[[3-(trifluoromethyl)phenyl]thio]- (CA INDEX NAME)




RN 477886-19-4 HCAPLUS

CN Pyrimidine, 4-[(methylthio)methyl]-6-phenoxy-2-phenyl- (CA INDEX NAME)




RN 478031-54-8 HCAPLUS

CN Pyrimidine, 4-[(4-chlorophenyl)thio]-6-[(methylsulfonyl)methyl]-2-phenyl-
(CA INDEX NAME)




RN 478031-59-3 HCAPLUS

CN Benzoic acid, 2-[[6-[(methylsulfonyl)methyl]-2-phenyl-4-pyrimidinyl]thio]-, methyl ester (CA INDEX NAME)




RN 478031-64-0 HCAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[(methylthio)methyl]-N,2-diphenyl- (CA INDEX NAME)




RN 487015-37-2 HCAPLUS

CN Benzoic acid, 3-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 499975-26-7 HCAPLUS
 CN 4-Pyrimidinamine, N,2-diphenyl-6-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 09:48:12 ON 24 NOV 2009
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Nov 20, 2009 (20091120/UP).

=> d his ful

(FILE 'HOME' ENTERED AT 08:52:46 ON 24 NOV 2009)

FILE 'STNGUIDE' ENTERED AT 08:52:49 ON 24 NOV 2009

FILE 'ZCAPLUS' ENTERED AT 08:53:24 ON 24 NOV 2009
E US2007-595734/APPS

L1 FILE 'HCAPLUS' ENTERED AT 08:53:41 ON 24 NOV 2009
1 SEA SPE=ON ABB=ON PLU=ON US2007-595734/APPS
D SCAN

FILE 'STNGUIDE' ENTERED AT 08:53:50 ON 24 NOV 2009

L2 FILE 'WPIX' ENTERED AT 08:54:09 ON 24 NOV 2009
1 SEA SPE=ON ABB=ON PLU=ON US2007-595734/APPS
D SCAN

FILE 'REGISTRY' ENTERED AT 08:54:24 ON 24 NOV 2009

L3 FILE 'HCAPLUS' ENTERED AT 08:54:28 ON 24 NOV 2009
TRA PLU=ON L1 1- RN : 143 TERMS

L4 FILE 'REGISTRY' ENTERED AT 08:54:28 ON 24 NOV 2009
143 SEA SPE=ON ABB=ON PLU=ON L3

L5 FILE 'LREGISTRY' ENTERED AT 08:55:03 ON 24 NOV 2009
STR

L6 FILE 'REGISTRY' ENTERED AT 08:58:49 ON 24 NOV 2009
50 SEA SSS SAM L5

L7 FILE 'LREGISTRY' ENTERED AT 09:01:02 ON 24 NOV 2009
STR L5

L8 FILE 'REGISTRY' ENTERED AT 09:01:36 ON 24 NOV 2009
50 SEA SSS SAM L7

FILE 'STNGUIDE' ENTERED AT 09:02:23 ON 24 NOV 2009
D QUE STAT

L9 FILE 'REGISTRY' ENTERED AT 09:05:23 ON 24 NOV 2009
27538 SEA SSS FUL L7
SAVE TEMP L9 JAI734PSET1/A

L10 59 SEA SPE=ON ABB=ON PLU=ON L4 NOT L9
L11 5 SEA SPE=ON ABB=ON PLU=ON L10 AND NCNC3/ES
D SCAN

L12 FILE 'LREGISTRY' ENTERED AT 09:06:54 ON 24 NOV 2009
STR L7

L13 FILE 'REGISTRY' ENTERED AT 09:09:54 ON 24 NOV 2009
50 SEA SUB=L9 SSS SAM L12
D QUE STAT

L14 FILE 'REGISTRY' ENTERED AT 09:13:45 ON 24 NOV 2009
1556 SEA SUB=L9 SSS FUL L12
SAVE TEMP L14 JAI734RSET1/A

FILE 'STNGUIDE' ENTERED AT 09:14:32 ON 24 NOV 2009
D SAVED

FILE 'ZCAPLUS' ENTERED AT 09:15:41 ON 24 NOV 2009

L15 QUE SPE=ON ABB=ON PLU=ON MARTIN, R?/AU,AUTH
L16 QUE SPE=ON ABB=ON PLU=ON MARTIN, D?/AU,AUTH
L17 QUE SPE=ON ABB=ON PLU=ON MOHAN, R?/AU,AUTH
L18 QUE SPE=ON ABB=ON PLU=ON ORDENTLICH, P?/AU,AUTH
L19 QUE SPE=ON ABB=ON PLU=ON EXELIXIS/CS,SO,PA

FILE 'REGISTRY' ENTERED AT 09:18:19 ON 24 NOV 2009

L20 91 SEA SPE=ON ABB=ON PLU=ON L4 NOT L14

FILE 'HCAPLUS' ENTERED AT 09:18:37 ON 24 NOV 2009

L21 99 SEA SPE=ON ABB=ON PLU=ON L14
L22 1883 SEA SPE=ON ABB=ON PLU=ON L9
L23 515 SEA SPE=ON ABB=ON PLU=ON (L21 OR L22) (L) (THU OR PKT OR PAC
OR DMA OR BAC)/RL
L24 564 SEA SPE=ON ABB=ON PLU=ON (L21 OR L22) AND PHARM?/SC,SX
L*** DEL 713 S L21-L22 AND (TREAT? OR THERAP? OR REMED? OR MEDIC? OR ?PHARM?
L25 178 SEA SPE=ON ABB=ON PLU=ON (L21 OR L22) (L) (TREAT? OR
THERAP? OR REMED? OR MEDIC? OR ?PHARM? OR BIOPHARM?)
L26 656 SEA SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25)
L27 55 SEA SPE=ON ABB=ON PLU=ON L26 AND L21

FILE 'ZCAPLUS' ENTERED AT 09:21:43 ON 24 NOV 2009

L28 QUE SPE=ON ABB=ON PLU=ON AY<2008 OR PY<2008 OR PRY<2008 OR
MY<2008 OR REVIEW/DT

FILE 'HCAPLUS' ENTERED AT 09:22:17 ON 24 NOV 2009

L29 1 SEA SPE=ON ABB=ON PLU=ON L27 AND (L15 OR L16 OR L17 OR L18)
L30 0 SEA SPE=ON ABB=ON PLU=ON L1 NOT L29
L31 54 SEA SPE=ON ABB=ON PLU=ON L27 NOT L29
L*** DEL 0 S L31 AND L28]
L32 38 SEA SPE=ON ABB=ON PLU=ON L31 AND L28

FILE 'STNGUIDE' ENTERED AT 09:24:07 ON 24 NOV 2009

FILE 'WPIX' ENTERED AT 09:24:17 ON 24 NOV 2009

D QUE L9
L33 50 SEA SSS SAM L7
D TRI 1-3
L34 1954 SEA SSS FUL L7
SAVE TEMP L34 JAI734WPIS/A
L35 235 SEA SPE=ON ABB=ON PLU=ON L34/DCR
L36 159 SEA SPE=ON ABB=ON PLU=ON L35 AND (A61K? OR A61P? OR
A61Q?)/IPC
L37 15 SEA SUB=L34 SSS SAM L12
D QUE STAT
L38 116 SEA SUB=L34 SSS FUL L12
SAVE TEMP L38 JAI734WPISR/A
L39 18 SEA SPE=ON ABB=ON PLU=ON L38/DCR
L40 1 SEA SPE=ON ABB=ON PLU=ON L39 AND (L15 OR L16 OR L17 OR L18)
L41 0 SEA SPE=ON ABB=ON PLU=ON L2 NOT L40
L42 17 SEA SPE=ON ABB=ON PLU=ON L39 NOT L40
L43 16 SEA SPE=ON ABB=ON PLU=ON L42 AND L28
D TRI 1-16

FILE 'REGISTRY' ENTERED AT 09:29:39 ON 24 NOV 2009

FILE 'STNGUIDE' ENTERED AT 09:29:46 ON 24 NOV 2009
D SAVED

L44 FILE 'REGISTRY' ENTERED AT 09:30:09 ON 24 NOV 2009
2 SEA SPE=ON ABB=ON PLU=ON L9 AND (MEDLINE OR BIOSIS OR
EMBASE OR BIOTECHNO OR CABA OR AGRICOLA OR DRUGU OR VETU OR
CROPU)/LC

FILE 'MEDLINE, BIOSIS, EMBASE, BIOTECHNO, CABA, AGRICOLA, DRUGU, VETU,
CROPU' ENTERED AT 09:31:00 ON 24 NOV 2009

L45 FILE 'MEDLINE, BIOSIS, EMBASE, BIOTECHNO, CABA, AGRICOLA, DRUGU, VETU'
ENTERED AT 09:31:14 ON 24 NOV 2009
L46 6 SEA SPE=ON ABB=ON PLU=ON L44
0 SEA SPE=ON ABB=ON PLU=ON L45 AND (L15 OR L16 OR L17 OR L18)
L47 6 SEA SPE=ON ABB=ON PLU=ON L45 NOT L46
L48 6 SEA SPE=ON ABB=ON PLU=ON L47 AND L28

FILE 'STNGUIDE' ENTERED AT 09:32:39 ON 24 NOV 2009

L49 FILE 'MEDLINE, BIOSIS, EMBASE, CABA, CEABA-VTB, PASCAL, JAPIO, LIFESCI,
L50 BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, AGRICOLA, CROPU,
CROPB, FSTA, FROSTI, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT
09:33:42 ON 24 NOV 2009
159573 SEA SPE=ON ABB=ON PLU=ON ?PYRIMIDIN?/IT,II,CC,CT,ST,STP
143 SEA SPE=ON ABB=ON PLU=ON L49 AND (L15 OR L16 OR L17 OR L18)
L51 0 SEA SPE=ON ABB=ON PLU=ON L50 AND L19

FILE 'STNGUIDE' ENTERED AT 09:35:20 ON 24 NOV 2009

D QUE STAT L9
D QUE STAT L14
D QUE NOS L32
D QUE STAT L34
D QUE STAT L38
D QUE NOS L43
D QUE NOS L48

L52 FILE 'HCAPLUS, WPIX, BIOSIS' ENTERED AT 09:37:45 ON 24 NOV 2009
50 DUP REM L32 L43 L48 (10 DUPLICATES REMOVED)
ANSWERS '1-38' FROM FILE HCAPLUS
ANSWERS '39-44' FROM FILE WPIX
ANSWERS '45-50' FROM FILE BIOSIS
SAVE TEMP L52 JAI734MAIN/A

FILE 'STNGUIDE' ENTERED AT 09:37:59 ON 24 NOV 2009

FILE 'HCAPLUS, WPIX, BIOSIS' ENTERED AT 09:38:39 ON 24 NOV 2009
D IBIB ED ABS HITIND HITSTR 1-20

FILE 'STNGUIDE' ENTERED AT 09:40:22 ON 24 NOV 2009

FILE 'HCAPLUS, WPIX, BIOSIS' ENTERED AT 09:43:43 ON 24 NOV 2009
D IBIB ED ABS HITIND HITSTR 21-38

FILE 'STNGUIDE' ENTERED AT 09:44:23 ON 24 NOV 2009

FILE 'HCAPLUS, WPIX, BIOSIS' ENTERED AT 09:45:18 ON 24 NOV 2009
D IALL ABEQ TECH ABEX FRAGHITSTR 39-44

FILE 'STNGUIDE' ENTERED AT 09:45:24 ON 24 NOV 2009

FILE 'HCAPLUS, WPIX, BIOSIS' ENTERED AT 09:45:52 ON 24 NOV 2009
D IBIB ED AB IND 45-50

FILE 'STNGUIDE' ENTERED AT 09:45:55 ON 24 NOV 2009
D QUE NOS L29
D QUE NOS L40
D QUE NOS L46
D QUE NOS L51

L53 FILE 'HCAPLUS, WPIX' ENTERED AT 09:47:09 ON 24 NOV 2009
1 DUP REM L29 L40 L46 L51 (1 DUPLICATE REMOVED)
ANSWER '1' FROM FILE HCAPLUS
SAVE TEMP L53 JAI734INV/A

FILE 'STNGUIDE' ENTERED AT 09:47:21 ON 24 NOV 2009

FILE 'HCAPLUS' ENTERED AT 09:47:34 ON 24 NOV 2009
D IBIB ED ABS HITIND HITSTR

FILE 'STNGUIDE' ENTERED AT 09:47:52 ON 24 NOV 2009

FILE 'STNGUIDE' ENTERED AT 09:48:12 ON 24 NOV 2009

FILE HOME

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 20, 2009 (20091120/UP).

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 24 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009 (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

ZCaplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Nov 2009 VOL 151 ISS 22
 FILE LAST UPDATED: 22 Nov 2009 (20091122/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

FILE WPIX

FILE LAST UPDATED: 20 NOV 2009 <20091120/UP>
 MOST RECENT UPDATE: 200975 <200975/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms and FI-Terms have been updated with reclassifications to end of September 2009.
 No update date (UP) has been created for the reclassified documents, but they can be identified by
 specific update codes (see HELP CLA for details) <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Japanese FI-TERM thesaurus in field /FCL added --> see NEWS <<<

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE MEDLINE

FILE LAST UPDATED: 18 Nov 2009 (20091118/UP). FILE COVERS 1949 TO DATE.

MEDLINE and LMEEDLINE have been updated with the 2009 Medical Subject Headings (MeSH) vocabulary and tree numbers from the U.S. National Library of Medicine (NLM). Additional information is available at

http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.

On February 21, 2009, MEDLINE was reloaded. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE BIOSIS

FILE COVERS 1926 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 18 November 2009 (20091118/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE EMBASE
FILE COVERS 1974 TO 23 Nov 2009 (20091123/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOTECHNO
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>
FILE COVERS 1980 TO 2003.
THIS FILE IS A STATIC FILE WITH NO UPDATES

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CT AND BASIC INDEX <<<

FILE CABA
FILE COVERS 1973 TO 5 Nov 2009 (20091105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE AGRICOLA

FILE COVERS 1970 TO 16 Nov 2009 (20091116/ED)

Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted material. All rights reserved. (2009)

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE DRUGU
FILE LAST UPDATED: 18 NOV 2009 <20091118/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE VETU
FILE LAST UPDATED: 2 JAN 2002 <20020102/UP>
FILE COVERS 1983-2001

FILE CROPU

FILE LAST UPDATED: 5 JAN 2004 <20040105/UP>
FILE COVERS 1985 TO 2003

<<< CROPU IS A STATIC FILE WITH NO UPDATES >>>

FILE CEABA-VTB
FILE LAST UPDATED: 23 NOV 2009 <20091123/UP>
FILE COVERS 1966 TO DATE

>>> DECHEMA, the producer of CEABA-VTB is using a new classification scheme.

The new classification schemes are available as a PDF file and may be downloaded free-of-charge from:

<http://www.stn-international.com/cc-de.html>

and

<http://www.stn-international.com/cc-en.html><<<

FILE PASCAL
FILE LAST UPDATED: 23 NOV 2009 <20091123/UP>
FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE JAPIO
FILE LAST UPDATED: 9 NOV 2009 <20091109/UP>
MOST RECENT PUBLICATION DATE: 30 JUL 2009 <20090730/PD>
>>> GRAPHIC IMAGES AVAILABLE <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION (SLART) IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE LIFESCI
FILE COVERS 1978 TO 3 Nov 2009 (20091103/ED)

FILE BIOENG
FILE LAST UPDATED: 12 NOV 2009 <20091112/UP>
FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
THE BASIC INDEX <<<

FILE BIOTECHDS
FILE LAST UPDATED: 18 NOV 2009 <20091118/UP>
FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<

FILE DRUGB
>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE VETB
FILE LAST UPDATED: 25 SEP 94 <940925/UP>
FILE COVERS 1968-1982

FILE CROPB

10/595,734

FILE LAST LOADED: 11 NOV 94 <941111/UP>

<<< CROPB IS A STATIC FILE WITH NO UPDATES >>>

FILE FSTA

FILE LAST UPDATED: 23 NOV 2009 <20091123/UP>

FILE COVERS 1969 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN THE BASIC INDEX (/BI) FIELD <<<

FILE FROSTI

FILE LAST UPDATED: 23 NOV 2009 <20091123/UP>

FILE COVERS 1972 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE BASIC INDEX (/BI) FIELD <<<

FILE SCISEARCH

FILE COVERS 1974 TO 20 Nov 2009 (20091120/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CONFSCI

FILE COVERS 1973 TO 30 Jun 2009 (20090630/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS

FILE COVERS 1861 TO 22 NOV 2009 (20091122/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

FILE RDISCLOSURE

FILE LAST UPDATED: 13 NOV 2009 <20091113/UP>

FILE COVERS 1960 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE BASIC INDEX (/BI) AND TITLE (/TI) FIELDS <<<

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=>